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Preface to ”Selected Papers from the 3rd International
Symposium on Life Science”
Studies on marine natural compounds are becoming increasingly interdisciplinary. In obtaining
and discussing new valuable scientific data, a wide range of different specialists have become
involved, from environmental chemists to hydrobiologists and pharmacologists. Long-term studies
at our G.B. Elyakov Pacific Institute of Bioorganic Chemistry (PIBOC), belonging to the Russian
Academy of Science, have led to the isolation and structural elucidations of many hundreds of marine
natural compounds including low molecular weight bioregulators and biopolymers. A series of
marine drugs, food supplements, and functional food products were created on this basis. Some of
them have been approved for industrial production and medicinal or other applications in Russia.
These studies were conducted in collaboration with scientists from many countries around the
world. Fruitful discussions on domestic and international scientific conferences were useful for
the development of such studies. The Third International Symposium on Life Science, held 4–8
September, 2019 in Vladivostok, was organized by this Institute. Scientists from several geographic
areas of the Russian Federation, from Moscow to Vladivostok, as well as chemists and biologists
from Germany, the Republic of Korea, the Peoples Republic of China, and Taiwan, participated in
this Symposium and delivered 81 lectures and poster presentations. The regular sub-symposium
of the series Korus (Korean–Russian symposiums) was held within the framework of this scientific
meeting. This was the third conference of this series, which started with the Symposium in 2012.
The aim of the Symposium is to share advanced ideas not only in the field of marine natural products
but also in organic and inorganic syntheses, molecular immunology, biotechnology, pharmacology,
and molecular genetics to promote the obtaining of new important scientific results in life science.
In accordance with invitation and sponsor support of the international scientific journal Marine
Drugs, this Special Issue of this journal was published. This Issue focuses its attention on bioactive
compounds from sea urchins, particularly quinoid pigments, like echinochrome A and spinochromes.
Their diverse biomedicinal properties, stability, and possibility to be obtained using organic synthesis
methods have attracted attention to these biologically active compounds. Studies on many other
important groups of natural products, including enzymes and lectins, sterol sulfates, and alkaloids,
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The search for and isolation of marine biologically active compounds, as well as relevant studies
on their structure and properties are important for the adding knowledge about molecular diversity
in nature and creation of medicines and other useful products on this basis. Long-term studies by G.
B. Elyakov Pacific Institute of Bioorganic Chemistry (PIBOC) belonging to the Russian Academy of
Sciences have led to the isolation and structural elucidation of many hundreds of new marine natural
compounds as well as to creation of a series of marine drugs, food additives, and functional food
ingredients which were approved for industrial production and medicinal or other applications in
Russia. PIBOC actively collaborates with scientists from many countries of the world and performs
regular marine expeditions in the North-Western Pacific and other geographic areas using R/V
“Academik Oparin”. Colleagues from other countries, particularly from Vietnam, also participate
in these expeditions. Over the course of its more than 50-year history, our institute has repeatedly
organized international scientific conferences.
The Third International Symposium on Life Science, held September 4–8 in Vladivostok, has been
also organized by PIBOC. Scientists from several towns of the Russian Federation from Moscow to
Vladivostok, as well as chemists and biologists from Germany, the Republic of Korea, the Peoples
Republic of China, and Taiwan attended this Symposium and delivered 81 plenary lectures, and oral
and poster presentations co-authored by scientists from several other countries. A sub-symposium
of the Korus series (Korean-Russian symposiums, started from 2012) was held in the frameworks of
this scientific meeting. The aim the Third Symposium on Life Science was to share advanced ideas
not only in the field of chemistry of marine natural products, but also in determination of molecular
mechanisms of action of new marine metabolites, pharmacology, enzymology, and molecular genetics
in order to achieve important new scientific results.
The Special Issue “Selected Papers from the Third International Symposium on Life Science
(http:/mdpi.com/journal/marinedrugs/special_issues/Selected Papers from the Third International
Symposium on Life Science) in the open access journal Marine Drugs (ISSN 1660-3397) was running
from the end of 2018 to the end of 2019. Totally, it comprises 17 articles, concerning with different aspects
of Life Science and recent experimental studies, carried out on the basis of marine natural products.
Structures and biological activities of low molecular weight secondary metabolites from marine
organisms were discussed in several selected papers. Tabakmakher et al. from PIBOC and colleagues
from University Medical Center Hamburg-Eppendorf, Germany, and Institute of Marine Biochemistry,
Vietnam, have described seven new polysulfated sterols isolated from the Vietnamese marine sponge
Halichondria vansoesti. Of particular interest is the fact that compounds similar to some steroids
isolated by this group which contain both bromine and chlorine atoms have never been found among
marine steroids. The effects of these compounds on human prostate cancer cells, expression of the
prostate-specific antigen (PSA), and glucose uptake have been discussed. This was the first report
on the ability of marine steroids to suppress PSA expression/androgen receptor signaling in cancer
cells [1].
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A series of oxysterols including 4 previously unknown compounds has been isolated by
Kolesnikova et al. from extracts of a sponge Inflatella sp. collected in the Sea of Okhotsk [2].
The influence of isolated compounds on the viability and reactive oxygen species (ROS) formation
in neuronal Neuro2a cells using 6-hydroxydopamine-induced cell model of Parkinson’s disease was
clarified. Some compounds of this series showed the essential neuroprotective activity in these in vitro
experiments, probably due ROS scavenging effect.
Yurchenko et al. from PIBOC together with Vietnamese colleagues from Institute of Technology
Research and Application (Nhatrang) and Graduate University of Science and Technology (Hanoi)
have isolated and studied a new melatonin analogue, 6-hydroxy-N-acetyl-β-oxotryptamine, from
the marine-derived fungus Penicillium sp. KMM 4672 and several other compounds of different
chemical nature from Aspergillus flocculosis and Aspergillus sp. Activities of these metabolites in the
6-hydroxydopamine- and paraquat-induced Parkinson’s disease cell models were studied. The new
melatonin analogue protects Neuro2a cells more effectively in these experiments in comparison with
melatonin itself [3].
Ga-Bin Park et al. from Kosin and Jnje Universities (Republic of Korea) have discussed interesting
activities of gliotoxin, a mycotoxin, containing disulfide bond in a piperazine ring and an aromatic amino
acid residue and isolated from the marine fungus Aspergillus fumigatus. Its action on paclitaxel-resistant
ovarian cancer cells has been studied. They have shown that treatment with gliotoxin at nanomolar
concentrations inhibits growth and reduces resistance to cytotoxic agents in these cancer cells.
Gliotoxin induces apoptotic cell death in an autophagy-dependent manner via the death-associated
protein kinase-1 (DAPK1)-TAp63 signaling pathway. The treatment with gliotoxin before paclitaxel
treatment inhibited the expression of multidrug resistant-associated proteins and increases expression
of DAPK1 and TAp63. The obtained results suggest that DAPK1-mediated TAp63 upregulation is one
of the critical pathways inducing apoptosis in chemoresistant cancer cells [4].
The possible microbial origin of some highly active marine metabolites, such as toxins and
antitumor agents isolated from invertebrates, has previously been the subject of discussions. Indeed, it
has been found that many marine invertebrates contain endo- and epibiotic microorganisms and that
some metabolites found in marine invertebrates are structurally related to bacterial natural products.
This suggests the microbial origin of some marine invertebrate metabolites [5]. Moreover, microbial
origin of bryostatins in bryozoans and some other natural products in lithistid sponges was confirmed
by experiments [6].
In this Issue, Makarieva et al. (PIBOC) have reported isolation of more than 20 bacterial
strains from the secreted mucus trapping of polychaete Chaetopterus variopedatus, and the strain
CB-1-14 was recognized as a new species belonging to the genus Vibrio. This bacterium was cultured,
and 6-epi-monanchorin A was obtained from both cells and culture broth using preparative HPLC.
This natural compound along with the related guanidine alkaloid monanchorin were earlier found
only in marine sponges and the same polychaete species. Thus, the microbial origin of this guanidine
alkaloid in marine invertebrates has been established [7].
Venoms of sea anemones are well known as a rich source of peptides acting on different molecular
targets such as enzymes, membrane receptors and ion channels. Magnificamide, the major α-amylase
inhibitor, comprising of 44 amino acid residues (4770 Da), was isolated from the sea anemone Heteractis
magnifica mucus. Sintsova and colleagues from PIBOC and University of Lueven, Belgium, have
reported that the recombinant magnificamide inhibits porcine and human saliva α-amylases in low
nanomolar concentrations and could be considered as a promising drug candidate for the type 2
diabetes treatment [8].
A series of articles has been published by Korean scientists, in majority from National mitochondrial
signaling of cardiovascular and metabolic disease center (Pusan, Republic of Korea) and their colleagues
from other Korean Universities with participation of Russian co-authors from PIBOC. Professor Jin Park
is scientific leader of many such studies. They have investigated molecular mechanisms of action of the
Russian medicine Histochrome and active substance of this drug, echinochrome A (Ech A). In its two
2
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drug forms, Histochrome has been permitted for clinical application in cardiology and ophthalmology
in the Russian Federation. In the published papers, other potential applications of these biopreparations
and new peculiarities of their action on cellular and organism levels have been considered.
Ga-Bin Park and co-authors have investigated a possibility to use Ech A as a well-established and
non-toxic antioxidant to facilitate ex vivo application of sensitive to oxidative damage hematopoetic
stem and progenitor cells (HSPCs), released from the bone morrow. Ech A promoted ex vivo expansion
of peripheral blood-derived CD34+ cells by suppressing reactive oxygen species generation and
p38 MAPK/JNK phosphorylation in them. Activation of Lyn kinase and p110δ as a mechanism to
enhance expansion of CD34+ cells was also shown. An assumption that Ech A initially induces
Src/Lyn activation, upregulates p110δ, and finally activate PI3K/Akt pathway was made. More or equal
hematopoietic colony forming cells were induced by CD34+ cells expanded in the presence of Ech A in
comparison with unexpanded CD34+ cells. Therefore, Ech A is an effective agent for promoting cell
proliferation and maintaining the stemness of HSPCs. It is beneficial to maintain self-renewal potential
of CD34+ cells during the ex vivo and possibly in vivo expansion of HSPCs [9].
In the related article, Jl Hye Park and collaborators has discussed the results of the studies on cell
protective effect of Histochrome under oxidative stress in human cardiac progenitor cells (hCPCs).
There are small portions of these stem cells in ischemic hearts, where they participate in repairing
the damaged heart tissues. Histochrome does not influence surface expression markers of hCPCs.
It reduces cellular and mitochondrial ROS levels in these cells at oxidative stress, induced by H2O2,
protects hCPCs, and shows anti-apoptotic effects through downregulation of pro-apoptotic signals and
upregulation of anti-apoptotic signals. Histochrome delayed the progression of cellular senescence
in hCPCs. It was concluded that the use of histochrome as biosafe agent is promising as potential
therapeutic strategy at application of patients-derived hCPCs to treat cardiovascular diseases [10].
In confirmation of positive effects of Ech A at cardiovascular problems, Ran Kim and co-authors
have reported a significant effect of Ech A on the injured region and behavioral decline at ischemic
stroke in a rat middle cerebral artery occlusion model after reperfusion. Ech A alleviated the infarcted
brain region and encouraged affirmative behavioral changes after ischemic stroke. It altered the
expression levels of cell viability-related factors. It was concluded that the protective role of this natural
compound against cell death is connected with its antioxidant effect [11].
In their paper, Su-Jeong Oh and co-authors have discussed a beneficial impact of Ech A on
inflammatory bowel disease, using a murine model of experimental colitis. Intravenous injection of
this compound prevented subsequent lethality and body weight loss in colitis-induced mice. In in vitro
experiments, this preparation stimulated generation of regulatory T cells, suppressed the activation of
proinflammatory M1 type macrophages and induced the production of M2 type macrophages. It has
been suggested that due to these features of the action, Ech A can correct imbalances in the intestinal
immune system, help resolve inflammation and initiate tissue repair [12].
Unexpectedly, the Russian team from PIBOC, G.M. Somov Institute of Epidemiology and
Microbiology (Vladivostok), and Institute of Vaccines and Sera (Moscow) has found that Ech A not
only exhibits anti-oxidant properties, but also shows anti-viral activities against tick-borne encephalitis
virus and herpes simplex virus type 1. A mixture of Ech A, ascorbic acid and tocopherol (5:5:1) showed
even higher anti-oxidant and anti-viral effects in comparison with Ech A itself [13].
Not only Ech A, but also some other quinoid pigments from sea urchins, so-called spinochromes,
have also been shown to be potential therapeutic agents. In fact, Chang Shin Yoon and co-authors have
discussed the results of the studies on protective action of spinochrome D (spD), a structural analogue
of Ech A, on cardiomyocytes against doxorubicin (Dox). As it is well known, doxorubicin demonstrates
suppressive activity against different cancers, but, being cardiotoxic, it increases ROS level in heart
cells. Authors of this article have reported that spD protected the Ac16 human cardiomyocyte cell line
against Dox cytotoxicity, but did affect anticancer properties of DOX in relation of MCF-7 human breast
tumor cells. As it was established by proteomic and metabolomic analyses, its action led to alterations
in glutathione metabolism. The increase of ATP level and oxygen consumption rate, induced by spD,
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was detected in galactose-treated AC-16 cardiomyocytes. These findings suggested that spD could be
considered as a potential cardioprotective agent at Dox therapy of oncological patients [14].
Sokolova and colleagues from PIBOC reported that Ech A is soluble in aqueous solutions of
carrageenans from red algae. Its complexes with carrageenans showed the ability to decrease expression
of pro-inflammatory cytokines Il-6 and TNFα and increase the expression of anti-inflammatory cytokine
Il-10. Thus, carrageenans can modulate biological properties of Ech A [15].
Problems of the studies on biopolymer natural compounds and last results, obtained by participants
of the symposium at investigation of the corresponding biopreparations were also discussed and
later published as scientific articles involved in this issue. For example, a group of co-authors
from PIBOC and Far East Federal University has published the results of mutagenesis studies and
structure-function relationship of GalNac/Gal lectin and its mutant forms. This lectin, named CGL,
from the mussel Crenomytilus grayanus (family Mytilidae, class Bivalvia) is a representative of novel
lectin family with β-trefoil fold. The crystal structure of this lection and mutagenesis studies revealed
three carbohydrate-binding sites capable to recognize globotriose on the surface of breast cancer cells.
In their article, Kovalchuk and colleagues have analyzed how alanine substitution of His 37, His 129,
Glu-75, His 85, Asn 27, and Asn 119 in these sites affects mucin-binding capability of CGL. It was shown
that this binding is determined by the number of hydrogen bonds in CGL-ligand complexes [16].
The review of Besednova and coauthors “Metabolites of Seaweeds as Potential Agents for
the Prevention and Therapy of Influenza Infection” (G.M. Somov Institute of Epidemiology and
Microbiology) contains analysis of literature data about anti-influenza effects of algal polysaccharides
such as fucoidans, carrageenans, and ulvans as well as other biopolymer substances from algae (lectins
and polyphenols). It was concluded that use of recently developed drugs can lead to the selection of
resistant viral strains. That is why some metabolites from algae with a broad spectrum of anti-viral
activity could be of interest as a potential basis for creation of new drugs [17].
The obtaining of recombinant form of alkaline hosphatase/phosphodiesterase, Cam PhoD, from
the marine bacterium Cobetia amphilecti KMM 296, expressed in Escherichia coli cells, has been described
in the article of Noskova et al from PIBOC and Far East Federal University. The enzyme catalyzes
the cleavage of diester and phosphate bonds in nucleotides. It was shown that Cam PhoD, exhibiting
maximum activity in the presence of Co2+ and Fe3+ ions, is a new member of PhoD family [18].
Genomic studies on two recently described species of marine bacteria, Zobellia amuskyensis and
Zobellia laminariae from the PIBOC Collection of marine microorganisms (KMM), have been discussed
in the paper of Chernysheva et al. Two novel draft genomes were obtained and compared with known
genomes of this genus representatives. Pan-genome of this genus is composed of 4853 orthologous
clusters. Carbohydrate active enzyme repertoires were highly diverse and biotechnogically promising
as biocatalysts for obtaining of oligosacchharides and other products with possible applications in
food and pharmaceutical industries [19].
In summary, this issue covers a series of in their majority experimental studies recently carried
out in the field of marine bioactive low molecular weight and biopolymer substances. In their
publications, scientists from Russia, the Republic of Korea, Vietnam, Germany, and Belgium have
discussed new results obtained at the search for new marine natural compounds, their isolation and
structure determination, biological activity, interaction with molecular targets, biomedicinal properties,
biogenesis, and perspectives of practical application. A wide spectrum of biological activities was
reported for these compounds, including antitumor, neuroprotective, anti-inflammatory, antioxidant,
antiviral, and other useful properties. In my opinion, the discovered new properties found for
echinochrome A, the active substance of the Russian drugs belonging to the Histochrome series, are of
particular interest and should open the way to new areas of medical use of this type drugs.
As a guest editor, I am thankful to all scientists from diverse research institutes and universities,
who contributed to the success of a special Issue “Selected Papers from the Third International
Symposium on Life Science”.
Conflicts of Interest: The author declares no conflict of interest.
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Abstract: Seven new unusual polysulfated steroids—topsentiasterol sulfate G (1), topsentiasterol
sulfate I (2), topsentiasterol sulfate H (3), bromotopsentiasterol sulfate D (4), dichlorotopsentiasterol
sulfate D (8), bromochlorotopsentiasterol sulfate D (9), and 4β-hydroxyhalistanol sulfate C (10), as
well as three previously described—topsentiasterol sulfate D (7), chlorotopsentiasterol sulfate D
(5) and iodotopsentiasterol sulfate D (6) have been isolated from the marine sponge Halichondria
vansoesti. Structures of these compounds were determined by detailed analysis of 1D- and 2D-NMR
and HRESIMS data, as well as chemical transformations. The effects of the compounds on human
prostate cancer cells PC-3 and 22Rv1 were investigated.
Keywords: marine sponge; Halichondria vansoesti; trisulfated steroids; topsentiasterol sulfates;
halistanol sulfates; anticancer activity; PSA expression; glucose uptake
1. Introduction
Biologically active trisulfated steroids are characteristic secondary metabolites found in some
marine sponges. These polar steroids comprise several structural subgroups in the sponges. The
first compound, bearing a common 2β,3α,6α-trisulfoxy steroid nucleus, halistanol sulfate, was
isolated in 1981 from the Okinawan sponge Halichondria cf. moorei [1] (Figure S1). The subgroup
also includes sokotrasterol sulfate from the sponge Halichondria sp. [2], halistanol sulfates A-J and
polasterol B, found in the sponges Epipolasis sp. [3,4], Pseudoaxinissa digitata [5], and Halichondria sp. [6],
ophirapsranol trisulfate from Topsentia ophiraphidites [7], four sterols isolated from the sponges Trachyopsis
halichondroides and Cymbastela coralliophila [8], amaranzoles A-F from Phorbas amaranthus [9,10], and
topsentinol K trisulfate from the sponge Topsentia sp. [11]. Another subgroup of these metabolites
consists of ibisterol sulfates and lembesterol A from the sponges Topsentia sp. [12], Xestospongia sp. [13],
and Petrosia strongilata [14]. In their steroid nuclei, 2β,3α,6α-trisulfoxy functionality is combined with
a C-9(11)-double bond and a methyl group at C-14. One more subgroup includes topsentiasterol
sulfates A–E from the sponge Topsentia sp. [15], Sch 575867 from the deep-water sponge belonging to
the family Astroscleridae [16], spheciosterol sulfates from the sponge Spheciospongia sp. [17], as well as
chloro- and iodotopsentiasterol sulfates D, isolated from the sponge Topsentia sp. in our laboratory [18].
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These compounds contain a common Δ9(11)-unsaturated, 4β-hydroxy-14α-methyl, 2β,3α,6α-trisulfated
steroid nucleus.
Inadditiontounusual structural features, trisulfatedsteroidspossesspromisingbiologicalproperties [19].
In fact, a broad range of activities has been described to trisulfate steroids such as antibacterial [1,15,20],
antifungal [15,16,21], antiviral (including anti-HIV and anti-HSV effects) [5,12,13,22,23], antiparasitic [21],
and antiplatelet activities [24]. In addition, the inhibition of different enzymes [6,11,18], promotion of
angiogenesis [25], and antitumor activity against various tumor cell lines [7,15,17,26] have been described.
Thus, the search for new trisulfated steroids from sponges, including the analyses of their chemical structures
and physiological properties, continues to be a promising area of research. Hopefully, this may lead to the
development of a new generation of drugs for a broad spectrum of diseases.
In the course of our ongoing interest in new biologically active secondary metabolites of marine
invertebrates, Halichondria vansoesti sponge, collected in Vietnamese waters during the 49th scientific
cruise aboard the R/V ‘Academic Oparin’, was investigated. As a result, ten trisulfated steroids 1–10
were isolated (Figure 1). Using NMR spectroscopy, including 1H, 13C, HSQC, COSY, HMBC, and
NOESY, as well as high-resolution mass spectrometry and chemical transformations, 1–4 and 8–10 were
identified as new, unusual analogues of topsentiasterol sulfates and halistanol sulfates. Compounds
5–7 were previously known as chlorotopsentiasterol sulfate D, iodotopsentiasterol sulfates D [18], and
topsentiasterol sulfate D, respectively [15]. Herein, we report the isolation, structural elucidation,
proposed biosynthetic pathways, and the study of the biological activities of the isolated compounds.
Figure 1. The structures of 1−10.
2. Results and Discussion
Concentrated EtOH extract of the sponge Halichondria vansoesti was partitioned between aqueous
EtOH and n-hexane. The aqueous EtOH-soluble materials were further applied on a reversed-phase
column chromatography (YMC-gel) and eluted successively with H2O→EtOH:H2O (3:7)→EtOH:H2O
(2:3)→EtOH:H2O (1:1)→EtOH:H2O (3:2) resulting in several subfractions. Subfractions obtained by
elution with EtOH:H2O (3:7) to EtOH:H2O (6:4) were further purified by a reversed-phase HPLC
(YMC-ODS-A) to give 1, 2 and 4–10. The subfraction, eluted with H2O, was further extracted with
BuOH, after which the butanol solution was concentrated and subjected to a reversed-phase HPLC
(YMC-ODS-A) to obtain 3.
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The molecular formula of 1, C30H44NNa3O14S3, was established from the [M3Na − Na]− ion peak
at m/z 784.1724 in the (−)-HRESIMS. In addition, the peaks at m/z 380.5927 and 246.0657, corresponding
to doubly-, and triply-charged ions ([M3Na − 2Na]2− and [M3Na − 3Na]3−), respectively, were indicated
in the (−)-HRESIMS of 1 (Figure S2).
The data of 1D- and 2D-NMR spectra of 1 (Tables 1 and 2, Figures S3–S7) indicated that this
compound contained five methyl groups, including three angular methyl groups in the steroid nucleus
(δH 0.70/δC 15.6, δH 0.82/δC 19.4, δH 1.44/δC 26.0) and two methyl groups of the side chain (δH 0.92/δC
19.5, δH 1.13/δC 20.1), eight methylene groups (including a N-substituted methylene), eleven methine
groups, including four oxygenated methines (δH 4.98/δC 76.4, δH 4.83/δC 76.6, δH 4.78/δC 77.1, δH
4.49/δC 69.2), three quaternarysp3 carbons (δC 15.6, δC 26.0, δC 19.4), two trisubstituted double bonds
(δH 5.35/δC 118.2, 147.1, δH 6.85/δC 139.4, 144.3), and an amide carbon (δC 177.6).
Table 1. 1H NMR data for 1–4, 8 and 10.
Position
1 a (δH, Mult, J
in Hz)
2 a (δH, Mult, J
in Hz)
3 b (δH, Mult, J
in Hz)
4 c (δH, Mult, J in Hz)
8 c (δH, Mult, J
in Hz)
10 c (δH, Mult, J
in Hz)
1a 1.84 dd (3.6, 14.5) 1.84 brd (14.5) 1.87 dd (3.6, 14.6) 1.83 dd (3.7, 14.5) 1.84 brd (14.8) 1.46 dd (3.6,14.5)
1b 2.39 brd (14.5) 2.41 brd (14.5) 2.37 brd (14.6) 2.40 brd (14.5) 2.38 brd (14.8) 2.29 brd (14.5)
2 4.98 m 4.98 m 4.96 m 4.97 m 4.98 m 4.87 m
3 4.78 m 4.77 m 4.77 m 4.76 m 4.80 m 4.74 m
4 4.49 m 4.49 m 4.48 m 4.49 m 4.48 m 4.45 m
5 1.51 dd (2.5, 11.4) 1.51 dd (2.7, 11.4) 1.52 dd (2.6, 11.4) 1.51 dd (2.9, 11.3) 1.50 dd (2.5, 11.5) 1.48 m
6 4.83 dt (4.5, 11.4) 4.83 dt (4.5, 11.4) 4.83 dt (4.4, 11.4) 4.83 dt (4.4, 11.3) 4.83 dt (4.5, 11.5) 4.60 dt (4.5, 11.3)
7a 1.58 q (11.9) 1.58 q (11.9) 1.57 dt (11.4, 12.9) 1.57 m 1.57 m 1.11 m
7b 2.23 dt (4.6, 11.9) 2.23 dt (4.6, 11.9) 2.22 dt (4.4, 11.8) 2.21 dt (5.0, 12.0) 2.23 dt (4.5, 11.5) 2.32 dt (4.2, 12.1)
8 2.51 m 2.51 m 2.48 m 2.49 m 2.50 m 1.58 m
9 0.71 m
11a 5.35 brd (5.6) 5.35 5.33 brd (5.8) 5.35 dt (2.0, 6.2) 5.35 dt (2.0, 6.2) 1.50 m
11b 1.34 m
12a 2.13 brd (17.6) 2.13 brd (17.3) 2.10 brd (17.1) 2.11 brd (17.5) 2.12 brd (17.5) 1.14 m
12b 1,97 dd (5.5, 17.6) 1.97 dd (5.9, 17.3) 1.95 dd (5.9, 17.1) 1.95 ddd (1.5, 6.1, 17.5) 1.95 dd (6.0, 17.5) 2.01 dt (12.5, 3.4)
14 1.11 m
15a 1.39 m 1.39 m 1.30 m 1.37 m 1.38 m 1.62 m
15b 1.47 m 1.46 m 1.41 m 1.45 m 1.46 m 1.12 m
16a 1.33 m 1.33 m 1.30 m 1.25 m 1.27 m 1.28 m
16b 1.91 m 1.91 m 1.92 m 1.86 m 1.87 m 1.85 m
17 1.66 q (9.4) 1.66 q (9.4) 1.64 q (9.3) 1.63 m 1.63 m 1.13 m
18 0.70 s 0.71 s 0.68 s 0.68 s 0.69 s 0.69 s
19 1.44 s 1.45 s 1.42 s 1.44 s 1.45 s 1.29 s
20 1.42 m 1.43 m 1.38 1.37 m 1.45 s 1.38 m
21 0.92 d (6.5) 0.92 d (6.5) 0.90 d (6.5) 0.90 d (6.5) 0.90 d (6.5) 0.93 d (6.6)
22a 1.09 m 1.09 m 1.08 m 1.04 m 1.05 m 1.01 m
22b 1.49 m 1.43 m 1.40 m 1.45 m 1.46 m
23a 1.51 m 1.52 m 1.42 m 1.38 m 1.36 m 1.18 m
23b 1.55 m 1.55 m 1.46 m 1.62 m 1.61 m
24a 2.48 m 2.48 m 2.69 m 2.45 m 2.55 m 1.11 m
24b 1.12 m
25 1.53 m
26 0.87 d (6.6)
27 6.85 br s 6.93 br s 5.92 br s 6.39 d (2.0) 6.31 s 0.87 d (6.6)
28 3.92 br s 5.91 br s 7.48 d (2.0)
29 1.13 d (6.9) 1.15 d (6.9) 1.10 d (7.0) 1.14 d (7.0) 1.15 d (6.9)
30 0.82 s 0.82 s 0.82 s 0.81 s 0.81 s
31a 3.74 m
31b 3.85 m
32 1.24 t (7.1)
a Measured in CD3OD at 500 MHz. b Measured in a mixture of CD3OD + CDCl3 (~10:1) at 700 MHz. c Measured in
CD3OD at 700 MHz.
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Table 2. 13C NMR Data of 1–4, 8, and 10.
Position 1 a (δC, Type) 2
a (δC, Type) 3
b (δC, Type) 4
a (δC, Type) 8
a (δC, Type) 10
a (δC, Type)
1 37.9, CH2 37.8, CH2 37.7, CH2 37.8, CH2 38.0, CH2 39.3, CH2
2 76.4, CH 76.4, CH 76.3, CH 76.4, CH 76.4, CH 76.3, CH
3 77.1, CH 77.2, CH 76.8, CH 77.1, CH 77.2, CH 77.3, CH
4 69.2, CH 69.2, CH 69.0, CH 69.2, CH 69.2, CH 69.0, CH
5 48.7, CH 48.6, CH 48.3, CH 48.6, CH 48.7, CH 50.8, CH
6 76.6, CH 76.4, CH 76.5, CH 76.6, CH 76.6, CH 76.4, CH
7 36.1, CH2 36.1, CH2 35.8, CH2 36.1, CH2 36.1, CH2 40.8, CH2
8 42.0, CH 42.0, CH 41.7, CH 42.0, CH 42.0, CH 35.9, CH
9 147.1, C 147.2, C 147.1, C 147.1, C 147.2, C 57.1, CH
10 40.1, C 40.2, C 40.1, C 40.2, C 40.1, C 37.6, C
11 118.2, CH 118.2, CH 118.2, CH 118.2, CH 118.2, CH 22.0, CH2
12 38.9, CH2 38.9, CH2 38.7, CH2 38.9, CH2 38.9, CH2 41.7, CH2
13 46.2, C 46.2, C 46.2, C 46.2, C 46.2, C 44.4, C
14 48.7, C 48.7, C 48.7, C 48.7, C 48.7, C 58.2, CH
15 35.5, CH2 35.5, CH2 35.3, CH2 35.5, CH2 35.4, CH2 25.8, CH2
16 29.5, CH2 29.5, CH2 29.3, CH2 29.4, CH2 29.5, CH2 29.8, CH2
17 52.8, CH 52.8, CH 52.7, CH 52.8, CH 52.8, CH 58.2, CH
18 15.6, CH3 15.7, CH3 15.6, CH3 15.6, CH3 15.6, CH3 13.1, CH3
19 26.0, CH3 26.0, CH3 25.8, CH3 26.0, CH3 26.0, CH3 18.0, CH3
20 37.9, CH 37.8, CH 37.7, CH 38.0, CH 38.0, CH 37.7, CH
21 19.5, CH3 19.4, CH3 19.4, CH3 19.6, CH3 19.5, CH3 19.8, CH3
22 35.3, CH2 35.2, CH2 35.4, CH2 35.8, CH2 35.7, CH2 37.9, CH2
23 33.8, CH2 33.4, CH2 34.2, CH2 35.4, CH2 35.4, CH2 25.5, CH2
24 32.4, CH 32.5, CH 39.7, CH 32.2, CH 32.5, CH 41.3, CH2
25 144.3, C 144.6, C 157.9, C 133.6, C 129.9, C 29.7, CH
26 177.6, C 173.7, C 171.9, C 126.4, C 132.1, C 23.5, CH3
27 139.4, CH 144.4, CH 125.9, CH 112.4, CH 109.6, CH 23.8, CH3
28 48.3, CH2 104.0, CH 166.8, C 146.0, CH 136.1, C
29 20.1, CH3 19.5, CH3 20.5, CH3 21.7, CH3 21.4, CH3
30 19.4, CH3 19.4, CH3 19.4, CH3 19.4, CH3 19.4, CH3
31 67.1, CH2
32 16.1, CH3
a Measured in CD3OD at 175 MHz. b Measured in a mixture of CD3OD + CDCl3 (~10:1) at 175 MHz.
Further analysis of the 1D- and 2D-NMR data of 1, and the comparison of its NMR data with those
in the literature revealed that 1 contains a Δ9(11)-4β-hydroxy-14α-methyl-2β,3α,6α-trisulfated steroid
core (Figure 2, substructure I) and the same side chain, containing C-20 (21) to C-24 (29) (Figure 2,
substructure III), as that found in the previously described topsentiasterol sulfates A–E [14], Sch
575867 [16], spheciosterol sulfates A–C [17], and chloro- and iodotopsentiasterol sulfates D (5,6) [18].
The 1H and 13C NMR spectra of 1 (Tables 1 and 2, Figures S3 and S4) were almost identical to those
of topsentiasterol sulfate C [15]. The only exceptions were the signals of the protons linked to C-27
and C-28, which were shifted to lower frequencies (δH 6.85/δC 139.4, δH 3.92/δC 48.3) in the spectrum
of 1. Moreover, the HRESIMS (Figure S2) data showed that the molecular mass of 1 was 1 amu less
than that of topsentiasterol sulfate C. Based on the above data, and in combination with 2D NMR data
(Figures S5–S7), the presence of the 1,5-dihydro-2H-pyrrol-2-one portion in the terminal part of the
side chain of 1 (Figure 2, substructure III) was proposed. To the best of our knowledge, this is the
first report on the 1,5-dihydro-2H-pyrrol-2-one moiety found in polysulfated steroids from sponges.
Comparison of the NOESY (Figure S8) data of the steroid nucleus of 1 with those of topsentiasterol
sulfate C and the related analogs [15–18] suggests that all the stereogenic centers of these compounds
have the same relative configurations. Key NOESY correlations of the steroid core of 1 are shown in
Figure 3. Thus, 1 is a new analogue of the topsentiasterol sulfate C [15], containing a unique structural
element with a nitrogen atom in the side chain. Therefore, it was named topsentiasterol sulfate G.
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Figure 2. Substructures of 1–4 and 8–10 with the key COSY (bold line) and HMBC (arrow line)
correlations.
 
Figure 3. Key NOESY correlations of 1 and 10.
Detailed studies of the 1D- and 2D-NMR spectra of 1–4, 8 and 9 (including the determination
of the relative configuration of stereogenic centers using NOESY data, Tables 1 and 2, Figure 3) were
performed. The generated data were compared to those of the known analogs, such as topsentiasterol
sulfates A–E [15], Sch 575867 [16], spheciosterol sulfates A–C [17], chlorotopsentiasterol sulfate D (5),
and iodotopsentiasterol sulfate D (6) [18]. Indeed, signals of the steroid nuclei in these compounds and
in the isolated polysulfated steroids were almost identical. Therefore, it was proposed that 1–4, 8 and 9
have the same Δ9(11)-4β-hydroxy-14α-methyl-2β,3α,6α-trisulfated steroid nucleus, with a variation of
the side chain.
The molecular formula of 2, C32H47Na3O16S3, was established from the [M3Na −Na]− ion peak
at m/z 829.1834 in the (−)-HRESIMS. In addition, the peaks at m/z 403.0980 and 261.0694 in the
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(−)-HRESIMS of 2 were observed, corresponding to the doubly- and triply-charged ions ([M3Na −
2Na]2− and [M3Na − 3Na]3−, respectively) (Figure S9).
The 1H and 13C NMR data (CD3OD, Tables 1 and 2, Figures S10 and S11) of the side chain of
2 resemble those of topsentiasterol sulfate A [15], except for the presence of the methyl group at δH
1.24 t, J = 7.1/δC 16.1 (C-32) and a methylene group at δH 3.74, 3.85/δC 67.1 (C-31). Further analyses
of the 2D-NMR spectral data, including COSY and HMBC spectra (Figures S12 and S14), revealed
the following correlations: H-32/H-31, H-31/C-32, H-31/C-28, H-28/C-31 (Figure 2, substructure IV).
In addition, HRESIMS spectrum showed that the molecular weight of 2 is 28 amu more than that of
topsentiasterol sulfate A [15]. Based on these data, 2 was elucidated as the ethyl ester of topsentiasterol
sulfate A [15]. Since 2 has not been previously reported, it was named topsentiasterol sulfate I.
The molecular formula of 3, C30H43Na3O17S3, was established from the [M3Na − H]− ion peak
at m/z 839.1253 in the (−)-HRESIMS spectrum. In addition, the peaks at m/z 408.0685 and 264.3826
in the HRESIMS of 3 corresponding to the doubly- and triply-charged ions ([M3Na-Na-H]2− and
[M3Na-2Na-H]3−, respectively) were observed (Figure S16).
The 13C and 1H NMR of 3 (CD3OD+CDCl3, ~10:1, Tables 1 and 2, Figures S17 and S18) exhibited the
signals of two carboxyl carbon (δC 166.8 and 171.9) and a trisubstituted double bond (δH 5.92/δC 125.9,
157.9). The HMBC spectrum of 3, recorded in DMSO-d6 (Figure S21), displayed correlations from H-29
to C-26 and H-27 to C-28. Based on these data and mass spectrometry data, the presence of 2-substituted
maleic acid in the side chain of 3 was suggested (Figure 2, substructure V). The Z-configuration of the
double bond in this fragment was established using NOESY experiment, in which a correlation from
H-29 to H-27 was observed (Figure S22).
To confirm the structure of 3, a methylation with diazomethane was carried out. The structure of
the resulting product 3a was clarified using 2D-NMR and HRESIMS. Cross peaks from OMe-26 to C-26
and OMe-28 to C-28 were observed in the HMBC spectrum (Figure 2, substructure Va). In addition,
the peaks of the [M3Na − Na]−and [M3Na − 2Na]2− ions were observed in the (−)-HRESIMS at m/z
845.1764 and 411.0943, respectively (Figure S23). These data revealed that a dimethyl maleate was at
the terminal of the side chain of the methylated derivative, as in the previously described topsensterol
A, a polyhydroxylated steroid from the sponge Topsentia sp. [27]. Additionally, the desulfation reaction
of 3 with trifluoroacetic acid was carried out. The structure of the obtained product (11) was established
from the analysis of the HRESIMS data (Figure 4, Figure S24).
 
Figure 4. The scheme of the desulfation reaction of 3.
Thus, 3 is a new analogue of polysulfated steroids from sponges, with a 2-substituted maleic acid
in the terminal part of the side chain.
Compound 4 was isolated as an inseparable mixture with the previously reported
chlorotopsentiasterol sulfate D (5) and iodotopsentiasterol sulfate D (6) [18] (2:7:1). Detailed analysis of
the HRESIMS (Figure S25), 1D- and 2D-NMR spectra (Tables 1 and 2, Figures S26–S31) of the mixture, as
well as the comparison of these data with those for the previously described compounds [15–18], led to
the identification of the structure 4. The molecular formula of 4 was determined as C30H42BrNa3O14S3
from the (−)-HRESIMS whose peaks of singly-, doubly-, and triply-charged ions were observed (m/z
847.0736, [M3Na − Na]−, m/z 412.0424, [M3Na − 2Na]2−, m/z 267.0321, [M3Na − 3Na]3−, respectively)
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(Figure S25). Measured intensities of the isotope peaks of 4 (412.0424 (100.0%), 412.5440 (36.3%),
413.0415 (122.0%), 413.5429 (41.6%), 414.0391 (61.7%) is in a good agreement with the calculation
intensities of the isotope peaks for [M3Na − 2Na]2− (412.0414 (100%), 412.5430 (35.8%), 413.0406
(119.8%), 413.5420 (41.3%), 414.0404 (24.0%)). The 1H NMR spectrum (CD3OD, Table 1, Figure S26)
displayed the higher frequency-shifted three pairs of doublets corresponding to H-27 and H-28 of
bromo-, chloro-, and iodo- of 3-substituted furans. Comparison of the chemical shift values of these
signals to those of chloro-and iodotopsentiasterol sulfates D from the literature [18] allowed us to
assign the proton signals at δH 6.39 (H-27) and 7.48 (H-28) to 4 (Table 1). Using the integration of the
signals corresponding to H-27 and H-28 in the 1H spectra of the mixture containing 4, 5, and 6 showed
that the mixture contains about 20% bromotopsentiasterol sulfate D (4) and 70% and 10% of chloro-
and iodo-derivatives (5,6) [18], respectively. Additional interpretation of the COSY, HSQC, and HMBC
data confirmed that 4 is composed of the substructures I and VI (Figure 2, Figures S28–S30).
New trisulfated steroids, dichlorotopsentiasterol sulfate D (8) and bromochlorotopsentiasterol
sulfate D (9), were isolated as an inseparable mixture. Attempts to separate 8 and 9 using repetitive
HPLC failed, however, based on HRESIMS and 1D- and 2D-NMR data, it was estimated as a 9:1 mixture
of 8 and 9. The molecular formulae of the 8 and 9, C30H41Cl2Na3O14S3 and C30H41ClBrNa3O14S3,
were established from the [M3Na −Na]− ion peaks at m/z 837.0837 and 881.0340 of the (−)-HRESIMS
spectrum. The predominant peaks at m/z 407.0480 and 429.0227 corresponded to a doubly-charged
ions [M3Na − 2Na]2−, similar to that in the MS of some pentacyclic guanidine alkaloids [28–31], and
two-headed sphingolipids [32]. Moreover, triply-charged ions [M3Na − 3Na]3− in the spectra of both
compounds were also observed (m/z 263.7026 and 278.3516, respectively) (Figure S32). Intensities of the
isotope peaks calculated for 8 confirm the proposed molecular formula C30H41Cl2Na3O14S3 (measured:
407.0480 (100%), 407.5496 (37.2%), 408.0485 (87.6%), 408.5499 (30.8%), 409.0471 (26.6%); calculated
for [M3Na − 2Na]2−: 407.0472 (100%), 407.5488 (35.8%), 408.0461 (86.5%), 408.5474 (29.36%), 409.0452
(26.7%)). Intensities of the isotope peaks calculated for 9 confirm the proposed molecular formula
C30H41ClBrNa3O14S3 (measured: 429.0227 (100.0%), 429.5244 (35.3%), 430.0219 (149.4%), 430.5233
(52.0%), 431.0213 (61.9%), 431.5225 (19.7%); calculated for [M3Na − 2Na]2−: 429.0220 (100.0%), 429.5235
(35.8%), 430.0210 (151.8%), 430.5224 (52.7%), 431.0201 (62.3%), 431.5213 (19.9%)).
The 1H and 13C NMR spectra of the mixture of 8 and 9 (CD3OD, Tables 1 and 2, Figures S33 and
S34) closely resembled those of chlorotopsentiasterol sulfate D (5) [18]. The main differences between
the NMR spectra of these compounds were the singlet of H-27 at δH 6.31 for 8 and δH 6.44 for 9
(integrating these signals, a ratio of 8 to 9 was established as 9:1), instead of two characteristic doublets
at δH 6.39 and 7.36, corresponding to H-27 and H-28 in the 1H NMR spectrum of monochlorinated
compound 5 [18]. Analysis of the COSY, HSQC, and HMBC spectrum confirmed the substructures I
and VII (Figure 2, Figures S35–S37) in 8.
To determine the positions of the halogen atoms in 9, we have carried out careful analysis of the
1H NMR and COSY spectra of the mixture of 4 and 5 (Table 1, Figures S28 and S37a) and detected
two cross-peaks δH 2.45 (H-24)/δH 1.14 (H-29) corresponding of 4 (26-bromo) and 5 δH 2.56 (H-24)/δH
1.15 (H-29) (26-chloro) in the COSY spectrum. Therefore, in the case of a bulkier bromine substituent
at C-26 the chemical shifts of H-24 and H-29 were observed in a higher field. Taking into attention,
that the COSY spectra of 8 + 9 (Table 1, Figures S35 and S37a) showed only one cross-peak δH 2.55
(H-24)/δH 1.15 (H-29) similar to the cross-peak in the spectrum of 4, the position of the chlorine atom
at C-26 in 9 was established. Based on this data and the HRESIMS data (see above), structure 9 was
assigned to the bromochlorotopsentiasterol sulfate D. Nevertheless, the localization of Cl- at C-26 and
Br at C-28 in 9 need to be further confirmed.
Compounds 8 and 9 represent the first dihalogenated trisulfated steroids found in sponges.
The molecular formula of 10, C27H45Na3O13S3, was established from the [M3Na −Na]− ion peak at
m/z 719.1819 in the (−)-HRESIMS. The base peaks at m/z 348.0969 corresponded to the doubly-charged
ion [M3Na − 2Na]2− (Figure S38).
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Detailed analysis of the 1H and 13C NMR, COSY, HSQC, HMBC, and NOESY spectra of 10
(CD3OD, Tables 1 and 2, Figure 2, substructures II and VIII, Figures S39–S44) and a comparison of its
1H and 13C chemical shift values with those reported in the literature for the previously described
trisulfated steroids [1–18], indicated that 10 is a previously unreported 4β-hydroxy derivative of
halistanol sulfate C [3], which was named 4β-hydroxyhalistanol sulfate C.
Interestingly, unlike all the previously described trisulfated steroids containing 4β-hydroxy
group [15–18], 10 does not contain a C-9/C-11-double bond and the α-methyl group at C-14. Thus, 10
is the first member of a new structural subgroup of trisulfated steroids from sponges.
The biosynthesis of unusual side chains of trisulfated steroids, such as 1–9, could be hypothesized
to originate from codisterol (12) (Figure S45) [33]. This process could proceed via the C-27 alkylation
of 12, followed by the proton loss and several reactions such as amination or hydratation of double
bonds accompanied with cyclization, oxidation, hydrolysis, and halogenation, which would result in
the formation of 1–6, 8, and 9 (Scheme 1).
Scheme 1. Proposed biogenesis of the side chains in 1–9.
The biological activities of 3, 7, and 10, as well as of the mixtures of 4 + 5 + 6 and 8 + 9
were investigated using human prostate cancer cells PC-3 and 22Rv1. PC-3 cells are known to be
androgen-independent as they do not express the androgen receptor (AR(-)). 22Rv1 expresses both
the androgen receptor (AR(+)), and the androgen receptor splice variant 7 (AR-V7(+)), the expression
of AR-V7 mediates the resistant of this cell line to androgen-deprivation therapy [34,35]. PSA is a
downstream target gene of the androgen receptor (AR) pathway. Thus, suppression of PSA expression
may indicate the inhibition of AR-signaling. AR-signaling is essential for the growth and survival of a
significant number of prostate cancer cell types. In fact, downregulation of AR signaling mediated by
androgen withdrawal is the standard first-line therapy for advanced human prostate cancer [36]. The
isolated compounds and the mixtures were found to inhibit the expression of PSA (prostate-specific
antigen) in human drug-resistant 22Rv1 cells (Figure 5A). Compound 3 and the mixture of 4 + 5 + 6,
suppressed PSA expression at a concentration as low as 10 μM (Figure 5A). Note, the IC50s for all the
isolated compounds determined with the MTT assay in PC-3 and 22Rv1 cells were >100 μM, which
could be due to the androgen-independent nature of these particular prostate cancer cell lines.
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Figure 5. Effects of the compounds on prostate cancer cells. (A): Effect on the PSA expression. 22Rv1
cells were treated with the compounds for 24 h, then the proteins were extracted and examined with
Western blotting. β-Actin was used as a loading control. (B): Effect on glucose uptake. PC-3 cells were
seeded in the 96-well plate, treated with the test compounds for 24 h in FBS- and glucose-free media,
incubated with 2-NBDG, and then the fluorescence was measured. Apigenin (50 μM) was used as a
positive control (Apig). Cells treated with vehicle (DMSO) were used as a control (Con). The glucose
uptake was normalized to the cell viability, measured by the MTS test. Significant difference from the
control is shown as follows: * p < 0.05 (Student’s t-test).
Additionally, 3 and 7, as well as the mixtures of 4 + 5 + 6 and 8 + 9 suppressed glucose uptake
in 22Rv1 cells (Figure 5B), whereas 10 did not exhibit this effect (data not shown). Cancer cells
are characterized by increased glucose consumption, which is related to their rapid growth and
metabolism [37]. Inhibition of glucose uptake either by nutrient deprivation or inhibitors, may
suppress cancer cells proliferation and/or sensitize cancer cells to standard therapies. Moreover, recent
studies suggested a possible crosstalk between glycolysis and AR-signaling [38]. However, cytotoxic
effects and proliferation inhibition were observed only at high concentrations of the isolated compounds
(data not shown). Nevertheless, due to the promising activity on AR-receptor signaling and glucose
uptake, 3 and 7, as well as the mixtures of 4 + 5 + 6 and 8 + 9 may serve as starting compounds for a
development of novel prostate cancer drugs. To the best of our knowledge, this is the very first report
on the ability of marine-derived steroid compounds to suppress the PSA expression/androgen receptor
signaling, as well as glucose uptake in cancer cells.
3. Materials and Methods
3.1. General Procedures
Optical rotations were measured using a Perkin-Elmer 343 polarimeter. The 1H- and 13C
NMR spectra were recorded on an Avance III-700 spectrometer at 700 and 175 MHz, respectively.
Chemical shifts were referenced to the corresponding residual solvent signal (δH 3.30/δC 49.60 in
CD3OD). The HRESIMS spectra were recorded on a Bruker maXis Impact II mass spectrometer
(Bruker, Germany). Low-pressure column liquid chromatography was performed using YMC-GEL
ODS-A. HPLC was performed using an Agilent Series 1100 Instrument equipped with a differential
refractometer RIDDE14901810 and an YMC-ODS-A (250 × 10 mm) column. Sorbfil Si gel plates
(4.5 × 6.0 cm, 5–17 μm, Sorbpolimer, Krasnodar, Russia) were used for thin-layer chromatography.
MTT reduction was measured using the F200PRO reader (TECAN, Männedorf, Switzerland).
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3.2. Animal Material
The sponge Halichondria vansoesti (order Suberitida, family Halichondriidae; Figure S46) was
collected at a depth of 5–12 m by hand via scuba diving during the 49th scientific cruise on board
R/V “Academik Oparin”, in the period from 10 November, 2016 to 3 January, 2017, in the South
China Sea (the territorial waters of Vietnam, 12◦34′02 N; 109◦24′26 E). The sponge material was
identified by Grebnev B.B. A voucher specimen is kept under the registration number N 049-232
in the marine invertebrate collection of the G. B. Elyakov Pacific Institute of Bioorganic Chemistry
(Vladivostok, Russia).
3.3. Extraction and Isolation
The sample of the sponge Halichondria vansoesti was immediately frozen after collection and kept at
−20 ◦C. The biological materials (dry weight 13.7 g) were chopped into small pieces and extracted with
EtOH (200 mL × 3). The combined EtOH solution was concentrated to obtain the crude ethanol extract
(7.9 g), which was partitioned between n-hexane and aqueous EtOH (9:4). The aqueous ethanol-soluble
materials (6.4 g) was concentrated and further fractionated by CC on YMC-GEL (2.5 × 15 cm) and
eluted successively with H2O→EtOH:H2O (3:7)→EtOH:H2O (2:3)→EtOH:H2O (1:1)→EtOH:H2O
(3:2). Each of the subfractions obtained by elution with EtOH:H2O (3:7) to EtOH:H2O (3:2) were then
concentrated (243 mg, 213 mg, 120 mg, 153 mg, respectively) and subjected to repeated preparative
HPLC (YMC-ODS-A, 65:35:1 EtOH/H2O/1M CH3COONH4 to give 1 (3.3 mg), 2 (2.3 mg), 7 (15.0 mg),
10 (13.5 mg) and mixtures of 4 + 5 + 6 (12.8 mg) and of 8 + 9 (11.0 mg). The subfraction eluted with
H2O was further extracted with BuOH, after which the butanol extract was concentrated (691 mg) and
subjected to preparative HPLC (YMC-ODS-A, 30:70:1 EtOH/H2O/1M CH3COONH4 to give 3 (4.7 mg).
3.4. Compound Characterization Data
Topsentiasterol sulfate G (1). Yield 0.024% of the dry weight of the sponge; amorphous powder; [α]20D :
+ 48 (c 0.23, MeOH); 1H- and 13C NMR data, see Tables 1 and 2; HRESIMS m/z 784.1724 [M3Na − Na]−,
380.5927 [M3Na − 2Na]2−, 246.0657 [M3Na − 3Na]3− (calc. for C30H44NNa3O14S3 784.1725, 380.5916,
246.0647, respectively).
Topsentiasterol sulfate I (2). Yield 0.017% of the dry weight of the sponge; amorphous powder; [α]20D : +
69 (c 0.15, MeOH); 1H- and 13C NMR data, see Tables 1 and 2; HRESIMS m/z 829.1834 [M3Na −Na]−,
403.0980 [M3Na − 2Na]2−, 261.0694 [M3Na − 3Na]3− (calc. for C32H47Na3O16S3, 829.1827, 403.0967,
261.0681, respectively).
Topsentiasterol sulfate H (3). Yield 0.034% of the dry weight of the sponge; amorphous powder;
[α]20D : + 39 (c 0.19, EtOH);
1H- and 13C NMR data, see Tables 1 and 2; HRESIMS m/z 839.1253 [M3Na −
H]−, 408.0685 [M3Na −Na −H]2−, 264.3826 [M3Na − 2Na −H]3− (calc. for C30H43Na3O17S3 839.1283,
408.0695, 264.3833, respectively).
Bromotopsentiasterol sulfate D, (4, in mixture with 5 and 6). Amorphous powder; 1H- and 13C-NMR
data (of 4), see Tables 1 and 2; HRESIMS m/z 847.0736 [M3Na −Na]−, 412.0424 [M3Na − 2Na]2−, 267.0321
[M3Na − 3Na]3− (calc. for C30H42BrNa3O14S3, 847.0721, 412.0414, 267.0312, respectively).
Mixture of the dichlorotopsentiasterol sulfate D and bromochlorotophentiasterol sulfate D (8 + 9, 9:1).
Amorphous powder; 1H- and 13C-NMR data (for 8), see Tables 1 and 2; HRESIMS (for 8 and 9) m/z
837.0837 and 881.0340 [M3Na −Na]−, 407.0480 and 429.0227 [M3Na − 2Na]2−, 263.7026 and 278.3516
[M3Na − 3Na]3− (calc. for C30H41Cl2Na3O14S3 and C30H41ClBrNa3O14S3, 837.0836 and 881.0331,
407.0472, and 429.0220, 263.7017 and 278.3513, respectively).
4β-hydroxyhalistanol sulfate C (10). Yield 0.099% of the dry weight of the sponge; amorphous powder;
[α]20D : + 40 (c 0.28, MeOH);
1H- and 13C-NMR data, see Tables 1 and 2; HRESIMS m/z 719.1819 [M3Na −
Na]−, 348.0969 [M3Na − 2Na]2−, (calc. for C27H45Na3O13S3 719.1823, 348.0965, respectively).
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3.5. Methylation of 3
Compound 3 (0.5 mg) was converted to methyl ester 3a by treatment with an excess (1.5 mL) of a
saturated solution of diazomethane in diethyl ether. The obtained derivative 3a was analyzed using
2D-NMR and HRESIMS (Figure 2, substructure Va, Figure S23).
3.6. Desulfation of 3
Compound 3 (<0.1 mg) was dissolved in 500 μL H2O and 16 μL of concentrated TFA was added
and kept at 100 ◦C for 4 h. The reaction mixture was concentrated and purified by CC on YMC-GEL (1.5
× 2 cm) and eluted successively with H2O→EtOH. The subfraction eluted with EtOH was concentrated
to give 11. The obtained derivative was analyzed using HRESIMS (Figure 4, Figure S24).
3.7. Bioactivity Assay
3.7.1. Reagents
The MTT reagent (Thiazolyl blue tetrazolium bromide) was purchased from Sigma (Taufkirchen,
Germany). The MTS reagent (Cell Titer 96 Aqueous One Solution Reagent) was purchased from
Promega (Madison, WI, USA).
3.7.2. Cell Lines and Culture Conditions
22Rv1 and PC-3 cell lines (human prostate cancer cell lines) were purchased from ATCC. Cells
were cultured in monolayer in 10% FBS/RPMI media according to the manufacture’s protocols and
were regularly checked for mycoplasma contamination.
3.7.3. In Vitro MTT- and MTS-Based Drug Sensitivity Assay
The in vitro cytotoxic activity of the isolated compounds was evaluated by the MTT assay
(performed as described previously [39]). For glucose uptake assay (3.7.5. Glucose uptake assay, see
below) the viability was determined using the MTS assay (performed as described previously [40]).
Treatment time was 48 h.
3.7.4. Western Blotting
Preparation of the samples and Western blotting were performed as described previously [41].
For the detection of PSA and β-actin expression, the anti-PSA/KLK3 (Cell Signaling, #5365, 1:1000) and
anti-β-actin-HRP (Santa Cruz, sc-1616, 1:10,000) antibodies were used. Treatment time was 24 h.
3.7.5. Glucose Uptake Assay
The examination of the effect of the compounds on glucose uptake was carried out using PC-3
cells and the Glucose Uptake Cell-Based Assay Kit (Cayman Chemicals, Ann Arbor, MI, USA) and
normalized to the cell viability measured using the MTS test [40]. 12,000 cells per well were seeded in
two 96-well plates in 100 μL of media per well, incubated overnight, and treated with the drugs in
100 μL of FBS-free and glucose-free RPMI media per well for 24 h. For glucose uptake measurements,
10 μL of the 2-NBDG solution in FBS-free and glucose-free RPMI media (glucose uptake measurements,
final 2-NBDG concentration in the wells was 50 μg/mL) of the vehicle (for cell viability measurements)
was added to each well. After 6 h of incubation, the cells were washed twice with PBS (200 μL/well).
Next, for the evaluation of glucose uptake, 100 μL of PBS was added to each well. The fluorescence
was measured using Infinite F200PRO reader (TECAN, Männedorf, Switzerland). For cell viability
measurements, the 100 μL of culture media containing MTS reagent was added to each well, and cell
viability was measured using an Infinite F200PRO reader according to the manufacture’s protocol.
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3.7.6. Statistical Analysis
All assays were repeated at least three times. Results are expressed as the mean ± standard
deviation (SD). Student’s t-test was used to estimate the significance: * p < 0.05.
4. Conclusions
Ten polysulfated steroids 1–10 were isolated from the Vietnamese marine sponge Halichondria
vansoesti. The structures of seven previously unreported compounds (1–4 and 8–10) were established
by 1D- and 2D-NMR spectroscopy, HRESIMS, and chemical transformations. Compounds 1–4, 8, and
9 are new analogues of topsentiasterol sulfates. The characteristic Δ9(11)-4β-hydroxy-14α-methyl-2β,
3α, 6α-trisulfated steroid nucleus and unusual side chains, not previously described in trisulfated
steroids from sponges, were found in the structures of these compounds. Compound 10 is a new
analogue of halistanol sulfate, containing a 4β-hydroxy-2β, 3α, 6α-trisulfated steroid nucleus and this
is the first report of this structure in sponge polar steroids. We proposed hypothetical pathways for the
biosynthesis of the side chains in new topsentiasterol sulfates. Some of the isolated trisulfated steroids
were able to suppress PSA expression and glucose uptake in human prostate cancer cells and thus may
serve as starting compounds for the development of novel prostate cancer drugs.
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Abstract: Four new oxysterols 1–4 along with previously known oxygenated sterols 5–14 were
isolated from the sponge Inflatella sp., collected from the Sea of Okhotsk. Structures of 1–4 were
elucidated by the detailed NMR spectroscopic and mass-spectrometric analyses as well as by
comparison of the corresponding experimental data with those reported in literature. The influence
of compounds 1–14 on the viability of neuronal Neuro2a cells treated by 6-hydroxydopamine and
reactive oxygen species (ROS) formation in these cells was investigated.
Keywords: secondary metabolites; oxygenated steroids; marine sponge; Inflatella; NMR; ROS;
Parkinson’s disease; structure-activity relationship
1. Introduction
Oxysterols, formed either enzymatically or by auto-oxidation, have a second oxygen function in
addition to that of C-3 when compared with natural sterols. These compounds are of particular interest
due to important biological functions of some of them and various bioactivities, including effects
on lipid metabolism, platelet aggregation, apoptosis, different receptors and proteins [1]. Generally,
oxysterols attract a great attention by the contribution to many physiological processes, including
those connected with pathophysiology of the neurodegenerative diseases [2]. As a key trend, the roles
of two brain sterols, 24S-hydroxycholesterol and 27-hydroxycholesterol, have been studied for years
and discussed in multiple reports [3–5]. Among others, 24S-hydroxycholesterol has been reported to
be markedly reduced in the circulation of patients with Parkinson’s disease (PD) [4]. The treatment
with 27-hydroxycholesterol or a combination of 24S-hydroxycholesterol and 27-hydroxycholesterol
reduced the levels of noradrenaline, whereas the treatment with 24S-hydroxycholesterol alone had
no effect. With these results, the authors demonstrated that oxysterols could regulate the proteins
involved in the development of PD [5].
Recently, some other oxysterols were found to be exported from the brain: 7β-hydroxycholesterol,
7-ketocholesterol, 3β,5α-dihydroxycholestan-6-one, 7α-hydroxy-3-oxocholest-4-enoic acid,
7α,25-dihydroxycholest-4-en-3-one, and (25R)-7α,26-dihydroxycholest-4-en-3-one. It was underlined
that these transfers were observed when total oxysterols were measured [6,7]. These facts give a new
quest to disclose possible roles and bioactivities of non-common oxysterols, including those of marine
origin, in development of PD and other neurodegenerative diseases.
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Recent studies highlighted the point that even well-known oxygenated sterols might be a critical
source of new medicine leads. Thus, hecogenin and cholest-4-en-3-one showed significant inhibitory
activity (EC50 values of 116.3 and 390.6 μM, respectively) against the human β-site amyloid cleaving
enzyme (BACE1), which has been considered as an effective drug target for treatment of Alzheimer’s
disease [8].
The search for new oxysterols in marine organisms and the studies on their action in model cell
systems could be also considered as an approach to the creation of new pharmaceutical leads against
neurodegenerative diseases. As a part of our chemical investigations of steroidal compounds from
marine sponges [9–11], we have studied oxysterols of a cold-water marine sponge Inflatella sp. The
sponges belonging to the genus Inflatella are insufficiently studied for their secondary metabolites,
though some bioactivities of their extracts were noted [12]. The ethanol extract of the studied Inflatella
sp. sample was preliminary analyzed by thin-layer chromatography during the screening of sponge
samples from PIBOC collection. The results revealed that in contrast with extracts of other sponges, it
contained the oxygenated steroids visually detected on chromatograms as a number of bright colored
spots (Figure S1). Herein we describe the isolation and structural elucidation of fourteen individual
oxysterols of Inflatella sp., including four new compounds as well as the results of their biotesting
using a cell model of PD. Part of this work has been presented at the 3rd International Symposium on
Life Sciences, Vladivostok, Russia, September 2018.
2. Results and Discussion
The ethanol extract of a sponge Inflatella sp., collected in the Sea of Okhotsk, was concentrated
and partitioned between distilled water and CHCl3. The obtained organic layer was further separated
using a combination of column chromatography and normal- or reverse-phase HPLC to yield
compounds 1–14 (Figure 1). To identify the structures of isolated compounds, along with the
absolute stereochemistry, their NMR and HRESI MS characteristics were analyzed and compared with
previously published data [13–18].
Figure 1. Structures of compounds 1–14.
Compound 1 was isolated as white amorphous powder with molecular formula C28H46O2,
established from (+) HRESI MS (m/z 437.3393 [M + Na]+) and 13C NMR spectroscopic data (Figures S2
22
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and S4; Table 1). The 1H and 13C NMR spectra (Tables 1 and 2; Figures S3 and S4) brought out
signals characteristics of steroidal derivatives. Namely, the 1H NMR (Table 2) and HSQC (Figure S7)
spectra allowed to refer signals of five methyl groups as belonging to Me-18 (δH 0.71, s; δC 12.4),
Me-19 (δH 0.92, s; δC 14.9), Me-21 (δH 0.96, d, J = 6.5 Hz; δC 18.9), Me-26 (δH 1.03, d, J = 6.8 Hz;
δC 22.1), and Me-27 (δH 1.02, d, J = 6.8 Hz; δC 22.2). The chemical shifts at δH 4.12, m; δC 67.4,
(HC-3), at δH 5.57, dd, J = 9.8, 2.7 Hz; δC 133.5, (HC-6) and at δH 5.63, dd, J = 9.8, 1.6 Hz; δC 133.4
(HC-7) along with oxygenated non-protonated carbon signal δC 74.2 (C-5), suggested the 3β,5α-6-ene
steroidal core [13,14]. It was supported by close similarity of the corresponding 13C NMR signals of 1
and known cholest-6-ene-3β,5α-diol while the epimoric compound with 3β,5β-6-ene core was quite
different [13]. As the signals at δH 4.66 (s) and 4.72 (s) showed an exo-methylene double bond (δC 106.3
and 157.1), the 24(28)-ergostene side-chain was deduced for compound 1. Therefore, the structure of
new compound 1 was established as 24-methylcholesta-6,24(28)-diene-3β,5α-diol.
Table 1. 13C NMR data of Compounds 1–4 (δ in ppm, CDCl3).
No. 1 a 2 a 3 b 4 a
1 28.5 36.7 37.0 37.0
2 30.8 28.1 31.4 31.6
3 67.4 76.6 71.4 71.5
4 41.2 75.2 42.1 41.8
5 74.2 142.1 146.2 143.7
6 133.5 117.8 123.9 125.5
7 133.4 31.6 65.3 73.4
8 38.7 31.5 37.5 40.9
9 45.3 50.5 42.3 48.3
10 38.3 38.1 37.4 36.5
11 21.3 20.9 20.7 21.1
12 40.3 39.8 39.1 39.5
13 44.0 42.3 42.0 42.8
14 54.2 56.8 49.5 56.0
15 24.1 24.3 24.2 26.3
16 28.8 28.2 28.4 28.6
17 56.1 56.0 55.8 55.4
18 12.4 11.9 11.9 12.1
19 14.9 20.2 18.2 19.2
20 36.0 35.8 39.8 39.7
21 18.9 18.7 20.8 20.9
22 34.9 34.7 133.6 133.5
23 31.3 31.0 134.9 135.0
24 157.1 156.9
25 34.1 33.8 30.9 30.9
26 22.1 21.9 22.7 22.7
27 22.2 22.0 22.7 22.7
28 106.3 106.0
a Spectra recorded at 125.76 MHz; b spectra recorded at 176.04 MHz.
Compound 2 has the molecular formula C28H46O2 that was determined by (+) HRESI MS m/z
437.3393 [M + Na]+ and 13C NMR (Figures S2 and S9; Table 1). The NMR data of 2 (Tables 1 and 2;
Figures S8–S11) also confirmed its steroidal framework. At first, they showed the same type of
side-chain in the structure 2 as in 1 by the presence of very close chemical shifts in the spectra of both
compounds. The remaining signals were attributed to Me-18 (δH 0.69, s; δC 11.9), Me-19 (δH 1.03, s; δC
20.2), 4α-OH (δH 4.06, m; δC 75.2), and trisubstituted 5(6)-double bond (δH 5.74, dt, J = 5.5, 2.2 Hz; δC
117.8, HC-6 and δC 142.2, C-5) of the previously described 4α-hydroxylated tetracyclic system. Really,
the both 4α-hydroxy- and 4β-hydroxycholesterols were obtained and well characterized during the
investigation of cholesterol autoxidation [15]. As a result of the thorough comparison of 1D and 2D
23
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NMR experimental data of 2 with published values, the structure of this new oxysterol was deduced
as 24-methylcholesta-5,24(28)-diene-3β,4α-diol.
Table 2. 1H NMR data of Compounds 1–4 (δ in ppm, J in Hz, CDCl3).
No. a 1 b 2 c 3 c 4 b
















3 4.12, m 3.27, td (10.5, 4.9) 3.39, m 3.55, m
4 α: 1.80, dd (12.4, 4.9)
β: 1.64, m 4.06, m
α: 2.34, ddd (13.2, 4.9, 2.2)
β: 2.29, ddt (13.2, 11.3, 1.8)
α: 2.34, ddd (13.2, 5.2, 2.3)
β: 2.26, ddt (13.2, 11.3, 2.2)
5
6 5.57, dd (9.8, 2.7) 5.74, dt (5.5, 2.2) 5.60, dd (5.3, 1.6) 5.29, br t (2.2)
7 5.63, dd (9.8, 1.6) α: 1.58, m
β: 2.10, m 3.85, br s 3.84, dt (8.3, 2.2)
8 1.93, m 1.44, m 1.47, m 1.40, m
9 1.48, dd (11.6, 3.9) 0.99, m 1.23, m 1.03, m
10








12 α: 1.23, m
β: 2.05, dt (12.5, 3.1)
α: 1.18, td (12.7, 5.2)
β: 2.03, dt (12.7, 3.7)
α: 1.19, m




14 1.23, m 1.00, m 1.44, m 1.16, m
















17 1.17, m 1.14, m 1.20, m 1.12, m
18 0.71, s 0.69, s 0.70, s 0.70, s
19 0.92, s 1.03, s 1.00, s 1.35, s
20 1.43, m 1.42, m 2.01, m 2.00, m
21 0.96, d (6.5) 0.95, d (6.6) 1.01, d (6.7) 1.01, d (6.6)
22 1.16, m1.55, m
1.16, m
1.55, m 5.18, dd (15.4, 8.4) 5.18, dd (15.4, 8.4)
23 1.88, m2.10, ddd (15.4, 11.5, 4.8)
1.88, m
2.09, m 5.27, dd (15.3, 6.6) 5.28, dd (15.4, 6.5)
24
25 2.23, sept (6.8) 2.23, sept (7.0) 2.19, br sept (6.7) 2.19, br sept (6.7)
26 1.03, d (6.8) 1.02, d (7.0) 0.94, d (6.7) 0.95, d (6.7)
27 1.02, d (6.8) 1.03, d (7.0) 0.94, d (6.7) 0.95, d (6.7)
28 4.66, s4.72, s
4.66, s
4.72, s
a Assignments were made with the aid of the 1H-1H COSY and HSQC spectra; b spectra recorded at 500.13 MHz; c
spectra recorded at 700.13 MHz.
The structure of the compound 3 corresponds to the molecular formula C26H42O2 (HRESI MS
m/z 409.3081 [M + Na]+) (Figures S2 and S14; Table 1). It has a common Δ5-3β,7α-diol steroidal core
that has been confirmed by the signals of Me-18 (δH 0.70, s; δC 11.9), Me-19 (δH 1.00, s; δC 18.2), two
methines, connected with hydroxy groups (δH 3.59, m; δC 71.4, HC-3 and δH 3.85, br s; δC 65.3, HC-7),
and the 5(6)-double bond (δH 5.60, dd, J = 5.3, 1.6 Hz; δC 123.9, HC-6 and δC 146.2, C-5) [16]. However,
the molecular formula and characteristic signals of the 22E-double bond (δH 5.18, dd, J = 15.3, 6.6 Hz;
δC 133.6, HC-22 and δH 5.27, dd, J = 15.3, 6.6 Hz; δC 134.9, HC-23), as well as Me-26,27 signals (δH
0.94, d, J = 6.7 Hz; 6H; δC 22.7) showed that this new steroid was characterized by the presence of the
22E-unsaturated 24-nor-side chain [17] (Tables 1 and 2; Figures S13–S18). Finally, the structure of new
oxysterol 3 was determined as (22E)-24-nor-cholesta-5,22-diene-3β,7α-diol (3) that was also in good
agreement with ROESY and HMBC data (Figures S16 and S18).
The C26H42O2 molecular formula ((+) HRESI MS m/z 409.3081 [M + Na]+) of compound 4 together
with similar NMR spectral characteristics (Tables 1 and 2; Figures S2, S19–S24) suggested the presence
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of a side-chain the same as in compound 3. The core parts of these compounds also demonstrated a
set of close 1H NMR signals except for the chemical shift values, constants, and multiplicity of H-6
(δH 5.29, t, J = 2.2 Hz) and H-7 (δH 3.85, dt, J = 8.3, 2.2 Hz). Both mentioned signals were similar
to those described previously [16,18] and suggested the 7β-OH stereochemistry in 4. All these data
along with confirmation by ROESY and HMBC spectra (Figures S22 and S24) allowed to establish the
(22E)-24-nor-cholesta-5,22-diene-3β,7β-diol (4) structure of this new oxysterol.
Additionally, the remaining ten isolated compounds 5–14 were identified as known oxygenated
steroidal derivatives by spectroscopic methods and comparison with reported data including NMR
spectra [16,18–20]. Most of them were described as naturally occurring metabolites possessing
diverse biological activities. Thus, (22E)-cholesta-5,22-diene-3β,7α-diol (5) was originally isolated
from the marine sponge Cliona copiosa [16], and demonstrated anti-inflammatory, analgesic
and gastroprotective activities as a component of ethanolic fraction of gorgonian Eunicella
singularis [21]. The (22E)-cholesta-5,22-diene-3β,7β-diol (6) [16] deterred starfish predators [22].
Selective activity towards DNA repair-deficient yeast mutants and cytotoxicity towards wild-type
P-388 murine leukemia cells [23] were showed for 24-methylene-5-cholestene-3β,7α-diol (7) [18].
Moreover, the compound 7 was noted as a potential drug development candidate for Alzheimer’s
disease due to inhibitory potential against butyrylcholinesterase (BuChE) with IC50 9.5 μM [24].
The 24-methylene-5-cholestene-3β,7β-diol (8) [18] was completely inactive in the screening for
DNA-damaging agents in the RAD 52 yeast assay (while its epimer 7 was active with IC50 7 μg/mL),
and showed moderate cytotoxic activity (IC50 31 μM) in the Vero cell assay, indicating that 7β-OH
compound acted by a different mechanism in comparison with its α-counterpart [25]. Both compounds
7 and 8 were also noted as constituents of the royal jelly of honeybees [26].
To the best of our knowledge there are not any reported bioassay
results in relation to (22E,24S)-24-methylcholesta-5,22-diene-3β,7α-diol
(9) [16], (22E,24S)-24-methylcholesta-5,22-diene-3β,7β-diol (10) [16,18], and
(22E,24R)-24-methylcholesta-5,22-diene-3β,7α-diol (11) [16,19]. 7β-Hydroxycholesterol (12)
isolated from the Red Sea grass Thalassodendron ciliatum displayed an inhibitory activity against
breast carcinoma cell line MCF-7 (IC50 18.6 ± 0.72 μM) and liver carcinoma cell line Hep G2 (IC50
25.4 ± 0.38 μM). However, it did not show the anti-inflammatory action on carrageenan-induced
rat hind paw edema model [27]. When human THP-1 macrophages were exposed with an
atheroma-relevant mixture of 7β-hydroxycholesterol (12) and 7-ketocholesterol followed by proteome
analysis, the alterations in macrophage proteome were indicated with a significant differential
expression of 19 proteins [28].
3β-Hydroxy-24-methylene-5-cholesten-7-one (13) [18] exhibited the potent inhibitory activity
on the interleukin-6 production, with 54.0% inhibition at 10 μM and IC50 9.4 ± 1.2 μM [29].
24-Methylenecholest-4-ene-3β,6β-diol (14) [20] demonstrated the cytotoxic activity against the
leukemia P-388 cell line with an IC50 1 μg/mL [30].
Encouraged with the short literature review presented above, that shows different attractive
bioactivities of oxysterols, we have made an attempt to evaluate the action of the isolated compounds
1–14 on viability of Neuro2a cells and reactive oxygen species (ROS) formation in these cells. In fact,
neuroblastoma cells treated by 6-hydroxydopamine (6-OHDA) are used as a cell model of PD [31].
Compounds 4, 5, 9 and 12 did not show any notable effects on Neuro2a cell viability. Compounds
1, 2, 7, 8, 13 and 14 demonstrated slight cytotoxic activity at concentration 100 μM and decreased
viability of Neuro2a cells on 25%, 17%, 44%, 27%, 38% and 33%, respectively. It is of interest that all of
them have the same structural peculiarity, being the 24 (28)-unsaturated derivatives of ergostane series.
No compounds decreasing cell viability more than 50% were found. At concentration of 10 μM, the
oxysteroids 1–14 were non-toxic against these neuronal cells, and were used in next experiments at the
non-toxic concentrations (Figure S25). Moreover, compounds 3, 6, 10 and 11 increased the viability of
Neuro 2a cells in comparison with non-treated cells, when MTT cell viability test was used (Figure 2a
and Figure S25).
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Figure 2. Compounds 3, 6, 10 and 11: (a) Caused a statistically significant overestimation of MTT
reduction in MTT cell viability assay; (b) did not statistically significant affect activity of nonspecific
esterase in fluorescein diacetate cell viability test. * Statistically significant differences (p ≤ 0.05)
between results for control cells and cells incubated with these compounds.
Applied MTT assay is one of the most widely exploited approaches in research for measuring
cell proliferation, viability and drug cytotoxicity. In living cells, the water-soluble yellow dye MTT
is reduced to a dark purple (blue-magenta) colored formazan precipitate, which can be analyzed
colorimetrically after dissolving in an organic solvent. It was shown, that the MTT reduction site
is not only mitochondria. Non-mitochondrial, cytosolic and microsomal MTT reduction makes the
major contribution to an overall reduction. Changes in the activity of dozens of the mitochondrial and
non-mitochondrial oxidoreductases, cellular metabolic and energy perturbations, and oxidative stress
may significantly impact the MTT assay read out [32].
To study action of the tested compounds on cells in details, we additionally used fluorescein
diacetate (FDA) assay based on nonspecific esterase activity measuring and thus examined the influence
of compounds 3, 6, 10 and 11 on proliferation or/and viability of Neuro 2a cells [33]. Compounds 3,
6, 10 and 11 did not increase the fluorescence intensity in FDA assay in comparison with control and
therefore did not influence significantly on nonspecific esterase activity in Neuro2a cells (Figure 2b).
Hence, we could conclude that the observed increasing of MTT reduction was not caused by the
influence of tested compounds on cell proliferation.
In fact, the overestimation in MTT assay of the compounds 3, 6, 10 and 11 could be caused by
alternative metabolic processes. For example, the overestimation reported for rottlerin was explained
by dissipation of the inner mitochondrial membrane potential, acceleration of electron transfer and
increasing of dehydrogenases activity, oxygen consumption and NADH oxidation [33]. On the other
hand the polyphenolic antioxidant resveratrol exhibited increasing of MTT-reducing activity without
a corresponding increasing of living cells number [34]. The ability of resveratrol to down-regulate
NADPH-oxidase leading to decreased ROS production and thereby provide a protective effect in
cardiovascular and neurodegenerative diseases is also well known [35].
As the above reviewed reports described the influence of compounds on intracellular ROS
formation, we investigated the effect of compounds 1–14 on ROS formation in Neuro 2a cells by
short-time 2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) test. Oxysterols 1–4, 8, 10 and 13 at
concentrations of 1 or/and 10 μM slightly decreased the ROS level in Neuro2a cells by 12–16%, while
the increasing in ROS formation was not detected for all the studied compounds (Figure S26).
PD is the one of the most common age-related motoric neurodegenerative disease, regardless of
countries and regions [36]. Pathogenesis of PD includes neuronal death as a result of oxidative stress
involved intracellular level of ROS increasing. In this reason, compounds exhibited ROS-scavenger
activities could be interesting as neuroprotective agents. All isolated compounds 1–14 were studied in
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6-OHDA-induced Neuro2a cell model of PD (Figure S26). Only compounds 3, 4 and 11 affected on
viability of 6-OHDA-treated cells (Figure 3a) and ROS formation in these cells (Figure 3b).
Figure 3. Influence of compounds 3, 4 and 11 in 6-OHDA-treated Neuro2a cells: (a) on cell
viability; (b) on ROS formation. * Statistically significant differences (p ≤ 0.05) between results for
6-OHDA-treated cells and cells incubated with compounds.
As a result, compound 3 increased the viability of 6-OHDA-treated cells by 18% (at the dose of
10 μM) and 22% (1 μM), while compounds 4 and 11 increased cell viability by 28% (10 μM) and 18%
(10 μM), correspondingly. All these compounds decreased ROS formation in 6-OHDA-treated cells to
normal value in similar manner. Thus, compound 4 exhibits the essential neuroprotective activity in
6-OHDA-induced model of Parkinson’s disease, probably due to ROS scavenging effect. Oxysterols 3,
6, 10 and 11 may positively influence on metabolic processes in the Neuro2a cells because they show
the overestimation of survival in MTT assay.
3. Materials and Methods
3.1. General Methods
Optical rotations were measured on a Perkin-Elmer 343 digital polarimeter (Perkin Elmer,
Waltham, MA, USA). The 1H and 13C NMR spectra were recorded in CDCl3 using Bruker Avance III
500 (Bruker BioSpin GmbH, Rheinstetten, Germany) (500.13/125.77 MHz) or Avance III 700 Bruker
FT-NMR (Bruker BioSpin GmbH, Rheinstetten, Germany) (700.13/176.04 MHz) spectrometers. HRESI
and ESI mass spectra were recorded on an Agilent 6510 Q-TOF LC/MS mass spectrometer (Agilent
Technologies, Santa Clara, CA, USA), and samples were dissolved in methanol (c 0.01 mg/mL). TLC
was carried out on silica gel plates (CTX-1A, 5-17 μm, Sorbfil, Russia) and spots were visualized
by spraying with aqueous 10% H2SO4 followed by heating. Column chromatography (CC) was
performed on silica gel (KSK, 50−160 mesh, Sorbfil, Russia) and YMC ODS-A (12 nm, S-75 um, YMC
Co., Ishikawa, Japan). HPLC was performed using an Agilent 1100 Series chromatograph with a
differential refractometer (Agilent Technologies, Santa Clara, CA, USA). The reversed-phase columns
(YMC-Pack ODS-A, YMC Co., Ishikawa, Japan, 10 mm × 250 mm, 5 μm and 4.6 mm × 250 mm,
5 μm) and normal-phase column (Ultrashere-Si, Beckman Instruments, Inc., Berkeley, CA, USA,
10 mm × 250 mm, 5 μm) were used for HPLC. Yields are based on dry weight of the sponge.
3.2. Animal Material
The samples of an Inflatella sp. sponge were collected by dredging near Kashevarov Bank, the Sea
of Okhotsk (55◦30′ N; 146◦05′ E, Russia) at a depth of 214–197 m and were freeze dried after collection.
The species was identified by Dr. Krasokhin V. B. from G.B. Elyakov Pacific Institute of Bioorganic
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Chemistry, FEB RAS. A voucher specimen (PIBOC O07-33(11)) is deposited at the G.B. Elyakov Pacific
Institute of Bioorganic Chemistry, FEB RAS (Vladivostok, Russia).
3.3. Extraction and Isolation
The sponge material (dry weight 216 g) was chopped into pieces and extracted with EtOH at
room temperature. The ethanol soluble materials (21.0 g) were obtained after concentration of the
extract was dissolved in distilled water (300 mL) and partitioned in turn with CHCl3 (200 mL × 3).
Evaporation of the chloroform extracts gave dark green gum (12.7 g) that was further separated on a
silica gel column (7 cm × 10 cm) using the mixtures of CHCl3/EtOH as stepwise eluent systems to
yield the fractions A–F (Figure S1).
Fraction D (301.4 mg), eluted with CHCl3/EtOH (15:1), was separated by column chromatography
(CC) (YMC ODS-A, 15 mm × 100 mm, MeOH/H2O, 90–100%) to yield three subfractions (D1–D3).
The subfraction D1 (128.5 mg) was further subjected to silica gel CC (hexane/EtOAc stepwise systems)
to obtain three subfractions. The subfraction D1.2 (17.0 mg) was purified by normal-phase HPLC
(Ultrasphere-Si, hexane/EtOAc, 1:1, 2 mL/min) to yield compound 13 (6.3 mg, 0.003%). Subfraction
D1.3 (6.6 mg) was separated by reverse-phase HPLC (YMC-Pack ODS-A, 10 mm × 250 mm, 95%
MeOH, 2 mL/min) to obtain compounds 1 (0.8 mg, 0.0004%), 3 (0.4 mg, 0.003%) and 7 (1.8 mg, 0.012%).
Fraction E (904.4 mg), eluted with CHCl3/EtOH (10:1), was fractionated by silica gel CC
(25 mm × 60 mm, hexane/EtOAc, 1:1) to yield four smaller fractions. Fraction E2 (227.4 mg) was
subjected to normal-phase HPLC (Ultrasphere-Si, hexane/EtOAc, 1:1, 2 mL/min) resulting in three
subfractions. The first subfraction E2.1 (4.0 mg) was purified using reverse-phase HPLC (YMC-Pack
ODS-A, 4.6 mm × 250 mm, 90% EtOH, 0.6 mL/min) to afford compound 2 (0.8 mg, 0.0004%) and to
re-isolate metabolite 13 (1.1 mg). As a result of the process of E2.2 (22.9 mg) reverse-phase separation
(YMC-Pack ODS-A, 10 mm × 250 mm, 2 mL/min) in 95% MeOH, the compounds 4 (1.0 mg, 0.0005%),
6 (2.4 mg, 0.001%), 8 (6.3 mg, 0.003%), 10 (2.0 mg, 0.0009%) and 12 (1.7 mg, 0.0008%) were obtained.
The last mentioned HPLC procedures and 94% MeOH as eluent were used for the subfraction E2.3
that allowed us to isolate the individual steroids 5 (6.8 mg, 0.003%), 9 (3.3 mg, 0.002%), 11 (8.0 mg,
0.004%), 14 (1.3 mg, 0.0006%) and to gain new portions of the metabolites 3 (5.8 mg) and 7 (24.3 mg).
3.3.1. 24-Methylcholesta-6,24(28)-diene-3β,5α-diol (1)
White amorphous powder; [α]22D +45.0 (c 0.02, CHCl3);
1H and 13C NMR data (CDCl3), see Tables 1
and 2; EIMS m/z: 414 [M]+ (10), 396 [M − H2O]+(100), 378 (15), 363 (20), 312 (8), 276 (8), 141 (12), 109
(14); (+) HRESI MS m/z 437.3393 [M + Na]+ (calcd. for C28H46O2Na, 437.3390).
3.3.2. 24-Methylcholesta-5,24(28)-diene-3β,4α-diol (2)
White amorphous powder; [α]22D +50.0 (c 0.08, CHCl3);
1H and 13C NMR data (CDCl3), see Tables 1
and 2; (+) HRESI MS m/z 437.3393 [M + Na]+ (calcd. for C28H46O2Na, 437.3390).
3.3.3. (22E)-24-Nor-cholesta-5,22-diene-3β,7α-diol (3)
White amorphous powder; [α]22D −47.5 (c 0.04, CHCl3); 1H and 13C NMR data (CDCl3), see
Tables 1 and 2; (+) HRESI MS m/z 409.3081 [M+Na]+ (calcd. for C26H42O2Na, 409.3077).
3.3.4. (22E)-24-Nor-cholesta-5,22-diene-3β,7β-diol (4)
White amorphous powder; [α]22D −9.0 (c 0.10, CHCl3); 1H and 13C NMR data (CDCl3), see Tables 1
and 2; (+) HRESI MS m/z 409.3081 [M + Na]+ (calcd. for C26H42O2Na, 409.3077).
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3.4. Biological Activities
3.4.1. Cell Line and Culture Condition
The neuroblastoma cell line Neuro2a was purchased from ATCC. Cells were cultured according
to the manufacturer instructions in DMEM medium containing 10% fetal bovine serum (Biolot, Russia)
and 1% penicillin/streptomycin (Invitrogen). Cells were incubated at 37 ◦C in a humidified atmosphere
containing 5% (v/v) CO2.
3.4.2. MTT Assay
Cell suspension (1 × 103 cells/well) was incubated with different concentration of compounds
during 24 h. After that, cell viability was determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) method as manufacturer described (Sigma-Aldrich, St. Louis, MO, USA).
3.4.3. Nonspecific Esterase Activity Assay
Cell suspension (1 × 103 cells/well) was incubated with different concentrations of the studied
compounds during 24 h. A stock solution of the fluorescein diacetate (FDA) (Sigma-Aldrich, USA)
in DMSO (1 mg/mL) was prepared. After incubation of the cells with compounds, FDA solution
(50 μg/mL) was added to each well and the plate was incubated at 37 ◦C for 15 min. Cells were
washed with phosphate buffer saline and fluorescence was measured with a Fluoroskan Ascent plate
reader (ThermoLabsystems, Finland) at λex = 485 nm and λem = 518 nm. Cell viability was expressed
as the percent of control.
3.4.4. 6-OHDA-Induced In Vitro Model of Parkinson’s Disease
The neuroprotective activity of the studied compounds in 6-hydroxydopamine-induced cell
model of Parkinson’s disease was investigated as described previously [37]. Neuroblastoma Neuro2a
line cells (1 × 103 cells/well) were treated with compounds at concentrations of 1 and 10 μM during
1 h, after that 6-OHDA (Sigma-Aldrich, USA) at concentration of 50 μM was added in each well and
neuroblastoma cells were cultivated during 24 h. After that, viability of cells was measured by MTT
assay. The results were presented as percent of control data.
3.4.5. Reactive Oxygen Species (ROS) Level Analysis
Cell suspensions (1 × 103 cells/well) were incubated during 1 h with 1 and 10 μM solutions of the
tested compounds. Non-treated and treated with 6-OHDA at concentration of 50 μM (Sigma-Aldrich,
USA) cells were used as negative and positive controls, respectively. The portion (20 μL) of
2′,7′-dichlorodihydrofluorescein diacetate (H2DCF-DA) stock solution (Molecular Probes, Eugene,
OR, USA) with concentration of 100 mM was added in each well and the microplate was incubated
for an additional 10 min at 37 ◦C. The intensity of dichlorofluorescin fluorescence was measured at
λex = 485 nm, and λem = 518 nm with plate reader PHERAstar FS (BMG Labtech, Ortenberg, Germany).
The data were processed by MARS Data Analysis v. 3.01R2 (BMG Labtech, Ortenberg, Germany).
In other experiments, cells were incubated with compounds during 1 h. Then, 6-OHDA (50 μM) was
added in each well for 30 min and ROS levels were measured. All obtained results were presented as
percent of negative control data.
4. Conclusions
A sponge Inflatella sp. contains a variety of oxysterols differing from each other in positions of
additional hydroxy or oxo groups of their tetracyclic core and in structures of side chains. Fourteen
oxidized sterols, including four previously unknown compounds, were isolated. Structures of new
oxysterols have been established. Previously known compounds were structurally identified by
comparison of their NMR and MS spectra with those reported in literature. All of the obtained
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compounds were studied in the 6-hydroxydopamine-induced cell model of Parkinson’s disease. At
least, one new oxysterol, (22E)-24-nor-cholesta-5,22-diene-3β,7β-diol (4), showed a substantial activity
in this test and might be used for the further studies as a drug candidate.
Supplementary Materials: 1H and 13C spectra of new compounds 1–4 are available online at http://www.mdpi.
com/1660-3397/16/11/458/s1, Figure S1: Experimental Section, Figure S2: HRESI MS Spectra (Positive Ion
Mode) of compounds 1–4 in CDCl3, Figure S3: 1H NMR (500.13 MHz) spectrum of 1 in CDCl3, Figure S4: 13C
NMR (125.76 MHz) spectrum of 1 in CDCl3, Figure S5: COSY NMR (700.13 MHz) spectrum of 1 in CDCl3, Figure
S6: ROESY NMR (500.13 MHz) spectrum of 1 in CDCl3, Figure S7: HSQC NMR (700.13 MHz) spectrum of 1 in
CDCl3, Figure S8: 1H NMR (700.13 MHz) spectrum of 2 in CDCl3, Figure S9: 13C NMR (125.76 MHz) spectrum
of 2 in CDCl3, Figure S10: COSY NMR (700.13 MHz) spectrum of 2 in CDCl3, Figure S11: ROESY NMR (700.13
MHz) spectrum of 2 in CDCl3, Figure S12: HSQC NMR (700.13 MHz) spectrum of 2 in CDCl3, Figure S13: 1H
NMR (700.13 MHz) spectrum of 3 in CDCl3, Figure S14: 13C NMR (176.04 MHz) spectrum of 3 in CDCl3, Figure
S15: COSY NMR (700.13 MHz) spectrum of 3 in CDCl3, Figure S16: ROESY NMR (700.13 MHz) spectrum of 3 in
CDCl3, Figure S17: HSQC NMR (700.13 MHz) spectrum of 3 in CDCl3, Figure S18: HMBC NMR (700.13 MHz)
spectrum of 3 in CDCl3, Figure S19: 1H NMR (500.13 MHz) spectrum of 4 in CDCl3, Figure S20: 13C NMR (125.76
MHz) spectrum of 4 in CDCl3, Figure S21: COSY NMR (500.13 MHz) spectrum of 4 in CDCl3, Figure S22: ROESY
NMR (500.13 MHz) spectrum of 4 in CDCl3, Figure S23: HSQC NMR (500.13 MHz) spectrum of 4 in CDCl3,
S24: HSQC NMR (500.13 MHz) spectrum of 4 in CDCl3, Figure S25: Viability of Neuro2a cells, Figure S26 ROS
formation in Neuro2a cells, Figure S27: Viability of Neuro2a cells treated with 6-OHDA.
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Abstract: A new melatonin analogue 6-hydroxy-N-acetyl-β-oxotryptamine (1) was isolated from
the marine-derived fungus Penicillium sp. KMM 4672. It is the second case of melatonin-related
compounds isolation from microfilamentous fungi. The neuroprotective activities of this metabolite,
as well as 3-methylorsellinic acid (2) and 8-methoxy-3,5-dimethylisochroman-6-ol (3) from
Penicillium sp. KMM 4672, candidusin A (4) and 4”-dehydroxycandidusin A (5) from Aspergillus sp.
KMM 4676, and diketopiperazine mactanamide (6) from Aspergillus flocculosus, were investigated
in the 6-hydroxydopamine (6-OHDA)- and paraquat (PQ)-induced Parkinson’s disease (PD) cell
models. All of them protected Neuro2a cells against the damaging influence of 6-OHDA to varying
degrees. This effect may be realized via a reactive oxygen species (ROS) scavenging pathway. The
new melatonin analogue more effectively protected Neuro2A cells against the 6-OHDA-induced
neuronal death, in comparison with melatonin, as well as against the PQ-induced neurotoxicity.
Dehydroxylation at C-3” and C-4” significantly increased free radical scavenging and neuroprotective
activity of candidusin-related p-terphenyl polyketides in both the 6-OHDA- and PQ-induced
PD models.
Keywords: neuroprotective activity; Parkinson’s disease; ROS; DPPH-scavenging activity; 6-OHDA;
paraquat; marine fungal metabolites
1. Introduction
Currently, Parkinson’s disease is one of the most common age-related motoric neurodegenerative
diseases, regardless of countries and regions. This disease is characterized clinically by resting
tremor, bradykinesia, rigidity, and postural instability, that significantly worsen the life quality of
patients [1]. Pathogenesis of PD includes neuronal death as a result of oxidative stress involving the
increase in the intracellular level of reactive oxygen species (ROS) and reactive nitrogen species. The
hyperproduction of ROS may cause several forms of cell damage, such as increasing DNA damage,
lipid, and protein peroxidation which can promote mitochondrial injury. In addition, some of the
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studies show that ROS can cause mitochondrial dysfunction and activation of apoptosis-related
death signaling, which lead to neuronal cell death. These findings show the requirement of using
antioxidants as a therapeutic intervention in PD in addition to other protective agents [2]. To
estimate the antioxidative properties of neuroprotective agents, both cell-free and cell assays may
be used. One of the most popular cell-free tests in natural product antioxidant studies is the
2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging assay [3]. A widely used cell test
is ROS level determination using 2′,7′-dichlorofluorescin diacetate, that is deesterified intracellularly,
and turns into the highly fluorescent 2′,7′-dichlorofluorescein upon oxidation [4].
PD etiology may be linked to several factors, including genetic susceptibility and environmental
elements. Regarding environmental factors, several dopaminergic neurotoxins, including
6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), have been
identified. Moreover, some pesticides/herbicides, such as rotenone, paraquat (PQ), maneb (MB), and
mancozeb (MZ), cause neurotoxicity, and induce a PD-like pathology. As a result, 6-OHDA and MPTP
are common models used in PD research, and pesticide-based approaches have become secondary
models of study [5,6].
It is known that marine fungi produce polyketides with antioxidant and neuroprotective
properties [7–9]. For example, gentisyl derivatives aspergentisyls A and B, and auroglaucin-related
compounds from the marine-derived Aspergillus glaucus exhibited a strong radical-scavenging activity
in DPPH test, with an IC50 of 7.6–24.2 μM [7]. Terrestrol G, a dimeric derivative of gentisyl alcohol
from the marine sediment-derived fungus Penicillium terrestre, exhibited DPPH-scavenging properties
with an IC50 of 4.1 μM [10].
Diketopiperazines are widespread marine fungal products with different biological activities,
including free radical scavenging and neuroprotection [11,12]. Gliotoxin from Pseudallescheria sp.,
neoechinulin E, and cryptoechinulin D, exhibited DPPH scavenger activity with IC50 values of 5.2,
46.0, and 23.6 μM, respectively [13,14]. Neoechinulin A from Eurotium rubrum protected PC12 cells
from the cytotoxic influence of MPTP neurotoxin [15].
Some other metabolites of marine fungi also show a neuroprotective effect in the in vitro and
in vivo models of Parkinson’s disease [16]. Xyloketal B, from Xylaria sp., scavenged free radicals
in DPPH assay, and protected PC12 cells against ischemia-induced cell injury and MPTP-induced
neurotoxicity [17]. About 40 synthetic derivatives of xyloketal B were investigated in various in vivo
Parkinson’s models, and some of them showed significant activities [18]. Secalonic acid A from
Aspergillus ochraceus and Paecilomyces sp. protected against MPTP-induced dopaminergic neuronal cell
death in mouse PD model, in nigral neurons, and SH-SY5Y cells [19].
In this paper, we described the isolation and identification of new alkaloid and known
polyketides from the marine fungus Penicillium sp. KMM 4672, known diketopiperazine alkaloid from
Aspergillus flocculosus, polyketides reported earlier from Aspergillus sp. KMM 4676, as well as free
radical scavenging and neuroprotective activities of these compounds in two cell models of Parkinson’s
disease induced by 6-hydroxydopamine and paraquat.
2. Results and Discussion
2.1. Isolation and Identification of Compounds
Recently, we have found new natural compounds whose structures have not been established,
possibly due to their insufficient content, along with several new and known compounds from a
marine algicolous fungus Penicillium sp. KMM 4672 [20,21]. A repeated cultivation of this fungus, in
the same conditions, was carried out to obtain a sufficient amount of unidentified compounds. As a
result, these compounds were identified as new melatonin derivative (1), known o-orsellinic acid (2)
and isochromene (3) derivatives (Figure 1).
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Figure 1. The structures of investigated compounds.
6-Hydroxy-N-acetyl-β-oxotryptamine (1) was isolated as a white solid. An (–)HRESIMS spectrum
(Figure S8) of compound 1 contains a [M−H]– pseudomolecular peak at m/z 231.0772, which indicated
a molecular formula of C12H12N2O3 (calcd for C12H11N2O3,231.0775), which corresponded to six
double-bond equivalents. A careful inspection of NMR data of 1 (Table 1 and Figures S1–S7) revealed
the presence of one acetyl methyl, one methylene, four sp2-methines, four quaternary sp2-carbons, one
keto-group, and one amide carbonyl. In addition, the 1H NMR spectrum contains the signal of three
heteroatom protons. The coupling constant values of NH-1 (δH 11.55, d, J = 2.9 Hz), H-2 (δH 8.17, d,
J = 2.9 Hz), H-4 (δH 7.89, d, J = 8.6 Hz), H-5 (δH 6.68, dd, J = 8.6, 1.7 Hz), and H-7 (δH 6.80, d, J = 1.7 Hz),
together with the HMBC correlations from NH-1 to C-3a (δC 118.3), from H-2 to C-3a and C-7a (δC
137.6), from H-4 to C-3 (δC 114.1), C-6 (δC 154.0) and C-7a, from H-5 to C-3a and C-7 (δC 97.1), from H-7
to C-3a and C-5, and from 6-OH (δH 9.14) to C-5, C-6, and C-7, established the indole moiety with OH
group at C-6. This suggestion was additionally proved by ROESY correlation H-1/H-7. The HMBCs
from methylene H-2′ (δH 4.38) to C-1′ (δC 189.9) and C-4′ (δC 169.3), from H-3′ (δH 8.06) to C-4′, and from
H-5′ (δH 1.90) to C-4′ showed the side chain structure. The location of the side chain at C-3 was revealed
by the ROESYs of H-2′ with H-2 and H-4. Thus, the structure of 1 was elucidated to be very close to that
of known N-acetyl-β-oxotryptamine [22]. Similar melatonin-like compounds are usually isolated from
several bacterial species [23,24]. Recently, N-acetyl-β-oxotryptamine was reported from the medicinal
basidiomycete Inonotus vaninii [25], and from ascomycete Scopulariopsis sp. [26]. To our knowledge,
this study is the second case of isolation of related compounds from microfilamentous fungi.
Table 1. 1H and13C NMR data (700/176 MHz, δ in ppm, DMSO-d6) for 6-hydroxy-N-acetyl-
β-oxotryptamine (1).
Position δC, mult δH (J in Hz)
1(NH) 11.55, d (2.9)
2 131.9, CH 8.17, d (2.9)
3 114.1, C
3a 118.3, C
4 121.5, CH 7.89, d 8.6)
5 111.9, CH 6.68, dd (8.6, 1.7)
6 154.0, C
7 97.1, CH 6.80, d (1.7)
7a 137.6, C
1′ 189.9, C
2′ 45.4, CH2 4.38, d (5.6)
3′(NH) 8.06, d (5.6)
4′ 169.3, C
5′ 22.4, CH3 1.90, s
6-OH 9.14, s
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Together with melatonin-related 1, the well-known fungal polyketides 3-methylorsellinic acid (2)
and 8-methoxy-3,5-dimethylisochroman-6-ol(3) were isolated from this fungus. Their structures were
identified by comparing the NMR and MS data (Figures S9–S13) with previously reported data [27,28].
The chemical composition of extract of an ascidian-derived fungus Aspergillus sp. KMM 4676 was
reported earlier [29,30]. p-Terphenyl polyketides, candidusin A (4) and 4”-dehydroxycandidusin A (5),
were major metabolites of this fungus.
The 2,5-diketopiperazine alkaloid mactanamide (6) was isolated from the Vietnamese
sediment-derived fungus Aspergillus flocculosus. The NMR data (Figures S14 and S15) for this
compound were identical with earlier published data [31]. It is only the third case of isolation
this compound.
2.2. Biological Activities of the Studied Compounds
2.2.1. 6-Hydroxy-N-acetyl-β-oxotryptamine (1)
6-Hydroxy-N-acetyl-β-oxotryptamine (1) was not cytotoxic against neuroblastoma Neuro2a cell
up to 100 μM. This compound scavenged DPPH radicals by 48% at 100 μM (Table 2).
Table 2. Radical scavenging and cytotoxicity activities of compounds 1–6.
Compounds
DPPH Radical Scavenging Cytotoxicity
% at 100 μM EC50, μM IC50, μM
1 51.9 ± 1.3 - >100
2 88.9 ± 2.9 - >100
3 62.0 ± 4.6 [16] - >100
4 67.8 ± 1.1 - 75.7 ± 5.6
5 50.6 ± 1.3 101.3 ± 2.8 78.9 ± 1.9
6 83.5 ± 0.2 - >100
Melatonin-like compound 1 showed a statistically significant reduction of reactive oxygen species
(ROS) level on 18% in the neuronal 6-OHDA-treated cells in the in vitro experiment (Figure 2).
Melatonin (1a), a well-known antioxidant and neuroprotective compound, was used to compare
with 1. It decreased ROS formation in the 6-OHDA-treated neuronal cell stronger in comparison
with 1.
Figure 2. Influence of compounds 1–6 on reactive oxygen species (ROS) formation in Neuro2a cells
treated with 6-hydroxydopamine (6-OHDA) for 30 min. * Difference between data for compounds and
for 6-OHDA was statistically significant with p ≤ 0.05.
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The neuroprotective effect of 1 was shown both in the Neuro2a cells treated 1 h before, as well as 1
h after, adding of 6-OHDA by 23% and 28%, respectively, at a concentration of only 10 μM. Melatonin
(1a) did not increase the viability of cells treated with neurotoxin in this experiment (Figure 3a). Our
experiments showed that 6-hydroxy-N-acetyl-β-oxotryptamine (1) more effectively protected Neuro2a
cells against 6-OHDA-induced neuronal death, in comparison with melatonin (1a).
Figure 3. Neuroprotective effects of compounds 1–6 on Neuro2a cells treated with 6-OHDA (50 μM).
All compounds were added to the cell suspension 1 h before treatment with 6-OHDA or 1 h after
treatment with 6-OHDA. (a) Viability of the 6-OHDA-treated cells incubated with compounds 1 and
1a at 10 μM; (b) Viability of 6-OHDA-treated cells incubated with compounds 2 and 3 at 10 μM;
(c) Viability of 6-OHDA-treated cells incubated with compounds 4 and 5 at 10 μM; (d) Viability of
the 6-OHDA-treated cells incubated with compound 6 (1 and 10 μM) * Difference between data for
compounds and for 6-OHDA was statistically significant with p ≤ 0.05.
In the PQ-induced PD model, compounds 1 and 1a (at concentration of 10 μM) were more effective
in comparison with their influence in the 6-OHDA-induced model, and decreased ROS formation in
the PQ-treated cells by 35% and 22%, respectively (Figure 4). As a result, increase of the PQ-treated
cell viability, by 40% and 24%, was observed (Figure 5).
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Figure 4. Effects of compounds 1–6 on ROS formation in Neuro2a cells treated with paraquat (PQ)
(500 μM) for 1 h. All compounds were added to the cell suspension 1 h before treatment with PQ.
* Difference between data for compounds and for PQ was statistically significant with p ≤ 0.05.
Figure 5. Neuroprotective effects of compounds 1–6 on Neuro2a cells treated with PQ (500 μM). All
compounds were added to the cell suspension 1 h before treatment with PQ. * Difference between data
for compounds and for PQ was statistically significant with p ≤ 0.05.
2.2.2. 3-O-Methylorsellinic acid (2) and 8-methoxy-3,5-dimethylisochroman-6-ol (3)
3-O-Methylorsellinic acid (2) and 8-methoxy-3,5-dimethylisochroman-6-ol (3) were not cytotoxic
against neuroblastoma Neuro2a cells up to 100 μM.
3-O-Methylorsellinic acid (2) at 100 μM scavenged 10% DPPH radicals in our experiments (Table 2).
For orsellinic acid and its derivatives, 2,20-azinobis(3-ethylbenzothiozoline-6-sulfonate cation (ABTS·+)
scavenger activities were recently reported [32]. 8-Methoxy-3,5-dimethylisochroman-6-ol (3) in DPPH
assay was not very effective; also, at 100 μM concentration, it reduced the free radical value by 35%, as
we reported earlier [33]. Nevertheless, in the 6-OHDA-treated Neuro2a cells, compounds 2 and 3 at a
concentration of 10 μM significantly decreased ROS formation by 30% and 45% respectively (Figure 2).
3-O-Methylorsellinic acid (2) statistically significantly increased 6-OHDA-treated cell viability
by 26%, when the compound was added to cells 1 h before adding 6-OHDA. When compound 2 was
added to cells 1 h after adding 6-OHDA, it had no neuroprotective effect.
8-Methoxy-3,5-dimethylisochroman-6-ol (3) statistically significantly increased the neuroblastoma
cell viability in the 6-OHDA-induced PD model by about 55%, regardless of when it was added to
cells (Figure 3b). Compounds 2 and 3 were effective at a concentration of only 10 μM.
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On the other hand, compounds 2 and 3 did not exhibit any protective effect on based on the
viability of cells treated with PQ, despite the fact that they reduced ROS formation in these cells
(Figures 4 and 5).
2.2.3. Candidusin A (4) and 4”-dehydroxycandidusin A (5)
Candidusin A (4) scavenged 32% of radicals in DPPH assay at a concentration 100 μM.
4”-Dehydroxycandidusine A (5) was more effective and scavenged 49% of radicals (Table 2).
Candidusin B (C-3” hydroxylated analogue of candidusin A) showed 59% DPPH radical scavenging at
a concentration of 100 μg/mL [34], i.e., at a molar concentration of the compound that was more than
2.7 times higher.
Earlier, candidusin A (4) showed cytotoxic activities against HL-60 (IC50 77.56 μM), A-549
(IC50 19.34 μM), and P-388 (IC50 46.83μM) tumor cells [35], while 4-dehydroxycandidusin A (5)
exhibited cytotoxic activities against KB (IC50 22.66 μM) and A 549 (IC50 34.01 μM) tumor cells [36]. In
our experiments, candidusin A (4) and 4”-dehydroxycandidusin A (5) had low cytotoxicity against
neuroblastoma Neuro2a cells with an IC50 of 75.7 and 78.9 μM, respectively (Table 2). These compounds
were used at a non-toxic concentration of 10 μM for the treatment of cells in PD models.
Candidusin A (4) did not have any effect on ROS formation in the 6-OHDA-treated cells
(Figure 2). 4”-Dehydroxycandidusin A (5) decreased the ROS level in 6-OHDA-treated cells by
34%, being more effective as a radical scavenger. Candidusin A (4) had no effect on the viability
of cells when it was added 1 h before treatment with 6-OHDA, and increased 6-OHDA-treated cell
viability by 24% at a concentration of only 10 μM, when it was added 1 h after 6-OHDA (Figure 3c).
4”-Dehydroxycandidusin A (5) increased cell viability by more than 80% (when the compound was
added 1 h before 6-OHDA) and 62% (when it was added 1 h after 6-OHDA). These effects were
observed at a concentration of 10 μM only. When the concentration of compound 5 was reduced
tenfold, its neuroprotective effect was not preserved.
In the PQ-induced model, compound 4 decreased ROS formation by 27% at a concentration of 10
μM. Compound 5 was more effective and statistically significantly decreased ROS formation by 19%
and 40%, at concentrations of 1 and 10 μM, respectively (Figure 4). Nevertheless, compound 4 did
not have any effect on the viability of the PQ-treated cells, but its 4”-dehydroxylated derivative (5)
statistically significantly increased the viability of these cells by 17% at concentration of 10 μM only
(Figure 5).
Thus, the presence of hydroxy groups at C-3” and C-4” in candidusins decreases the radical
scavenging activity of these compounds in the cell-free assay. Moreover, the hydroxylation at C-4”
results in the significant decreasing their neuroprotective effect.
2.2.4. Mactanamide (6)
Mactanamide (6) was not cytotoxic against neuroblastoma Neuro2a cells up to 100 μM.
Compound 6 scavenged 15% DPPH radicals in cell-free assays at a concentration of 100 μM
(Table 2). In cell experiments, this compound (6) demonstrated a significant antiradical effect: at 10
μM, it inhibited ROS formation in the 6-OHDA-treated neuronal cells by 30% (Figure 2).
Mactanamide (6) increased the 6-OHDA-treated cell viability by 42% at 10 μM in the
6-OHDA-induced PD model when the compound was added 1 h before neurotoxin. When its
concentration was reduced tenfold, its neuroprotective effect was preserved (Figure 3d).
In the PQ-treated cells, mactanamide (6) decreased ROS formation by 32% and 37%, at
concentrations of 1 and 10 μM, respectively (Figure 4). However, compound 6 did not show any
neuroprotective activity on the viability of the PQ-treated cells (Figure 5).
Earlier, mactanamide showed fungistatic activity against Candida albicans, and an influence on
osteoclast differentiation without any cytotoxicity [31,37]. Antioxidant and neuroprotective properties
of mactanamide were demonstrated, for the first time, in this investigation.
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Thus, compounds 1, 2, 3, and 6 were non-cytotoxic for Neuro2a cells up to a concentration
of 100 μM. Compounds 4 and 5 demonstrated low cytotoxicity with an IC50 of 75.7 and 78.9 μM,
respectively. This allowed investigating the neuroprotective activity of all compounds in non-toxic
concentrations of 1 and 10 μM. Neuroprotective effects of the compounds were studied in two PD
in vitro models using 6-OHDA and PQ as inducers of neuronal cell damage.
Melatonin-like compound 1 demonstrated an effect in increasing cell viability in both models,
but the effect on PQ-treated cells was more pronounced. In both cases, neuroprotective effects were
accompanied with a decrease of ROS formation in the 6-OHDA- and PQ-treated cells. Melatonin
(1a) decreased ROS formation in both PD models, but it increased cell viability in the PQ-induced
model only.
Polyketides 2 and 3 demonstrated ROS-decreasing effects in both PD models. Nevertheless, these
compounds increased cell viability in the 6-OHDA-induced model only.
Candidusin A (4) and 4”-dehydrocandidusin A (5) have minimal differences between their
chemical structures but this has a significant effect on their neuroprotective activity. In the 6-OHDA
and PQ models, compound 5 produced a significant increase of cell viability, whereas compound 4 did
not demonstrate any effect in the PQ model, and low increased cell viability on the 6-OHDA-treated
cells. A similar influence of both compounds on ROS formation in the 6-OHDA- and PQ-treated cells
was observed. Compound 4 had no significant effect on ROS formation in the 6-OHDA-treated cells,
and decreased ROS formation in the PQ-treated cells, at a concentration of only 10 μM. By contrast,
compound 5 was very effective in the 6-OHDA-induced PD model, and decreased ROS formation in
the PQ-treated cells at concentrations 1 and 10 μM.
Mactanamide (6) demonstrated a significant decrease of ROS formation in both the 6-OHDA-
and PQ-induced PD models. However, this 2,5-diketopiperasine alkaloid increased viability of the
6-OHDA-treated cells only, and did not have any statistically significant effects on viability of the
PQ-treated cells.
It should be noted that DPPH radical scavenging activity was shown for all compounds in varying
degrees, and decreasing of ROS formation in 6-OHDA- and PQ-treated cells could be the result of
radical scavenging by these compounds. However, differences between the effects of these compounds,
on ROS formation and cell viability in different PD models, were observed.
In our investigation, two PD-like cell models, induced by neurotoxin 6-OHDA and pesticide
paraquat, were used. Neurotoxins and pesticides share a common mechanism to induce damage to
dopaminergic neurons that is correlated with an increased oxidative status caused by high levels of
ROS, anions, and free radicals [6]. However, the effect of each of the inducers, on neurons, has the
same differences.
6-OHDA has a specific neurotoxic effect on neurons containing dopamine, serotonin, and
norepinephrine receptors. The structure of 6-OHDA is similar to dopamine and norepinephrine,
and, therefore, this neurotoxin uses the same catecholaminergic transport system (the dopamine and
norepinephrine transporters), and causes specific degeneration of dopaminergic and noradrenergic
neurons [6]. Inside neurons, 6-OHDA is rapidly autooxidized to hydrogen peroxide and paraquinone,
which are both highly toxic to mitochondria, by specifically affecting complex I. This process results
in an increase of ROS generation and cell death [38]. Moreover, it was reported that 6-OHDA
induces oxidative stress both during its autoxidation to p-quinone and, also, during one-electron
reduction of p-quinone to p-semiquinone, catalyzed by flavoenzymes that transfer one electron [39]. In
addition to these effects, 6-OHDA-induced cell death is dependent of such intracellular processes as
neuroinflammation, mitochondria dysfunction, endoplasmic reticulum stress, and autophagy [40].
Paraquat causes oxidative stress in neuronal cells by another pathway. Divalent paraquat
ion (PQ2+) is reduced to monovalent paraquat ion (PQ+) by NADPH-oxidase of mitochondrial
complex I. Subsequently, PQ+ accumulates in dopaminergic neurons and reestablishes a new redox
reaction intracellularly, leading to the generation of intracellular free radicals, such as superoxide and
dopamine-reactive substances. This will eventually lead to dopaminergic neuron cell death [41].
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Moreover, PQ toxicity correlates with DNA fragmentation, caspase-3 cascade modulation, and
dysregulation of autophagy [5,42].
Metabolic investigations of the molecular mechanisms associated with 6-OHDA and PQ toxicity
were carried out by NMR spectroscopy and mass spectrometry. It was shown that PQ selectively
upregulated the pentose phosphate pathway (PPP) to increase NADPH reducing equivalents, and
stimulate paraquat redox cycling, oxidative stress, and cell death. PQ also stimulated an increasing
in glucose uptake, the translocation of glucose transporters to the plasma membrane, and adenosine
monophosphate-activated protein kinase activation. In the contract, 6-OHDA did not demonstrate
an influence on PPP. In addition, while paraquat induced a reduction in glucose-dependent
glutamate-derived glutathione synthesis, 6-OHDA treatment increased this process [43,44].
In this study, we observed time differences between 6-OHDA and PQ effects on ROS formation in
Neuro2a cells (Figure S16). 6-OHDA caused an increase of ROS level of 30% for 30 min after addition to
the cell suspension. The effect of PQ on ROS formation was insignificant after 30 min, and an increase
of ROS levels in cells, by 39%, was observed 1 h after adding of PQ to the cell suspension.
Compounds 2, 3, and 6 demonstrated neuroprotective effects in the 6-OHDA-induced PD model
only. For this reason, they could protect Neuro2a cells against the damaging influence of products of
6-OHDA autooxidation, due to their antioxidant properties. Compound 5 increased the viability of
6-OHDA-treated cells by 80%, but it increased viability of PQ-treated cells by 17% only. This suggests
the same mechanism of action.
On the other hand, compounds 1 and 1a were more effective in the PQ-induced model, and
increased cell viability by 40% and 24%, respectively, whereas in the 6-OHDA-induced model,
compound 1 increased cell viability by 23% only, and melatonin (1a) was ineffective.
It was earlier published that melatonin and some related compounds demonstrated antioxidant
activity in cell-free assays [45], and different neuroprotective effects in the in vitro experiments [46–48].
Pre-treating of PC12 cells with melatonin for 3 h increased viability of the cells, and prevented apoptosis
in the 6-OHDA-induced PD model [49,50]. In addition, it was reported that melatonin diminished
caspase-3 enzyme activity, cleavage of DNA fragmentation factor 45, and DNA fragmentation observed
in the MPTP-treated neuroblastoma cells [46]. For this reason, melatonin-related compound 1 could
influence on viability of the PQ-treated cells in a similar manner.
3. Materials and Methods
3.1. General Experimental Procedures
NMR spectra were recorded in DMSO-d6 and acetone-d6 on a Bruker DPX-500 and DRX-700
(Bruker BioSpin GmbH, Rheinstetten, Germany) spectrometers, using TMS as an internal standard.
HRESIMS spectra were measured on a Maxis impact mass spectrometer (Bruker Daltonics GmbH,
Rheinstetten, Germany).
Low-pressure liquid column chromatography was performed using silica gel (50/100 μm, Imid
Ltd., Krasnodar, Russia). Plates (4.5 cm × 6.0 cm) precoated with silica gel (5–17 μm, Imid Ltd.,
Krasnodar, Russia) were used for thin-layer chromatography. Preparative HPLC was carried out
on a Shimadzu LC-20 chromatograph (Shimadzu USA Manufacturing, Canby, OR, USA) with a
Shimadzu RID-20A refractometer (Shimadzu Corporation, Kyoto, Japan) using a YMC ODS-AM (YMC
Co., Ishikawa, Japan) (5 μm, 10 mm × 250 mm) and YMC SIL (YMC Co., Ishikawa, Japan) (5 μm,
10 mm × 250 mm) columns.
Melatonin (1a) was purchased from «JSC «PE «Obolenskoe» (Obolensk, Russia).
3.2. Fungal Strain
The strain Penicillium sp. KMM 4672 was isolated from brown alga Padina sp. (Van Phong Bay,
South China Sea, Vietnam) on malt extract agar, and identified on the basis of morphological and
molecular features, as described earlier [20].
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The strain Aspergillus sp. KMM 4676 was isolated from an unidentified colonial ascidian (Shikotan
Island, Pacific Ocean) on malt extract agar, and identified on the basis of morphological and molecular
features as described earlier [30].
The strain Aspergillus flocculosus was isolated from a sediment sample (Nha Trang Bay, South
China Sea, Vietnam) by inoculating on modified Sabouraud medium (peptone 10 g, glucose 20 g,
agar 18 g, natural sea water 1000 mL, penicillin 1.5 g, streptomycin 1.5 g, pH 6.0–7.0). The fungus
was identified according to a molecular biological protocol by DNA amplification and sequencing
of the ITS region (GenBank accession number MH101466.1). BLAST search results indicated that the
sequence was 100% identical (796/796 bp) with the sequence of Aspergillus flocculosus strain NRRL
5224 (GenBank accession number EU021616.1).
3.3. Cultivation of Fungus
All the fungal strains were cultured at room temperature for three weeks in 500 mL Erlenmeyer
flasks, each containing rice (20.0 g), yeast extract (20.0 mg), KH2PO4 (10 mg), and natural sea water
(40 mL).
3.4. Extraction and Isolation
The main part of the isolation procedures of compounds from Penicillium sp. KMM 4672 was
described in a previous paper [20]. The n-hexane–EtOAc (95:5, 74.0 mg) fraction was purified by LH-20
column (80 cm × 2 cm) with CHCI3 to yield 2 (12.5 mg) and 3 (14.3 mg). The n-hexane–EtOAc (40:60,
54.0 mg) fraction was purified by HPLC on a YMC ODS-AM column, eluting with MeOH–H2O (65:35),
and then by HPLC on a YMC SIL column, eluting with MeOH–CHCl3 (5:95) to yield 1 (1.9 mg).
The main part of isolation procedures of compounds from Aspergillus sp. KMM 4676 were
described in a previous paper [30]. The n-hexane–EtOAc (80:20, 59.4 mg) fraction was purified
by HPLC on a YMC ODS-AM column, eluting with MeOH–H2O (65:35) to yield 5 (3.45 mg).
Another n-hexane–EtOAc (80:20, 157.7 mg) fraction was purified by HPLC on a YMC ODS-AM
column, eluting with MeOH–H2O (65:35), and then by HPLC on a YMC SIL column, eluting with
MeOH–CHCl3–NH4Ac (10:90:1) to yield 4 (6.74 mg).
The fungal mycelia of Aspergillus flocculosus with the medium were extracted for 24 h with
15 L of EtOAc. Evaporation of the solvent, under reduced pressure, gave a dark brown oil (5.0 g),
to which 250 mL H2O–EtOH (4:1) was added, and the mixture was thoroughly stirred to yield a
suspension. It was extracted, successively, with hexane (150 mL × 2), EtOAc (150 mL × 2), and
n-BuOH (150 mL × 2). After evaporation of the EtOAc layer, the residual materials (3.36 g) were
passed over a silica gel column (35.0 cm × 2.5 cm), which was eluted with a hexane–EtOAc gradient
(1:0–0:1). The n-hexane–EtOAc (75:25, 41.4 mg) fraction was purified by HPLC on a YMC SIL column,
eluting with MeOH–CHCl3-NH4Ac (97:3:1), and then by HPLC on a YMC ODS-AM column, eluting
with MeOH–H2O (75:25) to yield 6 (24.1 mg).
6-Hydroxy-N-acetyl-β-oxotryptamine (1): white powder; 1H and 13C NMR data see Table 1,
Figures S1–S7; HR ESIMS m/z 231.0772 [M−H]– (calcd for C12H11N2O3, 231.0775, Δ + 1.4 ppm)
(Figure S8).
3.5. Biological Activity of Compounds
3.5.1. Radical Scavenger Assay
DPPH radical scavenging activity of compounds was tested as described [51].
Compounds were dissolved in MeOH, and the solutions (160 μL) were dispensed into wells of a
96-well microplate. In all, 40 μL of the DPPH (Sigma-Aldrich, Steinheim, Germany) solution in MeOH
(1.5 × 10−4 M) was added to each well. Concentrations of compounds in mixture were 10 and 100 μM.
The mixture was shaken and left to stand for 30 min, and the absorbance of the resulting solution was
measured at 520 nm with a microplate reader MultiscanFC (ThermoScientific, Waltham, MA, USA).
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Radical scavenging activity of all compounds at 100 μM were presented as percent of MeOH data, and
the concentration of DPPH radical scavenging at 50% (EC50) was calculated for some compounds.
3.5.2. Cell Line and Culture Condition
The neuroblastoma cell line Neuro2a was purchased from ATCC. Cells were cultured in
DMEM medium containing 10% fetal bovine serum (Biolot, St. Petersburg, Russia) and 1%
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Cells were incubated at 37 ◦C in a humidified
atmosphere containing 5% (v/v) CO2.
3.5.3. Cell Viability Assay
Cell suspension (1 × 103 cells/well) was incubated with different concentration of compounds
for 24 h. After that, cell viability was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) method, according to the manufacturer’s instructions (Sigma-Aldrich,
St. Louis, MO, USA). The results were presented as percent of control data, and concentration required
for 50% inhibition of cell viability (IC50) was calculated.
3.5.4. 6-Hydroxydopamine-Induced In Vitro Model of Parkinson’s Disease
The neuroprotective activities of compounds in 6-hydroxydopamine-induced cell model of
Parkinson’s disease were examined, as described previously [52].
Neuroblastoma Neuro2a line cells (1 × 103 cells/well) were treated with 50 μM of
6-hydroxydopamine (Sigma-Aldrich, St. Louis, MO, USA) for 1 h and, after that, the investigated
compounds were added to the neuroblastoma cell suspension at a concentration of 1 and 10 μM. In
the other case, the substances were added to the cells 1 h before the addition of the neurotoxin. Cells
incubated without 6-OHDA and compounds, and with 6-OHDA only, were used as positive and
negative controls, respectively. After 24 h, viability of cells was measured using the MTT method. The
results were presented as a percent of positive control data.
3.5.5. Paraquat-Induced In Vitro Model of Parkinson’s Disease
Neuroblastoma Neuro2a line cells (1 × 103 cells/well) were treated with compounds at
concentrations of 1 and 10 μM for 1 h, and then 500 μM of paraquat (Sigma-Aldrich, St. Louis,
MO, USA) was added to the neuroblastoma cell suspension. Cells incubated without paraquat and
compounds, and with paraquat only, were used as positive and negative controls, respectively. The
viability of cells was measured after 24 h using the MTT method. The results were presented as percent
of positive control data.
3.5.6. Reactive Oxygen Species (ROS) Level Analysis in 6-OHDA- and PQ-Treated Cells
Cell suspensions (1 × 103 cells/well) were incubated with compound solutions (10 μM) for
1 h. Then, 6-OHDA at a concentration of 50 μM was added in each well, and cells were incubated
for 30 min. In other experiments, cells were incubated with PQ at a concentration of 500 μM for
30 min and 1 h. Cells incubated without 6-OHDA/PQ and compounds, and with 6-OHDA/PQ
only, were used as positive and negative controls, respectively. To study ROS formation, 20 μL of
2,7-dichlorodihydrofluorescein diacetate solution (Molecular Probes, Eugene, OR, USA) was added
to each well, such that the final concentration was 10 mM, and the microplate was incubated for an
additional 10 min at 37 ◦C. The intensity of dichlorofluorescein fluorescence was measured with plate
reader PHERAstar FS (BMG Labtech, Ortenberg, Germany) at λex = 485 nm, and λem = 518 nm. The
data were processed by MARS Data Analysis v. 3.01R2 (BMG Labtech, Ortenberg, Germany). The
results were presented as a percentage of positive control data.
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4. Conclusions
This study is the second case of isolation of melatonin-related compound from microfilamentous
fungi. The neuroprotective activity in the 6-OHDA- and PQ-induced PD cell models of this
and some other polyketides and alkaloids from marine-derived fungi were investigated. All of
them protected Neuro2a cells against the damaging influence of 6-OHDA to varying degrees.
We suppose that this effect is realized via a ROS scavenging pathway as one of the possibilities.
The new melatonin analogue, 6-hydroxy-N-acetyl-β-oxotryptamine, protected Neuro2A cells more
effectively against the 6-OHDA-induced neuronal death in comparison with melatonin. Moreover,
6-hydroxy-N-acetyl-β-oxotryptamine and melatonin protected Neuro2a cells against the damaging
influence of PQ in a similar manner. It was shown that dehydroxylation at C-3” and C-4”significantly
increases free radical scavenging and neuroprotective activity of candidusin-related p-terphenyl
polyketides in both the 6-OHDA- and PQ-induced PD models.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/11/457/
s1, Figures S1–S15. The NMR and mass spectra of compounds 1–3 and 6. Figure S16. ROS formation in the
6-OHDA- and PQ-treated Neuro2a cells.
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Abstract: Death-associated protein kinase 1 (DAPK1) expression induced by diverse death stimuli
mediates apoptotic activity in various cancers, including ovarian cancer. In addition, mutual
interaction between the tumor suppressor p53 and DAPK1 influences survival and death in several
cancer cell lines. However, the exact role and connection of DAPK1 and p53 family proteins (p53,
p63, and p73) in drug-resistant ovarian cancer cells have not been studied previously. In this study,
we investigated whether DAPK1 induction by gliotoxin derived from marine fungus regulates the
level of transcriptionally active p63 (TAp63) to promote apoptosis in an autophagy-dependent manner.
Pre-exposure of paclitaxel-resistant ovarian cancer cells to gliotoxin inhibited the expression of
multidrug resistant-associated proteins (MDR1 and MRP1-3), disrupted the mitochondrial membrane
potential, and induced caspase-dependent apoptosis through autophagy induction after subsequent
treatment with paclitaxel. Gene silencing of DAPK1 prevented TAp63-mediated downregulation
of MDR1 and MRP1-3 and autophagic cell death after sequential treatment with gliotoxin and then
paclitaxel. However, pretreatment with 3-methyladenine (3-MA), an autophagy inhibitor, had no effect
on the levels of DAPK1 and TAp63 or on the inhibition of MDR1 and MRP1-3. These results suggest
that DAPK1-mediated TAp63 upregulation is one of the critical pathways that induce apoptosis in
chemoresistant cancer cells.
Keywords: gliotoxin; DAPK1; TAp63; autophagy; drug resistance; ovarian cancer
1. Introduction
Death-associated protein kinase-1 (DAPK1) is a Ca2+/calmodulin (CaM)-regulated serine/threonine
kinase that mediates cell death [1]. Downregulation of DAPK1 by methylation in its promoter
region is detected in various cancers, including pancreas, lung, and head and neck. Low DAPK1
expression in these tumors is closely related to frequent lymph node metastasis and poor clinical
outcomes [2–4]. Overexpression or activation of DAPK1, as a tumor suppressor, is involved in cell
death. Ectopic DAPK expression induces p53-dependent apoptosis in mouse embryo fibroblasts [5],
and tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) induce DAPK1 expression
through inhibiting NF-κB activity [6]. DAPK1 activation not only requires cell cycle arrest and
caspase-dependent apoptosis [7] but also contributes to autophagic cell death by reducing the interaction
between Beclin-1 and Bcl-2 and Bcl-XL [8]. Furthermore, DAPK-1 induces caspase-independent cell
death through activating autophagosome formation [9]. However, DAPK1 sometimes antagonizes
apoptosis in a cell-type-dependent manner. DAPK1 depletion using antisense DAPK1 cDNA promotes
caspase-mediated apoptosis via TNF [10], and DAPK1 plays an essential role in the proliferation of
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p53-mutant estrogen receptor-negative breast cancer cells [11]. These results demonstrate that the role
and molecular mechanism of DAPK1 in human cancers are not clearly understood.
Tumor suppressor p53 expression responds to various types of cellular damage and stress,
including oncogenic stimuli [12,13]. Cells expressing wild-type p53 experience DAPK1 upregulation
after stimulation with anticancer drugs or UV exposure [14]. In contrast, DAPK1 overexpression
promotes p53 expression, resulting in the suppression of oncogenic transformation [5]. p53 mutations
that reduce or abolish its function are closely associated with anticancer drug resistance in various
cancers [15,16], whereas mutant p53 occurrence in ovarian cancer has no effect on apoptotic death
induced by paclitaxel [17]. Ovarian cancer co-expressing p53 and Bcl-2 has been shown to have the best
response to paclitaxel chemotherapy [18]. These contradictory results suggest that p53 and DAPK1
influence several different molecular pathways to induce cancer cell death, and the mutual relationship
between DAPK1 and p53 is dependent on cell type and cell conditions.
The p53 family is composed of three homologous proteins, p53, p63, and p73. These proteins
share essential structural domains and have similar cellular functions in proliferation, differentiation,
tumorigenesis, and death [19,20]. Transcriptionally active p63 (TAp63), a p53 isoform, plays a
critical role in not only intracellular fatty acid generation [21] but also tumor suppression [22] and
metastasis prevention [23]. We have previously reported that TAp63 activation induces apoptosis in
Epstein-Barr virus (EBV)-transformed B cells after treatment with baicalein [24], and TAp63 expression
in TLR4-stimulated colon cancer cells promotes fatty acid-mediated metastasis [25]. However, the
precise relationship between DAPK1 and TAp63 in modulating apoptosis in cancer is unclear, and the
autophagy-related signaling pathway regulated by TAp63 in cancer needs to be investigated.
Gliotoxin, a secondary metabolite of marine fungus Aspergillus fumigatus, is not only a member of
the epipolythiodioxopiperazine family but also characterized by a disulfide bond across a piperazine
ring and an aromatic amino acid [26,27]. Treatment with gliotoxin of mouse immune cells inhibits
nuclear factor kappa B (NF-κB), resulting in the downregulation of inflammatory genes activation [28].
Reactive oxygen species (ROS) induced by gliotoxin contribute to suppression of NF-κB, leading to
the apoptosis of human fibrosarcoma cell line (HT1080) [29]. Gliotoxin induces apoptosis in various
human cancers cells, including uterine cervix cancer cell line (Hela), chondrosarcoma cell line (SW1353),
chronic lymphocytic leukemia cell, and breast cancer cell line (MCF-7) [30–32]. Recently, it has been
reported that gliotoxin treatment induces apoptotic death in doxorubicin-resistant lung cancer cells
through disrupting mitochondrial function and activating p53 downstream target molecules [33].
However, the expression and specific role of DAPK1 in ovarian and paclitaxel-resistant ovarian
cancer cells after treatment with gliotoxin have not been studied. In this study, we investigated
whether DAPK1 regulates apoptotic death in paclitaxel-resistant ovarian cancer cells and examined the
relationship between DAPK1 and p53 family proteins in inducing autophagic cell death after treatment
with gliotoxin.
2. Results
2.1. Treatment with Gliotoxin Suppresses Growth and Reduces Resistance in Paclitaxel-Resistant Ovarian
Cancer Cells
We first determined the 50% inhibitory concentration (IC50) value of paclitaxel in ovarian cancer
cells using Cell Counting Kit-8 (CCK-8) assays as described in the Methods section. The IC50 values of
paclitaxel in CaOV3 and SKOV3 cells were 2.71 ± 0.01 nM and 5.15 ± 0.02 nM, respectively, at 48 h.
Established paclitaxel-resistant ovarian cancer cells showed profound morphological differences
compared to parental cell lines under microscope observation (Supplemental Figure S1A). Additionally,
paclitaxel-resistant CaOV3 cells (CaOV3/PTX_R) and SKOV3 cells (SKOV3/PTX_R) sustained their
proliferation rates after exposure to a high dose (100 nM) of paclitaxel (Supplemental Figure S1B).
We next investigated whether treating chemoresistant ovarian cancer cells with gliotoxin prevents
cell growth and induces apoptosis. Chemoresistant ovarian cancer cells not only upregulated
multidrug resistant-associated proteins (MDR1 and MRP1-3) but also induced the expression of
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anti-apoptotic proteins, including X-linked inhibitor of apoptosis protein (XIAP), and cell survival
(Figure 1A). Although exposure to gliotoxin slightly prevented the proliferation of CaOV3/PTX_R and
SKOV3/PTX_R cells (Figure 1B), treating drug-resistant ovarian cancer cells with gliotoxin failed to
induce cleaved caspase-9 (active p37) and caspase-3 (active p19/17) or the downstream target cleaved
poly (ADP-ribose) polymerase (PARP) (Figure 1C). However, the levels of drug-resistant proteins were
markedly decreased after treatment with gliotoxin (Figure 1D). These results suggest that gliotoxin
renders the chemoresistant ovarian cancer cells vulnerable to cytotoxic agents, even though the drug
alone could not induce the apoptotic death of cancer cells.
Figure 1. Treatment with gliotoxin (GTX) suppressed cell growth and reduced resistance in
paclitaxel-resistant ovarian cancer cells. (A) The chemical structure of gliotoxin used in the whole
experiment in this study. (B) Total protein from each group of PTX-sensitive cells (PTX_S) and
PTX-resistant cells (PTX_R) was analyzed by Western blotting with the indicated antibodies. The
expressions of multidrug resistant-associated proteins (MDR1-3), X-linked inhibitor of apoptosis protein
(XIAP), and surviving were increased in CaOV3/PTX_R and SKOV3/PTX_R cells (C) Cells were treated
with the indicated drug concentration for 24 h. Cell viability was measured using a Cell Counting Kit-8
assay. The absorbance at 450 nm is presented. n = 3. *p < 0.001 (GTX-treated PTX_S ovarian cancer cells
vs. DMSO-treated PTX_S ovarian cancer cells); **p < 0.001 (GTX-treated PTX_R ovarian cancer cells vs.
DMSO-treated PTX_R ovarian cancer cells). (D,E) Cells (1.5 × 105/well) were treated with 5 μM GTX for
24 h. Total protein was subjected to Western blot analysis with the indicated antibodies. β-actin served
as an internal control. Treatment with GTX of PTX_R ovarian cancer cells reduced the expression of
MDR1-3, XIAP, and surviving, but not the cleavage of caspase-9 (active p37/35) and caspase-3 (active
p19/17). The results are representative of three independent experiments.
2.2. Sequential Treatment with Gliotoxin Followed by Paclitaxel Promotes Apoptotic Death in
Paclitaxel-Resistant Ovarian Cancer Cells
As shown in Figure 1B, treatment with 5 μM GTX not only started to prevent the proliferation of
PTX-sensitive SKOV3 cells but also blocked the growth of CaOV3/PTX_R and SKOV3/PTX_R cells.
Furthermore, exposure to 5 μM GTX reduced in MDR1 and MRP1-3 expression in CaOV3/PTX_R
and SKOV3/PTX_R cells, but not the induction of active form caspase-9 and caspase-3. We also
observed that the exposure to 100 nM paclitaxel for 48 h induced nearly completely blocked the
proliferation of PTX-sensitive ovarian cancer cells, whereas the growth rate of CaOV3/PTX_R and
SKOV3/PTX_R cells was preserved (Figure S1). Based on these results, we next investigated whether
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co-treatment with gliotoxin and paclitaxel promotes apoptotic death in drug-resistant ovarian cancer
cells. To verify the sensitizing effect of gliotoxin to the anti-cancer drug through reducing MDR1
and MRP1-3 in paclitaxel-resistant ovarian cancer cells, CaOV3/PTX_R and SKOV3/PTX_R cells were
pre-exposed to gliotoxin (5 μM) for 8 h and then sequentially treated with paclitaxel (100 nM) for 48
h. Consecutive treatment with gliotoxin and paclitaxel significantly prevented CaOV3/PTX_R and
SKOV3/PTX_R cell growth compared to co-treatment and reverse sequential treatment (Figure 2A).
When CaOV3/PTX_R and SKOV3/PTX_R cells were treated with gliotoxin, and then paclitaxel, the
apoptotic death of chemoresistant ovarian cancer cells was synergistically increased (Figure 2B,C).
Furthermore, drug-resistant ovarian cancer cells treated with gliotoxin followed by paclitaxel exhibited
activation and cleavage of caspase-9, caspase-3, and PARP (Figure 2D). These results suggest that
pre-exposure to gliotoxin reverses paclitaxel resistance in chemoresistant ovarian cancer cells via the
induction of apoptotic death by chemotherapeutic agents.
Figure 2. Sequential treatment with gliotoxin followed by paclitaxel induces apoptotic death in
paclitaxel-resistant ovarian cancer cells. Cells were seeded into 96-well plates (1 × 104 cells/well) or
6-well plates (1.5 × 105 cells/well) and pre-treated with GTX (5 μM) for 8 h followed by PTX (100
nM) for 48 h. For comparison, untreated control cells were cultured with media in the presence of
DMSO. (A) Cell viability was measured using a Cell Counting Kit-8 assay. The absorbance at 450 nm
is presented. n = 3. *p < 0.001 (PTX_R ovarian cancer cells treated with GTX followed by PTX vs.
DMSO-treated PTX_R ovarian cancer cells). (B,C) To determine the degree of apoptosis, cells were
stained with annexin-V-FITC and 7-AAD and analyzed by flow cytometry. Dot-plot graphs show
the percentage of viable cells (annexin-V-/7-AAD-), early-stage apoptotic cells (annexin-V+/7-AAD-),
late-stage apoptotic cells (annexin-V+/7-AAD+), and necrotic cells (annexin-V-/7-AAD+). Late-stage
apoptotic cells (annexin-V+/7-AAD+) were evaluated by flow cytometry. # p < 0.005 (PTX_R ovarian
cancer cells treated with GTX, followed by PTX vs. DMSO-treated PTX_R ovarian cancer cells). To
measure Δψm disruption, cells were stained with DiOC6. Diminished DiOC6 fluorescence (%) indicates
Δψm disruption. ## p < 0.005 (PTX_R ovarian cancer cells treated with GTX, followed by PTX vs.
DMSO-treated PTX_R ovarian cancer cells). Each value is expressed as the mean ± SD from three
independent experiments (n = 3). (D) Whole cell lysates were subjected to Western blot analysis
using the indicated antibodies. Sequential treatment with GTX followed by PTX induced the activated
caspase-9 (active p37/35) and caspase-3 (active p19/17) in PTX_R ovarian cancer cells. β-actin served as
an internal control. The results are representative of three independent experiments.
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2.3. Pre-Exposure to Gliotoxin Followed by Paclitaxel Upregulates the TAp63 Expression, Leading to the
Caspase-Dependent Apoptosis in Drug-Resistant Ovarian Cancer Cells
We next investigated the underlying signaling pathway to determine the role and relationship
of DAPK1 and p53 family proteins. Although p53 expression was upregulated in CaOV3 and
SKOV3 cells after paclitaxel stimulation (Figure 3A), exposure to gliotoxin or paclitaxel failed to
induce p53 expression in CaOV3/PTX_R and SKOV3/PTX_R cells (Figure 3B). In contrast, cells treated
with gliotoxin followed by paclitaxel had increased expression of DAPK1 and TAp63, a p53 family
member (Figure 3B). To determine the role of TAp63 in the apoptotic death of CaOV3/PTX_R and
SKOV3/PTX_R cells, we transfected TAp63-expressing plasmids into drug-resistant ovarian cancer
cells. The expression of drug resistance-associated proteins was prominently lower in CaOV3/PTX_R
and SKOV3/PTX_R cells with forced TAp63 expression than in cells transfected with empty vector
(Figure 3C). Furthermore, TAp63 overexpression led to apoptosis in paclitaxel-resistant ovarian cancer
cells after treatment with paclitaxel (Figure 3D). Sequential treatment with gliotoxin followed by
paclitaxel induced the expression of autophagosome-related molecules (LC3-I/II and Beclin-1) and
the apoptosis-related protein, Bax (Figure S2). Although TAp63 gene silencing had no effect on
DAPK1 expression, reduced TAp63 expression prevented the induction of XIAP-associated factor
1 (XAF1), LC3-I/II, and Beclin-1, as well as the reductions in MDR1 and MRP1-3 expression, after
sequential treatment with gliotoxin and paclitaxel (Figure 3E). Targeted inhibition of TAp63 also
prevented the expression of cleaved and activated caspase-9, caspase-3, and PARP in CaOV3/PTX_R
and SKOV3/PTX_R cells after treatment with gliotoxin followed by paclitaxel (Figure 3F). These
results suggest that TAp63 expression plays an important role in enhancing apoptosis through the
downregulation of multidrug resistant-associated proteins.
2.4. DAPK1/TAp63-Mediated Autophagy Regulates Apoptotic Death in Drug-Resistant Ovarian Cancer Cells
after Consecutive Treatment with Gliotoxin and Paclitaxel
DAPK1 and p53 mutually induce apoptosis in cancer cells (6, 11). To determine the association
between DAPK1 and TAp63 in inducing apoptosis in CaOV3/PTX_R and SKOV3/PTX_R cells
after sequential treatment with gliotoxin and paclitaxel, we investigated the effect of DAPK1 on
TAp63 expression, autophagosome-related molecule levels, and mitochondrial membrane potential
changes. DAPK1-knockdown CaOV3/PTX_R and SKOV3/PTX_R cells exhibited suppressed TAp63,
XAF-1, LC3-I/II, and Beclin-1 expression and downregulated MDR1 and MRP1-3 expression after
sequential treatment with gliotoxin and then paclitaxel (Figure 4A). In addition, DAPK1 gene silencing
using siRNA prevented the cleavage of caspase-9, caspase-3, and PARP (Figure 4B) as well as the
depolarization of mitochondria membranes induced by treating paclitaxel-resistant ovarian cancer
cells with gliotoxin followed by paclitaxel (Figure 4C). We finally investigated the connection between
the DAPK1-TAp63 signaling pathway and autophagy-related cell death using 3-methyladenine
(3-MA), an autophagy inhibitor. Pre-exposure of CaOV3/PTX_R and SKOV3/PTX_R cells to 3-MA
had no effect on the expression of DAPK1, TAp63, and XAF1 after subsequent treatment with
gliotoxin and paclitaxel (Figure 5A), whereas multidrug resistant-associated protein levels remained
low (Figure 5A). Furthermore, 3-MA efficiently blocked the activation of the caspase-dependent
apoptotic pathway and the depolarization of mitochondria membranes after sequential treatment with
gliotoxin followed by paclitaxel (Figure 5B,C). These results suggest that DAPK1/TAp63-mediated
autophagy is one of the key downstream target pathways that induce apoptosis in drug-resistant
ovarian cancer cells and demonstrate that multidrug resistant-associated protein levels are regulated
in an autophagy-independent manner after sequential treatment with gliotoxin followed by paclitaxel.
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Figure 3. Pre-exposure to gliotoxin followed by paclitaxel induces caspase-dependent apoptosis in
drug-resistant ovarian cancer cells by upregulating TAp63 expression. (A,B) Cells were seeded into
6-well plates (1.5 × 105 cells/well), pre-treated with GTX (5 μM) for 8 h and then treated with PTX
(100 nM) for an additional 48 h. For comparison, untreated control cells were cultured with media in the
presence of DMSO. Total protein was subjected to Western blot analysis with the indicated antibodies.
The cells treated with GTX followed by PTX upregulated the expression of DAPK1 and TAp63. β-actin
served as an internal control. (C,D) Cells were transfected with either empty vector pcDNA3.1 or
TAp63 expression vector. (C) Transfection efficiency was determined by immunoblot using TAp63
and FLAG antibodies. Whole cell lysates were analyzed by Western blotting using the indicated
antibodies. Overexpression of TAp63 downregulated the levels of MDR1 and MRP1-3. (D) Percentages
of apoptotic cells were analyzed by annexin-V/7-AAD staining. The number of late-stage apoptotic cells
(annexin-V+/7-AAD+) was calculated by flow cytometry. (E,F) Cells (1.5 × 105/well) were pre-treated
with GTX (5 μM) for 8 h and then treated with PTX (100 nM) for an additional 24 h. Then, the cells were
transfected with 200 nM siRNA against TAp63 or control. Cells were used for further experiments 40 h
after transfection. The cells were analyzed by Western blotting with the indicated antibodies. Targeted
inhibition of TAp63 suppressed the expression of autophagosome-related LC3-I/II and Beclin-1 (E)
and prevented the upregulation of activated caspase-9 (active p37/35) and caspase-3 (active p19/17)
for apoptotic death (F). β-actin served as an internal control. The results are representative of three
independent experiments.
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Figure 4. Increased DAPK1 induced by pre-exposure to gliotoxin and paclitaxel upregulates TAp63
expression and autophagy signaling in drug-resistant ovarian cancer cells. The cells (1.5 × 105/well)
were pre-treated with GTX (5 μM) for 8 h and then treated with PTX (100 nM) for an additional
24 h. Next, cells were transfected with 200 nM siRNA against TAp63 or control. Cells were used for
further experiments 40 h after transfection. (A,B) The cells were analyzed by Western blotting with
the indicated antibodies. DAPK1 silencing prevented the activation of downstream target molecules,
including transcriptionally active p63 (TAp63), XIAP-associated factor 1 (XAF-1), LC3-I/II, and Beclin-1
as well as the cleavage of caspase-9 (active p37/35) and caspase-3 (active p19/17) by treatment with
gliotoxin followed by paclitaxel. β-actin served as an internal control. (C) To measure Δψm disruption,
cells were stained with DiOC6 and analyzed by flow cytometry. Diminished DiOC6 fluorescence (%)
indicates Δψm disruption. The results are representative of three independent experiments.
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Figure 5. DAPK1/TAp63-mediated autophagy induction mediates apoptotic death in drug-resistant
ovarian cancer cells after continuous treatment with gliotoxin and paclitaxel. (A–C) To inhibit
autophagic signaling, cells (1.5 × 105/well) were pre-exposed to 3-methyladenine (3-MA) (10 mM)
for 2 h. Cells were pre-treated with GTX (5 μM) for 8 h and then treated with PTX (100 nM) for an
additional 48 h. For comparison, untreated control cells were cultured with media in the presence of
DMSO. (A,B) Whole cell lysates were subjected to Western blot analysis using the indicated antibodies.
Pretreatment with 3-MA effective prevented the expression of autophagosome-related proteins (LC3-I/II
and Beclin-1) and cleaved form of caspase-9 (active p37/35) and caspase-3 (active p19/17), but had no
effect on downregulation of MDR-1 and MRP1-3 after treatment with gliotoxin followed by paclitaxel.
β-actin served as an internal control. (C) To measure Δψm disruption, cells were stained with DiOC6
and analyzed by flow cytometry. Diminished DiOC6 fluorescence (%) indicates Δψm disruption. The
results are representative of three independent experiments.
3. Discussion
The tumor suppressor p53 promotes autophagy by inducing various autophagy-related genes,
including DAPK1, a kinase acting in the early steps of autophagy [14,34]. DAPK1 overexpression
also promotes the activation of cell death-associated signaling pathways, including autophagy-related
apoptosis [1]. However, DAPK1 expression is frequently downregulated in B cell lymphoma and
non-small cell lung cancer through multiple mechanisms, including promoter methylation [35,36].
TAp63, a p53 family member sharing a transactivation domain, has been reported to regulate the same
target genes [19,20]. TAp63 not only inhibits cell growth but also prevents cell cycle progression in
p53-deficient cancer cells [37]. These reports demonstrate that DAPK1 plays an important role in
apoptosis induced by cytotoxic drug treatment and that the TAp63 and/or DAPK-related signaling
pathways are promising candidates for controlling cancer growth in certain tumor environments. In
this study, treatment with gliotoxin reversed the paclitaxel resistance of drug-resistant ovarian cancer
cells through the downregulation of multidrug resistant-associated proteins. In addition, sequential
treatment with gliotoxin followed by paclitaxel activated the DAPK1-mediated TAp63 signaling
pathway to induce autophagic cell death in paclitaxel-resistant ovarian cancer cells (Figure 6). These
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results suggest that monitoring TAp63 and DAPK1 expression level is critical for detecting paclitaxel
resistance and deciding whether to use paclitaxel in advanced or recurrent ovarian cancer patients.
 
Figure 6. Schematic diagram of the intracellular signaling mechanism after sequential treatment with
gliotoxin followed by paclitaxel in human ovarian cancer cells.
DAPK1 activation by cell death-inducing stimuli promotes apoptosis through the activation of
p53-dependent p14/p19ARF tumor suppressor genes [5]. DAPK1 overexpression activated autophagic
apoptotic death in a caspase-independent manner in breast and cervical cancer cells expressing
wild-type p53 [9]. In contrast, stimulation with TGF-beta resulted in DAPK1-induced mitochondrial
damage, leading to caspase-dependent apoptosis in a p53-depleted hepatoma cell line [38]. These
contradictory results demonstrate that the role of DAPK1 might require further study to understand
the connection with p53 or p53 family proteins in the apoptosis pathway. Although treating CaOV3
and SKOV3 cells with paclitaxel increased p53 expression, sequential exposure to gliotoxin followed
by paclitaxel upregulated the levels of DAPK1 and TAp63 but not p53 and TAp73 expression in
CaOV3/PTX_R and SKOV3/PTX_R cells. Furthermore, gene silencing of DAPK1 using siRNA in
CaOV3/PTX_R and SKOV3/PTX_R cells prevented autophagy induction, caspase activation, and
mitochondrial membrane disruption, as well as TAp63 activation. These results suggest that DAPK1
contributes to TAp63 activation to induce autophagic cell death in paclitaxel-resistant ovarian cancer
cells after consecutive treatment with gliotoxin and paclitaxel. However, the precise association based
on the molecular mechanism of DAPK1 and TAp63 in various cancer environments still needs to
be investigated.
Cells that survive previous chemotherapy obtain resistance to several anticancer drugs through
their development of various defense mechanisms, including promoting drug efflux capability, altering
drug metabolism, and changing drug targets [39]. Inactivation of p53 or mutant p53 in cancer cells
decreases drug accumulation through the upregulation of multidrug-resistance protein (MRP1), which
mediates ATP-dependent drug efflux [40]. Although exposure to gliotoxin induces mitochondrial
membrane disruption and p53-dependent apoptotic cell death in adriamycin-resistant non-small cell
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lung cancer cells [33], the acquired mechanism to overcome the cytotoxic effects of chemotherapeutic
drugs might be very diverse in cell type- or tumor environmental-dependent manners. In addition, the
contribution of other p53 family proteins in the absence of wild-type p53 to overcome anticancer drugs
is still unclear. Sequential treatment with gliotoxin, followed by paclitaxel increased the level of TAp63
in paclitaxel-resistant ovarian cancer cells. Furthermore, forced expression of TAp63 by transfection
with a TAp63-containing plasmid reduced the expression of multidrug resistant-associated proteins
(MDR1 and MRP1-3). These results suggest that TAp63 also plays an important role in modulating
drug resistance without wild-type p53.
Although pre-exposure to 3-MA before sequential treatment efficiently blocked cleaved caspase-9,
caspase-3, and PARP generation and prevented mitochondrial membrane disruption, pretreatment with
3-MA still inhibited multidrug resistant-associated protein levels but failed to attenuate DAPK1-TAp63
signaling pathway activation. These results suggest that the DAPK1-TAp63 pathway controls autophagy
induction and drug-resistant protein expression in an independent manner to promote the apoptotic
pathway after sequential treatment with gliotoxin, followed by paclitaxel (Figure 6).
Taken together, our results suggest that gliotoxin might be a promising agent to control advanced
or recurrent ovarian cancer in clinical situations by reducing paclitaxel resistance. Our data also
demonstrate that DAPK1 and TAp63 levels could be used as diagnostic or determining factors of drug
resistance before starting repeated chemotherapy against ovarian cancer.
4. Materials and Methods
4.1. Cell Lines and Reagents
Human ovarian cancer cell lines CaOV3 and SKOV3 (American Type Culture Collection (ATCC),
Manassas, VA, USA) were used in this study. These cells were cultured in DMEM and McCoy’s 5A
(Corning Incorporated, Corning, NY, USA) with 10% FBS (RMBIO, Missoula, MT, USA), glutamine, and
antibiotics and maintained at 37 ◦C under 5% CO2. Gliotoxin (GTX) and 3-methyladenine (3-MA) were
obtained from TOCRIS (Bristol, UK). Paclitaxel (PTX) was purchased from Sigma-Aldrich (St. Louis,
MO, USA). Paclitaxel-resistant sublines (CaOV3/PTX_R and SKOV3/PTX_R) were established in the
paclitaxel-sensitive (PTX_S) parent cell lines CaOV3 and SKOV3, respectively, by sequential exposure
of cells to increasing concentrations of PTX 2.5 ~ 100 nM over 6 months. Finally, the authenticity of
the drug-resistant sublines was confirmed by the ATCC Standards Development Organization (SDO)
through short tandem repeat profiling in accordance with the American National Standards Institute
(ANSI) Standard (ASN-0002).
4.2. Proliferation Assay with Cell Counting Kit-8
Cell proliferation was measured using a Cell Counting Kit-8 (CCK-8) (Enzo Life Sciences,
Farmingdale, NY, USA) as described in the supplier’s protocol. Cells were seeded into 96-well plates
(1 × 104 cells/well) and pre-treated with GTX (5 μM) for 8 h and then treated with PTX (100 nM) for an
additional 48 h. For comparison, non-treated control cells were cultured with media in the presence
of DMSO. After drug treatment, the cells were stained with 10 μL of CCK-8 dye in 90 μL of culture
medium for 2 h at 37 ◦C. The absorbance was measured at 450 nm.
4.3. Analysis of Apoptosis by Flow Cytometry
The percentages of cells undergoing apoptosis were measured by flow cytometry with fluorescein
isothiocyanate (FITC)-labeled annexin-V (BD Biosciences, San Diego, CA, USA) and 7-amino
actinomycin D (7-AAD) (BD Biosciences). The cells were suspended in 100 μL of 1× annexin-V
binding buffer; then, FITC-conjugated annexin-V (3 μL) and 7-AAD (3 μL) were added to the
suspensions, and the cells were kept at room temperature for 15 min in the dark. The stained cells
were monitored with a BD AccuriTM C6 (BD Biosciences).
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4.4. Measurement of Mitochondria Membrane Potential (ψm)
Changes in mitochondrial membrane potential were determined using DiOC6
(3,3’-dihexyloxacarbocyanine iodide; Molecular Probes, Eugene, OR). Cells were seeded into
96-well plates (1 × 104 cells/well), pre-treated with GTX (5 μM) for 8 h, and then treated with PTX
(100 nM) for an additional 48 h. Cells were harvested, washed twice with PBS, resuspended in
PBS supplemented with DiOC6 (20 nM), incubated in the dark at 37 ◦C for 15 min, and analyzed
immediately using a flow cytometer with an FL-1 filter.
4.5. Western Blot Analysis
Harvested cells were lysed with RIPA buffer (Elpis Biotech, Daejeon, Korea) supplemented with
a protease inhibitor cocktail and phosphatase inhibitors (Sigma-Aldrich). Equal amounts of protein
(10 μg/sample) determined with a BCA assay kit (Pierce, Rockford, IL, USA) were subsequently
loaded onto SDS-PAGE gels. After electrophoresis, the proteins were transferred onto nitrocellulose
membranes (Millipore Corp., Billerica, MA, USA). The membranes were blocked with 5% non-fat skim
milk and probed with primary antibodies. The expression level of target proteins was determined
using a chemiluminescence kit (Advansta Corp., Menlo Park, CA, USA) and an Amersham Imager
600 (GE Healthcare Life Sciences, Little Chalfont, UK). The expression levels of β-actin were used as
a control.
4.6. Small Interfering RNA (siRNA) Transfection
Human TAp63-siRNA (5’-GCA CAC AGA CAA AUG AAU UUU-3’), human DAPK1-siRNA
(5’-CAA CTA TGA TGT TAA CCA A-3’), and negative control-siRNA (Cat. No. SN-1001-CFG) were
obtained from Bioneer (Daejeon, Korea). Cells were seeded at a density of 1.5 × 105 per well in a 6-well
plate and grown overnight. The cells were then transfected with 200 nM siRNA using Lipofectamine
RNAiMAX Reagent (Invitrogen, Carlsbad, CA, USA) as described in the supplier’s protocol. The cells
were used for further experiments at 48 h after transfection.
4.7. TAp63 Overexpression Using Transient Transfection
Transient transfection of cultured cells was performed using Lipofectamine 2000 as described in the
supplier’s instructions. Cells were plated on 6-well culture plates at a density of 2 × 105 cells/well and
transfected the next day. Typically, 10 ng of construct DNA was transfected with 9 μL of Lipofectamine.
The cultured cells were transiently transfected with either a TAp63 expression vector of TAp63 cDNA
cloned into pcDNA3.1 (Addgene, Cambridge, MA, USA) or empty vector pcDNA3.1 (Invitrogen).
Cells were transfected for 48 h and analyzed by Western blotting.
4.8. Statistical Analysis
Student’s t-test and one-way analysis of variance (ANOVA) using SPSS version 24.0 statistical
software (IBM Corp., Armonk, NY, USA) were used for all statistical analyses. The data are presented
as the mean ± standard deviation (SD). Differences were determined to be statistically significant at
p < 0.05 and highly significant at p < 0.001.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/7/412/s1,
Figure S1: Establishment of paclitaxel-resistant ovarian cancer cells, Figure S2: Effect of GTX treatment on
autophagy and the Bcl-2 family in PTX-resistant ovarian cancer cells.
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Abstract: Twenty-three bacterial strains were isolated from the secreted mucus trapping net of the
marine polychaete Chaetopterus variopedatus (phylum Annelida) and twenty strains were identified
using 16S rRNA gene analysis. Strain CB1-14 was recognized as a new species of the genus Vibrio
using the eight-gene multilocus sequence analysis (MLSA) and genome sequences of nineteen type
Vibrio strains. This Vibrio sp. was cultured, and 6-epi-monanchorin (2), previously isolated from
the polychaete and two sponge species, was found in the cells and culture broth. The presence of
the 6-epi-monanchorin was confirmed by its isolation followed by 1H NMR and HRESIMS analysis.
These results showed the microbial origin of the bicyclic guanidine alkaloid 2 in C. variopedatus.
Keywords: guanidine alkaloids; 6-epi-monanchorin; HRESI MS; 1H NMR spectra; marine bacteria;
Vibrio sp.; polychaete; Chaetopterus variopedatus; 16S rRNA gene analysis; phylogenetic reconstruction
1. Introduction
Various guanidine-containing natural products, isolated from different marine invertebrates,
demonstrate antifungal, antibacterial, antiviral, and antitumor properties [1] and are suitable
compounds for drug development due to high levels of their bioactivities and water solubility.
Moreover, some natural guanidine-containing compounds, such as streptomycin, have already been
introduced in the clinic.
Most of the marine guanidine alkaloids found in marine sponges are polycyclic, and two
bicyclic representatives of this group, namely monanchorin (1) and 6-epi-monanchorin (2), are known.
These compounds were isolated from representatives of two phylogenetically distant taxa, namely
marine sponges Monanchora ungiculata and Halichondria panicea (phylum Porifera) [2,3], and marine
polychaete Chaetopterus variopedatus (phylum Annelida) [4]. Previously it has been reported that the
compound 1 shows weak cytotoxic activity against IC2 murine mast cells [2], while compounds 1
and 2 (Figure 1) are able to inhibit the migration and colony formation of cisplatin-resistant cancer
NCCIT-R cells [4].
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Figure 1. Structures of natural compounds 1 and 2.
The presence of the alkaloids 1 and 2 in such different taxa could indicate that a common
unidentified marine microorganism(s), accumulated in both sponges and the polychaete is a genuine
producer of these secondary metabolites of unknown biogenesis. Really, the presence of the same
secondary metabolites in distantly related animal taxa sometimes point to potential symbiotic or
dietary sources of the corresponding substances. However, experimental evidences of their microbial
origin were rarely obtained. Recently, we compared levels of these alkaloid content in different body
parts of the polychaete C. variopedatus [5,6]. Both alkaloids were predominant into the food net parts
of the animals and the content of 6-epi-monanchorin (2) was very high (5.0% of dry weight) [4].
These findings prompted us to undertake the present study. We have tried to identify the biogenetic
origin of the above mentioned polychaete metabolites.
2. Results and Discussion
2.1. Isolation of Microorganisms
The secreted mucous net of the polychaete was pre-rinsed in sterile sea water. Pieces of tissue
were aseptically removed and homogenized in sterile sea water. Bacterial strains were isolated by
plating samples of tissue homogenates onto medium plates containing the modified MN medium [7].
The plates were incubated aerobically at 20 ◦C for 7 days. The bacterial colonies that grew on the
DifcoTMMarine Agar 2216 Becton, Dickinson and Company (BD) with that medium were picked up
and classified morphologically and biochemically. Twenty-three bacterial strains were isolated in pure
cultures and then analyzed by MALDI MS.
2.2. Preliminary Identification of Potential Microorganism-Producers by Monitoring of the Compounds Giving
Ion Peaks at m/z 212.17 by MALDI MS, Characteristic of 1 and 2 MS
A preliminary screening procedure was carried out using Ultrafex III MALDI TOF/TOF mass
spectrometer and Biotyper Software (Bruker Daltonics) to select isolates for further analyses. Sample
preparation was carried out by “direct transfer” procedure (Ver. 2.0 Biotyper). Spectra were calibrated
with external calibration by Eschercihia coli DH5 alpha standard and protein calibration standard I
(Bruker Daltonics). The majority of identified bacterial strains were represented by Vibrio spp. and,
thus, Vibrio was the dominant group of bacteria cultured from the mucous net of this polychaete.
The occurrence of the compounds with a peak at m/z 212.17 in MALDI MS, presumably corresponding
to 6-epi-monanchorin or monanchorin (2 or 1), are shown in the Table 1. In total there were eleven
promising strains found, seven of which were identified as Vibrio spp. and gave this ion peak in MS.
It should be noted that the data obtained by this method should be considered as preliminary and did
not allow accurate identification, neither microorganisms nor target compounds.
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Table 1. Taxonomic position of microorganism-producers and occurrence of compounds with m/z
212.17 ion peak by MALDI MS data.
No Strain Taxon m/z 212.17 * No Strain Taxon m/z 212.17
1 CB1-3 nd nd 13 CB2-3 nd nd
2 CB1-5 nd nd 14 CB2-4 Vibrio sp. nd
3 CB1-6 nd nd 15 CB2-5 Vibrio sp. nd
4 CB-1-7 Vibrio sp. nd 16 CB2-6 Vibrio sp. +
5 CB1-8 nd nd 17 CB2-7 nd ad
6 CB1-9 nd ad 18 CB2-8 Vibrio sp. ad
7 CB1-10 Vibrio sp. ad 19 CB2-9 Vibrio sp. ad
8 CB1-11 Vibrio sp. ad 20 CB2-10 nd ad
9 CB1-12 nd nd 21 CB2-11 Vibrio sp. +
10 CB1-13 nd nd 22 CB2-12 Vibrio sp. ad
11 CB1-14 nd + 23 CB2-13 nd nd
12 CB2-1 Vibrio sp. nd
nd, not detected; ad, ambiguous detected; +, detected.
2.3. Identification of Compounds 1 or 2 by HRESIMS
The authentic identification of compounds 1 and 2 into the three promising strains such as
CB1-14, CB2-11, and CB2-6 (see Table 1) was carried out after isolation of these compounds by HPLC
followed by analysis with HRESIMS. The strains were incubated at 200 rpm in 100 mL of modified MN
liquid medium at 28 ◦C for 7 days. After incubation, the whole cultures were centrifuged to harvest
the bacterial cells. Then cells were suspended in water (30 ml), frozen, and subjected to ultrasonic
treatment. The suspension was extracted with EtOAc, and the organic phase was evaporated to dryness.
The resulting mixture was dissolved in a small amount of EtOH, and extracts were subjected to HPLC
on ODS-A columns. The fractions with retention times of 12 to 17 min were collected and analyzed by
HRESIMS. Compounds showing ion peak with m/z 212.1757 [M +H]+ (calcd for C11H22N3O, 212.1757)
were isolated from strains CB1-14 and CB2-11. Strain CB1-14 showed a more intense peak at m/z
212.1757 compared with that for CB2-11. Their mass spectra were identical to the spectra of standards.
As a result, monanchorins were identified in these two strains. However, in order to determine which
of two epimeric compounds was biosynthesized by these microorganisms, it was necessary to isolate
the alkaloids in amounts sufficient for the obtaining of NMR data.
2.4. Isolation and Identification of 6-epi-Monanchorin by 1H NMR Spectroscopy
The strain CB1-14 was chosen for preparative isolation of target compounds. After incubation of
12 L medium at 28 ◦C for 7 days, the culture broth of Vibrio sp. strain CB1-14 was separated from cells
by centrifugation. The 6-epi-monanchorin (2, Figure 1) was isolated from the EtOAc extracts of both
cells and lyophilized culture broth using reverse-phase HPLC. The structure was exactly identified on
the basis of 1H NMR and HRESIMS data by comparison with authentic sample [4]. As a result, it was
found that the CB1-14 strain biosynthesizes 6-epi-monanchorin (2). Monanchorin itself was not found
in this strain in amounts sufficient for NMR spectrum recording.
2.5. 16S rRNA Gene Sequence Analysis of Bacterial Isolates
Twenty bacterial isolates selected for screening for compounds 1 and 2 production were identified
by 16S rRNA gene analysis on the EzBiocloud server [8]. Based on the sequence comparison to reference
type strains, the isolates were assigned to the two bacterial phyla (Proteobacteria and Firmicutes).
Two isolates (CB1-13 and CB1-18) showed the highest similarity values with Bacillus hwajinpoensis
SW-72T (99.21%–99.24%) and Bacillus hemicentroti JSM 076093T (98.27%). One isolate (CB1-3) shared the
highest similarity value with Pseudovibrio japonicus WSF2T (99.2%), Pseudovibrio ascidiaceicola DSM 16392T
(98.99%), and Pseudovibrio denitrificans DSM 17465T (98.91%) from Alphaproteobacteria. The others
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were closely related to the species of the genus Vibrio from Gammaproteobacteria. The isolates CB1-14,
CB2-10, CB2-8, and CB1-5 showed 98.96%–99.58% sequence similarity with Vibrio hangzhouensis CN83T.
The other isolates CB2-5, CB1-7, and CB2-12 had 98.79%–100% sequence similarity with Vibrio barjaei
3062T and Vibrio thalassae MD16T. Most of isolates (CB1-1, CB1-10, CB1-11, CB2-4, CB2-9, CB2-11,
and CB2-13) shared the highest similarity values with Vibrio mediterranei CIP 103203T (99.65%) and
Vibrio shilonii AK1T (99.59%). Three isolates (CB1-6, CB2-1 and CB2-7) showed similarity values less
than 97.5% with reference type strains of the species of genus Vibrio.
The phylogenetic tree based on the 16S rRNA sequences (1438 bp) clearly showed that Vibrio
isolates grouped into four clades (Figure 2), three of which included the single type strains, V. barjaei or
V. hangzhouensis or V. mediterranei. The fourth clade was at the base of the genus Vibrio and did not
include any type strains.
Figure 2. Bacterial phylogenetic tree on the basis of 16S rRNA gene sequences of isolates recovered
from the mucus net of the C. variopedatus and closely related sequences of type strains. The tree topology
was obtained using the maximum likelihood method based on the Tamura three-parameter model.
Bootstrap values above 75% calculated from 1000 re-sampling are shown on the node. The scale bar
represents the number of substitutions per site.
Guided by the cutoff value at the species level equal to 98.65% [9] and phylogenetic positions,
the isolates CB1-13 and CB1-18 might be identified as B. hwajinpoensis and the isolate CB1-3 as P.
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japonicus. Among Vibrio isolates, the isolates CB2-5, CB1-7, and CB2-12 might be identified as V. barjaei,
the isolate CB1-5 as V. hangzhouensis, and the isolates CB1-1, CB1-10, CB1-11, CB2-4, CB2-9, CB2-11,
and CB2-13 as V. mediterranei. The clades, containing CB1-14 and CB2-1, might be distinguished as
candidates for new species. Thus, one of bacterial strain (CB1-14) presumably producing monanchorins
was identified as Vibrio sp., closely related to Vibrio hangzhouensis CN83T, but probably distinguished
from this species.
Therefore, the phylogenetic analysis revealed bacterial diversity in the mucus net of the C.
variopedatus. The dominant cultured bacteria were members of the genus Vibrio, belonging, at least,
to three different species.
2.6. Multilocus Sequence Analysis of CB1-14
The phylogenic analysis based on 16S rRNA gene sequences showed the isolate CB1-14 was
closely related to V. hangzhouensis CN83T, sharing 98.96% identity with this strain. It means that the
calculated identity value is within the boundary range proposed for delineating Vibrio species [10].
Since the 16S rRNA gene sequence did not help in differentiating closely related bacterial species,
the eight-gene MLSA was applied as that currently used for delimitating Vibrio species [11,12].
To overcome difficulties in application of universal primers for the MLSA, the draft genome
of CB1-14 was obtained and used to retrieve sequences of eight housekeeping genes. Following
previously described MLSA scheme [11] and using available genome sequences of nineteen type strains
including V. maritimus CAIM 1455T, V. variabilis CAIM 1457T, V. mediterranei NBRC 15635T, and V.
hangzhouensis CGMCC-1-7062T, the MLSA study was performed. Based on phylogenies generated by
ML (Maximum Likelihood), MP (Maximum Parsimony), and NJ (Neighbor Joining) methods (data are
not presented) and split tree decomposition analysis (Figure 3), the MLSA placed the isolate CB1-14
into the Mediterranei clade. Within the clade, the isolate CB1-14 formed a separate branch closely
related to V. maritimus CAIM 1455T and V. variabilis CAIM 1457T, with a high bootstrap support.
Figure 3. Concatenated split network tree based on eight gene loci. The ftsZ, gapA, gyrB, mreB, pyrH,
recA, rpoA, and topA gene sequences from 20 taxa were concatenated including the isolate CB1-14 (bold
font). Phylogenetic tree was generated using the SplitsTree4 program.
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Thus, the phylogenetic reconstruction showed that the isolate CB1-14 should be recognized as a
new species in the genus Vibrio. The valid description of this new species in Vibrio genus, isolated from
an organ of the polychaete, namely from its mucous net, will be done in a special journal.
Marine invertebrates are the oldest animals on Earth, distributed over all the ocean biomes from
polar to tropical waters and from shallow to very deep substrates. In the course of their evolution,
marine invertebrates have acquired long-term and stable associations with a wide diversity of bacteria,
cyanobacteria, archaea, and other groups of microbes, which make up to 60% of the biomass of
some these animals and are essential to their survival [13]. There are a number of reports that
cultures of microorganisms, isolated from marine sponge [14–19] and ascidian tissues [20], produce
secondary metabolites previously isolated from these invertebrates, that indicates their microbial
origin [13]. However, up to date, only biosurfactants were identified from polychaete-associated
microbial isolates [21]. Production of the 6-epi-monanchorin by Vibrio sp. CB1-14 isolate is completely
unprecedented. Most of the compounds so far isolated from Vibrio spp. were proved to be non-ribosomal
peptides or their hybrids. Only a few guanidine-containing secondary metabolites were isolated from
Vibrio, for example siderophore vanchrobactin from Vibrio anguillarum [22] as well as Na channel blocker
tetrodotoxin and its derivatives from bacteria V. alginolyticus, V. harveyi, V. fischeri, and Vibrio sp. [23–26].
Our finding that the Vibrio sp. CB1-14 isolate, obtained from polychaete food net and which is
able to biosynthesize compound 2, shows that this bacterium (and probably some other close related
species) has important unrecognized biosynthetic capabilities, and should be considered as a potential
microbial source of monanchorins. From the biotechnological viewpoint, the cultivation of bacteria
after optimization of 6-epi-monanchorin production could help to solve the recognized supply problem
of marine-derived drugs. Identification of this producer also opens prospects of bicyclic guanidine
alkaloid biosynthesis.
3. Materials and Methods
3.1. General
The 1H-NMR spectra were recorded on a Bruker Avance III-700 spectrometer in CDCl3. Chemical
shifts were referenced to the corresponding residual solvent signal (δH 7.26/δC 77.20 for CDCl3).
ESI mass spectra (including HRESIMS) were obtained on a Bruker maXis Impact II LC-MS spectrometer
by direct infusion in MeOH. MALDI-TOF mass spectra were obtained on a Bruker Ultraflex III TOF/TOF
laser desorption spectrometer coupled with delayed extraction using a Smartbeam MALDI 200 laser
with α-cyano-hydroxy cinnamic acid as the matrix. HPLC was performed on a Shimadzu instrument
with a RID-10A refractive index detector using a YMC-ODS-A (250 × 10 mm) column.
3.2. Animal Material
Three specimens of the polychaete C. variopedatus were collected from the coastal waters by scuba
at a depth of 6–10 m (salinity 33%, temperature 20) in Troitsa bay, Peter the Great Gulf, Sea of Japan,
Russia, in August 2016 and identified by Dr. B. B. Grebnev (GB Elyakov Pacific Institute of Bioorganic
Chemistry of Far Eastern Branch of Russian Academy of Sciences, Vladivostok, Russia).
3.3. Isolation of Microorganisms
The secreted mucous net of polychaete were pre-rinsed in sterilized sea water. Pieces of tissue
(about 1 g) were aseptically removed and homogenized in 5 mL sterilized sea water. Bacterial strains
were isolated by plating samples of tissue homogenate (0.1 mL) onto Petri dishes with the modified
MN medium containing 75% natural sea water, 25% distilled water, 0.12 mM CaCl2, 0.15 mM MgSO4
× 7H2O, 0.09 mM K2HPO4 × 3H2O, 8.8 mM NaNO3, 0.19 mM Na2CO3, 0.0013 mM disodium EDTA,
0.014 mM Citric acid ×H2O, 0.015 mM Ferric ammonium citrate, 1% Bacto agar at pH 8.5. These dishes
were incubated aerobically at 20 ◦C for 10 days. The bacterial colonies that grew on the modified MN
medium were picked up and then pure bacterial cultures were grown on DifcoTMMarine Agar 2216
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(BD) and classified morphologically and biochemically. Bacterial strains were stored in 30% glycerol
solution at −80 ◦C.
3.4. Identification of Microorganisms by MALDI MS
Bacterial isolates were stored at −80 ◦C on the Microbank system (VWR, Darmstadt, Germany).
Selected colonies were isolated from plates using a sterile pipette tip and applied directly onto a
384-position ground steel target plate (Bruker Daltonics, Bremen, Germany). The samples were
immediately mixed with 2 μL of saturated solution of α-cyano-hydroxy cinnamic acid (HCCA, Bruker
Daltonics) in 50% acetonitrile (Sigma–Aldrich, Taufkirchen, Germany), supplemented with 2.5%
trifluoroacetic acid (Roth, Karlsruhe, Germany). The matrix/sample spots were crystallized by air
drying. Spectra of bacterial strains from the KMM collection of our Institute, as well as reference strains
from different commercial collections, were used for comparison. Spectra were calibrated with external
calibration by Escherichia coli DH5 alpha standard and protein calibration standard I (Bruker Daltonics).
3.5. Incubation of Microorganisms for HRESI MS Analysis of Compounds
The bacterial strains (CB1-14, CB2-11, and CB2-6) were incubated at 200 rpm, at 28 ◦C for 7 days,
in the 100 mL liquid-modified MN medium. For preparative isolation of target compounds, the strain
CB1-14 was incubated at the same conditions using 12 L of the medium.
3.6. Isolation and Structure Identification of 6-epi-Monanchorin
After incubation, the cells and culture broth of Vibrio sp. (strain CB1-14) were separated by
centrifugation at 5000 rpm for 30 min. The cells were suspended in water (50 mL), frozen, and,
after de-freezing, subjected to ultrasonic treatment. Then the suspension was extracted with EtOAc,
and the organic phase was evaporated to dryness. Further chromatographic purification of the obtained
residue with reversed-phase HPLC (YMC-ODS-A, 250 × 10 mm) using EtOH-H2O (55:45% + 0.05%
TFA) gave pure compound 2.
6-epi-monanchorin (2, 0.2 mg), HRESI MS m/z 212.1757 [M + H]+ (calcd for C11H22N3O, 212.1757).
1H NMR (700 MHz, CDCl3): 8.74 (1H, br.s, H-2), 8.64 (1H, br.s, H-4), 7.08 (2H, br.s, H-10), 4.84 (1H, t,
J = 3.0 Hz, H-1), 3.90 (1H, ddd, J = 6.0, 1.6, 7.6 Hz, H-6), 3.33 (1H, dt, J = 6.0, 1.6 Hz, H-5), 2.36 (1H, m,
H-9a), 2.24 (2H, m, H-8), 2.13 (1H, m, H-9b), 1.74 (1H, m, H-11a), 1.52 (1H, m, H-11b), 1.40 (1H, m,
H- H-12a), 1.30 (5H, m, H-12b and H2-13 and H2-14), 0.89 (3H, t, J = 6.7 Hz, H3-15).
3.7. DNA Isolation and Amplification and Phylogenetic Analysis of 16S rDNA Gene
Genomic DNAs from bacterial isolates were prepared using NucleoSpin kit (Macherey-Nagel,
Germany) according to the recommendation provided by the manufacturer. PCR amplification
of 16S rDNA gene from all the isolates was performed according to [27], using primers BF-20
(5′-ATCACGCGTAAAAATCT-3′) and BR2-22 (5′-CCGCAATATCATTGGTGGT-3′), resulting in about
a 1500 bp length PCR product. The purified PCR fragments were sequenced using the ABI PRISM
3130xl Genetic Analyzer (Applied Biosystems) and by the BigDye v.3.1 sequencing kit (Applied
Biosystems) (see Table S1 in Supplementary Materials). Obtained sequences were analyzed on the
highest percentage of similarities using the Ez-taxon database [8] and the MEGA program version
7 [28]. The 16S rRNA phylogenetic tree was constructed using the maximum likelihood (ML) method
based on the Tamura 3-parameter model [29], with 1000 bootstrap replications in the MEGA program.
3.8. Genome Sequencing and Multilocus Sequence Analysis of CB1-14
A draft genome sequence of the isolate CB1-14 was obtained using 454 GS Junior (Roche Life
Science, USA). A de novo assembly was performed using Newbler version 3.0 software Junior (Roche
Life Science, USA). The genome sequence was assembled into 621 contigs with 14,322 bp of N50.
The estimated genome size was 5.3 Mb. Gene prediction and automated genome annotation were
69
Mar. Drugs 2019, 17, 213
carried out using RAST v. 2.0 with default parameters [30]. Sequences of eight protein-coding genes
(ftsZ, gapA, gyrB, mreB, pyrH, recA, rpoA, and topA) from twenty taxa were retrieved from the CB1-14
draft genome, and from the GenBank/DDBJ/EMBL databases. The MEGA program was used to
concatenate, align, and reconstruct the ML, maximum parsimony (MP), and neighbor-joining (NJ)
phylogenies with 1000 bootstrap replications. The best-fit model for protein evolution determined in
the MEGA program was HKY+G [31]. Split decomposition analysis was performed using SplitsTree
version 4.14.3 with a neighbor net drawing and a Jukes–Cantor correction [32,33].
4. Conclusions
Our results present the first evidence of the microbial origin of 6-epi-monanchorin (2), previously
isolated from the secreted mucus trapping net of the marine polychaete C. variopedatus. Using the 16S
rRNA gene analysis, it was revealed that diverse Vibrio species are dominant bacteria cultured from
the C. variopedatus mucus net. In addition, it was shown that these bacteria belong to several different
species of the genus Vibrio. The strain CB1-14, producing alkaloid 2, was recognized as a new species in
the genus Vibrio by phylogenetic reconstruction using eight protein-coding genes. Our results suggest
that filter-feeding polychaetes should be considered as a novel source of alkaloid-producing bacteria.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/4/213/s1.
HRESIMS spectra of 6-epi-monanchorin (2) isolated from polychaete Chaetopterus variopedatus and marine bacterium
Vibrio sp. CB1-14; 1H NMR spectra for 6-epi-monanchorin (2) isolated from polychaete Chaetopterus variopedatus and
marine bacterium Vibrio sp. CB1-14; HPLC chromatograms of culture medium extract and cells extracts of CB1-14
and Table S1. Accession numbers and Chimera identification of 16S rRNA of bacterial isolates. The GenBank
accession numbers for all 16S rRNA nucleotide sequences will be available on online on the NCBI server after 20
July 2019.
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Abstract: Sea anemones’ venom is rich in peptides acting on different biological targets, mainly on
cytoplasmic membranes and ion channels. These animals are also a source of pancreatic α-amylase
inhibitors, which have the ability to control the glucose level in the blood and can be used for the
treatment of prediabetes and type 2 diabetes mellitus. Recently we have isolated and characterized
magnificamide (44 aa, 4770 Da), the major α-amylase inhibitor of the sea anemone Heteractis magnifica
mucus, which shares 84% sequence identity with helianthamide from Stichodactyla helianthus. Herein,
we report some features in the action of a recombinant analog of magnificamide. The recombinant
peptide inhibits porcine pancreatic and human saliva α-amylases with Ki’s equal to 0.17 ± 0.06 nM
and 7.7 ± 1.5 nM, respectively, and does not show antimicrobial or channel modulating activities. We
have concluded that the main function of magnificamide is the inhibition of α-amylases; therefore, its
functionally active recombinant analog is a promising agent for further studies as a potential drug
candidate for the treatment of the type 2 diabetes mellitus.
Keywords: Cnidaria; sea anemones; venom; amylase inhibitors; defensin; diabetes
1. Introduction
Type 2 diabetes mellitus is a widespread disease (~8% of adults), often resulting from a metabolic
disorder caused by over-feeding, an unhealthy diet, and physical inactivity [1,2]. It covers all age groups
of the population, and recently it has spread epidemiologically among children and adolescents [3,4].
The blood glucose levels of diabetic patients reaches abnormally high values, which leads to serious
damage to many body systems, especially nerves and blood vessels, causing heart and kidney diseases,
blindness, and even the amputation of limbs [5]. The preferred way to maintain good health for people
with type 2 diabetes or prediabetes is a control of the input of glucose from the digestive tract into the
blood stream [6–8]. For this purpose, the medicines based on inhibitors of pancreatic α-amylase are
used. GlucobayTM, the active ingredient of which, acarbose, inhibits porcine pancreatic α-amylase
(PPA) and human saliva α-amylases (HSA) with Ki’s of 0.797 and 1.265 μM, respectively, is one of the
most common of that type of drug [9]. In some countries, medicinal plants are traditionally used to
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treat diabetes; the study of their composition revealed the presence of low molecular weight substances
inhibiting mammalian α-amylases [10,11]. Since the effectiveness of currently existing drugs is limited
and they have some side effects, the search for new highly effective inhibitors of pancreatic α-amylase
is an attractive goal in the field of drug discovery.
The medicines based on proteins and peptides are poorly represented in the pharmacological
market, but attract the interest of specialists due to their high selectivity and effectiveness, combined
with relative safety and good tolerability. A large number of proteinaceous α-amylase inhibitors have
been isolated from plants, but they are highly specific and interacted with plant α-amylases to control
the breakdown of stored starch or with insect α-amylases for defense [12]. Several very effective
proteinaceous inhibitors of mammalian, but not plant or microbial α-amylases were found in bacteria
belonging to the genus Streptomyces [13–16]. However, it was shown that α-amylase inhibitors isolated
from bacteria, for example, tendamistat (Ki 9−200 pM), have a high immunogenicity due to their
β-sandwich fold and cannot be used in clinical practice [17].
Among animals, amylase inhibitors were found only in sea anemones, ancient sessile predators
inhabiting marine environment. Helianthamide (PPA, Ki = 100 pM; human pancreatic α-amylase
(HPA), Ki = 10 pM), the first representative of a new group of α-amylase inhibitors belonging to
the β-defensins family, was isolated from Stichodactyla helianthus in 2016 [18]. This inhibitor is very
active, and in contrast to tendamistat, has a more compact structure, which significantly decreases
the likelihood of an immune response. Recently, as a result of the proteomic analysis of the sea
anemone H. magnifica mucus, we have revealed that α-amylase inhibitors are major components,
numbering dozens isoforms [19]. Major α-amylase inhibitor, magnificamide, was identified and
sequenced (44 aa, 4770 Da) [19]. It shares 84% of sequence identity to helianthamide (44 aa, 4716 Da).
The biological relevance of the presence of inhibitors of α-amylases in the mucus of Cnidaria, such
as the sea anemone H. magnifica, remains largely unexplained. It is hypothesized that inhibition of
α-amylase activity intervenes with the metabolism of starch, which forms a major source of nutrition
for many organisms. Organisms exposed to α-amylase inhibitors, therefore, suffer from a reduced
availability of carbohydrates that serve as an energy resource.
The results presented here are a continuation of an in depth study of magnificamide, more
precisely, of a recombinant analog of the peptide with a detailed investigation of its biological activity.
2. Results
2.1. Peptide Expression and Purification
To study the properties of peptides and then to develop peptide-based drugs, it is necessary to
obtain their recombinant analogues at sufficient qualities and quantities. The plasmid vector pET32b(+)
containing the gene of thioredoxin ensures high yields of cysteine-containing polypeptides with native
conformations, and was, therefore, chosen to create an expression construct. The synthetic gene
encoding magnificamide was cloned into pET32b(+) using restriction sites KpnI and XhoI (Figure 1a).
The resulting plasmid was transferred into Escherichia coli BL21(DE3) cells by electroporation and
expressed as a fusion protein Trx-magnificamide (Figure 1b).
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(a) (b) 
Figure 1. (a) Map of the pET32b(+)-magnificamide expression plasmid. A synthetic gene encoding the
magnificamide and enterokinase sites was cloned using the restriction sites for KpnI and XhoI. (b) The
scheme of fusion protein Trx-magnificamide and sequence of magnificamide (UniProtKB—C0HK71).
The fusion protein was isolated from the cell lysate by metal affinity chromatography, desalted,
hydrolyzed by enterokinase, and then the recombinant magnificamide (r-magnificamide) was purified
by RP-HPLC (Figure 2). After HPLC two fractions which inhibited PPA were obtained, one of them
contained the mature r-magnificamide (Figure 3a); the other one contained peptide with incorrect
folding (Figure 3b). The average yield of target peptide was equal to 4 mg per 1 L of cell culture (OD
A600 = 0.6–0.8).
Figure 2. The RP-HPLC elution profile of r-magnificamide, obtained as the result of hydrolysis of the
fusion protein Trx-magnificamide by enterokinase, on a Jupiter C4 column (Phenomenex, Torrance, CA,
USA) equilibrated by 0.1% TFA, pH 2.2, in a gradient of acetonitrile concentration (0%–70%) for 70 min
at 2 mL/min. Fraction 1 containing the mature peptide r-magnificamide (4770 Da) (Figure 3a) is filled
by dark grey color; fraction 2 containing peptide with incorrect folding (4777 Da) (Figure 3b) is filled by
light grey color.
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Figure 3. Mass spectra, m/z, of the peptides isolated by RP-HPLC (Figure 2): (a) mature r-magnificamide
from fraction 1 and (b) incorrectly folded r-magnificamide from fraction 2. m/z—mass-to-charge ratio;
a. u.—arbitrary units.
2.2. Secondary Structure of Peptides
To calculate the secondary structural elements of recombinant and native magnificamide, the
circular dichroism spectroscopy method was used. The spectra in the far UV region (190–240 nm)
were characterized by a minimum at 212 nm and a maximum at 203 nm. In the 225–235 nm range,
distinct shoulders were observed on the spectra’s curves due to the contribution of the disulfide groups’
absorption (Figure 4). The similarity between the circular dichroism (CD) spectra of magnificamide
and its recombinant analogue suggested that the recombinant peptide should be functional and can
be used successfully to study its biological activity. Moreover, the calculation of secondary structure
elements using Provenzer–Glockner method [20] revealed the complete identities of the peptides at the
secondary structure level (Table 1). It should be noted that content of α-helices of the magnificamide
was significantly lower than that of helianthamide, which might be reflected in the difference in their
spatial structures and biological activity.
Figure 4. Circular dichroism (CD) spectra of native magnificamide (black line) and recombinant
magnificamide (grey line) in 0.01M phosphate buffer, pH 7.0, far or peptide bond UV region.
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StructureI II III I II III
Magnificamide 0.0 1.7 1.7 21.4 13.7 35.1 24.3 38.9
r-Magnificamide 0.1 1.1 1.2 18.2 14.7 32.9 22.2 43.7
Helianthamide 19 32 18 31
r-Helianthamide 11 33 23 33
2.3. Molecular Modeling
The spatial structure models of magnificamide were generated using the homology modeling
approach with MOE 2016.08 software (Montreal, QC, Canada) [21]. The atom coordinates of the
helianthamide from S. helianthus, extracted from the complex with porcine pancreatic α-amylase (PDB
ID 4XON) were used as a template. Then the solvated models were optimized using the 400 ns MD
simulations in Amber10: EHT force field and the most energetically favorable state of magnificamide
was selected (Figure 5b). The molecule has a characteristic fold stabilized by 3 disulfide bridges,
including a β-sheet, formed by four strands, an α-helix, and several loops, as well as sufficiently mobile
C and N-terminal regions. The content of secondary structure elements agrees well with the data of
CD spectroscopy of the native peptide. Despite the relatively high RMSD value for 44 Cα atoms of
magnificamide model relative to the prototype—2.46 Å, the model quality assessment showed no
conformational constraints (ψ and ϕ-angles) of amino acid residues, which indicates the good quality
of the generated model. It turned out that the largest deviation (from 2 Å to 5.6 Å) involved the flexible
parts of the structure in the sequence regions 1–4, 10–12, 18–20, and 32–33. It should be noted that
these areas either included variable amino acid residues or were localized in close proximity to those
(Figure 5a). The mapping of magnificamide variable residues revealed an interesting feature. In fact,
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Figure 5. (a) Alignment of sea anemone α-amylase inhibitors: magnificamide H. magnifica [18] and
helianthamide from S. helianthus [17] amino acid sequences and their spatial structures. (b) The
ribbon diagrams of magnificamide and helianthamide spatial structures are colored according to
the structure elements; the side chains of the variable residues magnificamide are shown as sticks
and labeled. Molecular dipole and hydrophobic moments are indicated by blue and green arrows,
respectively. (c) Magnificamide and helianthamide molecular surfaces are colored according to surface
charge distribution.
Using the MOE 2016.08 program, the physicochemical characteristics of the inhibitor were
evaluated and the surface properties of magnificamide were analyzed to compare them with
helianthamide (Table 2). It was shown that, despite its greater compactness, this molecule was
characterized by a larger hydrophobic surface area, as well as a redistribution of the localization of
charged regions (Figure 5c). This is manifested in a change in both the magnitude and direction of the
dipole, and in the hydrophobic moments of the molecules (Figure 5b; Table 2).
Table 2. Physico-chemical characteristics of the α-amylase inhibitors.
Physico-Chemical Characteristics Magnificamide Helianthamide (PDB ID 4XON)
Radius of hydration (Å) 10.25 10.21
Hydrophilic surface area (Å2) 2009.0 1976.3
Hydrophobic surface area (Å2) 1553.0 1275.4
WDW volume (Å3) 3727.1 4157.9
Isoelectric point 5.81 5.33
Charge −1.21 −1.82
Dipole moment (D) 161.86 96.07
Hydrophobic moment 145.7 165.9
2.4. Study of Antimicrobial Activity
Since the main function of defensins in most organisms-producers is the protection against
microorganisms [22–28], we performed a screening of potential antimicrobial activity displayed by
r-magnificamide. It did not reveal activity against fungi, Gram-positive or Gram-negative bacteria
(Table 3).
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Table 3. Antimicrobial activity of r-magnificamide.
Organisms r-Magnificamide (1, 5, 10, 20 μM)
Gram-positive Staphylococcus aureus ATCC 21027 Not active
Bacillus subtilis ATCC6633 Not active
Gram-negative Escherichia coli VKPM B-7935 Not active
Pseudomonas aeruginosa ATCC 27853 Not active
Fungi Candida albicans KMM 455 Not active
2.5. Study of Channel Modulating Activity
Since defensins are widely present in animal venoms, also known as toxins with modulating
effects on the activity of ion channels [23,29–33], we performed an extensive electrophysiological
screening of r-magnificamide against 18 subtypes of voltage-gated potassium and voltage-gated sodium
channels (mammalian channels: Kv1.1, Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv1.6, Kv2.1, Kv3.1, Kv4.2, Kv10.1,
hERG, Nav1.2, Nav1.4, Nav1.5, Nav1.6 and Nav1.8; insect channels: Shaker and BgNav1) (Table 4).
r-Magnificamide did not reveal ion channel modulating activity, from which it can be surmised, to
conclude, that the main biological function of magnificamide is the inhibition of α-amylases.
Table 4. Electrophysiological study of r-magnificamide.
Channels r-Magnificamide (10 μM)
Voltage-gated potassium
channels
Kv1.1, Kv1.2, Kv1.3, Kv1.4, Kv1.5, Kv1.6,








2.6. Study of Mammalian α-Amylase Inhibition
Since magnificamide shared a high sequential and structural similarity with the competitive
tight-binding inhibitor helianthamide, it was predicted to possess analogous kinetic features. For a
quantitative assessment of tight-binding inhibitor potency, Morrison’s method was applied [34,35].
This method uses the Morrison quadratic equation (Equation (1)) for fitting inhibitor-response data





















Recombinant magnificamide inhibition constants against porcine pancreatic α-amylase (PPA)
and human salivary α-amylase (HSA) were determined. Kinetic assays revealed that recombinant
magnificamide was indeed a potent nanomolar tight-binding inhibitor: Ki against PPA was
0.17 ± 0.06 nM; Ki against HSA was 7.7 ± 1.5 nM (Figure 6).
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Figure 6. Amylase inhibition curves using r-magnificamide. Fixed concentrations of each enzyme (PPA
on (a) and HSA on (b)) were mixed with increasing concentrations of r-magnificamide (displayed in
nM). Each connecting line represents the best fits to the quadratic Morrison equation for tight binding
inhibitors [35].
3. Discussion
Sea anemones are ancient sessile predators inhabiting the marine environment. They have
specialized stinging cells which contain venom rich in peptides acting on different biological targets,
mainly cytoplasmic membranes [36–38] and ion channels [39–44]. Venom with such a complex
composition ensured the existence of sea anemones for millions of years [45]. Recently, it has been
shown that sea anemones also present a source of pancreatic α-amylase inhibitors belonging to the
β-defensin family [18,19]. In the venoms of sea anemones, the β-defensin fold is widely recruited to
create toxins modulating ion channel activity, interestingly, often with little amino acid sequence identity,
but with similar spatial structure. According to Mitchell and coauthors, cnidarian β-defensin-like
toxins can be divided into four main groups: APETx-like, BDS-like, Nv1-like, and ShI-like [46].
Representatives of APETx-like and BDS-like groups interact with ASICs, hERG, voltage-gated sodium,
and potassium ion channels [33,47–49]. Some of them, crassicorin I and II from Urticina crassicornis,
reveal paralytic activity against crustaceans, as well as antimicrobial activity against Gram-positive
and Gram-negative bacterial strains [33]. Nv1-like and ShI-like peptides are often a major content of
sea anemones’ venom and modulate voltage-gated sodium ion channels [50,51]. Helianthamide-like
peptides represent a separate group [46] suggesting a different activity.
Taking into account the wide variety of sea anemone defensin-functions, we conducted a study of
activity of magnificamide on various ion channels (Table 4) and found no activity. No antimicrobial
activity against Gram-positive, Gram-negative bacteria, or fungi was observed either (Table 3). Thus,
structural remoteness may occur due to narrow specialization of sea anemones’ helianthamide-like
peptides. The presence of numerous digestive enzyme (proteinases and amylases) inhibitors [19] in
sea anemone venoms is per se an interesting defensive strategy, similar to plant protection from insects
and herbivores.
From a practical point of view, pancreatic α-amylase inhibitors effectively control the influx of
glucose into the bloodstream from the gastrointestinal tract [18,19]. Inhibitors of pancreatic α-amylase
have a great pharmacological potential for the prevention and treatment of metabolic disorders and
type 2 diabetes mellitus. In this work we have shown that magnificamide was an effective inhibitor
of mammalian α-amylases. The homologue of magnificamide, helianthamide from S. helianthus,
inhibited PPA with very close Ki (Table 5). Sea anemone inhibitors had great inhibitory activity against
mammalian α-amylases (Table 5); the combination of such activity with a compact fold could be used
to create new drugs.
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Table 5. Mammalian α-amylase inhibitors from different sources.
Inhibitor name Source Mr, Da Ki, M Enzyme Reference
Peptides

























Montbretin A Crocosmia sp. 789 8.1 × 10−9 HPA [11]
Moreover, for the first time, sea anemone peptides’ ability to inhibit HSA was clarified on the
example of magnificamide, with Ki equal to 7.7 nM. Inhibition of salivary α-amylase allows for blocking
the digestion of starch upon the first stages of entering the body. In addition, it may be useful for the
treatment of diseases the of oral cavity, including caries. Caries is a multifactorial disease, a significant
role in the development of which is played by oral Streptococci, capable of binding salivary α-amylase
and using sugar that can be broken down by it for their own needs. The binding of Streptococci to
salivary α-amylase also contributes to the formation of biofilms and the demineralization of teeth [52].
It has been shown that cherry and tea extracts exhibiting inhibitory activity for salivary α-amylase
could inhibit the growth of oral Streptococci (in particular Streptococcus mutans) [53–55]. Given a stable
structure and high activity of magnificamide, it may also find an application in the form of chewing
gum, as was shown for cherry extract [53].
4. Materials and Methods
4.1. Obtaining the Recombinant Magnificamide
The synthetic gene encoding the target peptide was cloned into a pET32b(+) (Novagen, Germany)
vector using the restriction sites for KpnI and XhoI by JSC "Eurogen" company, Moscow, Russia. The
resulted construct was checked by sequencing to verify the open reading frame.
The expression construction pET32b(+)/magnificamide was used for the transformation of BL21(DE3)
E. coli cells by electroporation using a Multiporator (Eppendorf, Hamburg, Germany) device. Cells
were screened on LB agarose plates containing 100 μg/mL carbenicillin (Invitrogen, Carlsbad, CA, USA).
Next the transformed cells were cultured in LB medium (1 L) containing 100 μg/mL carbenicillin at 37 ◦C
to the optical density of (at A600) 0.6–0.8. Isopropyl-β,D-thiogalactopyranoside (IPTG) (Invitrogen,
Carlsbad, CA, USA) was added to a final concentration of 0.2 mM for induction of expression. The
cells were grown for 16 h at 18 ◦C for the production of the fusion protein in a soluble form and then
cells were precipitated from the culture medium by centrifugation at 8000 rpm for 6 min. Cells were
lysed by ultra-sonication on a Sonopuls 2070 instrument (Bandeling, Berlin, Germany). The fusion
protein Trx-magnificamide was isolated from the cell lysate by metal affinity chromatography on
the Ni-NTA-agarose (Qiagen, Hilden, Germany) in native conditions. Then the fusion protein was
desalted using Amicon Ultra-15 Centrifugal Filter Units 3000 NMWL (Millipore, Burlington, MA, USA),
followed by hydrolysis by Enterokinase (NEB, Ipswich, MA, USA) according to the manufacturer’s
instructions. Recombinant magnificamide was purified from the reaction mixture by RP-HPLC, using
a Jupiter C4 column (Phenomenex, Torrance, CA, USA), equilibrated with 0.1% TFA at pH 2.2, in a
gradient of acetonitrile (with concentrations from 0%–70%) for 70 min at 2 mL/min. The retention time
of the target peptide was 30 min.
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4.2. Mass Spectrometry Analysis
MALDI-TOF MS spectra of the peptide fractions obtained by RP-HPLC were recorded using an
Ultra Flex III MALDI-TOF/TOF mass spectrometer (Bruker, Bremen, Germany) with a nitrogen laser
(Smart Beam, 355 nm), reflector, and the potential LIFT™ tandem modes of operation. Sinapinic acid
was used as a matrix. An external calibration was employed using a peptide sample [56] with m/z
6107 Da and its doubly-charged variant at m/z 3053 Da.
4.3. Assay of Porcine Pancreatic α-Amylase Inhibitory Activity
The porcine α-amylase (PPA) inhibitory activity of the peptide fractions obtained by RP-HPLC was
tested by the following procedure. Experimental samples (10 μL) were added to 80 μL of 50 mM sodium
phosphate, 100 mM sodium chloride buffer (pH 7.0), and PPA (A4268) (1 μg/mL) (Sigma Aldrich,
St. Louis, MO, USA), and incubated for 10 min at RT. The substrate solution, 2-chloro-4-nitrophenyl
α-D-maltotrioside (CNPG3) (Sigma Aldrich, St. Louis, MO, USA), was added to the reaction mixture
(1 mM) and incubated for 10 min at RT. The optical absorption was measured on an xMark microplate
spectrophotometer (BioRad, Hercules, CA, USA) at 405 nm. Acarbose (1mg/mL) (Sigma Aldrich, St.
Louis, MO, USA) was used as a positive control.
4.4. Circular Dichroism Spectroscopy
Circular dichroism (CD) spectra were recorded on Chirascan-plus CD spectropolarimeter (Applied
Photophysics, Leatherhead, UK) in quartz cells with an optical path length of 0.1 cm for the peptide
region spectrum. The cuvette with the solution of the native and recombinant peptides (50 μg/mL) in a
0.01 M sodium phosphate buffer was incubated at 25 ◦C for 20–25 min before recording the CD spectrum.
The content of secondary structure elements of peptides was calculated by the Provenzer–Glockner
method [20], using advanced Provencher calculation programs from the CDPro software package
(Leatherhead, UK) [57].
4.5. Homology Modeling
The generation of a theoretical model of the spatial structure of magnificamide, as well as the
valuation of its physico-chemical characteristics, were performed using the specialized software MOE
2016.08 (Montreal, QC, Canada) [21]. Simulation of the molecular dynamics of magnificamide in an
aqueous environment, as well as the physicochemical characteristics valuation of α-amylase inhibitors,
were performed in Amber10: EHT force field.
4.6. In Vitro Antimicrobial Activity Assay
The antimicrobial activity of r-magnificamide was tested against Gram-positive (Staphylococcus
aureus ATCC 21027 and Bacillus subtilis ATCC6633), Gram-negative bacteria (Escherichia coli VKPM
B-7935 and Pseudomonas aeruginosa ATCC 27853), and the fungus Candida albicans KMM 455 by the
agar dilution method. Microbial strains were taken from the American Type Culture Collection
(ATCC), Russian National Collection of Industrial Microorganisms (VKPM), and Collection of Marine
Microorganisms (KMM) (Pacific Institute of Bioorganic Chemistry FEB RAS). To obtain a microbial
lawn, 0.1 mL of a cell suspension (0.5 × 108 cells/mL) was uniformly distributed on agar surface in
Petri dishes (15 g/L tryptic soy broth, 2 g/L bacto yeast extract, 1 g/L glucose, and 20 g/L agar for
bacteria; for fungi 10 g/L of glucose was added). Wells with a diameter of 6 mm were punched into the
agar and filled with 100 μL of the peptide solution at concentrations 1, 5, 10, and 20 μM. The plates
were then incubated for 18 h at 37 ◦C for bacteria, and at 30 ◦C for the fungus. Minimum inhibitory
concentration was determined by measuring the clear zone of inhibition around each well. All assays
were performed independently three times.
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4.7. Electrophysiology
For the expression of Nav channels (mammalian rNav1.2, rNav1.4, hNav1.5, mNav1.6 and hNav1.8
channels; the insect channel BgNav1 from Blattella germanica; and the auxiliary subunits rβ1, hβ1, and
TipE) and Kv channels (mammalian rKv1.1, rKv1.2, hKv1.3, rKv1.4, rKv1.5, rKv1.6, rKv2.1, hKv3.1,
rKv4.2, hKv10.1, and hERG; and Drosophila Shaker’s IR) in Xenopus laevis oocytes; the linearized plasmids
were transcribed using the T7 or SP6 mMESSAGE-mMACHINE transcription kit (Ambion, Carlsbad,
CA, USA). The harvesting of stage V–VI oocytes from anesthetized female Xenopus laevis frog was
previously described [58]. Oocytes were injected with 50 nL of cRNA at a concentration of 1 ng/nL
using a microinjector (Drummond Scientific, Broomall, PA, USA). The oocytes were incubated in a
solution containing 96-mM NaCl, 2-mM KCl, 1.8-mM CaCl2, 2-mM MgCl2, and 5-mM HEPES (pH 7.4),
supplemented with 50 mg/L gentamycin sulfate.
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 ◦C) using
a Geneclamp 500 amplifier (Molecular Devices, Downingtown, PA, USA) controlled by a pClamp
data acquisition system (Axon Instruments, Union City, CA, USA). Whole cell currents from oocytes
were recorded 1–4 days after injection. The bath solution’s composition was 96-mM NaCl, 2-mM KCl,
1.8-mM CaCl2, 2-mM MgCl2, and 5-mM HEPES (pH 7.4). Toxins were applied directly to the bath.
Resistances of both electrodes were kept between 0.8 and 1.5 MΩ. The elicited currents were sampled
at 20 kHz (Nav) or 2 kHz (Kv), filtered at 2 kHz (Nav) or 0.5 kHz (Kv) using a four-pole low-pass Bessel
filter. Leak subtraction was performed using a -P/4 protocol. Only data obtained from cells exhibiting
currents with peak amplitudes below 2 μA were considered for analysis. For the electrophysiological
analysis, a number of protocols were applied from a holding potential of −90 mV with a start-to-start
interval of 0.2 Hz. Kv1.1–Kv1.6 and Shaker currents were evoked by 250-ms depolarizations to 0 mV
followed by a 250 ms pulse to −50 mV from a holding potential of −90 mV. Current traces of hERG
channels were elicited by applying a +40 mV prepulse for 2 s followed by −120 mV for 2 s. Kv2.1,
Kv3.1, and Kv4.2 currents were elicited by 250 ms pulses to +20 mV from a holding potential of −90 mV.
Kv10.1 currents were evoked by 2-s depolarizing pulses to 0 mV from a holding potential of −90 mV.
Sodium current traces were evoked by 100-ms depolarization to the voltage corresponding to maximal
sodium current in control conditions. All data were analyzed using pClamp Clampfit 10.0 (Molecular
Devices, Downingtown, PA, USA) and Origin 7.5 software (Originlab, Northampton, MA, USA).
4.8. Determination of Ki Against Porcine Pancreatic and Human Saliva α-Amylases
Kinetic assays were carried out at 37 ◦C in 50 mM sodium phosphate and 100 mM sodium chloride
(pH 7.0). 2-Chloro-4-nitrophenyl-α-maltotrioside (CNPG3) (Sigma Aldrich, St. Louis, MO, USA) was
used as the substrate and the optical absorption of the 2-chloro-4-nitrophenol was measured at 405 nm.
Reactions were run with final [CNPG3] = 1 mM ([S]/KM = 1.41, KM = 0.71 mM), nominal [E] = 20 nM for
PPA, [CNPG3] = 3.3 mM ([S]/KM = 0.97, KM = 3.4 mM), and nominal [E] = 100 nM for HSA to provide
sufficient analytical signal. Inhibitor dilution schemes were optimized considering recommendations
in [34].
The enzyme was pre-incubated with the inhibitor for 10 minutes before the addition of substrate
which launched the reaction. Reactions were monitored on an xMark microplate spectrophotometer
(BioRad, USA) in the kinetic mode for 30 min. The initial linear steady state region provided initial
rate values for each inhibitor concentration (υ), along with uninhibited rate values (υo). Measurements
were run in triplicate. Nonlinear least squares regression was carried out with GraphPad Prism 7.00
(San Diego, CA, USA). Fractional rates (υ/υo) were plotted against inhibitor concentrations and the set of
data points was fitted by the Morrison Ki regression algorithm [34,35]. Ki and [E] were simultaneously
treated as adjustable parameters following the approach described in [59]. Derived enzyme active sites
concentrations showed physically meaningful values close to nominal (34.6 and 132.5 nM for PPA and
HSA respectively). Best-fit constant values were presented as mean ± SE (n = 3).
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Abstract: Intracellular reactive oxygen species (ROS) play an important role in the proliferation
and differentiation of hematopoietic stem and progenitor cells (HSPCs). HSPCs are difficult to be
expanded ex vivo while maintaining their stemness when they are exposed to oxidative damage after
being released from the bone marrow. There have been efforts to overcome this limitation by using
various cytokine cocktails and antioxidants. In this study, we investigated the effects of echinochrome
A (Ech A)-a well-established and non-toxic antioxidant-on the ex vivo expansion of HSPCs by
analyzing a CD34+ cell population and their biological functions. We observed that Ech A-induced
suppression of ROS generation and p38-MAPK/JNK phosphorylation causes increased expansion
of CD34+ cells. Moreover, p38-MAPK/JNK inhibitors SB203580 and SP600125 promoted ex vivo
expansion of CD34+ cells. We also demonstrated that the activation of Lyn kinase and p110δ is a novel
mechanism for Ech A to enhance ex vivo expansion of CD34+ cells. Ech A upregulated phospho-Src,
phospho-Lyn, and p110δ expression. Furthermore, the Ech A-induced ex vivo expansion of CD34+
cells was inhibited by pretreatment with the Src family inhibitor PP1 and p110δ inhibitor CAL-101;
PP1 blocked p110δ upregulation and PI3K/Akt activation, whereas CAL-101 and PI3K/Akt pathway
inhibitor LY294002 did not block Src/Lyn activation. These results suggest that Ech A initially induces
Src/Lyn activation, upregulates p110δ expression, and finally activates the PI3K/Akt pathway. CD34+
cells expanded in the presence of Ech A produced equal or more hematopoietic colony-forming cells
than unexpanded CD34+ cells. In conclusion, Ech A promotes the ex vivo expansion of CD34+ cells
through Src/Lyn-mediated p110δ expression, suppression of ROS generation, and p38-MAPK/JNK
activation. Hence, Ech A is a potential candidate modality for the ex vivo, and possibly in vivo,
expansion of CD34+ cells.
Keywords: hematopoietic stem and progenitor cells; CD34+ cells; ex vivo expansion; Lyn; Src;
p110δ; ROS
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1. Introduction
Hematopoietic stem and progenitor cell (HSPC) transplantation is widely used for the treatment
of various hereditary diseases and blood-related malignancies, such as leukemia, and to promote
hematologic recovery following anticancer therapy [1]. HSPCs can be harvested from bone marrow,
umbilical cord blood (UCB), or mobilized peripheral blood (PB) using granulocyte colony-stimulating
factor (G-CSF) administration for autologous and allogeneic transplantation [2]. Currently, PB-HSPC
transplantation accounts for more than 60% of total HSPC transplantation worldwide, mainly due to
the less invasive collection procedures [3]. However, the insufficient number of HSPCs, even after
multiple days of collection, is a limiting factor for their clinical application of transplantation [4].
Several researchers are exploring ex vivo expansion of HSPCs to overcome this limitation; however,
ex vivo expansion remains a difficult challenge for HSPC-based therapies.
Reactive oxygen species (ROS) are generated in the mitochondria; they regulate proliferation,
differentiation, motility, and quiescence in many cell types, including HSPCs [5,6]. A previous study
using a mouse model showed that increased levels of ROS can promote the differentiation of stem
cells [7]. Quiescent HSPCs reside in a hypoxic niche in the bone marrow microenvironment that
protects them from oxidative stress caused by excessive ROS production, mitochondrial dysfunction,
or a combination of both [7,8]. HSPCs can proliferate and differentiate in the oxygen-rich vascular
niche, resulting in increased intracellular ROS levels. ROS can regulate HSPC activity and various
levels of ROS accumulation may affect the fate of HSPCs. High levels of ROS can trigger HSPC
dysfunction, aging, and DNA damage. On the contrary, moderate levels of ROS are necessary for the
proliferation, mobilization, and differentiation of HSPCs, and low-ROS cells have been shown to retain
long-term self-renewal ability [7,9–11]. Culture media with appropriate cytokines are usually required
for ex vivo cultures of HSPCs. However, it is still important to regulate the levels of ROS, as cytokine
treatment itself triggers intracellular ROS generation [12]. Antioxidants can effectively remove excess
ROS and maintain the redox balance of cells [13,14]. A recent study showed that N-acetyl cysteine
(NAC) can reduce ROS levels to enhance ex vivo expansion of HSPCs [15].
Src family kinases (SFKs), including Lyn, Fyn, Fgr, Yes, Lck, Hck, Blk, and Trk, are well known
for their contribution to malignant transformation and oncogenesis, and control downstream targets
to regulate cell proliferation, differentiation, adhesion, migration, and the cell cycle [16]. Because
of their role in cancer development and progression, SFKs have become critical targets for cancer
therapy [17]. In the immune system, the most well-known function of SFKS is their role in integrin
signaling [16]. Fyn and Lck kinases are also found in T cells and natural killer (NK) cells [18]. Lyn
is a non-receptor tyrosine kinase that is predominantly found in the hematopoietic cells of myeloid
and B lymphocyte lineages [19]. Lyn was originally identified as a hematopoietic-specific kinase; it is
expressed in multiple tissues and is involved in the signaling of the B-cell receptor [20], GM-CSF
receptor [21], erythropoietin (EPO) receptor [22], and c-kit [23]. Lyn phosphorylates several signaling
molecules, including PI3K, FAK [24], ras-GAP, and Stat5 [25]. Lyn also plays an important role in
acute myeloid leukemia (AML) cell proliferation [26], and the silencing of Lyn in imatinib-resistant
chronic myelogenous leukemia (CML) cells can induce apoptosis [27]. Lyn activation induces p110
expression, whereas Lyn inhibition decreased migration in ovarian cancer cells exposed to cigarette
smoke [28]. Colon cancer cells use Lyn for activation of the anti-apoptotic PI3K p110/Akt pathway and
the induction of epithelial-mesenchymal transition (EMT) [29]. Therefore, several pieces of evidence
show an important association of Lyn in both leukemia and solid tumor development. However,
the exact roles and Lyn/Src activation in the relationship with ROS during the ex vivo expansion of
HSPCs are still unclear.
Echinochrome A (Ech A) is a dark red pigment that is isolated from eggs, spines, and larvae
of sea urchins [30]. Ech A is known to possess antioxidant, antiviral, antialgal, and antimicrobial
activities [31,32]. Importantly, Ech A was shown to exhibit diverse intracellular antioxidant mechanisms,
including the elimination of free radicals [33], inhibition of pulmonary fibrosis [34], and chelation
of metal ions [35]. In this study, we demonstrate that Ech A is an effective agent to promote the
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ex vivo expansion of G-CSF-mobilized PB-derived CD34+ HSPCs through Src/Lyn-mediated p110δ
upregulation, the suppression of ROS generation, and p38-MAPK/JNK activation.
2. Results
2.1. Ech A Suppresses ROS Production and Promotes Expansion of PBMC-Derived CD34+ Cells
HSPCs reside in a hypoxic niche in the bone marrow, suggesting that HSPCs need to adopt
unique metabolic properties, including intracellular ROS levels. We found that PB-derived CD34+ cells
(PB-CD34+ cells) exhibit higher ROS levels than BM-derived CD34+ cells (Figure 1A). We then examined
whether Ech A can modulate ROS levels to cause an ex vivo expansion of PB-CD34+ cells. To determine
the optimal concentration of Ech A, G-CSF-mobilized PB mononuclear cells (PBMCs) were treated
with different concentrations of Ech A (0, 1, 10, 20, 50, and 100 μM) for 24 h, and the CD34+ cell number
was analyzed by flow cytometry. Cells treated with 10 μM Ech A for 24 h showed approximately
two-fold higher CD34+ cell number than those in the control group (Figure S1A); therefore, we chose
that condition for subsequent experiments. The effect of Ech A on the ex vivo expansion of PBMCs
containing CD34+ or purified PB-CD34+ was investigated after 1 day or 4 days of culture, respectively
(Figure 1B). The toxic reagent N-acetyl cysteine (NAC)—a well-known potent antioxidant—was used
as the positive control. Immunophenotypic analysis showed a significantly higher percentage of CD34+
cells and the CD34+ cell number in Ech A-treated group (PBMCs, 12.91% ± 3.22%, 2.05 ± 0.66-fold;
PB-CD34+ cells, 73.37% ± 1.11%, 4.95 ± 0.28-fold) than that in the control group (PBMCs, 7.07 ± 0.66%,
0.87 ± 0.08-fold; PB-CD34+ cells, 67.27 ± 1.79%, 3.71 ± 0.18-fold). As shown in Figure 1C, Ech A
dramatically suppressed intracellular ROS production in PBMCs and PB-CD34+ cells. Additionally,
H2O2 treatment showed dramatic suppression of PB-CD34+ cell expansion that was recovered by
Ech A treatment (Figure S2). These results suggest that Ech A promotes the ex vivo expansion of
PBMC-derived CD34+ cells by suppressing ROS levels.
2.2. Ech A Inhibits the Activation of p38-MAPK and JNK in PB-CD34+ Cells
After 1 or 4 days of culture, the levels of phosphorylated p38-MAPK and JNK were significantly
increased in the expanded cells (Figure 2A; negative control). However, the phosphorylation of
p38-MAPK and JNK was dramatically suppressed upon the treatment of Ech A or NAC (Figure 2A).
On the other hand, ERK1/2 phosphorylation remained unchanged in the cells. To examine whether
p38-MAPK/JNK activation inhibits the ex vivo expansion of human PB-CD34+ cells, cells were cultured
in the presence of vehicle (0.1% DMSO), SB203580 (SB; 5 μM), or SP600125 (SP; 5 μM) for 1 or 4 days.
The expanded cells were harvested for cell counts, and the analysis of CD34 expression by flow
cytometry. As illustrated in Figure 2B, the total number of PBMCs was comparable irrespective of
whether cells were incubated with or without SB or SP. Cell cultures with SB or SP showed a considerable
increase in the number of CD34+ cells compared to the DMSO control group. In particular, the number
of CD34+ cells was approximately 1.5-fold higher in the presence of SB (PBMCs, 2.17% ± 0.06%,
1.45 ± 0.05-fold; PB-CD34+ cells, 72.27% ± 5.01%, 6.38 ± 0.27-fold) or SP (PBMCs, 2.33% ± 0.31%,
1.51 ± 0.22-fold; PB-CD34+ cells, 71.27% ± 7.83%, 6.34 ± 0.61-fold) than that in the DMSO control group
(PBMCs, 1.33% ± 0.06%, 0.85 ± 0.07-fold; PB-CD34+ cells, 55.00% ± 0.56%, 4.43 ± 0.05-fold). However,
ROS levels in PB-CD34+ cells were unaffected by SB or SP (Figure 2C). These results suggest that
p38-MAPK/JNK inhibition increases the ex vivo expansion of CD34+ cells, even at high ROS levels.
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Figure 1. Ech A increases PB-CD34+ cell expansion by inhibiting reactive oxygen species’ (ROS)
generation. (A) Cells were treated with 10 μM 2′7′-dichlorodihydro-fluorescein diacetate for 30 min.
The values in the 2′7′-dichlorofluorescein histograms indicate MFI (mean fluorescence intensity).
(B,C) Cells were treated with 10 μM Ech A for 1 day (PB mononuclear cells, PBMCs) or 4 days
(PB-CD34+ cells). For NAC treatment, cells were treated with 5 mM NAC for 4 h, washed, suspended in
complete medium, and incubated for an additional 1 day (PBMCs) or 4 days (PB-CD34+ cells). (B) Total
cell number was measured using the ADAM-MC automated mammalian cell counter (NanoEntech,
Seoul, Korea). For flow cytometric immunophenotypic analysis, cells were stained with CD34-PE,
CD38-FITC, CD45-APC, and 7-AAD. Each value was expressed as the mean± SEM of three independent
experiments. (C) Cells were treated with 10 μM 2′7′-dichlorodihydro-fluorescein diacetate for 30 min
and ROS levels were subsequently measured usingthe flow cytometer.
Figure 2. Ech A enhances PB-CD34+ cell expansion by suppressing the activation of p38-MAPK and JNK.
Cells were treated with 10 μM Ech A for 1 day (PBMCs) or 4 days (PB-CD34+ cells). For NAC treatment,
cells were treated with 5 mM NAC for 4 h, washed, suspended in complete medium, and incubated for
an additional 1 day (PBMCs) or 4 days (PB-CD34+ cells). (A) Total protein was subjected to western
blot analysis with the indicated antibodies. β-actin served as the loading control. (B, C) Cells were
pretreated with SB203580 (10 μM) or SP600125 (10 μM) for 4 hr. (B) Total cell number was measured
using the ADAM-MC automated mammalian cell counter. For flow cytometric immunophenotypic
analysis, cells were stained with CD34-PE, CD38-FITC, CD45-APC, and 7-AAD. Each value was
expressed as the mean ± SEM of three independent experiments. (C) Cells were treated with 10 μM
2′7′-dichlorodihydro-fluorescein diacetate for 30 min. The values in the 2′7′-dichlorofluorescein
histograms indicate MFI.
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2.3. Ech A Regulates PB-CD34+ Cell Expansion via PI3K/Akt Pathway
We further assessed the possible molecular mechanisms underlying Ech A-mediated ex vivo
expansion of PB-CD34+ cells. Our results showed that phosphorylation of PI3K-p85 and Akt was
enhanced to a greater extent in Ech A- or NAC-treated cells than that in untreated cells (Figure 3A);
however, phospho-PTEN level were reduced. To verify the requirement of PI3K/Akt signaling
activation for PB-CD34+ cell expansion, we used the PI3K/Akt inhibitor LY294002. As shown in
Figure 3B, pretreatment of the Ech A or NAC treatment group with LY294002 (PBMCs, 7.83 ± 1.31%,
3.29 ± 0.73-fold; PB-CD34+ cells, 71.43 ± 6.45%, 9.55 ± 1.41-fold) substantially reduced the percentage
of CD34+ cells as well as CD34+ cell number compared to Ech A or NAC single treatment group
(PBMCs, 23.63 ± 1.7%, 14.43 ± 2.42-fold; PB-CD34+ cells, 84.43 ± 0.93%, 22.33 ± 1.49-fold).
 
Figure 3. Echinochrome A (Ech A) upregulates PB-CD34+ cell expansion by activating PI3K/Akt
pathway. Cells were treated with 10 μM Ech A for 1 day (PBMCs) or 4 days (PB-CD34+ cells). For NAC
treatment, cells were treated with 5 mM NAC for 4 h, washed, suspended in complete medium,
and incubated for an additional 1 day (PBMCs) or 4 days (PB-CD34+ cells). (A) Total cell lysates
for each condition were immunoblotted with the indicated antibodies. (B) Cell were pretreated
with LY294002 (10 μM) for 4 h. Total cell number was determined using the ADAM-MC automated
mammalian cell counter. For flow cytometric immunophenotypic analysis, cells were stained with
CD34-PE, CD38-FITC, CD45-APC, and 7-AAD. Each value was expressed as the mean ± SEM of three
independent experiments.
2.4. The PI3K p110δ Isoform Is Required for Ech A-Induced CD34+ Cell Expansion
Next, we examined which p110 isoforms were associated with the expansion of PB-CD34+ cells,
following Ech A or NAC treatment using antibodies, each specific for different p110 isoforms of PI3K.
Ech A- or NAC-treated PBMCs or PB-CD34+ cells showed a higher expression of p110δ than untreated
PB-CD34+ cells; however, p110α, p110β, and p110γ expression was not affected by Ech A or NAC
treatment (Figure 4A). To identify the role of p110δ in Ech A- or NAC-induced PB-CD34+ cell expansion,
cells were treated with Ech A or NAC in the presence or absence of the p110δ specific inhibitor, CAL-101.
The percentage of CD34+ cells and the CD34+ cell number in the Ech A or NAC single treatment group
(PBMCs, 23.63% ± 1.7%, 15.32 ± 1.27-fold; PB-CD34+ cells, 82.07% ± 0.32%, 18.55 ± 1.12-fold) were
remarkably decreased by CAL-101 pretreatment (PBMCs, 7.57% ± 1.99%, 3.37 ± 0.74-fold; PB-CD34+
cells, 70.67% ± 2.73%, 7.93 ± 1.23-fold) (Figure 4B).
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Figure 4. Ech A induces the activation of the PI3K p110δ isoform for PB-CD34+ cell expansion. Cells
were treated with 10 μM Ech A for 1 day (PBMCs) or 4 days (PB-CD34+ cells). For NAC treatment,
cells were treated with 5 mM NAC for 4 h, washed, suspended in complete medium, and incubated for
an additional 1 day (PBMCs) or 4 days (PB-CD34+ cells). (A) Total protein was subjected to western
blot analysis with the indicated antibodies. (B) Cells were pretreated with CAL-101 (20 μM) for 4 h.
Total cell number was determined using the ADAM-MC automated mammalian cell counter. For flow
cytometric immunophenotypic analysis, cells were stained with CD34-PE, CD38-FITC, CD45-APC,
and 7-AAD. Each value was expressed as the mean ± SEM of three independent experiments.
2.5. Src/Lyn Is a Major Upstream Signal for Ech A-Induced p110δ-Mediated CD34+ Cell Expansion
We also investigated Src family kinases associated with the increased expression of p110δ upon
Ech A or NAC treatment in PB-CD34+ cells. Compared with untreated controls, treatment with Ech
A or NAC increased Src phosphorylation levels, but produced little effect on Fyn phosphorylation.
Interestingly, Lyn was significantly phosphorylated only by Ech A treatment, but not by NAC
(Figure 5A). To identify the requirement for the Src/Lyn pathway in Ech A- or NAC-induced p110δ
expression, we used the Src/Lyn inhibitor PP1. The percentages of CD34+ cells and the CD34+ cell
number in the Ech A or NAC single treatment group (PBMCs, 14.2%± 1.39%, 8.37± 0.13-fold; PB-CD34+
cells, 81.57% ± 1.88%, 9.43 ± 0.55-fold) were significantly lower than that in the PP1 pretreatment
group (PBMCs, 8.63% ± 2.65%, 4.41 ± 1.40-fold; PB-CD34+ cells, 70.27% ± 1.54%, 6.84 ± 0.11-fold)
(Figure 5B). To establish a possible link between Ech A- and NAC-induced Src/Lyn phosphorylation
and PI3K activation during the ex vivo expansion of CD34+ cells, we treated cells with PP1, LY294002,
or CAL-101. First, we confirmed the activity of various inhibitors used in this study on each target
molecule (Figure S3). As shown in Figure 5C, PP1 dramatically suppressed Ech A or NAC-mediated
expression of p110δ and PI3K/Akt activation. On the other hand, LY294002 and CAL-101 did not
inhibit Ech A- or NAC-induced Src/Lyn activation (Figure 5D,E). These results suggest that Lyn is
activated prior to p110δ and PI3K/Akt and plays a critical role as an upstream regulatory molecule in
Ech A-induced ex vivo expansion of PB-CD34+ cells.
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Figure 5. Src/Lyn is major upstream signal for p110δ-mediated CD34+ cell expansion by Ech A. Cells
were treated with 10 μM Ech A for 1 day (PBMCs) or 4 days (PB-CD34+ cells). For NAC treatment, cells
were treated with 5 mM NAC for 4 h, washed, suspended in complete medium, and incubated for an
additional 1 day (PBMCs) or 4 days (PB-CD34+ cells). (A,C–E) Total cell lysates for each condition were
harvested and immunoblotted with the indicated antibodies. (B–E) Cells were pretreated with PP1
(10 μM), LY294002 (10 μM), or CAL-101 (20 μM) for 4 h. (B) Total cell number was determined using
the ADAM-MC automated mammalian cell counter. For flow cytometric immunophenotypic analysis,
cells were stained with CD34-PE, CD38-FITC, CD45-APC, and 7-AAD. Each value was expressed as
the mean ± SEM of three independent experiments.
2.6. Ex Vivo Expanded CD34+ Cells Maintain Their Colony-Forming Capacity
As CFU indicates the presence of HSPCs, the colony forming potential (colony-forming
unit/burst-forming unit-erythroid (CFU/BFU-E), CFU-granulocyte/macrophage (CFU-GM), and
CFU-granulocyte/erythroid/macrophage/megakaryocytes (CFU-GEMM), and total CFU) of freshly
isolated CD34+ cells or CD34+ cells, expanded in the absence or presence of Ech A (10 μM) or
NAC (5 mM), was investigated (Figure 6). The frequency of CFU/BFU-E (Ech A, 173.3 ± 3.51; NAC,
181.7 ± 0.58) and total CFU (Ech A, 248.0 ± 5; NAC, 262.7 ± 1.53) in the 10 μM Ech A or 5 mM
NAC group was significantly higher than that in the unexpanded (CFU/BFU-E, 91.3 ± 6.11; total
CFU, 145.7 ± 6.03) or control expanded group (CFU/BFU-E, 99.3 ± 3.06; total CFU, 157.7 ± 3.06).
The frequency of CFU-GM (Ech A, 73.33 ± 2.08; NAC, 80 ± 2) and CFU-GEMM (Ech A, 1.33 ± 0.58;
NAC, 1 ± 0) was not vastly different from the unexpanded (CFU-GM, 52.67 ± 4.04; CFU-GEMM,
1.67 ± 0.58) or control group (CFU-GM, 57.3 ± 3.06; CFU-GEMM, 1 ± 0) (Figure 6A). Although the
number of CFU/BFU-E was higher in the Ech A and NAC expanded groups, the size of CFU/BFU-E
was larger in the unexpanded group (Figure 6B). Therefore, the addition of 10 μM Ech A certainly
improved ex vivo expansion of HSPC numbers, but the potency may have slightly decreased.
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Figure 6. Ex vivo expanded CD34+ cells maintain their colony-forming capabilities. Purified PB-CD34+
non-expanded cells, or cells expanded ex vivo in the presence or absence of NAC or Ech A for 4 days were
evaluated for pluripotency using hematopoietic colony-forming assays in semi-solid methylcellulose
media. (A) Colony-forming unit/burst-forming unit-erythroid (CFU/BFU-E), CFU-granulocyte/
macrophage (CFU-GM), and CFU-granulocyte/erythroid/macrophage/megakaryocytes (CFU-GEMM)
per 500 CD34+ cells plated were enumerated after 14 days of culture. (B) Representative images of
CFU/BFU-E, CFU-GM, and CFU-GEMM for each experimental condition. Magnification: ×200.
3. Discussion
HSPCs with self-renewal and multipotent capacity offer a valuable source for cell-based therapy
and regenerative medicine [36]. Many limitations facing during HSPC transplantations would
have been overcome if ex vivo HSPC expansion and maintenance become possible. However,
the characteristics of the HSPCs are often altered once they leave the hypoxic bone marrow niche,
affecting the quality and quantity of the cultured HSPCs. Studies have shown that the fate of HSPCs is
regulated by the microenvironment of the so-called “stem cell niches” that contain oxygen saturations
of approximately 5% [7]. The increased oxygen tension in normoxic cultures causes the stem cells
to lose their stemness [37]. Various attempts have been carried out to maintain the stemness of
HSPCs and to overcome the limitations associated with ex vivo culturing. These include the utility
of transcription factors, co-culturing with feeder cells [38], the addition of cytokine cocktails [39],
and genetic modification [40]. However, these approaches have some drawbacks, especially when used
in a clinical setting. A few previous studies have suggested that the use of antioxidants can ameliorate
oxidative stress-mediated damage in cultured HSPCs [41]. In this study, we investigated whether
PB-CD34+ cells can be efficiently expanded ex vivo by utilizing Ech A, which has been demonstrated
as an antioxidant in previous studies [32,34].
HSPCs remain quiescent in the osteoblastic niche—the lowest end of the oxygen gradient in the
bone marrow. However, in the oxygen-rich vascular niche, stem cells can proliferate and differentiate
closer to blood circulation, resulting in increased intracellular ROS levels. However, an extremely low
or high level of ROS would cause impaired repopulation capacity or trigger exhaustion of HSPCs [9].
Physiologically, with the aid of intracellular antioxidant enzyme systems and endogenous antioxidants,
HSPCs are able to cope with the damage caused by cumulative ROS [42]. However, the damage is
overwhelmed when HSPCs are subjected to ex vivo expansion, wherein a sharp increase in ROS levels
is often experienced. It is, therefore, critical to regulate the intracellular ROS levels during ex vivo
culturing for the better expansion and maintenance of HSPCs. It has been previously demonstrated that
a reduction in intracellular ROS levels by supplementing antioxidants or lowering oxygen tension in
cell cultures could improve HSPC expansion, and their engraftment and hematopoietic reconstitution
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abilities in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice [43]. Consistent
with this finding, PB-CD34+ cells provoked aberrant ROS generation in the normoxic culture (Figure 1A).
PB-CD34+ cells exhibited higher ROS levels than BM-CD34+ cells (Figure 1A). ROS is a critical mediator
of HSPC quiescence with p38-MAPK. Higher ROS levels can activate the p38-MAPK pathway, which
in turn can promote phosphorylation of p38-MAPK [44]. Our results also showed that PB-CD34+ cells
can upregulate phospho-p38-MAPK and phospho-JNK, likely due to high ROS levels (Figure 2A).
p38-MAPK plays a role in hematopoiesis regulation, particularly in erythropoiesis and granule
formation [45]. Recently, p38-MAPK was identified as an intrinsic modulator that can negatively
regulate HSPC self-renewal [46]. Therefore, both ROS and p38-MAPK have been shown to play an
important role in maintaining HSPC quiescence. Several studies have indicated that HSPCs lose
their ability to regenerate due to elevated ROS levels and specific phosphorylation of p38-MAPK.
Pharmacological inhibition of ROS or p38-MAPK activity can restore HSPC function in the ROShigh
mouse population and rescue these mice from bone marrow damage [7]. Treatment of Ech A and NAC
potently suppressed the activation of p38-MAPK and JNK, and the p38-MAPK inhibitor SB203580 and
the JNK inhibitor SP600125 promoted CD34+ cell expansion, potentially by inhibiting differentiation
(Figure 2). It is noteworthy that the suppression of ROS by Ech A ameliorated the activation of
p38-MAPK and JNK, suggesting that Ech A acts as an efficient antioxidant in the ex vivo culture of
PB-CD34+ cells, and subsequently promotes CD34+ cell expansion.
SFKs in hematopoietic tissues can function as primary regulatory factors, as described in the first
p60-Src gene perturbation experiment to confirm its role in osteopetrosis development [47]. Subsequent
studies revealed SFK activities in B cells, bone marrow, obese cell lines, and Lyn-expressing HSPCs
in all blood cell lines except T cells [19]. In some studies, Lyn was shown to play negative roles in
monocyte production and plasma cell function, as revealed in Lyn-/- mice by M-phi tumorigenesis [48]
and IgM hyperglobulinemia [20]. Although not widely studied, SFKs have also been suggested as
important regulators of erythropoiesis. Avian Src was originally discovered as an oncogene that
promotes sarcoma and erythroleukemia [49]. Interestingly, Lyn–/– mice among the SFK gene-deficient
mice showed an age-dependent increase in the production of splenic erythroblasts [50]. In BM-derived
cultures, early-stage Lyn–/– erythroblasts exhibited a reduced ability to expand and develop beyond
the Kit+CD71+ stage [51]. Therefore, SFKs, such as Lyn and Src, are major signaling mediators that
modulate diverse stimuli to regulate differentiation, migration, proliferation, apoptosis, and metabolism.
However, there is limited information regarding the precise role Lyn/Src and their underlying molecular
mechanisms in the ex vivo expansion of PB-CD34+ cells. PI3K/Akt signaling can be activated by
the downregulation of PTEN by BCR–ABL2. PTEN is a lipid phosphatase that interferes with PI3K
signaling by dephosphorylating phosphatidylinositol-3,4,5-trisphosphate. Class I PI3Ks consist of four
different catalytic isoforms (p110α, p110β, p110γ, and p110δ) and two standard regulatory subunits
(p85 and p101) [52]. PI3K plays an important role in HSPC maintenance and regulation of lineage
development [53]. In this study, we found, for the first time to our knowledge, that Ech A activates Lyn,
which in turn upregulates p110δ expression, and suppresses ROS production and p38-MAPK/JNK
phosphorylation, resulting in enhanced ex vivo expansion of PB-CD34+ cells (Figures 4 and 5).
Furthermore, the addition of Ech A increased CFU/BFU-E producing cell numbers (Figure 6), which
suggests that an appropriate use of Ech A is advantageous for CD34+ cells to maintain self-renewal
potential during ex vivo expansion.
Our findings, as summarized in Figure 7, demonstrate that Ech A can effectively inhibit ROS
production in PB-CD34+ cells. ROS-mediated p38-MAPK/JNK activation can reduce the number of
CD34+ cells, and decrease the self-renewal of PB-CD34+ cells, which was reversed by Ech A treatment.
Our results also demonstrate a novel Lyn-mediated p110δ expression by Ech A in PB-CD34+ cells,
although the precise molecular mechanism of Ech A-induced ex vivo expansion, especially how Lyn
and p110δ are coordinated in PB-CD34+ cells in response to Ech A, remains unclear. Taken together,
Ech A was found to be an effective agent for promoting cell proliferation and maintaining the stemness
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of HSPCs. Ech A is beneficial for CD34+ cells to maintain their self-renewal potential and function
during the ex vivo expansion, and possibly during in vivo expansion of HSPCs.
Figure 7. Schematic representation of Ech A and NAC in the ex vivo expansion of PB-CD34+ cells.
Mobilized PB-CD34+ cells showed higher ROS levels than BM-CD34+ cells. Ech A suppressed
intracellular ROS production in PB-CD34+ cells. Ech A also increased Lyn/Src phosphorylation and
PI3K/Akt activation. Our results suggest that Ech A promotes ex vivo expansion of CD34+ cells through
Lyn/Src-mediated p110δ expression.
4. Materials and Methods
4.1. Isolation of PBMCs and Purification of PB-CD34+ Cells
This study was conducted using samples from healthy donors and patients, and the study protocol
was approved by the Institutional Review Board at the Kosin University College of Medicine. Informed
consent for the study was obtained from all donors. Purified BM- or PB-CD34+ cells were obtained
either from BM (Lonza, Basel, Swizerland) or from small aliquots of mobilized PB from healthy donors
and patients. CD34+ cells from PBMCs were immunoselected using the MACS CD34 MicroBead kit
UltraPure (Miltenyi Biotec, Bergisch Gladbach, Germany). Human CD34+ cells were enriched from
PBMCs by magnetic bead positive selection using Miltenyi immunomagnetically activated cell sorter
(MACS; Miltenyi Biotec). PB-CD34+ cells were then stained for CD45, and the CD34+ purity of greater
than 95% was reanalyzed by flow cytometry. PB-CD34+ cells were expanded in serum-free medium
(SFEM) (Stem Cell Technologies, Vancouver, Canada) supplemented with 50 ng/mL rhSCF (PeproTech,
Rocky Hill, NJ, USA), 10 ng/mL rhIL3 (PeproTech), and 25 μg/mL LDL (Stem Cell Technologies).
4.2. Chemicals and Reagents
Ech A was received as a gift from G.B. Elyakov, Pacific Institute of Bioorganic Chemistry,
Vladivostok, Russia. PPI, SP600125, SB203580, LY294002, and CAL-101 were purchased from Selleck
Chemicals (Houston, TX, USA). NAC was obtained from Sigma-Aldrich (St. Louis, MO, USA).
4.3. Immunophenotypic Analysis by Flow Cytometry
PBMCs, PB-CD34+ cells, and BM-CD34+ cells were tested for cell surface antigen expression by
immunofluorescence and flow cytometric analysis. Cells were harvested and rinsed with PBS, following
which CD34-PE (Miltenyi Biotec, #130-113-179, 1:50), CD38-FITC (Miltenyi Biotec, #130-113-426, 1:50),
CD45RA-APC (Miltenyi Biotec, #130-117-742, 1:50), and 7-AAD (eBioscience, Waltham, MA, USA,
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3 μL/105 cells) were added. Thereafter, cells were incubated at 4 ◦C for 10 min in the dark. Finally,
the stained cells were analyzed using a BD AccuriTM C6 (BD Biosciences).
4.4. Determination of Intracellular ROS Production
The intracellular accumulation of ROS was determined by flow cytometry after staining with the
fluorescent probe DCFH-DA (10 μM, 2′,7′-dichlorodihydro-fluorescein diacetate; Molecular Probes,
Invitrogen, Milan, Italy). DCFH-DA was deacetylated in cells by esterase to a nonfluorescent compound
DCFH, which remains trapped within the cell and is cleaved and oxidized by ROS in the presence of
endogenous peroxidase to a highly fluorescent compound DCF (2′,7′-dichlorofluorescein). Cells were
incubated with 10 μM DCFH-DA for 30 min at 37 ◦C, washed, and resuspended in PBS. ROS levels
were monitored using a BD AccuriTM C6 (BD Biosciences).
4.5. Immunoblotting
Cells were lysed in RIPA (radioimmunoprecipitation assay) buffer (Elpis Biotech, Daejeon,
Korea) supplemented with a protease inhibitor cocktail (Calbiochem, La Jolla, CA, USA) and protein
phosphatase inhibitors (Calbiochem). Protein concentrations were determined using a BCA assay kit
(Pierce, Rockford, IL, USA). Proteins (10 μg/sample) were resolved in an SDS-PAGE gel and transferred
to a nitrocellulose membrane (Millipore Corp., Billerica, MA, USA). Membranes were blocked with
5% skim milk prior to western blot analysis. Chemiluminescence was detected using an ECL kit
(Advansta Corp., Menlo Park, CA, USA) and the Amersham Imager 600 (GE Healthcare Life Sciences,
Little Chalfont, UK). The following primary antibodies were used on fresh individual membranes to
minimize interference by stripping and reprobing: phospho-JNK (Thr183/Tyr185), JNK, phospho-p38
MAPK (Thr180/Tyr182), p38 MAPK, phospho-ERK1/2 (Thr202/Tyr204), ERK1/2, phospho-Src (Tyr416),
Src, phospho-Lyn (Tyr507), Lyn, phospho-Akt (Ser473), Akt, phospho-PI3K p85 (Tyr458/Tyr199), PI3K
p85, PI3K p110α, PI3K p110β, PI3K p110γ, PI3K p110δ, phospho-PTEN (Ser380/Thr382/383), PTEN,
and Fyn (Cell Signaling Technology, Beverly, MA, USA); and β-actin and phospho-Fyn (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). All the raw data from immunoblotting experiments are presented
in Figure S4.
4.6. Colony-Forming Cell (CFC) Assay
CD34+ cells (500 cells/dish) were plated in methylcellulose medium (Methocult H4100, STEMCELL
Technologies, Inc., Canada) supplemented with SCF (50 ng/mL), IL-3 (10 ng/mL), GM-CSF (10 ng/mL)
(PeproTech), and EPO (1 U/mL) in 35-mm culture dishes and incubated at 37 ◦C in a 5% CO2
chamber for 14 days. Colonies were counted and analyzed using a scoring grid and an inverted
microscope (Olympus, Japan). Colonies were classified based on their morphology as colony-forming
unit/burst-forming unit-erythroid (CFU/BFU-E), CFU-granulocyte/macrophage (CFU-GM), and
CFU-granulocyte/erythroid/macrophage/megakaryocytes (CFU-GEMM).
4.7. Statistical Analysis
The data were analyzed using Student’s t-tests and one-way analyses of variance (ANOVA) with
GraphPad Prism software, and are presented as standard error of the mean (SEM), unless otherwise
stated. Statistical significance was defined as * p < 0.01, ** p < 0.05, # p < 0.001, and ## p < 0.005.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/9/526/s1,
Figure S1: Dose-dependent effect of Ech A or NAC on ex vivo expansion of PBMCs; Figure S2: Ech A recovered
PB-CD34+ cell expansion that was suppressed by H2O2 treatment; Figure S3: Each inhibitor was confirmed to
work as expected; Figure S4: Raw data from immunoblotting experiments.
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Abstract: Cardiac progenitor cells (CPCs) are resident stem cells present in a small portion of
ischemic hearts and function in repairing the damaged heart tissue. Intense oxidative stress
impairs cell metabolism thereby decreasing cell viability. Protecting CPCs from undergoing cellular
apoptosis during oxidative stress is crucial in optimizing CPC-based therapy. Histochrome (sodium
salt of echinochrome A—a common sea urchin pigment) is an antioxidant drug that has been
clinically used as a pharmacologic agent for ischemia/reperfusion injury in Russia. However,
the mechanistic effect of histochrome on CPCs has never been reported. We investigated the
protective effect of histochrome pretreatment on human CPCs (hCPCs) against hydrogen peroxide
(H2O2)-induced oxidative stress. Annexin V/7-aminoactinomycin D (7-AAD) assay revealed that
histochrome-treated CPCs showed significant protective effects against H2O2-induced cell death.
The anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and Bcl-xL were significantly upregulated,
whereas the pro-apoptotic proteins BCL2-associated X (Bax), H2O2-induced cleaved caspase-3, and
the DNA damage marker, phosphorylated histone (γH2A.X) foci, were significantly downregulated
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upon histochrome treatment of hCPCs in vitro. Further, prolonged incubation with histochrome
alleviated the replicative cellular senescence of hCPCs. In conclusion, we report the protective effect
of histochrome against oxidative stress and present the use of a potent and bio-safe cell priming agent
as a potential therapeutic strategy in patient-derived hCPCs to treat heart disease.
Keywords: cardiac progenitor cells; histochrome; echinochrome A; oxidative stress; cell therapy
1. Introduction
Stem cells have been reported to recover damaged hearts from myocardial infarction and have
been investigated for use in myocardial regeneration [1–3]. Cardiac progenitor cells (CPCs) were first
identified by Anversa et al. [4]. CPCs are classified as a prevailing stem cell population in the heart and
have crucial roles in cardiac homeostasis [5,6]. CPCs can differentiate into multiple cell lineages of the
heart, and thus, are a promising cell resource for regenerating ischemic hearts [7]. Recent preclinical
studies suggest that transplantation of CPCs into the ischemic myocardium can significantly improve
cardiac regeneration via the formation of vasculature and new myocytes [8–10]. Furthermore, CPCs
have the potential to produce and remodel extracellular matrix (ECM) proteins [11], trigger CPC
proliferation, and stimulate growth factor secretion [12]. According to these positive results, CPC
might be a promising stem cell source in cardiovascular regeneration. However, current evidence
suggests that poor viability of engrafted CPCs in the infarcted myocardium primarily restricts the
therapeutic efficacy of CPCs [13,14]. Thus, increasing the survival of CPCs can be a beneficial strategy
to enhance the therapeutic effect in ischemic heart disease.
Reactive oxygen species (ROS), such as hydrogen peroxide (H2O2), superoxide radicals, and
hydroxyl radicals, are produced during infarction or reperfusion of ischemic hearts [15]. ROS
involvement has been reported in various important development processes, cell signaling, and
regulation of homeostasis [16]. Low levels of ROS are involved in the regulation of stem cell fate
decision, stem cell proliferation, differentiation, and survival [17]. However, excessive ROS production
leads to impaired cell metabolism and decreased cell viability [18], thereby inhibiting transplanted
CPCs to regenerate the damaged heart [19]. Consequently, protecting CPCs from undergoing apoptosis
and enhancing their ability to survive under oxidative stress is crucial in optimizing CPC-based therapy.
Echinochrome A is a common sea urchin pigment [20] that has a chemical structure of
6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone (Figure 1A) and exhibits antioxidant, anti-viral [21],
anti-inflammatory [22], and anti-diabetic activities [23]. Echinochrome A prevents mitochondrial
dysfunction and activation of mitogen-activated protein kinase (MAPK) cell death signaling
pathways caused by cardiotoxic drug treatment [24]. Echinochrome A regulates mitochondrial
biogenesis in cardiomyocytes by upregulating the transcription of mitochondrial regulatory genes,
such as mitochondrial transcriptional factor A (TFAM), nuclear respiratory factor (NRF-1), and
proliferator-activated receptor gamma co-activator (PGC-1α) [25]. Echinochrome A inhibits the
phosphorylation of serine-16 and threonine-17, located in the active center of phospholamban
(membrane phosphoprotein and main regulator of the SERCA2A receptor responsible for the transfer
of calcium ions from the cytosol to the sarcoplasmic reticulum), preventing ischemic myocardial
damage by reducing the infarction zone [26].
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Echinochrome A is insoluble in water, however, its water-soluble sodium salt is used for
medical applications, which is manufactured under inert conditions in ampoules and is known as the
Histochrome® drug. Histochrome has been used in Russia in ophtalmological and cardiological clinical
practice. In ophthalmology, histochrome is used for the treatment of degenerative diseases of the retina
and cornea, macular degeneration, primary open-angle glaucoma, diabetic retinopathy, hemorrhage in
the vitreous body, retina, and anterior chamber, and dyscirculatory disorder in the central artery and
vein of the retina [27]. An overview of clinical applications of histochrome in cardiology is presented
in monography [28]. In the first place, histochrome has been used for the treatment of myocardial
ischemia/reperfusion injury. Even a single injection of histochrome immediately after reperfusion
recovered the ECG signs of myocardial necrosis and significantly (up to 30%) reduces the necrosis zone
after a 10-day course. The use of histochrome prevented lipid peroxidation, reduced the frequency
of left ventricular failure, did not affect the level of blood pressure and heart rate, and decreased the
frequency of post-infarction angina pectoris. Practical experience of histochrome treatment confirmed
the absence of any adverse effects and the safety of its application [28].
The cardioprotective effect of histochrome on patient-derived CPCs has never been reported.
Thus, we investigated whether pretreatment of CPCs with histochrome promotes cell survival against
oxidative stress during cardiac regeneration.
2. Results
2.1. Histochrome Does Not Affect Surface Expression Markers of Human Cardiac Progenitor Cells (hCPCs)
To evaluate the cytotoxicity of histochrome in human CPCs (hCPCs), hCPCs were treated with
different concentrations of histochrome for 24 h. Cell survival was found to be significantly increased
for 0.5 μM to 10 μM of histochrome and significantly decreased at concentrations above 100 μM (p < 0.01
versus 0 μM; Figure 1B). Based on the data obtained, we determined that histochrome concentration
under 50 μM used for the further experiments. No change in the morphology of hCPCs was observed
on pretreatment with 0 μM, 5 μM, 10 μM, and 20 μM concentrations of histochrome (Figure 1C).
To eliminate the possibility of change in CPC characteristics on pretreatment with histochrome, we
investigated typical surface expression markers of hCPCs using fluorescence-activated cell sorting
(FACS) analysis. As shown in Figure 1D, histochrome-treated CPCs showed positive expression
of cardiac stem cell markers such as mast/stem cell growth factor receptor kit (c-kit), cluster of
differentiation 66 (CD166), CD29, CD105, and CD44. However, negative expression was observed for
hematopoietic markers, such as CD45 and CD34, in pretreated hCPCs compared to that in control cells.
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Figure 1. Effects of histochrome treatment on human cardiac progenitor cells (hCPCs) characterization.
(A) Chemical structure of echinochrome A—active substance of the histochrome drug. (B) hCPCs were
treated with different concentrations of histochrome for 24 h and viability was measured using cell
viability, Proliferation & Cytotoxicity assay (CCK assay). Data are presented as the mean ± standard
deviation (SD). **, p < 0.01 versus 0 μM, ***, p < 0.001 versus 0 μM. n = 6 (C) Morphological analysis of
hCPCs pretreated with histochrome. Scale bar = 100 μm, (D) Expression of stem cell marker by flow
cytometric analysis, n = 3. Error bars indicate standard effort of the mean (S.E.M)
2.2. Histochrome Reduced Cellular and Mitochondrial Reactive Oxygen Species (ROS) Levels in hCPCs during
H2O2-Induced Oxidative Stress
To investigate whether pretreating hCPCs with histochrome protects them against oxidative
stress, we performed a cellular ROS staining assay. Cellular ROS-tagged green intensity was found to
be significantly increased upon exposure to H2O2 (Figure 2A). We observed that pretreatment with
histochrome decreased the cellular ROS levels in a dose-dependent manner. The 2’,7’–difluorofluorescin
diacetate (H2-DFFDA) assay revealed that pretreatment with 10 μM of histochrome significantly
decreased cellular ROS levels (Figure 2B). Furthermore, we investigated the effects of pretreatment
with histochrome on mitochondrial superoxide production in hCPCs. The increased production
of mitochondrial superoxide caused by H2O2 addition was found to be significantly reduced in
histochrome-treated hCPCs (Figure 2C). Our data suggested that histochrome has intracellular ROS
scavenging activity in hCPCs under oxidative stress.
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Figure 2. Intracellular reactive oxygen species (ROS) and mitochondrial ROS scavenging activity of
histochrome in hCPCs. (A) hCPCs were pretreated with histochrome at 0 μM, 5 μM, 10 μM, and 20 μM
for 24 h followed by the addition of 600 μM H2O2 for 1 h. Intracellular ROS scavenging activity was
measured using CellRox staining. Representative image of increased intensity of CellRox produced by
ROS and decreased intensity on pretreating with histochrome. Data are presented as the mean ± SD of
three independent experiments. Scale bar = 100 μm, ### p < 0.01 versus -H2O2 -histochrome; * p < 0.05;
** p < 0.01 versus +H2O2 -histochrome, n = 3. Error bars indicate S.E.M. (B) 2’,7’–difluorofluorescin
diacetate (H2-DFFDA)assay was used to measure cellular ROS production. *** p < 0.001 versus -H2O2
-histochrome; ###, p < 0.001 versus +H2O2 -histochrome, n = 3. Error bars indicate S.E.M. (C) After
pretreatment with histochrome for 24 h, hCPCs were exposed to H2O2 for 1 h and mitochondrial
superoxide production was measured with MitoSOX staining. Representative image of the increased
intensity of MitoSOX and decreased intensity on pretreatment with histochrome. Scale bar = 100 μm.
2.3. Anti-Apoptotic Effect of Histochrome against H2O2-Induced Cell Death
To investigate the anti-apoptotic effects of histochrome in hCPCs, cells were treated with 1 mM
H2O2 for 4 h and cell apoptosis was evaluated using flow cytometry by staining with Annexin V
and 7-aminoactinomycin D (7-AAD). Annexin V/7-AAD assay revealed that treatment with H2O2
significantly increased the percentage of apoptotic cells (+H2O2, -Histochrome; 14.3% ± 2.36%)
compared to the percentage of apoptotic cells in the non-treated control group (-H2O2, -Histochrome;
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-8.7% ± 0.84%, -H2O2, +Histochrome; 5.6% ± 0.40%, Figure 3A). In contrast, pretreatment of hCPCs
with 10 μM of histochrome significantly increased the percentage of viable cells (+H2O2, +Histochrome;
95.2% ± 0.40%, Figure 3A) while decreasing the number of apoptotic cells (+H2O2, +Histochrome;
2.4% ± 0.49%, Figure 3A). We also investigated the effect of histochrome on cell morphology using
phase contrast microscopy (Figure 3B). H2O2 treatment caused abnormal morphology and reduced
cell viability. However, pretreatment with histochrome attenuated the morphological change induced
by H2O2. In addition, live cell imaging analysis suggested that pretreatment with histochrome under
the H2O2-induced oxidative stress condition significantly increased the number of live cells in a
dose-dependent manner (Figure 3C).
 
Figure 3. Anti-apoptotic effect of histochrome against H2O2-induced cell death. (A) hCPCs were
pretreated with 10 μM of histochrome for 24 h and then exposed to 1 mM H2O2 for 4 h. Apoptotic
cells were quantified by fluorescence-activated cell sorting (FACS) analysis with Annexin V / 7-AAD
staining. ** p < 0.01; *** p < 0.001 versus -H2O2 -histochrome; ### p < 0.001 versus +H2O2 -histochrome.
(B) Representative images showing the morphology of hCPCs pretreated with histochrome (0 μM,
5 μM, 10 μM, and 20 μM) in the presence of H2O2-induced oxidative stress. Morphology of hCPCs
was observed by phase contrast microscope. Scale bar = 50 μm (C) Live cells were quantified by
phalloidin (green fluorescence) intensity. *** p < 0.001 versus -H2O2 -histochrome; # p < 0.05 versus
+H2O2 -histochrome. Scale bar = 100 μm, n = 3. Error bars indicate S.E.M.
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2.4. Histochrome Protects hCPCs against Oxidative Stress through Downregulation of Pro-Apoptotic Signals
and Upregulation of Anti-Apoptotic Signals
Further, we investigated the expression of apoptosis-related proteins by western blotting.
Pretreatment with histochrome was observed to reduce expression of pro-apoptotic protein, Bcl-2
associated X (Bax) while promoting the expression of anti-apoptotic proteins, B-cell lymphoma 2 (Bcl-2),
and Bcl-xL. In addition, pretreatment with histochrome remarkably decreased the expression levels
of cytochrome C and cleaved-caspase-3 (Figure 4A). Our data suggested that histochrome protects
hCPCs against oxidative stress through decreased pro-apoptotic signals and increased anti-apoptotic
signals. Further, we checked DNA damage marker, phosphorylated histone (γH2A.X) foci by
immunocytochemistry (Figure 4B). We found that pretreatment of hCPCs with histochrome prevented
DNA damage caused by oxidative stress. Overall, our results suggested that pretreatment with
histochrome regulates cell apoptosis by altering cell survival signals and inhibiting ROS-induced
DNA damage.
 
Figure 4. hCPCs pretreated with histochrome show downregulation of pro-apoptotic signals and
upregulation of anti-apoptotic signals under the oxidative stress condition. (A) hCPCs were pretreated
with histochrome for 24 h, oxidative stress was induced in hCPCs by 1 mM H2O2. Expression of
apoptosis signaling-related proteins was determined by western blotting. (B) Immunofluorescence
was performed with the DNA damage marker γH2A.X to quantify DNA damage of hCPCs. Images
were captured using a LionHeart FX automated microscope (Biotek, Winooski, VT, USA). *** p < 0.001
versus +H2O2, n = 5. Error bars indicate S.E.M.
2.5. Prolonged Treatment with Histochrome Attenuates Cellular Senescence in hCPCs
Several antioxidants have been reported to be associated with inhibition of cellular
senescence [29–31]. To examine whether histochrome affects cellular senescence, we investigated
the long-term effect of histochrome treatment on an in vitro culture of hCPCs. Evaluation of
senescence-associated β galactosidase (SA-β-gal) activity in senescent hCPCs (passage 13) revealed
a significant increase in the number of SA-β-gal positive cells (sene; 40.7% ± 3.07%) (Figure 5).
However, increased SA-β-gal positive cells were significantly downregulated (sene+Histochrome;
31.3% ± 2.87%) on prolong treatment of hCPCs with histochrome. This suggested that long-term
treatment of histochrome alleviates replicative cellular senescence in hCPCs.
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Figure 5. Effect of prolonged treatment with histochrome on hCPCs senescence. (A) Representing
images of senescence-β-galactosidase (SA- β-gal) stained hCPCs (Scalebar = 50 μm). (B) SA- β-gal
positive cells were quantified and presented as a graph (*** p < 0.001, versus Young; ### p < 0.001,
versus Sene) Error bars indicate S.E.M. Abbreviation: Sene, senescent hCPCs (passage 13); sene +
histochrome, prolonged treatment with histochrome (till passage 13).
3. Discussion
To enhance the engraftment rate of transplanted cells, several studies have been performed
focusing on cell priming, using physical stimulations such as heat shock, and chemical stimulations
using natural products and growth factors. Recently, stem cell priming using natural products has
been proposed as a new strategy to enhance the cell activity and promote stable and efficient cell
functioning. In our previous study, we demonstrated that pretreatment with fucoidan, a marine-sulfated
polysaccharide derived from seaweeds, inhibits cellular senescence and promotes neo-vasculogenic
potential [32].
In this study, we identified a novel priming factor for enhancing cell therapy potentials
against oxidative stress. A recent study has revealed that echinochrome A promotes cardiomyocyte
differentiation of mouse embryonic stem cells via direct binding to serine-threonine kinase PKCι and
inhibition of its activity [33]. We are the first to report the effects of histochrome on hCPCs. In the
present study, we demonstrated that pretreatment with histochrome enhanced the survival of hCPCs
against oxidative stress. Further, pretreatment with different concentrations (0 μM, 5 μM, 10 μM,
15 μM, and 20 μM) of histochrome did not alter the expression of multipotent cardiac stem cell markers
such as c-kit (Histo 0 μM; 99.9% ± 0.1%, Histo 5 μM; 99.9% ± 0.1%, Histo 10 μM; 99.8% ± 0.1%, and
Histo 20 μM; 99.9% ± 0.1%, respectively); CD29 (Histo 0 μM; 99.9% ± 0.1%, Histo 5 μM; 99.6% ±
0.1%, Histo 10 μM; 99.1% ± 0.2%, and Histo 20 μM; 93.7% ± 5.6%, respectively); CD166 (Histo 0 μM;
88.9% ± 1.5%, Histo 5 μM; 80.2% ± 2.7%, Histo 10 μM; 80.9% ± 1.5%, and Histo 20 μM; 79.8% ± 2.1%,
respectively); CD105 (Histo 0 μM; 95.0% ± 0.8%, Histo 5 μM; 98.5% ± 0.1%, Histo 10 μM; 97.8% ±
0.1%, and Histo 20 μM; 99.7% ± 0.1%, respectively); and CD44 (Histo 0 μM; 97.8% ± 1.0%, Histo 5 μM;
99.5% ± 0.1%, Histo 10 μM; 99.4% ± 0.2%, and Histo 20 μM; 99.6% ± 0.1%, respectively). In contrast,
histochrome-treated hCPCs showed negative expression of hematopoietic markers such as CD34 (Histo
0 μM; 0.7% ± 0.01%, Histo 5 μM; 1.1% ± 0.1%, Histo 10 μM; 0.6% ± 0.1%, and Histo 20 μM; 1.0% ±
0.2%, respectively) and CD45 (Histo 0 μM; 0.1% ± 0.1%, Histo 5 μM; 0.1% ± 0.06%, Histo 10 μM; 0%,
and Histo 20 μM; 0%, respectively).
In ischemic heart disease, ROS is produced upon reperfusion [34]. Excessive ROS formation
promotes cell death which induces development and progression of cardiovascular disease [35].
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The generation of ROS is associated with alteration in electrophysiology leading to myocardial
ischemia [36]. In addition, mitochondrial ROS scavenging has been reported for its potential to prevent
cardiac failure [37]. It is necessary to target intracellular ROS and mitochondrial ROS to prevent cell
death caused by oxidative stress. Histochrome showed high intracellular ROS scavenging activity
and reduced production of mitochondrial superoxide in hCPCs. Furthermore, pretreatment with
histochrome revealed an anti-apoptotic effect against H2O2-induced cell death.
The Bcl-2-family members (Bcl-2, Bcl-xL, Bax) are predominant regulators of cell cycle progression
and apoptosis [38]. Specifically, Bcl-2 and Bcl-xL are well-known negative regulators of apoptosis which
promote cell survival [39]. On the other hand, the apoptosis regulator Bax inhibits cell survival [40] and
cell cycle progression [41]. In this study, pretreatment with histochrome upregulated the expression of
Bcl-2 and Bcl-xl and downregulated that of Bax under the H2O2-induced oxidative stress condition.
DNA damage induces the formation of double stranded breaks (DSBs) and stimulates phosphorylation
of histone H2AX [42]. Subsequently, γ-H2A.X is used as a reference marker for DNA damage. In our
study, pretreatment of hCPCs with histochrome reduced the expression of the DNA damage marker,
γH2A.X foci under the oxidative stress condition. Thus, we concluded that histochrome prevents
ROS-mediated DNA damage in hCPCs (Figure 6).
 
Figure 6. Schematic representation of cytoprotective effects of histochrome against H2O2-induced cell
death via reduction of DNA damage and activation of survival signaling.
Any cell undergoes a limited number of divisions and thus, following a certain number of cell
cycles, it enters an irreversible cell cycle arrest which is referred to as cellular senescence [43]. Stem
cell therapy for regeneration of tissues requires over hundreds of millions of cells [44]. Repetitive
in vitro cultures are essential and cellular senescence is a major threat in such stem cell therapies. Thus,
preventing cellular senescence is a promising strategy in stem cell therapy. SA-β-gal assay revealed
that histochrome delayed the progression of cellular senescence in hCPCs. Thus, our study suggests
that histochrome can be a potential effective strategy to overcome cellular senescence.
Overall, our present study demonstrated that histochrome protects hCPCs against oxidative stress
by regulating cell survival signaling. Furthermore, histochrome prevents cellular senescence of hCPCs.
Thus, our study presents a simple and effective strategy to improve cell survival in post-transplanted
CPCs under ischemic oxidative stress conditions and improve the efficiency in myocardial regeneration.
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4. Materials and Methods
4.1. Cell Cultures and Treatment
Human fetal right auricle(RA) tissue was received from Pusan National University YangSan
Hospital and the study was approved by the Institutional Review Board (IRB) (IRB No. 05-2015-133).
C-kit positive hCPCs were isolated and cultured, as previously reported [45,46]. hCPCs were maintained
at 37 °C with 5% CO2 in Ham’s Nutrient Mixture F-12 (Hyclone, GE Healthcare, Chicago, IL, USA) and
supplemented with 10% Fetal bovine serum (FBS; Gibco#16000-044, Thermo Fisher Scientific, Carlsbad,
CA, USA), 1% penicillin-streptomycin (PS; Welgene, Daegu, Republic of Korea), 0.005 unit/mL of
human erythropoietin (hEPO, R&D systems, Minneapolis, MN, USA), 10 ng/mL of recombinant human
basic fibroblast growth factor (rb-FGF, Peprotech, Rocky Hill, NJ, USA), and 2 mM of glutathione
(Sigma-Aldrich, St. Louis, CA, USA). Passages 4–10 were utilized for the experiments as passage 13 was
found to be senescent cells. hCPCs were treated with different concentrations of H2O2 (Sigma-Aldrich,
St. Louis, CA, USA) and a final concentration of 600 μM (to investigate the antioxidant effect), 1 mM
(to confirm anti-apoptotic effect) was used.
The standardized substance echinochrome A (registration number in Russian Federation is
P N002362/01) was isolated from the sea urchin Scaphechinus mirabilis by a previously described
method [47]. The purity of echinochrome A (99.0%) was confirmed using LC-MS data (Shimadzu
LCMS-2020, Kyoto, Japan). Purified echinochrome A appeared as red–brown needles, had a melting
point of 221 ◦C, and similar nuclear magnetic resonance (NMR) spectra to that reported previously [47].
We used a solution of echinochrome A sodium salts in ampoules with trade name Histochrome®.
Histochrome was generated by combining echinochrome A (1 g) with sodium carbonate (0.4 g) in a
water solution heated in inert gas until CO2 was completely removed. This solution at a concentration
of 0.2 mg/mL echinochrome A (750 μM) was sealed in ampoules in inert gas. After opening of
the ampoule, histochrome was used as a stock solution to be diluted with appropriate solvents or
culture media.
4.2. Cell Cytotoxicity Assay
To determine cell cytotoxicity, hCPCs were seeded at 5000 cells/well in a 96-well plate. The
following day, cells were pretreated with different concentrations of histochrome and incubated for
24 h. Cell viability was evaluated using a cell-counting kit (CCK) cell viability assay kit (#CCK-3000,
DonginLS, Seoul, Republic of Korea), following the manufacturer’s instructions [48,49]. The cell
viability was measured by incubating cells with the CCK solution. The plates were incubated for
1 h, and the absorbance of each well was measured. Absorbance was measured at 450 nm using a
microplate reader (TECAN, Mannedorf, Switzerland ). Cell viability of the experimental group was
represented as percentage to 0 μM.
4.3. Western Blot Analysis
For western blotting, hCPCs pretreated with different concentrations of histochrome were
exposed to 1 mM H2O2 (Sigma-Aldrich, St. Louis, CA, USA) for 4 hours. Further, cells were
lysed in the Radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitor and
phosphatase inhibitor. Equivalent concentration of proteins (20 μg) were separated on sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 0.45 μm PVDF
membrane (Millipore, Billerica, MA, USA). The membranes were blocked with 5% skim milk and
incubated with primary antibodies overnight at 4 °C: cleaved-caspase 3 (Cell Signaling, Danvers,
MA, USA), Bax, Bcl-2, Bcl-xL, cytochrome C, β-actin (Santa Cruz Biotechnology, Dallas, TX, USA),
and γH2A.X (Abcam, Cambridge, UK). Further, the membranes were incubated with Horseradish
peroxidase (HRP) -conjugated secondary antibody for 1 h at room temperature. The chemiluminescence
signal were detected using enhanced chemiluminescence (ECL) reagent (Millipore, Billerica, MA, USA).
112
Mar. Drugs 2019, 17, 368
4.4. Immunocytochemistry
For immunocytochemistry, hCPCs were seeded at a density of 50,000 cells per well in a 2-well
chamber slide (BioTek, Winooski, VT, USA). After pretreatment with histochrome for 24 h, cells
were washed once with PBS and fixed in 4% paraformaldehyde (PFA) for 10 min. Cells were then
permeabilized in 0.1% Triton X-100 + 0.01 M Glycine + Phosphate-buffered saline (PBS) solution for
30 min. Slides were blocked with 10% normal goat serum in PBST (0.1% Triton X-100 in PBS) and
incubated for 1 h at room temperature. γH2A.X (phospho S139) antibody (#ab11174, 1:500 dilute in
blocking buffer, Abcam, Cambridge, UK) was diluted in blocking solution and incubated overnight at
4 °C. The following day, slides were washed 3 times with PBS and incubated with Alexa Flour 488
goat IgG anti-rabbit antibody (1:200, Invitrogen, Carlsbad, CA, USA), and incubated for 1 hour in the
dark. Following cell wash twice, cells were mounted using ProLong diamond anti-fade mountant
with 4′,6-diamidino-2-phenylindole (DAPI). Slides were analyzed under a Lionheart FX automated
microscope (BioTek, Winooski, VT, USA)
4.5. Flow Cytometry Analysis
To examine c-kit expression, hCPCs were fixed in 4% PFA for 10 min and washed with PBS.
The cells were fixed and permeabilized as previously described [50]. The fixed cells were incubated
with c-kit antibody (#130-091-733, Miltenyi Biotec, Bergisch Gladbach, Germany) for 30 min at 4 °C.
For expression analysis of other stem cell markers, hCPCs were suspended in 100 μL FACS buffer
(2 mM EDTA, 2% FBS in PBS solution) and incubated with CD34 (#55373, BD Bioscience, Franklin
Lakes, NJ, USA), CD45 (#560839, BD Bioscience, Franklin Lakes, NJ, USA), CD166 (#559263, BD
Bioscience, Franklin Lakes, NJ, USA), CD29 (#555443, BD Bioscience, Franklin Lakes, NJ, USA), CD105
(#560829, BD Bioscience, Franklin Lakes, NJ, USA), and CD90 (#130-097-930, Miltenyi Biotec, Bergisch
Gladbach, Germany) FACS antibody. After incubation for 30 min, the cells were washed three times
and resuspended in 100 μL FACS buffer. Expression of stem cell markers was analyzed on a BD Accuri
flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA).
4.6. ROS Measurement
Intracellular ROS levels were detected using CellROX green reagent (#C10444, Thermo Fisher
Scientific, Carlsbad, CA, USA). Cells were stained according to the manufacturer’s instructions. Imaging
and quantification of cellular ROS levels were performed using the CX7 High-Content Screening (HCS)
System (Thermo Fisher Scientific, Carlsbad, CA, USA). For H2-DFFDA assay, hCPCs were harvested
using Accutase (Sigma-Aldrich, St. Louis, CA, USA) and incubated with 10 μM carboxy-H2-DFFDA at
37 °C in the dark. After washing with PBS, the cells were resuspended in 100 μL of FACS buffer. The
intracellular ROS level was assessed based on the fluorescence intensity of the cells.
4.7. Mitochondrial Superoxide Measurement
hCPCs were plated on a confocal plate (50,000 cells per well) and incubated overnight. The
following day, cells were pretreated with/without histochrome (in 2% Ham’s F-12 medium) and
incubated for 24 h. Cells were washed and incubated in low serum Ham’s F-12 medium supplemented
with 5 μM MitoSOX Red (#M36008, Thermo Fisher Scientific, Carlsbad, CA, USA ) and 100 nM
Mitotracker green (#M7514, Thermo Fisher Scientific, Carlsbad, CA, USA) for 30 min. Further, the cells
were washed twice with PBS prior to analysis using a Lionheart FX automated microscope (BioTek,
Winooski, VT, USA).
4.8. Cell Death Assay
hCPCs were pretreated with histochrome for 24 h in low serum (2% FBS) Ham’s F-12 medium.
After incubation, cells were washed with PBS and exposed to 1 mM H2O2 for 4 h in low serum medium.
Further, cells were harvested and suspended in 1 × annexin binding buffer supplemented with Annexin
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V (AnV; BD Pharminogen, #550475, San Diego, CA, USA) and 7-AAD(BD Pharminogen, San Diego,
CA, USA).
4.9. Live Cell Imaging
For quantification of live cells in H2O2-induced oxidative stress, cells were stained with calcein
(#R37601, Thermo Fisher Scientific, Carlsbad, CA, USA). Nuclei were stained with NucBlue Live Ready
Probes Reagent (#R37605, Thermo Fisher Scientific, Carlsbad, CA, USA). Live cells were observed
under the CX7 High-Content Screening (HCS) System (100×, Thermo Fisher Scientific, Carlsbad, CA,
USA). Images were captured (25 images per well) and experiments were repeated four times. Green
fluorescence indicated live cells.
4.10. Senescence Associated β-galactosidase Staining
Senescent cells were quantified by SA-β-gal assay kit (#9860, Cell Signaling Technology, Beverly,
MA, USA) according to the manufacturer’s instructions. After X-gal staining, images were captured
using an Olympus microscope (OLYMPUS, Tokyo, Japan). Each experiment was repeated three times.
4.11. Statistical Analysis
Data are presented as means ± standard deviation (SD). Statistical significance was assessed by
student’s t-test to compare between the two groups. p < 0.05 was considered statically significant.
5. Conclusions
Pretreatment with histochrome (sodium salt of echinochrome A—a common sea urchin pigment)
enhances cell survival under oxidative stress conditions by regulating the apoptosis signaling pathway
and preventing DNA damage. Furthermore, histochrome attenuates cellular senescence in hCPCs.
Our results suggest that pretreating c-kit-positive hCPCs with histochrome before transplantation
might be a potential therapeutic strategy in treating ischemic heart disease.
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Abstract: Of late, researchers have taken interest in alternative medicines for the treatment of brain
ischemic stroke, where full recovery is rarely seen despite advanced medical technologies. Due to its
antioxidant activity, Echinochrome A (Ech A), a natural compound found in sea urchins, has acquired
attention as an alternative clinical trial source for the treatment of ischemic stroke. The current
study demonstrates considerable potential of Ech A as a medication for cerebral ischemic injury.
To confirm the effects of Ech A on the recovery of the injured region and behavioral decline, Ech A
was administered through the external carotid artery in a rat middle cerebral artery occlusion model
after reperfusion. The expression level of cell viability-related factors was also examined to confirm
the mechanism of brain physiological restoration. Based on the results obtained, we propose that Ech
A ameliorates the physiological deterioration by its antioxidant effect which plays a protective role
against cell death, subsequent to post cerebral ischemic stroke.
Keywords: echinochrome A; brain ischemic stroke; cell survival
1. Introduction
Although medical knowledge and technology have advanced considerably, cerebral ischemic
stroke patients experience pain with severe disabilities and high mortality due to brain damage
resulting from middle cerebral artery occlusion (MCAo) [1,2]. The progression of pathological changes
in acute ischemic stroke includes oxidative stress, free radical production, brain edema, neuronal
apoptosis, and finally death [3,4]. Intravenous recombinant tissue plasminogen activator (rtPA) or other
agents such as anti-cytokines, calcium channel blockers, and free radical scavengers for therapeutic
thrombolysis are the generally applied treatments in the early stage of the disease [5]. However, there
is rarely a complete recovery of ischemia neuronal damage. Therefore, in recent years, researchers
have recognized the importance of finding inventive strategies for the restoration of brain injury.
Natural derived products, including molecules from marine organisms, have gained recognition
as alternative therapeutic sources. The past decade has seen a rise in the application of various
compounds from isolated marine species as a popular and promising therapeutic approach for human
diseases [6]. Marine organisms are capable of overcoming some insuperable conditions such as light,
temperature, pressure, and oxygen and ion concentration due to their distinct habitat environment [7].
Echinochrome A (Ech A), a dark red pigment, is most commonly extracted from the shells, spines,
and eggs of sea urchins [8]. The biologically active compound possesses antiviral, antialgal, and
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antioxidant properties [8,9]. Ech A is an active substance in the cardioprotective drug Histochrome,
registered in Russia (P N002363/01). It presented a positive outcome in animal disease model with
experimental hemorrhagic stroke as previously described [10]. Histochrome accelerates the alleviation
of neurological symptoms and edema, which are mainly caused by the release of free iron and oxidative
stress. The effects of Ech A on ischemic stroke have not been previously studied. In particular, the
high antioxidant efficacy exerts a beneficial advantage in the research of stroke [11]. Oxidative stress
contributes to irreversible pathophysiological cellular damages during the initial and later phases of
ischemic stroke [11]. Despite the restoration of blood flow to rescue the ischemic brain, reperfusion is
known to aggravate oxidative stress damage and generate reactive oxygen species (ROS) [12]. Ech A
neutralizes the iron cations that accumulate in the region of ischemic damaged tissue [12]. However,
researchers have rarely considered Ech A as a therapeutic candidate to overcome brain ischemic stroke.
Based on the results obtained using an experimental rat MCAo model, we demonstrate the
potential of Ech A for treating brain ischemic stroke. In the present study, the therapeutic effects of Ech
A were evaluated. The administration of Ech A recovered the brain region and alleviated the repressed
behaviors in the rat MCAo model. Our results indicate that the administration of Ech A influences the
expression of cell viability related factors, thereby confirming its effect on physiological improvements.
2. Results and Discussion
2.1. Ech A Mitigates Cerebral Ischemic Injury
To confirm the mitigative effect of Ech A on cerebral ischemic disease, rat MCAo models were
exposed to 10 μM Ech A and subsequently assessed for brain infarct volume and water content. We
used 2,3,5-triphenyltetrazolium chloride (TTC) staining, one of the most conventional methods, to
visualize the infarct region of the ischemic cerebrum. Ech A substantially shows the visual recovery
reducing the brain infarct volumes at 7 days after reperfusion (Figure 1A). Alleviation of the injured
area after exposure to Ech A was confirmed by comparing the percentage of white region in the control
brain with the Ech A treatment group through TTC staining (Sham: 0.0%, control group: 52.7%, 10 μM
Ech A: 21.9%) (Figure 1B). Next, we investigated the water content of rat MCAo model brain tissue,
which is a marker of severe ischemic injury [13]. The water content is used to signify the ischemic brain
edema in the infarct hemisphere [14], and to examine the effect of Ech A treatment on the blood–brain
barrier (BBB) leakage in this study. Cerebral edema plays a key role in fatal outcomes associated with
numerous neurological conditions, including ischemic stroke [15]. The percentage of water content in
the control group was increased, as compared to the sham group. The Ech A-treated group revealed
decreased water content as compared to the control group (sham: 79.4%, control: 81.7%, 10 μM Ech A:
80.3%) (Figure 1C). Taken together, we construe that Ech A presents the visual restoration in the infarct
cerebrum of rat MCAo models. However, the functional recovery and the reparative mechanism by
Ech A treatment on brain ischemic disease remain to be identified.
2.2. Ech A Encourages Affirmative Behavioral Changes after Ischemic Stroke
Functional assessments were applied to determine behavioral changes in the rat model for
aggressive central nervous damage [16]. Two methods, namely, the cylinder test and swim test, were
adopted and modified. The cylinder test evaluates the frequency of forelimb use and asymmetric
movement in postural weight support [17]. In the cylinder test, cerebrally injured rats (control group)
exhibited increased asymmetry use, especially practical use of the unaffected forelimb, when compared
to the sham group. Furthermore, the 10 μM Ech A-treated group showed behavioral recovery with
increased use of both forelimbs and decreased use of the unaffected forelimb, as compared to the
control group (simultaneous use: sham 38.0%, control 26.0%, 10 μM Ech A 35.0%; unaffected use: sham
26.0%, control 39.0%, 10 μM Ech A 32.0%) (Figure 2A).
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Figure 1. Echinochrome A (Ech A) alleviates the infarcted brain region of rat middle cerebral artery
occlusion (MCAo). (A) Representative TTC staining of brain sections of the damaged area in the
sham, control and 10 μM Ech A treatment groups of a rat MCAo/reperfusion model. (* p < 0.05).
(B) Quantification of size in the infarcted brain region from each experimental group. (C) Quantification
of water content in infarcted brain region from each experimental group (** p < 0.01).
Stroke results in the reduction of predominant activities such as mobility, climbing, and
swimming [18]. Since the forced swim test (FST) is frequently used to confirm these activities,
this method was applied to assess the antidepressant-like behavior in MCAo models [18]. In this test,
while brain infarct rats showed increasing immobility, the behavioral recovered rats (after 10 μM Ech A
treatment) show alleviated immobility time during the FST (sham: 33 s, control: 81 s, 10 μM Ech A: 51
s) (Figure 2B). Our results indicate that treatment with an appropriate amount of Ech A enhances the
motor ability in brain ischemic disease.
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Figure 2. Declined movements are restored after Ech A treatment following ischemic stroke. (A) Assessment
of percent use of affected (left), unaffected (right), and simultaneous (both) forelimbs on the wall of the
cylinder (* p < 0.05). (B) Total amount of immobility time in the forced swim test (# p < 0.01 compared with
the values of the sham group; ** p < 0.01 compared with the values of the control group).
2.3. Ech A Affects the Expression of Cell Survival-Related Molecules of Rat Ischemic Stroke Brain
To demonstrate the mechanism of physiological improvements, which include the restoration
of the damaged brain region and the intensification of attenuated behavior after Ech A treatment,
we focused on the occurrences after ischemia reperfusion injury. Ischemia reperfusion-injured brain
suffers from oxidative stress and induces the cell death regulating pathway [19]. Considering this, we
investigated the expression levels of cell viability-related factors in our experimental animal model,
including Bcl-2, Caspase-3, Bax (Figure 3A), p-ERK/ERK, p-AKT/AKT (Figure 3B), and brain-derived
neurotrophic factor (BDNF) (Figure 3C). The effect of Ech A treatment on the expression of these
regulators was estimated in the brain tissue of MCAo rats. Bcl-2, caspase-3, and Bax work as major
mediators for cell survival and death and are activated by various stimuli [18,19]. Bcl-2, an apoptosis
inhibitor, is a key player in the mechanism of anti-apoptosis [20,21]. In contrast, caspase-3 and Bax
are pro-apoptosis molecules which signify the onset of apoptosis [21]. Compared to the control
group, Ech A treatment in the MCAo rat model significantly increased the expression level of Bcl-2
and decreases the levels of caspase-3 and Bax. The extracellular signal-related kinases (ERK) are
essential regulators associated with vital cellular functions, including cell proliferation, differentiation,
migration, senescence, and apoptosis in the generic mitogen-activated protein kinase (MAPK) signaling
pathway [22]. Furthermore, in the PI3K/AKT/mTOR signaling pathway, AKT is also a core component
of various processes of cellular activities, including nutrient uptake, anabolic reactions, metabolism,
cell growth, proliferation, differentiation, apoptosis, and survival [23]. Our results indicate an increase
in the expression levels of p-ERK/ERK and p-AKT/AKT in the Ech A-treated MCAo rat model as
compared to the control group. The brain-derived neurotrophic factor (BDNF) significantly supports
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neuronal differentiation and survival, synaptic formation and plasticity, and neurogenesis, and has
been widely researched in various neurological conditions [24]. Our studies reveal increased BDNF
expression in the brain of MCAo rat model after exposure to Ech A, as compared to the control group.
Taken together, these findings confirm that Ech A relieves the physiological decline in the MCAo rat
model by increasing and supporting cell survival in the injured brain region.
Figure 3. Ech A treatment in cerebral injured brain alters the expression levels of cell viability-related
factors. (A) The protein expression levels of cell survival and death regulators, such as Bcl-2, caspase-3,
and Bax. (B) The protein expression levels of key players in vital cellular function regulation pathways,
such as ERK and AKT. (C) The mRNA expression level of BDNF, supporting cell survival alteration in
the injured brain region (* p < 0.05).
3. Experimental Section
3.1. Chemical
Ech A (6-ethyl-2,3,5,7,8-pentahydroxynaphthalene-1,4-dion) was isolated from the sand dollar
Scaphechinus mirabilis using an extraction method as previously described [25]. The purity of Ech A
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(>99%) was confirmed by liquid chromatography-mass spectrometry (Shimadzu LCMS-2020, Kyoto,
Japan). We used 0.02% Ech A with saline solution.
3.2. Preparation of Ischemic Stroke Rat Models
3.2.1. Animals
Nine-week-old male Sprague Dawley (SD) rats (290–300 g; KOATECH, Gyeonggi-do, Korea) were
handled in accordance with the animal welfare guidelines issued by the Korean National Institute of
Health and the Korean Academy of Medical Sciences for the care and use of laboratory animals.
3.2.2. Middle Cerebral Artery Occlusion
We applied a modified surgical procedure of the standard method [26,27]. Briefly, rats were
anesthetized with isoflurane in a mixture of 30% oxygen and 70% nitrous oxide. Using an operative
microscope, a 3-0 nylon suture was inserted into the internal carotid artery (ICA) through the external
carotid artery (ECA). After 90 min of occlusion, the suture was withdrawn for 7 days for reperfusion.
The animals were randomly divided into three groups (n = 12 per group): group I, sham-operation
(sham), group II, MCAo/reperfusion-induced ischemic group with saline treatment (control), group III,
MCAo/reperfusion-induced ischemic group with 10 μM Ech A treatment.
3.3. Behavioral Test
We modified the FST and cylinder test to determine the motor ability of experimental animals.
For the FST, at 7 days after reperfusion, rats were placed in an open cylinder (height: 60 cm, diameter:
20 cm) which was filled with water for 6 min, and their duration of immobility was measured for the
last 4 min. In the cylinder test, rats were placed in a transparent cylinder (height: 30 cm, diameter:
20 cm) for 6 min. The use of their forelimbs was recorded for the last 4 min. The number of right
and left forelimbs used independently, and both forelimbs use simultaneously, were observed and
recorded. Each experiment was repeated five times.
3.4. Measurement of Brain Infarct Volume and Water Content
All animals were euthanized 7 days after MCAo operation. Brains were collected and sectioned
into 2.0 mm coronal slices to assess the brain infarct volume. The brain sections were stained with TTC
and the percentage of infarct volume was calculated by assessing the stained brain area using ImageJ
software. To measure the brain water content, the pons and olfactory bulbs were removed and the
wet weight (ww) of the brain was measured. The brains were subsequently dried at 110 ◦C for 24 h,
and the dry weight (dw) of the brain was examined. The percentage water content in the brain was
assessed using the following formula:
Water content: (ww − dw)/ww × 100%
3.5. Western Blot
Brain tissues were homogenized in lysis buffer (Cell Signaling Technology, Beverly, MA, USA)
to collect the total proteins. Quantified proteins were separated by SDS-PAGE and transferred to
polyvinylidene fluoride microporous membrane (Millipore, Temecula, CA, USA). The membranes
were blocked with 0.1% Tween 20 in Tris-buffered saline containing 5% nonfat milk for 1 h at room
temperature, and subsequently incubated with the primary antibody (Bcl-2, caspase-3, Bax, p-ERK, and
ERK; Santa Cruz Biotechnology, Dallas, TX, USA; p-Akt, Akt, and β-actin; Cell Signaling Technology).
3.6. Polymerase Chain Reaction (PCR) Analysis
The total RNA of brain tissues was extracted using the Hybrid-R RNA purification kit
(GeneAll, Seoul, Korea), and converted to cDNA using the cDNA synthesis kit (Thermo
124
Mar. Drugs 2019, 17, 501
Scientific, Vilnius, Lithuania). Amplification was performed in a DNA thermal cycler using the
following synthesized primers: 5′-GATGAGGACCAGAAGGTTCG-3′ (forward) and 5′-GATTGGGTA
GTTCGGCATTG-3′ (reverse) for BDNF; 5′-GCTGGGGCTCACCTGAAGGG-3′ (forward) and
5′-GGATGACCTTGCCCACAGCC-3′ (reverse) for GAPDH.
3.7. Statistical Analysis
All experimental data are presented as mean ± standard error of the mean (SEM). Comparisons
between more than two groups were performed by one-way ANOVA using Bonferroni’s correction.
A p-value < 0.05 is considered significant.
4. Conclusions
Until recently, Ech A was rarely used for the treatment of brain ischemic stroke. Our findings
indicate that Ech A as a novel therapeutic source from the ocean has considerable efficacy for cerebral
ischemic injury. We demonstrate that Ech A restores the damaged brain area and strengthens the
behavioral deterioration by supporting the expression of cell viability-related factors after brain
ischemic stroke. Taken together, the results of this study propose a new application as a potential
therapeutic agent for this marine drug.
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Abstract: Echinochrome A (Ech A), a natural pigment extracted from sea urchins, is the active
ingredient of a marine-derived pharmaceutical called ‘histochrome’. Since it exhibits several
biological activities including anti-oxidative and anti-inflammatory effects, it has been applied to
the management of cardiac injury and ocular degenerative disorders in Russia and its protective
role has been studied for other pathologic conditions. In the present study, we sought to investigate
the therapeutic potential of Ech A for inflammatory bowel disease (IBD) using a murine model of
experimental colitis. We found that intravenous injection of Ech A significantly prevented body
weight loss and subsequent lethality in colitis-induced mice. Interestingly, T cell proliferation was
significantly inhibited upon Ech A treatment in vitro. During the helper T (Th) cell differentiation
process, Ech A stimulated the generation regulatory T (Treg) cells that modulate the inflammatory
response and immune homeostasis. Moreover, Ech A treatment suppressed the in vitro activation of
pro-inflammatory M1 type macrophages, while inducing the production of M2 type macrophages that
promote the resolution of inflammation and initiate tissue repair. Based on these results, we suggest
that Ech A could provide a beneficial impact on IBD by correcting the imbalance in the intestinal
immune system.
Keywords: echinochrome A; marine drugs; inflammatory bowel disease; regulatory T
cells; macrophages
1. Introduction
Echinochrome A (Ech A) is a dark red pigment separated from sea urchin shell and spine and
has a chemical structure of 6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone [1,2]. As a main active
component of a commercial therapeutic agent called ‘histochrome’, Ech A has been used for the
treatment of cardiovascular disorders and ophthalmopathic complications in Russia [3–5]. Among
the several biological benefits of Ech A, anti-oxidant and anti-inflammatory capacity is proposed as a
major underlying therapeutic mechanism. Indeed, Ech A has been shown to attenuate the oxidative
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stress caused by reactive oxygen species (ROS) and cardiac toxic drugs, providing mitochondrial
protection of cardiomyocyte [6]. Park et al. have reported similar observations showing that Ech A
reduced both cellular and mitochondrial ROS levels of patient-derived cardiac progenitors during the
oxidative stress situation [7]. The anti-oxidative and anti-viral activity of Ech A has also been proved
in vitro using a tick-borne encephalitis virus and herpes simplex virus type 1-infected cell models [8].
The therapeutic potential of Ech A was also evaluated in an experimental gastric ulcer model where
Ech A provided anti-ulcerogenic effects by increasing endogenous enzymatic and non-enzymatic
antioxidant levels in vivo [9]. In another study, Ech A treatment could reduce ROS production and
pro-inflammatory tumor necrosis factor-α (TNF-α) secretion in a rat model of acute uveitis induced
by lipopolysaccharide injection [10]. These previous findings imply that Ech A could exert a wide
range of therapeutic impacts on other oxidative stress-related and inflammatory pathologic conditions;
however, the cell-type specific regulation of Ech A on the immune system, which consists of various
innate and adaptive immune cells, has not been elucidated yet.
Inflammatory bowel disease (IBD) is an intractable, chronic inflammatory disease of the digestive
tract and Crohn's disease (CD) and ulcerative colitis (UC) are the major types of IBD [11,12]. The
etiology and pathogenic mechanisms of IBD remain largely unknown and both environmental factors
and genetic factors combined with immunological dysfunction seem to drive IBD development. To
attenuate the excessive immune response, advanced immunotherapy using immune-modulators such
as inflammatory cytokine blockers has been used recently; however, the presence of non-responder
and uncontrolled side effects are the common challenging issues when using immunotherapy [13,14].
Therefore, there has been an unmet need to develop novel therapeutics for the effective management
of IBD.
In this study, we investigated whether Ech A could exhibit a protective role in IBD progression
using a chemical colitogen dextran sodium sulfate (DSS)-induced colitis mice model. To explore the
therapeutic mechanism of Ech A, we also performed in vitro proliferation and polarization experiments
with two major innate and adaptive immune cells, macrophage and CD4+ helper T cells (Th cells),
respectively. Our in vivo findings suggest that Ech A could attenuate the clinical signs, as well as
histological improvement, for the first time in a colitis model which represents IBD. More importantly,
in vitro results demonstrate that the anti-inflammatory function of Ech A is manifested by, in part,
inducing immunomodulatory effector cells, such as M2 macrophages and Treg cells.
2. Results and Discussion
2.1. Ech A Treatment Exerted a Protective Effect against DSS-Induced Colitis In Vivo
To evaluate the therapeutic effects of Ech A on IBD, we gave a single intravenous (i.v) injection of
Ech A or vehicle to DSS-induced colitis mice at day 1 and monitored the survival rate, body weight and
disease activity index for 12 days. We found that a high dose (10 mg/kg; E10) of Ech A could significantly
reduce body weight loss and increase the survival rate of colitis affected mice when compared with
vehicle (+) and a low dose of Ech A (1 mg/kg; E1) treated groups (Figure 1A). According to the disease
activity index score, clinical symptoms were also improved by Ech A treatment in a dose-dependent
manner (Figure 1B). In the gross examination of the large intestine, pathologic shortening of the colon
length due to colitis was reversed by the administration of Ech A (Figure 1C). H&E staining-based
histopathological analysis revealed that typical pathologic signs of the colitis-affected damaged colon
such as loss of epithelial structure and irregular morphology of crypts were ameliorated upon the
administration of 10 mg/kg Ech A (Figure 1D). In addition, we found that excessive accumulation of
immune cells within the epithelial and mesenchymal layer of the damaged colon was prevented upon
Ech A treatment, suggesting that Ech A could exhibit anti-inflammatory roles in the in vivo mouse
model (Figure 1D). Therefore, we concluded that Ech A could alleviate disease symptoms and play
protective roles in DSS-induced colitis mice.
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Figure 1. Echinochrome A (Ech A) administration provided therapeutic effects on DSS-induced colitis
mice in a dose-dependent manner. (A) Body weight and survival rate monitoring results are shown.
The body weight at day 0 considered was as 100%. Numbers in parentheses represent the percentage
of dead mice. (B) Disease activity index score for colitis severity at day 12 was significantly reduced in
the E10 group. (C) Colon length measurement results showing the protective role of Ech A against
DSS-induced colonic damage. (D) The histopathological score of the colitis-affected and normal colon
was evaluated with H&E stained tissue section. In total, six animals per group were used. Results are
shown as mean ± SD. In (B) and (C), p-value significance was calculated by comparing other groups
against the (+) group (marked as +). * P < 0.05, ** P < 0.01, *** P < 0.001.
2.2. Ech A Suppressed the Proliferation of Human MNCs and T Lymphocytes In Vitro
Based on the fact that excessive activation of the intestinal mucosal immune system triggered by
increased epithelial permeability leads to aggravation of IBD progression [15,16], we next investigated
whether Ech A could regulate the proliferation, differentiation and activation of various immune cells
in vitro to explore the underlying therapeutic mechanisms of Ech A on the colitis model. First, we
performed a mixed lymphocyte reaction (MLR) to evaluate the effect of Ech A on the expansion of
human mononuclear cells (MNCs) and T lymphocytes. To stimulate in vitro proliferation, MNCs
were treated with a non-specific mitogen concanavalin A (Con A) and cell proliferation capacity was
evaluated using flow cytometry at day 5. Interestingly, the proliferation of Con A-treated MNCs was
inhibited upon Ech A administration in a dose-dependent manner (Figure 2A,B). The percentage
of proliferating cells in the control group was 60.4%, while it decreased to 49.3% and 37% upon 5
μM and 10 μM of Ech A treatment, respectively. Similarly, Ech A reduced the proliferation rate of
CD3/CD28-stimulated T cells when compared with vehicle-treated samples (VC group: 72.2%; 5 μM
Ech A group: 63.6%; 10 μM Ech A group: 54.9%) (Figure 2C,D), implying that Ech A could regulate
immune cell proliferation in vitro.
2.3. Ech A Induced the Generation of Regulatory T Cells In Vitro
It is well known that naive Th (Th0) cells can differentiate into various subtypes of active Th cells
such as Th1, Th2 and Treg cells upon specific cues and each type of mature Th cell plays a distinct and
pivotal role in various disease developments including IBD [17,18]. Therefore, next we isolated CD4+
naive Th0 cells from human cord blood then performed a differentiation experiment following the
typical procedure with or without Ech A to evaluate the impact of Ech A on Th cell polarization. As
shown in Figure 3, flow cytometry analysis on cell surface markers revealed that Ech A provided no
significant impact on Th1/2 polarization in vitro (Figure 3A,B). On the other hand, Ech A treatment
could stimulate the generation of Treg cells; indeed, approximately 10% of total Ech A-treated cells
expressed the marker of the Treg cell marker Foxp3, while the spontaneous induction ratio of Treg cells
were less than 1% on average (Figure 3C).
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Figure 2. Ech A impact on mixed lymphocyte reaction (MLR) in vitro. CFSE-labeled human mononuclear
cells (MNCs) were cultured for five days in the presence of mitogen or antibodies for CD3/28 with or
without Ech A treatment, then the percentage of proliferated cells was evaluated using flow cytometry. The
proliferation of both MNCs (A,B) and T cells (C,D) was reduced by Ech A treatment in a dose-dependent
manner. VC, vehicle-treated control. ** P < 0.01. Results are shown as mean ± SD.
Figure 3. Ech A impact on Th cell polarization in vitro. (A,B) the percentages of IFN-γ + and IL-4+
cells among CD4+ Th cells were evaluated using flow cytometry to determine the induction ratio
of Th1 and Th2 cells, respectively. No significant change was observed upon Ech A treatment. (C)
Spontaneous generation of Foxp3+ Treg cells among CD4+ Th cells upon vehicle and Ech A treatment
was assessed using flow cytometry. Ech A treatment led to an increase in Treg population compared to
the vehicle-treated group. VC, vehicle-treated control. * P < 0.05, ** P < 0.001. Results are shown as
mean ± SD.
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2.4. Ech A Could Modulate the Polarization of Resting Macrophages into M1 and M2 Type In Vitro
As a key component of the innate immune system, macrophages play important roles in the host
defense reaction by mediating acute inflammatory response against danger signals and promoting
stimulation of the adaptive immune system [19]. Typically, two main subtypes of macrophages
have been described after polarization: Classically activated M1 type (M1) and alternative M2 type
(M2) [20]. In general, M1 macrophages tend to mediate the excessive and persistent pro-inflammatory
responses, while M2 macrophages are known to contribute to tissue regeneration and resolution
of inflammation. Given that chronic inflammation with the M1/M2 polarization balance skewed
toward the M1 phenotype is the major characteristic of IBD progression [21,22], modulation of
macrophage activity could be another therapeutic target. Thus, we conducted an in vitro experiment
to evaluate the influence of Ech A on M1/M2 differentiation. For M1 type polarization, phorbol
12-myristate-13-acetate (PMA)-treated THP1 macrophages were further stimulated with LPS and
IFN-γ. As expected, M1 macrophages produced a high level of tumor necrosis factor-alpha (TNF-α)
upon stimulation (Figure 4A). It was noted that Ech A could reduce M1-derived TNF-α secretion in
a dose-dependent manner (Figure 4A). On the contrary, the basal secretion level of interleukin 10
(IL-10) was increased in the presence of Ech A, indicating that Ech A could induce the spontaneous M2
polarization in vitro (Figure 4B).
Figure 4. Ech A impact on M1/M2 macrophage polarization in vitro. (A) After five days of M1 induction,
TNF-α concentration in the culture supernatant was measured by ELISA to estimate the M1 polarization
efficiency. It is noted that Ech A prevented M1 polarization in vitro in a dose-dependent manner. (B)
The IL-10 secretion level was determined using ELISA to evaluate the spontaneous M2 induction
efficiency. Ech A treated macrophages were differentiated into M2 macrophages more effectively
compared to vehicle-treated cells; (–), no induction control; (+), polarization induced control. The
p-value significance was calculated by comparing other groups against the (+) and (–) groups (marked
as +) in A and B, respectively. * P < 0.05, ** P < 0.01, *** P < 0.001. Results are shown as mean ± SD.
From the in vivo observation, Ech A provided significant protection against experimental colitis
as it alleviated disease severity and increased the survival rate of mice. In the histomorphological
analysis of the colon, marked loss of villus-crypt structure accompanied with edematous erosion and
granulation tissue formation was attenuated by Ech A injection. Ech A also decreased the degree
of inflammatory cell infiltrates in a dose-dependent manner, suggesting that Ech A could exhibit an
anti-inflammatory capacity in the IBD status.
Importantly, following in vitro Th cell differentiation, the experiment revealed that Ech A treatment
could promote Treg generation without affecting the Th1 or Th2 populations. Considering that Treg
cells function as a key immunomodulator that regulates activation of other Th cells, Ech A could
contribute to correct the immunological imbalance in vivo by inducing the Treg population, although
it does not directly regulate Th1 or Th2 polarization. Indeed, Tsai et al. have reported that a member of
the lectin family galectin-3 prevents colitis progression while galectin-3 knockout mice suffered from
more severe symptoms than controls, and the therapeutic impact of galectin-3 was abrogated by CD25
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neutralization, implying the importance of Treg cells in this context [23]. Here we also demonstrated
that Ech A could regulate the direction of macrophagic polarization toward M2 differentiation. M1
suppression and/or M2 induction strategies have proven beneficial for IBD treatment. Abron et al. have
reported that the soy bean-derived natural agent genistein reduced the severity of DSS-induced colitis
by transforming M1 macrophages into M2 type followed by the reduction of pro-inflammatory cytokine
levels [24]. In addition, adipose-tissue-derived mesenchymal stem cells could provide protection in
colitis mice models via TNF-α-induced gene/protein 6-mediated M2 induction [25]. In particular, the
TNF-α inhibitory effect of Ech A could be directly applicable for IBD therapeutics considering that
TNF-α expressing immune cells are increased in the intestinal tract of IBD patients and TNF-α blockers,
as well as anti-TNF-α agents, have been approved in clinic for IBD treatment [26].
To further highlight the benefits of Ech A application, the underlying mechanisms of Ech A
mediated immune cell fate regulation should be explored for the fundamental understanding of the
Ech A therapeutic function. According to a recent study, Ech A could stimulate ex vivo expansion
of CD34+ hematopoietic stem/progenitor cells (HSPC) with enhanced colony-forming capacity via
suppression of intracellular ROS generation [27]. Mechanistically, ex vivo treatment of Ech A or
anti-oxidant agent N-acetyl cysteine could not only inhibit oxidative stress-associated P38 MAPK
activation but also increase Lyn/Src phosphorylation followed by activation of the PI3K-Akt signaling
pathway, leading to high-quality HSPC expansion. Therefore, it would be worthwhile to investigate
the therapeutic contribution of the anti-oxidative capacity of Ech A in IBD prevention in terms of
HSPC-derived immune cell proliferation and differentiation. In addition, Ech A could bind directly to
protein kinase C-iota (PKC i) and enhanced myocardial cell differentiation of mouse embryonic stem
cells by antagonizing its activity [28]. Considering that the PKC family plays an important role in Th
cell homeostasis [29,30], Ech A might regulate PKC activity to induce Treg population followed by M2
macrophagic activation.
In conclusion, we demonstrate the therapeutic potential of Ech A for IBD for the first time. We
also emphasize that Ech A could induce immunomodulatory effector cell generation such as Treg
cells and M2 macrophages along with suppression of pro-inflammatory M1 macrophage, leading to
attenuation of excessive inflammation. These data suggest that Ech A could exert immune-cell type
specific regulatory roles in vitro and possibly in vivo. Therefore, our findings not only suggest Ech A
as a novel potent therapeutic agent for incurable IBD but also contribute to expanding the therapeutic
utility of Ech A for various inflammatory diseases.
3. Materials and Methods
3.1. DSS-Induced Experimental Colitis Mice Modeling and Monitoring
All experiments were approved by and followed the regulations of the Institute of Laboratory
Animals Resources (PNU-2018-2034, Pusan National University). Experimental colitis was induced in
mice by the addition of 3% (wt/vol) DSS (MP Biochemicals, Solon, OH, USA) in drinking water for 7
days as previously described [31]. Four groups were designed as positive (DSS, n = 6) or negative
(no DSS, n = 6) controls and a low-dose (1 mg/kg, n = 6) and a high dose (10 mg/kg, n = 6) of Ech A
treated group. Ech A was administrated at day 1 via i.v injection, while a vehicle (0.1% DMSO in PBS)
was given to negative control mice instead. Total 12 day-long daily monitoring for body weight and
survival rate was conducted. On day 12, the disease activity index of surviving animals was scored by
assessing stool consistency, rectal bleeding and coat roughness (grade from 0 to 4), general activity and
bedding contamination with stool and blood (graded from 0 to 2). All subjects were then sacrificed for
the evaluation of gross pathologic severity (measuring colon length) and further histological analysis
using H&E staining.
132
Mar. Drugs 2019, 17, 622
3.2. Mixed Leukocyte Reaction
For MLR, human MNCs were labeled using the CellTrace CFSE cell labeling kit (Invitrogen, Grand
Island, NY, USA) following the manufacturer‘s instructions. Cells were then seeded in a 6-well plate at
a density of 5 × 104 /well and cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) with supplement
of 10% FBS (Gibco) and 100 U/mL penicillin/streptomycin (Gibco) in the presence of Con A (5 μg/mL
for MNC proliferation) (Sigma, St. Lois, MO, USA) or anti-CD3/anti-CD28 (5 μg/mL and 2 μg/mL,
respectively, for T cell proliferation) (eBioscience, San Diego, CA, USA) for 5 days. To assess the Ech A
impact on cell proliferation, Ech A or vehicle was also treated during the culture period. After 5 days,
cells were harvested and prepared for flow cytometry analysis.
3.3. Isolation and Culture of Human CD4+ Naïve Th (Th0) Cells
This study was approved by the Institutional Review Board of Pusan National University
(H-1802-006-063). MNCs were isolated from human cord blood provided by Busan/Ulsan/Gyeongnam
Cord Blood Bank using HetaSep (Stem Cell Technologies, British Columbia, Canada) and Lymphoprep
(Stem Cell Technologies) as per the manufacturer’s instructions. Total naive Th0 cells were then purified
by negative selection with magnetic beads provided in the Human Naive CD4+ T Cell Isolation Kit II
(Miltenyi Biotec, Bergisch Gladbach, Germany). Purified cells were determined for their purity (more
than 95% CD4+ cells) and then plated in the density of 1 × 106 cells/well in a 12-well culture plate and
cultured in expansion media consisting of the ImmunoCult-XF T Cell Expansion Medium (Stem Cell
Technologies), ImmunoCult Human CD3/CD28/CD2 T Cell Activator (Stem Cell Technologies) and
IL-2 (Peprotech, Rocky Hill, NJ, USA).
3.4. Th1, Th2 and Treg Cell Differentiation
For Th1 polarization, purified CD4+ Th0 cells were cultured in expansion media supplemented
with IL-12 (10 ng/mL) (Peprotech) and anti-IL-4 neutralizing antibodies (5 μg/mL) (BD Bioscience, San
Jose, CA, USA) for 5 days. For Th2 induction, purified CD4+ Th0 cells were cultured in expansion
media with IL-4 (20 ng/mL) (Peprotech) and anti-IFN-γ neutralizing antibodies (5 μg/mL) (BioxCell,
West Lebanon, NH, USA) for 5 days. To evaluate the spontaneous induction ratio of Treg cells, purified
CD4+ Th0 cells were cultured in expansion media for 5 days without any lineage-specific stimulants.
To assess the Ech A impact on Th cell polarization, Ech A or vehicle was also treated during the
culture period.
3.5. Flow Cytometry Analysis
To stimulate the production of lineage-specific markers, differentiated Th cells were treated with
50 ng/mL of PMA (Sigma) and 1 μM of Ionomycin (Sigma) with transport inhibitor GolgiStop (BD
Biosciences) for 4 h. Cells were washed with PBS 4 times then incubated with FITC conjugated
anti-human CD4 (BD Bioscience) at 4 ◦C for 30 min in the dark. After surface marker staining, cells
were fixed and permeabilized using fixation and permeabilization buffer (BD Bioscience) then further
stained with PerCP-Cy5.5-conjugated anti-human IFN-γ (BD Bioscience), APC-conjugated anti-human
IL-4 (BD Bioscience), and PerCP-Cy5.5-conjugated anti-human FoxP3 (BD Bioscience) at 4 ◦C for 30
min in the dark. Nonspecific isotype-matched antibodies served as controls. Samples were analyzed
with the BD FACS Verse flow cytometer (BD Biosciences) and data analysis was performed using
FlowJo software.
3.6. Macrophage Polarization
THP1 cells were maintained in RPMI 1640 (Gibco, Grand Island, NY, USA) with a supplement of
10% FBS (Gibco) and 100 U/mL penicillin/streptomycin (Gibco). To induce monocytic differentiation,
THP1 cells were plated at a density of 4 × 105 /well on 6-well culture plate and pre-treated with PMA
(Sigma) for 48 h. After PMA treatment, cells were stabilized for another 24 h in the maintenance
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media. Macrophages were then polarized in M1 macrophages by incubation with 20 ng/mL of IFN-γ
(Peprotech) and 10 μg/mL of LPS (Sigma) for 5 days. PMA-pretreated cells were cultured within the
maintenance media for 5 days without any lineage-specific stimulants for the spontaneous polarization
towards M2 macrophages. To assess the Ech A impact on macrophage polarization, Ech A or vehicle
was also treated during the culture period. Five days later, the culture supernatant was collected and
secreted cytokine levels were estimated using human TNF-α and the IL-10 Duoset ELISA kit (R&D
system, Abingdon, UK).
3.7. Data Analysis
At least three individual experiments were conducted for in vitro experiments. Data are presented
as mean ± standard error of the mean (SEM). All of the statistical comparisons were performed using
one-way ANOVA followed by a Bonferroni post hoc test for multigroup comparisons using GraphPad
Prism software (GraphPad Software, San Diego, CA, USA); p-values under 0.05 was considered
statistically significant.
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Abstract: The aim of this study was to examine the in vitro antioxidant and antiviral activities of
echinochrome A and echinochrome-based antioxidant composition against tick-borne encephalitis
virus (TBEV) and herpes simplex virus type 1 (HSV-1). The antioxidant composition, which is a
mixture of echinochrome A, ascorbic acid, and α-tocopherol (5:5:1), showed higher antioxidant and
antiviral effects than echinochrome A. We suppose that echinochrome A and its composition can both
directly affect virus particles and indirectly enhance antioxidant defense mechanisms in the hosting
cell. The obtained results allow considering the echinochrome A and the composition of antioxidants
on its basis as the promising agents with the both antioxidant and antiviral activities.
Keywords: echinochrome A; composition of antioxidants; antioxidant activity; antiviral activity
1. Introduction
Oxidative stress, arising through production of free radicals including reactive oxygen species
(ROS), is usually defined as a disturbance in the balance between the level of ROS and antioxidant
defenses [1]. Viral infections, along with other numerous human diseases, are accompanied by
oxidative stress, which plays an important role in their pathogenesis [2,3]. Oxidative processes
promote virus replication in infected cells, decrease cell proliferation, and induce cell apoptosis [4].
Intensification of the processes of free radical lipid oxidation and the sharp suppression of the
antioxidant and antiradical protection system of the body are observed in patients with neurotropic
virus infections such as tick-borne encephalitis [5] and herpes simplex [6,7]. Central nervous
system tissues are especially sensitive to lipid peroxidation due to their high lipid content [8].
The lipid peroxides resulting from the ROS-induced peroxidation of membrane phospholipids, such as
malondialdehyde, can transverse the circulation and cell membranes, with the resultant dysfunction
of vital cellular processes such as membrane transport and mitochondrial respiration [9].
Antioxidants with different mechanisms of action are used to prevent or treat various diseases
that are associated with oxidative stress and possess therapeutic effects in many cases [10–12]. Since the
most important aspect of the treatment of viral diseases is the suppression of viral replication followed
by cell survival, the search for drugs that have antiviral properties among antioxidants is promising.
There are many examples showing that natural antioxidants such as vitamins C and E (ascorbic acid
and α-tocopherol, respectively), curcumin, various polyphenols, and others are promising agents for
antiviral therapy, since they decrease ROS levels in infected cells, the expression of pro-apoptotic
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signaling molecules, and modulate the cellular levels of stress-related proteins such as c-Jun N-terminal
kinases (JNK), phospho-p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated
kinases (ERK-1/2), and transcription factor NF-kB [13–18].
A well-known natural antioxidant echinochrome A (naphthoquinonoid pigment of sea urchins) is
the active substance of the Russian drug Histochrome®, which is used in cardiology for the treatment
of ischemic heart disease and myocardial infarction, and in ophthalmology for the treatment of
degenerative diseases of the retina and cornea, macular degeneration, primary open-angle glaucoma,
and others [19,20].
The aim of this research was to study the in vitro antioxidant and antiviral activities of
echinochrome A (Ech) and the compositions based on Ech, including also other antioxidants,
against RNA-containing tick-borne encephalitis virus (TBEV) and DNA-containing herpes simplex
virus type 1 (HSV-1).
This paper was prepared for printing on the basis of materials presented as a lecture on the Third
International Symposium on Life Science, Vladivostok, Russia, September 2018.
2. Results
2.1. Antioxidant Activity of Ech Formulations Alone or Combined with Other Antioxidants
We have compared antioxidant properties of Ech, α-tocopherol (Toc), and ascorbic acid (Asc),
as well as their combinations, using the model of linetol peroxidation. The procedure that we applied
relates to simple gravimetric methods via the measurement of weight increases following oxygen
fixation on fatty acids [21]. Action of the studied substances on linetol was characterized as the
induction time of the lipid auto-oxidation reaction (Δτ, h-difference between times necessary for
linetol oxidation in the presence and absence of an antioxidant). The determination of antioxidant
activities made it possible not only to compare the antioxidant activities of the studied substances with
each other, but also to find the optimal ratio of antioxidants in the most active compositions. It was
established that Toc was the most effective antioxidant in this experiment (Δτ 125 h) (Table 1). Ech was
some less effective (Δτ 100 h), while Asc showed no antioxidant effect on this model. The low efficiency
of Asc may be explained by its high susceptibility to auto-oxidation in linetol solution. It is known
that in experiments in vitro, Asc lacks antioxidant activity in the absence of Toc. This observation was
confirmed by our experiments (Δτ of the mixture Asc + Toc (2:1) was 195 h, which is more than effect
of Toc itself). A mixture of all three antioxidants (Ech + Asc + Toc) demonstrated a stronger effect on
a model of linetol auto-oxidation as a result of the synergy of these compounds (Δτ 223 h) (Table 1).
We calculated the effect of synergism (in %) according to Kancheva et al. by the formulas for binary
and ternary mixtures of antioxidants [22].
Table 1. Antioxidant activity of the formulations on a model of linetol auto-oxidation. 1
Antioxidants and their Compositions Δτ, h The Efficiency of the Composition Compared to Ech
Ech 100 ± 5 -
Asc 24 ± 3 -
Toc 125 ± 7 -
Ech + Asc (1:1) 69 ± 4 No effect
Ech + Toc (1:1) 201 ± 8 * Synergism 8%
Asc + Toc (2:1) 195 ± 7 * Synergism 7%
Ech + Asc + Toc (5:5:1) 223 ± 10 ** Synergism 40%
Control-linetol 24 ± 2
1 The concentration of Ech, Asc, Toc and their compositions in test medium was of 0.05 mg/mL. * Statistically
significant differences between Ech and antioxidant compositions (p ≤ 0.05); ** statistically significant differences
between three-component and two-component mixtures of antioxidants (p ≤ 0.05). Asc: ascorbic acid,
Ech: echinochrome A, Toc: α-tocopherol.
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2.2. Antioxidant Activity of the Formulations Against LPS-Induced ROS Formation in Vero Cells
To determine whether Ech alone or combined with other antioxidants is able to decrease
intracellular ROS level in Vero cells, we used the model of E. coli lipopolysaccharide (LPS)-induced
ROS formation. The ROS levels in Vero cells treated with LPS increased by 20% in comparison to
control–untreated cells (Figure 1). Ech, Ech + Asc + Toc, and Asc + Toc decreased the ROS formation
by 61%, 68%, and 50% in Vero cells, correspondingly, in comparison to LPS-treated cells.
Figure 1. Influence of Ech and studied formulations on the lipopolysaccharide (LPS)-induced reactive
oxygen species (ROS) formations in Vero cells. The formulations were tested at a concentration of five
μg/mL. * p < 0.05; ** statistically significant differences between Asc + Toc and Ech (p ≤ 0.05).
Ech and its composition with Asc and Toc showed significant antioxidant effects on both
experimental models, which makes them promising agents for further investigations on TBEV and
HSV-1 replications accompanied by oxidative stress.
2.3. Cytotoxicity and Antiviral Activity of Formulations.
Cytotoxicity assay was carried out to determine the concentration range of formulations for the
subsequent study of its antiviral activity in the non-toxic range for pig embryo kidney (PK) and Vero
cells. Acyclovir and ribavirin were used as standard antivirals for HSV-1 and TBEV, respectively.
Based on the obtained methylthiazolyltetrazolium bromide (MTT) assay results, 50% cytotoxic
concentrations (CC50) against PK and Vero cells were determined for all of the studied formulations
(Table 2). Further antiviral activity assay was performed at the concentrations of the formulations
below 400 μg/mL.
Table 2. Cytotoxic and antiviral activities of formulations against tick-borne encephalitis virus (TBEV)
and herpes simplex virus type 1 (HSV-1).
Formulation
TBEV HSV-1
CC50 (μg/mL) IC50 (μg/mL) SI CC50 (μg/mL) IC50 (μg/mL) SI
Ech + Asc + Toc (5:5:1) 57.9 ± 2.3 * 12.6 ± 1.5 ** 4.8 ± 0.5 ** 66.7 ± 3.2 * 11.2 ± 1.2 ** 6.0 ± 0.6 **
Ech 54.4 ± 1.8 * 21.8 ± 2.6 * 2.5 ± 0.2 * 60.5 ± 3.1 * 18.8 ± 2.1 * 3.2 ± 0.3 *
Asc + Toc (5:1) 521.7 ± 5.3 1304 ± 145 0.4 ± 0.1 530.9 ± 9.4 885 ± 97 0.6 ± 0.1
Ribavirin 2010 ± 180 30.5 ± 4.6 66.0 ± 5.4
Acyclovir 1470 ± 160 10.8 ± 1.2 133.6 ± 12.0
CC50-50% cytotoxic concentration of a formulation, IC50-50% virus-inhibiting concentration of a formulation,
SI: selective index of the formulation. * Statistically significant differences between Asc + Toc and other formulation
(p ≤ 0.05), ** statistically significant differences between antioxidant composition and Ech (p ≤ 0.05).
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The anti-TBEV and anti-HSV-1 activity of tested formulations were assessed using cytopathic
effect (CPE) inhibition assay. PK and Vero cells infected with the 10-fold dilutions of corresponding
virus were simultaneously treated with different concentrations of the formulations. It was found
that the formulations inhibited virus-induced CPE in a dose-dependent manner, and values of the
50% inhibitory concentrations (IC50) and selective indices (SI) of the tested formulations for both
viruses are presented in the Table 2. Ech and the Ech + Asc + Toc composition revealed moderate
antiviral activities against TBEV and HSV-1 compared with Asc + Toc. Furthermore, based on IC50
and SI values, the Ech + Asc + Toc composition was more active toward TBEV and HSV-1 than Ech
and Asc + Toc (p ≤ 0.05) (Table 2). The obtained data revealed that the presence of Asc and Toc in
composition with Ech enhances antiviral activity of this formulation up to two times compared with
Ech alone.
2.4. Time-of-Formulation-Addition Assay
The inhibitory effects of tested formulations on different stages of TBEV and HSV-1 replication
cycles were studied by time-of-addition experiments via MTT assay (Figure 2). Cells were pretreated
with formulations before viral infection (pretreatment of cells), viruses were incubated with
formulations before cell infection (pretreatment of virus), or infected cells were incubated with
formulations after penetration of the virus into host cells (treatment of infected cells).
Figure 2. Antiviral action of the formulations on different stages of virus replication cycles. * Statistically
significant differences between Asc + Toc and other formulation (p ≤ 0.05), ** statistically significant
differences between antioxidant composition and Ech (p ≤ 0.05).
In the case of the pretreatment of viruses with the formulations (direct virucidal effect), Ech and
the Ech + Asc + Toc composition considerably suppressed TBEV infection: inhibition rates (IR) were of
75 ± 4% and 89 ± 5%, respectively (p < 0.05). The corresponding pretreatment of HSV-1 by Ech and
the Ech + Asc + Toc composition completely protected cells against this infection. However, only a
minor effect on HSV-1 infection was detected when the virus was pretreated with acyclovir (Figure 2).
The treatment of PK and Vero cells with the tested formulations before infection (preventive effect)
was much less effective. Ech, the Ech + Asc + Toc composition, and the Asc + Toc composition showed
almost no preventive action against both virus infections. The same results were found when Vero
cells were pretreated with acyclovir prior to infection.
When the formulations were added at an early stage of virus replication (one hour after infection),
Ech and the Ech + Asc + Toc composition possessed moderate virus-inhibiting effects against TBEV
infection with an IR of 21 ± 2% and 36 ± 3%, respectively, and against HSV-1 with an IR of 28 ± 3%
and 43 ± 4%, respectively, compared to an inactive Asc + Toc formulation (~10%, p < 0.05). Meanwhile,
acyclovir showed the highest antiviral activity, with an inhibition of the HSV-1 replication of 79 ± 4%.
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3. Discussion
It was of interest that the Ech + Asc + Toc composition, which included three different antioxidants,
demonstrated the most potent antioxidant action. Therefore, this composition showed a pronounced
synergistic effect, which means that its antioxidant activity was much higher compared to each of
the components added in the same amount to stabilize the lipid substrate due to the continuous
regeneration of Toc from both the Ech and Asc. Moreover, the synergistic action of Ech in combination
with other antioxidants was not so far reported. Ech and the Ech + Asc + Toc composition demonstrated
high antioxidant activity on the model of LPS-induced ROS formation in Vero cells.
Since Ech and its composition with Asc and Toc showed significant antioxidant effects on both
experimental models, and because of the ability of Ech to overcome the blood–brain barrier [23],
further investigations of their effects on the replication cycles of neurotropic viruses such as TBEV
and HSV-1 accompanied by oxidative stress were performed. Earlier combinations of antiviral agents
with antioxidants have been used for the treatment of some other viral infections, for example,
at influenza-associated complications [24]. In this study, we have shown the possibility of enhancing
the antioxidant and antiviral effects of Ech due to combination with other antioxidants. We have found
that the most effective method of application of Ech and the studied composition is the pretreatment
of viruses with the formulations (virucidal action). The antioxidant composition Ech + Asc + Toc also
demonstrated stronger antiviral activity against TBEV and HSV-1 compared to Ech. The inhibitory
concentrations (IC50) of the composition were half that of Ech, while the selective indices (SI) were
twice as large as those of Ech (Table 2). It should be noted that regardless of the method of exposure of
viruses and cells to the formulations, the virus inhibition rates of the composition of antioxidants was
higher than that by Ech itself (p < 0.05, Figure 1).
It was shown that the main mechanism of the in vitro action of Ech and the composition of
antioxidants at the stages of the life cycles of TBEV and HSV-1 is a direct inactivation of virus particles
(Figure 2). Many authors have suggested that the virucidal activity of polyphenols (Ech is considered
a polyphenol as well) might be caused by direct action on the viral particles inhibiting the adsorption
of the virus to the host cell receptors [25–27]. At the same time, Li et al. reported that polyphenols can
cause irreversible damage or the reversible blocking of certain regions of the viral capsid protein [28].
We suppose that Ech and its composition with antioxidants can bind with some envelope virus proteins
that are necessary for the adsorption of the virus to cells. Since many polyphenols exhibit antioxidant
and antiviral properties, we can assume that the activity of Ech and its composition in relation to TBEV
and HSV-1 can also be caused by interfering with the redox imbalance caused by these viruses [16].
Thus, Ech, either alone or in varying compositions, can both directly affect virus particles and indirectly
enhance the antioxidant defense mechanisms in the hosting cell.
Thus, the ability of Ech and its compositions to inactivate HSV-1 and TBEV virus particles makes
it useful as an antiviral agent in preventing de novo viral infection, and thereby could help control
viral spread and limit recurrent infections.
Our data on the antioxidant and antiviral activities of Ech—which earlier have been applied to
the treatment of cardiovascular and eye diseases—and antioxidant composition based on Ech indicate
the necessity of further studies of these formulations for the development of promising antiviral drugs.
4. Materials and Methods
4.1. Viruses and Cell Cultures
The RNA-containing tick-borne encephalitis virus (TBEV) strain Dal’negorsk that was isolated
in 1973 from the brain of a patient with a fatal outcome of TBE, and characterized as a Far Eastern
subtype, was used (Gene Bank Whole Genome Sequence Number: FJ402886) [29]. The DNA-containing
herpes virus (HSV-1, strain VR3) was obtained from the National Collection of US Viruses (Rockville,
MD, USA).
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TBEV was grown on the pig embryo kidney (PK) cells using medium 199 supplemented with
10% fetal bovine serum (FBS) and 100 U/mL gentamicin. HSV-1 was grown in African green monkey
kidney (Vero) cells using Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS,
gentamicin, and glutamine.
Viral titers were determined by cytopathic effect (CPE) assay and expressed as the 50% tissue
culture infectious dose (TCID50/mL). The TBEV titer was 108.8 TCID50/mL, and the titer of HSV-1 was
108.25 TCID50/mL.
4.2. Studied Formulations
Echinochrome A (Ech, 2,3,5,7,8-pentahydroxy-6-ethyl-1,4-naphthoquinone) 98.0%, pharmaceutical,
state registration number PN002362/01-2003, G.B. Elyakov Pacific Institute of Bioorganic Chemistry
FEB RAS, Russia.
Ascorbic acid (Asc) 99.8%, pharmaceutical, AppliChem, Germany.
α-Tocopherol (Toc) ≥96%, pharmaceutical, Carl Roth, Germany.
The composition of antioxidants Ech + Asc + Toc at the weight ratio of 5:5:1.
The composition containing Asc and Toc at the weight ratio of 5:1.
Ribavirin®, pharmaceutical, Vertex, Russia.
Acyclovir®, pharmaceutical, Belmedpreparation, Republic of Belarus.
The tested formulations were dissolved in dimethylsulfoxide (DMSO, Sigma, Saint-Louis, MO,
USA) and stored at −20 ◦C. The stock solutions (10 mg/mL) of formulations were diluted with a
suitable cell culture medium so that the final concentration of DMSO was 0.5%.
4.3. Determination of Antioxidant Activity of the Formulations
Antioxidant activity of the formulations was determined on a model of linetol peroxidation
containing a complex mixture of ethyl esters of polyunsaturated fatty acids (oleic, linoleic, and linolenic)
of linseed oil at 37 ◦C [30]. Stock solutions of Ech, Asc, and Toc were prepared at a concentration of
10 mg/mL in ethanol. Two-component and three-component antioxidant compositions were obtained
by mixing the volumes of stock solutions in the indicated proportions. First, 10 μL of each solution
and 300 μL of linetol were placed in a glass vial. The reaction vessels were placed in an incubator
(37 ◦C). The concentration of antioxidant in linetol in all cases was 0.05 mg/mL, or 0.005%. The mass
of the reaction mixtures pre-cooled to room temperature was measured twice a day (accuracy 0.0005 g).
When the mass of increased by 10 mg, the reaction was stopped. All of the experiments were repeated
three times. The period of linetol oxidation inhibition (Δτ) was calculated as the difference between
times necessary for the weight of linetol to increase by 10 mg in experiments with and without the
addition of antioxidants using the formula Δτ = τ− τ0, where τ is the time of linetol oxidation initiation
in the presence of an antioxidant (h); and τ0 is the time of linetol oxidation initiation without the
addition of an antioxidant (h).
4.4. Antioxidant Activity of the Formulations Against LPS-Induced ROS Formation in Vero Cells
The Vero cells that were grown on 96-well plates (1 × 104 cells/well) were washed from the growth
medium and treated with 100 μL/well of the tested compounds (five μg/mL) and 10 μL/well LPS from
E. coli serotype 055:B5 (Sigma, 1.0 μg/mL), which were both dissolved in PBS and cultured at 37 ◦C in a
CO2-incubator for one hour. For the ROS levels measurement, 20 μL of 2,7-dichlorodihydrofluorescein
diacetate (DCF-DA, Sigma, final concentration 10 μM) solution was added to each well, and the
plates were incubated for 30 min at 37 ◦C. The intensity of DCF-DA fluorescence was measured at λex
485 n/λem 518 nm using the plate reader PHERAstar FS (BMG Labtech, Offenburg, Germany) [31].
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4.5. Cytotoxicity Assay of the Formulations
The cytotoxicity of the tested formulations was estimated by MTT assay in PK and Vero cell
lines [32,33]. A monolayer of cells (1 × 104 cells/well) grown in 96-well plates was treated with
different concentrations of tested formulations (from 0 to 2000 μg/mL) and cultured at 37 ◦C in
a CO2-incubator for six days; untreated cells were used as controls. Then 20 μL of MTT solution
(5 mg/mL) (methylthiazolyltetrazolium bromide, Sigma, Saint-Louis, MO, USA) was added in each
well followed by incubation at 37 ◦C for one hour. The MTT solution was removed, and 150 μL/well
of isopropanol was added. Optical density (OD) was measured at 540 nm using an ELISA microplate
reader (Labsystems Multiskan RC, Vantaa, Finland) with a reference absorbance at 620 nm. The viability
of the cells was calculated as (ODt)/(ODc) × 100%, where ODt and ODc correspond to the absorbance
of treated and control cells, respectively. Cytotoxicity was expressed as 50% cytotoxic concentration
(CC50) of the tested formulation that reduced the viability of treated cells by 50% compared with
control cells. Experiments were performed in triplicate and repeated three times.
4.6. Antiviral Activity ASSAY of Formulations
The antiviral activity of formulations against TBEV and HSV-1 was evaluated using cytopathic
effect (CPE) inhibition assay in PK and Vero cells, respectively. The overnight monolayer of cells
grown on 96-well plates (1 × 104 cells/well) was infected with 100 μl/well of serial dilutions of
virus suspension (10−1–10−8) and simultaneously treated by formulations (100 μL/well in triplicate)
of different concentrations (from 0 to 400 μg/mL) for one hour at 37 ◦C. After virus absorption,
the virus–formulations mixture was removed; the cells were washed, and a maintenance medium with
1% FBS was added. The plates were kept at 37 ◦C in CO2-incubator for six days for TBEV or for three
days for HSV-1 until CPE appeared. The antiviral activity was determined by the difference of the viral
titers between treated infected cells and untreated infected cells and expressed as the inhibition rate
(IR, %), using the formula [27]: IR = (1 − T/C) × 100, where T is the antilog of the formulations-treated
viral titers and C is the antilog of the control (without formulations) viral titers. The concentration
of formulation that reduced the virus-induced CPE by 50% was determined as the 50% inhibitory
concentration (IC50). The selectivity index (SI) was calculated as the ratio of CC50 to IC50. Experiments
were repeated three times.
4.7. Time-of-Formulation-Addition assay
PK and Vero cells were grown in 96-well plates (1 × 104 cells/well). An infectious dose of
both TBEV and HSV-1 was of 100 TCID50/mL, tested formulations were used at a concentration of
20 μg/mL, and acyclovir was used at a concentration of 10 μg/mL. The plates were kept at 37 ◦C in
CO2-incubator for six days for TBEV or for three days for HSV-1 until 80–90% CPE was observed in
viruses control compared with cells control.
- Pretreatment of cells with formulations. Monolayer of cells was pretreated with formulations in
triplicate and incubated at 37 ◦C for one hour. Thereafter, the cells were washed and infected with
virus at 37 ◦C for one hour. The cells were washed to remove unabsorbed virus and incubated
with maintenance medium until CPE was observed.
- Pretreatment of virus with formulations. The virus was mixed with formulations at a ratio 1:1
(v/v), incubated for one hour at 37 ◦C, then applied to monolayer of cells in triplicate. After one
hour adsorption at 37 ◦C, cells were washed, and maintenance medium was added, followed by
incubation until CPE was observed.
- Treatment of infected cells. Monolayer of cells was infected with the virus at 37 ◦C for one
hour, then washed, treated with tested formulations in triplicate, and incubated until CPE
was appeared.
Antiviral activity of formulations was assessed by MTT test, and the viral inhibition rate
(IR, %) was calculated according to the formula [34], IR = (ODtv − ODcv)/(ODcd − Odcv) × 100,
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where ODtv represents the OD of cells infected with virus and treated with the test formulation;
ODcv corresponds to the OD of the untreated virus-infected cells, and ODcd is OD of control (untreated
and noninfected) cells.
4.8. Statistical Analysis
CC50 and IC50 were calculated by regression analysis of the dose–response curve.
Statistical processing of the data was performed using Statistica 10.0 software. The results are given
as mean ± standard deviation (SD). The differences between parameters of control and experimental
groups were estimated using the Wilcoxon test. Differences were considered significant at p ≤ 0.05.
5. Conclusions
We have shown that the both Ech, an active substance of the permitted to clinical application in
Russia drugs, belonging the Histochrome series, and an antioxidant composition, containing Ech, Asc,
and Toc (5:5:1), possess in vitro antiviral activity against RNA-containing tick-borne encephalitis virus
and DNA-containing herpes simplex virus type 1. The studied composition of antioxidants exhibits
more potent antioxidant and antiviral properties than Ech itself, thus demonstrating the synergistic
effects of its components.
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Abstract: Doxorubicin, an anthracycline from Streptomyces peucetius, exhibits antitumor activity
against various cancers. However, doxorubicin is cardiotoxic at cumulative doses, causing increases
in intracellular reactive oxygen species in the heart. Spinochrome D (SpD) has a structure of
2,3,5,6,8-pentahydroxy-1,4-naphthoquinone and is a structural analogue of well-known sea urchin
pigment echinochrome A. We previously reported that echinochrome A is cardioprotective against
doxorubicin toxicity. In the present study, we assessed the cardioprotective effects of SpD against
doxorubicin and determined the underlying mechanism. 1H-NMR-based metabolomics and mass
spectrometry-based proteomics were utilized to characterize the metabolites and proteins induced
by SpD in a human cardiomyocyte cell line (AC16) and human breast cancer cell line (MCF-7).
Multivariate analyses identified 12 discriminating metabolites (variable importance in projection > 1.0)
and 1814 proteins from SpD-treated AC16 cells. Proteomics and metabolomics analyses showed that
glutathione metabolism was significantly influenced by SpD treatment in AC16 cells. SpD treatment
increased ATP production and the oxygen consumption rate in D-galactose-treated AC16 cells. SpD
protected AC16 cells from doxorubicin cytotoxicity, but it did not affect the anticancer properties.
With SpD treatment, the mitochondrial membrane potential and mitochondrial calcium localization
were significantly different between cardiomyocytes and cancer cell lines. Our findings suggest that
SpD could be cardioprotective against the cytotoxicity of doxorubicin.
Keywords: Spinochrome D; doxorubicin; cardioprotective effect
1. Introduction
Echinochrome A has a chemical structure of 6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone,
which exhibits cardioprotective activity and reduces the myocardial ischemia/reperfusion injury
via its antioxidant effect and enhancement of mitochondria biogenesis [1–3]. Echinochrome A has
a number of structural analogues and together they comprise the class of spinochrome pigments
of sea urchins. Biological effects of spinochromes were investigated mainly on crude extracts [4]
and there is not so much information on the activity of individual pigments, particularly regarding
cardioprotective ability. Spinochrome D (SpD) is one of six main spinochromes and it is biosynthesized
by many sea urchin species (Figure 1A) [5]. SpD is a side product of echinochrome A isolation from
the flat sea urchin Scaphechinus mirabilis, which is utilized for the preparation of the active substance
Mar. Drugs 2019, 17, 2; doi:10.3390/md17010002 www.mdpi.com/journal/marinedrugs147
Mar. Drugs 2019, 17, 2
of the antioxidant and the cardioprotective drug Histochrome® [6]. Nevertheless, the content of SpD
in sea urchins is usually pretty low (0.001–0.003% of dry weight), but recently by Balaneva et al. was
developed a simple and effective synthesis scheme with the yield of SpD in 58% [7]. SpD might be
assumed to inherit the cardioprotective ability of echinochrome A, but the detailed mechanism has
been unknown.
Figure 1. Spinochrome D (SpD) protected cardiac cells from the cytotoxicity of doxorubicin.
(A) Chemical structure of SpD (MW, 238.15044); (B) AC16 human cardiomyocytes were treated
with 0–200 μM SpD for 24 h and cell viability was measured using a Cell Counting Kit-8 reagent
(CCK-8) assay. SpD did not affect the cell viability of cardiomyocytes. * p < 0.05 compared with
control; (C) Treatment with SpD (10 μM, 24 h) attenuated the cardiotoxicity of doxorubicin (0.1 μM) in
AC16 cells.
Doxorubicin is an anthracycline that was firstly extracted from Streptomyces peucetius and it has
been routinely used for the treatment of several cancers, including breast, lung, gastric, ovarian,
non-Hodgkin’s, and Hodgkin’s lymphoma [8,9]. There are several proposed anti-cancer mechanisms
of doxorubicin, including intercalation into DNA and generation of reactive oxygen species (ROS).
The inhibition of topoisomerase II has been known to induce apoptosis in cells [10–12].
Unfortunately, cumulative dose of doxorubicin over 550 mg/m2 body surface area has been known
to develop cardiomyopathy [13,14]. The exact mechanism of cardiomyopathy is still controversial
but iron-related free radical formation and mitochondrial disruption have been considered to be the
main causes [15]. There have been trials to overcome the doxorubicin’s cardiac toxicity by reducing its
oxygen radical formation to achieve important accomplishment [16–18].
In the present study, we demonstrated that SpD has a cardio-protective effect against the cardiac
toxicity of doxorubicin without interfering the cytotoxicity to cancer cell lines. We used an integration of
1H-NMR based metabolomics and mass-spectrometry based proteomics to specify molecular pathways
that are affected by SpD treatment in human cardiomyocytes. We also measured changes of the
mitochondrial membrane potential and mitochondrial calcium in SpD treated human cardiomyocytes.
2. Results
2.1. SpD Protected AC16 Cells against Doxorubicin Cytotoxicity
Human cardiomyocyte AC16 cells were treated with SpD at 1–200 μM (Figure 1B). We found no
harmful effects on cell viability. Identical concentrations of SpD were tested on rat cardiomyocyte
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H9c2 cells and also they showed no effect on cell viability (Figure S1). The cell viability of AC16 cells
decreased after 0.1 μM doxorubicin treatment for 24 h, and an exposure duration of 48 h resulted in cell
death for the majority of cells (data not shown). However, adding 10 μM SpD treatment in addition to
doxorubicin for 24 h led to 80–90% AC16 cell survival (Figure 1C).
2.2. Liquid Chromatography–Mass Spectrometry-MS (LC-MS/MS)-Based Proteomics Analyses of
SpD/Doxorubicin-Treated AC16 Cells
We performed LC-MS/MS analysis of cell lysates from SpD-treated and -untreated AC16 cells
with or without doxorubicin for 24 h. The detected proteins are shown in Venn diagrams (Figure 2A,B)
and full lists (Supplementary Information 2). We found networks of proteins forming clusters that are
centered on “mitochondria” (Figure 2C and Figure S5). The affected pathways based on the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database listed proteins participating in gap junction,
focal adhesion, aminoacyl-tRNA biosynthesis, and glutathione metabolism (Figure 2D).
Figure 2. Mass spectrometry-based proteomics of SpD-treated AC16 cells. Liquid
Chromatography–Mass Spectrometry-MS (LC-MS/MS) spectrometry-based proteomics detected
proteins from SpD (10 μM, 24 h) (A) and SpD/doxorubicin (B) treated AC16 cells; (C) Search Tool for
the Retrieval of Interacting Genes/Proteins (STRING) analysis showed that altered metabolic proteins
clustered around “mitochondria” which are represented as red colored nodes. All filled nodes represent
the 3D structures of proteins are known; and, (D) The top 10 influenced metabolic pathways are shown
from the STRING analysis (Kyoto Encyclopedia of Genes and Genomes (KEGG) database).
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2.3. 1H-NMR Mediated Metabolomics Analysis of SpD-Treated AC16 Cells
To identify metabolite alterations that are induced by SpD, we used 1H-NMR spectroscopy to
characterize 30 mg of AC16 cells incubated with SpD (10 μM) for 24 h. Metabolic profiling (Chenomx,
Edmonton, AB, Canada) was used to identify 32 metabolites in SpD-treated AC16 cells and untreated
control cells (Table 1).
Table 1. Identified metabolites and their corresponding concentrations (mM; mean, standard deviation),
as determined by Chenomx NMR Suit 7.1® peak fitting of individual 1H-NMR spectra (600 MHz) for
SpD (10 μM) treated AC16 cells (30 mg, n = 3).
Metabolite
Control SpD
Mean (mM) S.D. Mean (mM) S.D.
Acetate 8.218 5.815 4.820 1.541
Alanine 1.236 0.665 1.341 0.315
Asparagine 0.388 0.194 0.397 0.095
Aspartate 0.412 0.139 0.428 0.138
Choline 0.751 0.437 0.831 0.111
Creatine 0.463 0.190 0.557 0.051
Formate 0.230 0.034 0.197 0.048
Fumarate 0.143 0.047 0.164 0.043
Glutamate 2.877 1.640 3.622 0.791
Glutamine 0.129 0.048 0.101 0.006
Glutathione 0.383 0.158 0.572 0.081
Glycerol 0.912 0.405 0.788 0.088
Glycine 1.650 0.952 1.900 0.656
Hypoxanthine 0.285 0.222 0.349 0.089
Inosine 0.169 0.068 0.209 0.056
Isoleucine 0.169 0.080 0.235 0.031
Lactate 9.551 3.793 12.374 2.715
Leucine 0.829 0.536 0.824 0.073
Lysine 0.783 0.489 0.719 0.124
Methionine 0.064 0.017 0.090 0.029
O-Phosphocholine 0.274 0.124 0.392 0.066
O-Phosphoethanolamine 0.939 0.468 1.068 0.091
Phenylalanine 0.376 0.200 0.364 0.018
Proline 0.907 0.435 1.114 0.202
Serine 0.948 0.536 0.790 0.352
Taurine 0.505 0.270 0.723 0.198
Threonine 0.853 0.434 0.846 0.152
Tyrosine 0.323 0.168 0.329 0.004
Uracil 0.363 0.243 0.279 0.021
Valine 0.479 0.272 0.474 0.073
myo-Inositol 1.198 0.554 1.750 0.352
sn-Glycero-3-phosphocholine (GPC) 0.123 0.058 0.245 0.068
After normalization of the data (Figure 3), univariate and multivariate statistical analyses were
used to comprehensively evaluate the effects of SpD on AC16 cells.
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Figure 3. Normalization of 1H-NMR aquired metabolite concentrations. The concentrations of
metabolites were normalized by log-transformation followed by Pareto scaling (mean-centered and
divided by the square root of the standard deviation of each variable). Changes of metabolites are
represented as ratios of control metabolites.
Univariate volcano plots of log2(FC) > 1.2 (p < 0.05) metabolites showed that the levels of
sn-glycero-3-phosphocholine (GPC), glutathione, myo-inositol, taurine, and O-phosphocholine were
increased, while the levels of acetate and glutamine were decreased, by SpD (Figure 4).
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Figure 4. Volcano plots for SpD-induced metabolic changes compared with controls (n = 3). Metabolites
are considered significant if log2(fold change) > 1.2. The p-value threshold was 0.05. The significantly
changed metabolites included acetate, glutamine, myo-inositol, glutathione, taurine, O-phosphocholine,
and sn-Glycero-3-phosphocholine (GPC).
Multivariate analysis is used to determine the relative differences in two or more systems that are
large and complex. Therefore, as shown in Figure 5A, we performed principal component analysis
(PCA) of metabolites from SpD-treated AC16 cells. The aim of PCA is to reduce the dimensionality of
original data within the preservation of the variance.
To calculate variable importance in projection (VIP) scores of metabolites, we performed partial
least-squares projections for latent structures-discriminant analysis (PLS-DA). Metabolites with VIP
scores larger than 1.0 were considered as important (Figure S2). To confirm the “goodness” of the
model and the predictive quality, we tested orthogonal partial least-squares projections to latent
structures-discriminant analyses (OPLS-DA) on data from SpD-treated AC16 cells and control cells
(Figure S3). In PCA, the SpD-treated group and control group revealed class differences showing 95%
confidence regions separating each other. We extended the supervised PLS regression using orthogonal
signal correction filters after selecting VIP > 1.0 metabolites. The metabolites from the SpD-treated
AC16 cells significantly differed from the control cell group in the OPLS-DA model. The R2Y model
quality parameter was 0.937, demonstrating that the OPLS-DA model was robust (R2Y value near 1.0),
and the Q2 parameter was 0.597, showing that the model was predictive (Q2 > 0.5) (Figure S3). The
loading plot of OPLS-DA is shown in Figure 5C. The heat-map analysis of VIP > 1.0 metabolites was
represented with logarithmic fold changes (Figure 5B). In comparison with the control group, the most
increased and decreased metabolites with SpD treatment were GPC and acetate, respectively.
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Figure 5. 1H-NMR metabolomics for SpD-treated AC16 cells. (A) Principal component analysis (PCA)
indicated that metabolites from the SpD-treated (10 μM, 24 h) group were significantly different from
those in the control group; (B) Heat-map analysis of metabolites with variable importance in projection
(VIP) score > 1.0. The logarithmic fold changes are shown below. GPC, sn-glycero-3-phosphocholine;
(C) The loading plots from orthogonal partial least-squares discriminant analysis (OPLS-DA) for SpD
metabolites compared with the control group.
To interpret metabolic changes, correlation networks were generated according to Pearson’s
correlation coefficients (|r| > 0.9) between metabolites, in a pair-wise fashion. In untreated controls,
acetate shared 28 correlations and GPC shared one correlation with other metabolites. Upon SpD
treatment, the number of correlations with acetate decreased to eight metabolites, while the number of
metabolites correlating with GPC increased to 11 (Figure 6A,B). Pathway enrichment analyses showed
that various metabolic processes, including inositol phosphate metabolism, glycerolipid metabolism,
and glutathione metabolism, were involved in the SpD treatment effects (Figure 6C and Figure S4).
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Figure 6. Network analysis of metabolites altered by SpD (10 μM, 24 h) treatment of AC16 cells.
Networks of metabolites according to their Pearson’s correlation coefficients were drawn using
Cytoscape program. The networks with significantly increased GPC and decreased acetate are marked
as red lines. (A) control and (B) SpD-treated cell metabolites; and, (C) Pathway impact analysis shows
the most affected metabolic pathways affected by SpD. Varying colors from yellow to red represent
metabolites’ significance in the data.
2.4. Glutathione Metabolism in AC16 Cells Was Significantly Influenced by SpD Treatment
The integration of the metabolomic and proteomic data was carried out by Integrated Molecular
Pathway Level Analysis (IMPaLa) to identify significantly influenced pathways from SpD-treated AC16
cells. The KEGG database showed that VIP > 1.0 metabolites were related to nine over-represented
pathways, including glutathione metabolism, protein digestion and absorption, gap junction, and
sulfur metabolism (Table 2). The related genes and metabolites are presented in Table S1. The directions
of changes in the metabolite-specified proteins are listed in Table 3.
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Table 2. Pathways determined from integration of metabolomic and proteomic data of SpD treated
AC16 cells. Identified proteins and metabolites were analyzed using Integrated Molecular Pathway















Glutathione metabolism 12 54 (54) 2 38 (38) 8 × 10−6 4 × 10−4
Protein digestion and
absorption 12 90 (90) 3 47 (47) 3 × 10
−5 9 × 10−4
Gap junction 16 88 (88) 1 11 (11) 7 × 10−5 0.002
Sulfur metabolism 4 10 (10) 2 33 (33) 8 × 10−5 0.002
Aminoacyl-tRNA biosynthesis 12 66 (66) 2 52 (52) 9 × 10−5 0.002
Choline metabolism in cancer 12 99 (99) 2 11 (11) 1 × 10−4 0.002
Central carbon metabolism
in cancer 11 65 (65) 2 37 (37) 1 × 10
−4 0.003
Long-term depression 9 60 (60) 1 9 (9) 0.003 0.033
Long-term potentiation 9 67 (67) 1 7 (7) 0.004 0.043
Table 3. Direction of log (FC) of metabolite-specified genes/proteins in SpD/Dox treated AC16.
Pathway Gene
Direction of Log(FC) vs. Control
Protein
SpD Dox Dox and SpD
Glutathione
metabolism TXNDC12 DOWN DOWN UP Thioredoxin domain-containing protein 12
Protein digestion
and absorption COL4A1 DOWN DOWN UP Collagen alpha-1(IV) chain
COL5A2 DOWN DOWN UP Collagen alpha-2(V) chain
Gap junction MAPK3 DOWN UP DOWN Mitogen-activated protein kinase
MAP2K1 UP DOWN UP Dual specificity mitogen-activated proteinkinase kinase 1
Sulfur metabolism BPNT1 DOWN DOWN UP 3′(2′),5′-bisphosphate nucleotidase 1
Aminoacyl-tRNA
biosynthesis FARSB DOWN DOWN UP Phenylalanine–tRNA ligase beta subunit
TARS UP UP DOWN Threonine–tRNA ligase, cytoplasmic
Choline metabolism
in cancer MAP2K1 UP DOWN UP
Dual specificity mitogen-activated protein
kinase kinase 1
AKT2 DOWN UP UP RAC-beta serine/threonine-protein kinase
RAC1 DOWN DOWN UP Isoform B of Ras-related C3 botulinumtoxin substrate 1
RHEB DOWN UP UP GTP-binding protein Rheb
MAPK3 DOWN UP DOWN Mitogen-activated protein kinase
Central carbon
metabolism in cancer MAP2K1 UP DOWN UP
Dual specificity mitogen-activated protein
kinase kinase 1
PDHB UP DOWN DOWN Isoform 2 of Pyruvate dehydrogenase E1component subunit beta, mitochondrial
MTOR UP DOWN UP Serine/threonine-protein kinase mTOR
AKT2 DOWN UP UP RAC-beta serine/threonine-protein kinase
MAPK3 DOWN UP DOWN Mitogen-activated protein kinase
Long-term
depression MAP2K1 UP DOWN UP
Dual specificity mitogen-activated protein
kinase kinase 1
MAPK3 DOWN UP DOWN Mitogen-activated protein kinase
Long-term
potentiation MAP2K1 UP DOWN UP
Dual specificity mitogen-activated protein
kinase kinase 1
CAMK2D DOWN UP UP
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2.5. SpD Functioned as an Antioxidant in AC16 Cells
To test the antioxidant ability of SpD, oxidative stress was induced in AC16 cells using H2O2
or cobalt chloride with high glucose for 24 h. The DCF-DA fluorescence showed that SpD treatment




Figure 7. SpD showed antioxidant activity in AC16 cells treated with H2O2 or cobalt chloride and
hyperglycemic stress. (A) Reactive oxygen species generation was induced in AC16 cells using 1 mM
H2O2 and SpD (0–10 μM) was co-treated for 24 h. * p < 0.05 compared with 1mM H2O2 group without
SpD; (B) Cobalt chloride (a hypoxia-mimetic agent) and hyperglycemia (33.3 mM glucose in media)
were applied to AC16 cells. The cells were incubated with ′,7′-dichlorofluorescein diacetate (DCF-DA)
(20 μM) for 20 min at 37 ◦C and the intensity of fluorescence was measured at 485 nm. * p < 0.05
compared with no SpD treated group.
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2.6. SpD Increased Mitochondrial ATP Production and Oxygen Consumption
SpD treatment increased intracellular ATP production and the oxygen consumption rate (OCR) in
AC16 cells (Figure 8A,B). In addition, SpD treatment increased ATP production in H2O2-treated cells
(Figure 8C). Co-treatment with doxorubicin (0.1 μM) and SpD for 24 h increased ATP production as
compared to doxorubicin treatment alone (Figure 8D). In our study, SpD showed enhanced antioxidant




Figure 8. SpD caused increased ATP production and oxygen consumption rate (OCR) in AC16 cells.
(A) SpD (10 μM) increased ATP production in AC16 cells. D-galactose (10 mM) was added to reduce
cytosolic glycolytic ATP production. By changing energy metabolism in cardiomyocytes by replacing
glucose with galactose, high concentrations of galactose could prevent ATP production except that of
mitochondria by oxidative phosphorylation (OXPHOS); (B) SpD (10 μM) increased OCR. Antimycin
A (Ant, 1 μM, a Complex III inhibitor) was used as a cell-based negative control and glucose oxidase
(GOx, 1 mg/mL) was used as a cell-free positive control. (C) SpD increased ATP levels under H2O2
induced oxidative stress. (D) SpD increased ATP production in the presence of doxorubicin (0.1 μM).
* p < 0.05 compared with untreated controls, # p < 0.05 compared with the D-galactose-treated group.
2.7. SpD Protected against Doxorubicin-Induced Mitochondrial Damage in AC16 Cells
Using tetramethylrhodamine (TMRE) and rhodamine-2 (rhod-2) staining, we compared
mitochondrial membrane potential and mitochondrial Ca2+ in doxorubicin and SpD-treated AC16
cells (Figure 9). Doxorubicin treatment for 24 h decreased the TMRE intensity of AC16 cells
in a dose-dependent manner. The doxorubicin-treated cells also showed increased cytosolic
diffusion of rhod-2. We treated AC16 cells with 10 μM of SpD in the presence of 0.1–1.0 μM
doxorubicin. SpD treatment attenuated the loss of mitochondrial membrane potential that is induced
by doxorubicin (Figure 9A,B). SpD treatment reduced the cytosolic overload of mitochondrial Ca2+ in
doxorubicin-treated cells (Figure 9C,D).
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Figure 9. SpD attenuated doxorubicin-induced mitochondrial membrane potential and mitochondrial
calcium changes in AC16 cells. (A) Mitochondrial membrane potential (Δψm) in AC16 cells was
indicated by TMRE fluorescence. The cells were treated with doxorubicin (0.1–1.0 μM) with/without
SpD (10 μM); (B) The intensity of tetramethylrhodamine (TMRE) staining was measured using
fluorometry at 550Ex/590Em nm. Doxorubicin decreased mitochondrial membrane potential in
a dose-dependent manner. Co-treatment with SpD attenuated the membrane potential loss;
(C) Mitochondrial calcium was localized using rhod-2, a selective indicator for mitochondrial Ca2+;
and, (D) The intensity of rhod-2 was measured at 552Ex/581Em nm. Doxorubicin induced diffusion of
mitochondrial Ca2+ to the cytosolic space but SpD co-treatment attenuated the Ca2+ diffusion. * p < 0.05
compared with the doxorubicin-treated group.
2.8. SpD Did Not Interfere with the Anticancer Effects of Doxorubicin in MCF-7 Cells
SpD did not inhibit the cytotoxic activity of doxorubicin in MCF-7 cells (Figure 10). Human breast
cancer MCF-7 cells and human cervical cancer HeLa cells showed reduced cell viability after treatment
with SpD above 100 μM (Figure 10A and Figure S7A). When the SpD/doxorubicin co-treated cells
were compared with the cells that were treated with doxorubicin alone, there were no significant
differences in ROS level (Figure 10B), loss of mitochondrial membrane potential (Figure 10C,D), or
Ca2+ overload (Figure 10E,F). Similar experiments using the HeLa human cervical cancer cell line
showed the same lack of inhibition of cytotoxicity (Figure S7). Interestingly, SpD treatment inhibited
cell migration in a wound healing test (Figure S8).
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Figure 10. SpD did not inhibit the cytotoxicity of doxorubicin. (A) SpD induced MCF-7 cell
death at 100–200 μM. * p < 0.05 compared with the untreated control; (B) The co-treatment
of SpD and doxorubicin showed similar levels of ROS compared with the doxorubicin
alone group; (C) Mitochondrial membrane potential was visualized using TMRE staining in
SpD/doxorubicin-treated MCF-7 cells; (D) The TMRE intensity measured by fluorometry is shown;
(E) Mitochondrial Ca2+ level is indicated using rhod-2 dye in SpD/doxorubicin-treated MCF-7 cells;
(F) The rhod-2 intensity was measured by fluorometry. * p < 0.05 compared with doxorubicin treated
groups without SpD. ROS = reactive oxygen species.
3. Discussion
There have been many efforts to overcome the cardiotoxicity of doxorubicin in cancer treatment.
The IC50 (drug concentration required to inhibit cell growth by 50%) of doxorubicin for breast cancer
cell lines has been reported to be between 1–4 μM after 24 h treatment (IC50 = 1 μM for MCF-10F;
4 μM for MCF-7; and, 1 μM for MDA-MB-231 cells) [19]. We used 10 μM of SpD, which induced
no significant viability changes in either cardiomyocytes or cancer cells. From animal models using
Histochrome® (echinochrome A), 1–10 mg/kg of doses have been reported to act as antioxidant in
cardiomyocytes, which approximately correspond to 3–30 μM [20]. In our study, echinochrome A and
SpD showed cardioprotective activity when treated with 0.1 μM doxorubicin. In equimolar treatment,
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SpD showed better antioxidant activity and ATP production than echinochrome A. It might be
reasonable to assume that cell viability decreases with increased doxorubicin incubation time. However,
lower concentrations (<0.25 μM) of doxorubicin often show a low dose–time response relationship in
cancer cells [21]. Cardiomyocytes and cancer cells have different mechanisms of doxorubicin-induced
apoptosis. In cardiomyocytes, doxorubicin induces apoptosis by a H2O2-mediated mechanism, which
is largely independent of p53 activation. In contrast, the p53 tumor suppressor plays an important role
in doxorubicin-induced apoptosis in cancer cells [22–24].
Univariate analyses, such as fold change comparison, t-test, and volcano plot suggest overall
shapes of measured data and multivariate analyses, including PCA, PLS-DA, and OPLS-DA, often
reveal the latent structure of the data. When quantitatively analyzing multi-parametric metabolite
responses, it is critical to specify all of the independent and dependent variables to be included [25].
In biological systems, metabolites are the end product of enzymatic and other protein activity, and
therefore they are not independent from biological interactions. In our study, correlation network
analysis and pathway enrichment analysis of VIP > 1.0 metabolites (e.g., GPC, acetate) showed that
glycerolipid metabolism, glutathione metabolism, and pyruvate metabolism were significantly affected
by SpD treatment in cardiomyocyte [26]. In addition to production during ethanol metabolism, acetate
is transported into cells by proteins of the monocarboxylate transporter family or it is generated
intracellularly by protein deacetylases and acetyl-CoA hydrolases [27,28]. In the cytosol, CoA is
acetylated by acetyl-CoA synthetase to produce acetyl-CoA. In contrast, in mitochondria, acetyl-CoA
is produced through the pyruvate dehydrogenase complex reactions. Acetyl-CoA participates in the
citric acid cycle and β-oxidation of fatty acids to produce cellular energy (e.g., ATP). In addition to
increased acetate consumption, SpD might increase cytosolic glycolysis and entrance of glutamate
into the citric acid cycle, which could be shown by an increased lactate concentration and increased
ratio of glutamate to glutamine (from 20.9 to 35.3; calculated as shown in Table 1). SpD treatment
increased the accumulation of cytosolic osmolytes such as GPC, myo-inositol, and free amino acids
(e.g., taurine and glycine), which are critical for the viability of cells. The integrated analysis with
mass spectrometry based proteomics indicated that the glutathione metabolism of AC16 cells was
most affected by SpD treatment. Since we measured the reduced form of glutathione (GSH) using
Chenomx NMR Suit 7.1, the increased concentration of glutathione represents the increase of GSH
reduced glutathione/GSSG oxidized glutathione ratio. Using the luciferase mediated method, we confirmed
the increase of GSH/GSSG ratio in a dose-dependent manner (Figure S9).
Based on the acquired results, we hypothesized that SpD mainly exerted its function as antioxidant
in the process of protection of cardiomyocytes against the cytotoxicity of doxorubicin. Since the
cytotoxicity of doxorubicin on cardiomyocytes is known to be based on ROS increase, we tested
SpD activity in ROS generating environments. We tested 1 mM H2O2 concentration, which might
be increased by constitutively active NADPH oxidase 4 (NOX4) [29]. In addition, we assessed the
antioxidant ability of SpD in cobalt chloride and hyperglycemic condition. The hypoxia mimetic cobalt
chloride and hyperglycemic concentrations of glucose (33.3 mM) are known to increase intracellular
ROS [30–34]. Hyperglycemia induces hypoxia-induced cell death via the influx of calcium in diabetic
cardiomyopathy [35–37]. Oxidative stress might cause cardiac mitochondrial dysfunction, leading to
cell death [38,39].
Since the integrated analysis that is located the mitochondrial proteins clustered together at SpD
treatment, we had to focus the mitochondrial ATP production by SpD treatment. To differentiate
ATP production from the cytosol versus mitochondria, we added D-galactose (10 mM) to the culture
media. By competing with glucose in the cytosol, D-galactose reduces cytosolic glycolysis, resulting in
decreased cytosolic ATP production. Galactokinase produces galactose 1-phosphate from galactose,
utilizing ATP. Uridine diphosphate (UDP)-galactose 4-epimerase converts UDP-glucose and galactose
1-phosphate into UDP-galactose and glucose 1-phosphate, respectively. Galactose participates in
glycolysis by consuming ATP and reducing cytosolic glycolysis rates [40–42]. SpD treatment increased
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ATP production, even in 10 mM galactose media, which suggested the enhancement of mitochondrial
ATP production with increased OCR.
In cardiomyocytes, doxorubicin has been known to induce oxidized state in mitochondrial redox
potential to trigger mitochondrial depolarization and elevated calcium levels, which suppresses ATP
production via oxidative phosphorylation.
As the mitochondrial dysfunction occurs, the cells are subjected to ATP depletion and become
more dependent on ADP metabolism to compensate the ATP/ADP ratio [43]. In our study, the SpD
treatment did not inhibit the anticancer activity of doxorubicin while protecting cardiomyocytes at
identical concentration via increasing ATP production. Our approaches might provide some clues
for the potential cardioprotective mechanisms of SpD in a combination therapy with doxorubicin.
Nevertheless, further studies are still needed for evaluation of the drug.
4. Materials and Methods
4.1. Cell Culture and Treatment
Human cardiomyocyte cell line AC16 were purchased from Merch Company (SCC 109). Rat
cardiomyocyte cell line H9c2 (CRL-1466), human breast cancer cell line MCF-7 (HTB-22), and human
cervical cancer cell line HeLa (CCL-2) were purchased from America Tissue Type Collection (ATCC,
Bethesda, Rockville, MD, USA). Cells were routinely cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 25 mmol/L glucose and L-glutamine (Sigma, St. Louis, MO, USA) and 10%
fetal bovine serum (FBS) (HyClone, Logan, UT, USA). Cells were maintained at 37 ◦C and 5% CO2.
For 10 mM galactose DMEM, D-galactose (Sigma, St. Louis, MO, USA) was added to the media.
Spinochrome D (SpD, purity 98%) was isolated from the sea urchin Scaphechinus mirabilis, as described
in [44], as the red powder with m.p. >320 ◦C and spectral characteristics, as in [45].
4.1.1. Cell Viability Assay
Cells were seeded in 96-well plates at 2 × 104 cells/well until adherent. Cells were treated with
SpD for 24 h and then 10 μL of Cell Counting Kit-8 reagent (CCK-8, Dojindo Molecular Technologies,
Kyushu, Japan) was added into each well for 20–30 min at 37 ◦C. The absorbance was read using a
SpectraMax microplate reader (Molecular Devices, San Jose, CA, USA) at 450 nm.
4.1.2. Intracellular ATP Measurement
The ATP levels that are produced by cardiomyocytes were measured by the Luciferin-Luciferase
reaction, according to the manufacturer’s instructions (Cayman Chemicals, Ann Arbor, MI, USA).
Cells were plated at 2 × 104 cells/well in 96-well plates and incubated with test compounds at 37 ◦C
and 5% CO2 for 24 h. Cells were lysed using 50 μL of lysis buffer (Triton X100; 0.1%), mixed with
50 μL of ATP measurement solution containing Luciferin-Luciferase, and then incubated at room
temperature for 10–15 min. The luminescence was read using a luminometer (SpectraMax M2e;
Molecular Devices, Sunnyvale, CA, USA) and expressed as relative light units. The ATP levels of the
control and drug-treated samples were compared to ensure that the reading was exclusive to the ATP
produced by drug-treated cardiomyocytes.
4.1.3. Oxygen Consumption Ratio (OCR) Measurement
The OCR in cardiomyocytes was measured using a MitoXpress® probe (Cayman Chemicals,
Ann Arbor, MI, USA) according to the manufacturer’s instructions. Cells were plated at
2 × 104 cells/well in 96-well plates and incubated with SpD at 37 ◦C and 5% CO2 for 24 h. After
replacing the spent media with 160 μL of 10% FBS-DMEM containing SpD, 10 μL of MitoXpress® Xtra
Solution, and 100 μL of mineral oil were added to all wells. The plates were incubated at 37 ◦C and
5% CO2 for 10–20 min and then the fluorescence was read at 380 nm excitation/650 nm emission on a
fluorometer with a delay time of 100 μs (SpectraMax M2e).
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4.1.4. Intracellular ROS Levels
The ROS levels were measured using 2′,7′-dichlorofluorescein diacetate (DCF-DA)
(Sigma-Aldrich). Cells were plated at 2 × 104 cells/well in 96-well plates and incubated with
test compounds at 37 ◦C and 5% CO2 for 24 h. Subsequently, the cells were washed three times with
phosphate-buffered saline (PBS) and incubated in the dark with 20 μM DCF-DA for 30 min at 37 ◦C.
The cells were washed twice with PBS. The fluorescence was measured using a fluorometer at 485 nm
excitation/535 nm emission.
4.1.5. Measurement of Mitochondrial Membrane Potential
Mitochondrial membrane potential was measured using tetramethylrhodamine (TMRE; Thermo
Fisher Scientific, Scotts Valley, CA, USA). Cells were incubated with 200 nM TMRE in the dark
for 30 min at 37 ◦C and 5% CO2. After washing, the fluorescence was measured at 550 nm
excitation/590 nm emission and cells were imaged using a fluorescence microscope (Olympus, IX71;
Olympus, Tokyo, Japan).
4.1.6. Measurement of Mitochondrial Calcium
Mitochondrial calcium was measured using rhod-2/AM (TMRE; Thermo Fisher Scientific). Cells
were incubated with 1 μM rhod-2 for 30 min. After PBS washing, the fluorescence was measured at
552 nm excitation/581 nm emission and cells were imaged using a fluorescence microscope.
4.1.7. Cell Migration Assay
Scratch wound assays were used for cancer cell mobility analyses. MCF-7 and HeLa cells were
seeded into 25-well cell culture plates at a concentration of 2 × 104 cells and were maintained in 10%
FBS-DMEM until 70–80% confluent. The scratch was carefully made using a 20P sterile pipette tip. The
remaining cellular debris was gently removed with PBS. The wounded monolayer was incubated in
10% FBS-DMEM containing 10 μM SpD for 24 h. The cell migration was observed under 4× by using a
phase contrast microscope.
4.2. LC-MS/MS Analysis and Database Searching
The trypsinized peptides from 50 μg of SpD-treated cell supernatant were analyzed using an
LTQ-Orbitrap VelosTM mass spectrometer coupled with an EASY-nLC II (Thermo Fisher Scientific,
Waltham, MA, USA). The Uniprot human database was used for peptide searching. The protein
identification was confirmed if the normalized fold change (FC) was higher than 1.30 (upregulated)
or less than 0.77 (downregulated). The confidence level (CI) was 95% based on pair-wise analyses as
compared with untreated controls. Relative peptide abundance was quantified with Scaffold using the
Top 3 total ion chromatogram method. The differentially expressed proteins were categorized into
Gene Ontology terms, i.e., biological process, cellular component, and molecular function.
4.3. 1H-NMR Metabolomics
The high-resolution magic-angle spinning nuclear magnetic resonance (HR-MAS NMR) spectra
were recorded using an Agilent 600 MHz spectrometer that was equipped with a 4 mm gHX
NanoProbe (Agilent Technologies, Santa Clara, CA, USA). All spectra were acquired at 600.167 MHz.
The acquisition time was 1.703 s, relaxation delay was 1 s, and a total of 128 scans was obtained.
The Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence was used for the suppression of water and
compounds with high molecular mass. For data processing, Chenomx NMR Suit 7.1 professional
with the Chenomx 600 MHz library database were used (Chenomx Inc., Edmonton, AB, Canada).
The bin size for spectra was 0.001 ppm. The binning data were normalized to the total area.
PCA, partial least-squares discriminant analysis (PLS-DA), and orthogonal partial least-squares
discriminant analysis (OPLS-DA) were performed using SIMCA-P+ 12.0 (Umetrics, Malmö, Sweden).
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For visualization of VIP scores of metabolites and Metabolic Set Enrichment Analysis, web-based
software MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) was used.
4.4. Pathway Enrichment Analysis
Integrated Molecular Pathway Level Analysis (IMPaLa, http://impala.molgen.mpg.de/) was
used to specify the pathways that are affected by SpD. Only VIP > 1.0 metabolites and Log2(FC) > 1.2
proteins were considered. Search Tool for the Retrieval of Interacting Genes/Proteins (STRING,
https://string-db.org) and Cytoscape (downloaded at https://cytoscape.org) were used for clustering
molecular networks.
5. Conclusions
The present study investigated the effect of SpD on doxorubicin-treated cardiomyocytes through
an integration of metabolic and proteomic analyses. Univariate and multivariate analyses of
1H-NMR spectroscopy data identified the potentially affected metabolites and groups of proteins from
SpD-treated cardiomyocytes. Based on the 1H-NMR data, SpD increased glutathione, which regulates
intracellular ROS stress. In addition, SpD treatment increased cytosolic and mitochondrial ATP
production in cardiomyocytes, which was significantly correlated with increased lactate and decreased
acetate levels. Co-treatment with SpD protected doxorubicin-treated cardiomyocytes, reducing the
mitochondrial damage of doxorubicin. In contrast, SpD did not inhibit the cytotoxicity of doxorubicin
in cancer cells. The integrated metabolomics and proteomics data suggest the involvement of the
Akt/mTOR signaling pathway by which SpD might protect cardiomyocytes (Table 3). However,
further study is still needed to verify these relationships.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/17/1/2/s1,
Figure S1. Spinochrome D (SpD) showed no harmful effect on H9c2 rat cardiac cells. H9c2 rat embryonic
cardiomyocytes were treated with 0–200 μM of SpD for 24 h (2 × 104 cells/well, 96-well plates). The cell viability
was measured using CCK-8 assay. SpD did not affect on the cell viability of cardiomyocytes. * mark indicates
p < 0.05 compared with control. Figure S2. (A) PLS-DA from metabolites of SpD treated AC16 cells. (B) VIP > 0.1
metabolites from SpD treated AC16 cells from PLS-DA. Figure S3. OPLS-DA from metabolites of SpD treated
AC16 cells (R2X = 0.333; R2Y = 0.937; Q2 = 0.597). Figure S4. Metabolite sets enrichment overview in SpD
treated AC16 cells. Table S1. Genes and metabolites specified for the assigned pathways. Figure S5. STRING
analysis revealed that metabolism associated proteins forms clusters around mitochondria (marked as red circles).
Figure S6. Spinochrome D (SpD) showed enhanced antioxidant capacity compared with echinochrome A in AC16
and H9c2 cells. (A) SpD and echinochrome A showed no harmful effect on AC16 cells (2 × 104 cells/well, 96-well
plate, 24 h). (B) SpD and echinochrome A protected AC16 cells against the cytotoxicity of doxorubicin. (C) SpD
showed statistically enhanced antioxidant activity compared with echinochrome A. SpD produced enhanced ATP
production in (D) AC16 cells and (E) H9c2 cells compared with echinochrome A. (F) SpD and echinochrome A
showed enhanced OCR in AC16 cells. * mark indicates p < 0.05 compared with control. Figure S7. SpD did not
inhibit the cytotoxicity of doxorubicin. (A) Mitochondrial membrane potential and mitochondrial calcium was
visualized using TMRE and rhod-2 staining in MCF-7 cells. Doxorubicin decreased TMRE intensity and increased
rhod-2 intensity in dose-dependent manner. The co-treatment of SpD (10 μM) did not affect doxorubicin-induced
tendency of fluorescence intensity. (B) The fluorescence was measured using fluorescence spectrometer. SpD
co-treatment did not affect the intensity of TMRE, rhod-2, and DCF-DA in MCF-7 cells. (C) TMRE and rhod-2
fluorescence images from HeLa cells with doxorubicin/SpD. (D) The fluorescence measures indicated that SpD
did not affect the intensity of TMRE, rhod-2, and DCF-DA in HeLa cells. Figure S8. SpD inhibited cell migration
of cancer cells. 2 × 104 cells of MCF-7 and HeLa were plated in 25-well cell culture plates and scratch wounds
were made with 200 μL pipet tips. SpD was treated in 10–200 μM concentrations and incubated for 24 h. Figure S9.
Total glutathione and ratio of reduced glutathione to oxidized glutathione (GSH/GSSG). (A) Total glutathione
ratio (% of control) from SpD treated AC16 cells. (B) Ratio of reduced glutathione (GSH) to oxidized (GSSG)
glutathione normalized by total glutathione concentration from control. The GSH/GSSG assay was measured
using GSH/GSSG-GloTM Assay (Promega, WI, USA) according to the product’s manual. * and ** mark indicates
p < 0.05, p < 0.01 compared with control, respectively. Supplementary Information 2 lists all proteins detected by
mass-spectrometry of SpD treated AC16 cells.
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Abstract: Sea urchin pigment echinochrome A (Ech), a water-insoluble compound, is the active
substance in the cardioprotective and antioxidant drug Histochrome® (PIBOC FEB RAS, Moscow,
Russia). It has been established that Ech dissolves in aqueous solutions of carrageenans (CRGs).
Herein, we describe the effects of different types of CRGs on some properties of Ech. Our results
showed that CRGs significantly decreased the spermotoxicity of Ech, against the sea urchin
S. intermedius sperm. Ech, as well as its complex with CRG, did not affect the division and
development of early embryos of the sea urchin. Ech reduced reactive oxygen species production
(ROS) in neutrophils, caused by CRG. The obtained complexes of these substances with pro- and
anti-activating ROS formation properties illustrate the possibility of modulating the ROS induction,
using these compounds. The CRGs stimulate the induction of anti-inflammatory IL-10 synthesis,
whereas Ech inhibits this synthesis and increases the production of the pro-inflammatory cytokines
IL-6 and TNFα. The inclusion of Ech, in the complex with the CRGs, decreases Ech’s ability to
induce the expression of pro-inflammatory cytokines, especially TNFα, and increases the induction
of anti-inflammatory cytokine IL-10. Thus, CRGs modify the action of Ech, by decreasing its
pro-inflammatory effect. Whereas, the Ech’s protective action towards human epithelial HT-29
cells remains to be unaltered in the complex, with κ/β-CRG, under stress conditions.
Keywords: carrageenan; algae; echinochrome; reactive oxygen species; cytokines; HT-29
1. Introduction
With increasing awareness of functional properties of products from marine organisms, their
attractiveness, both as a source of nutritious food items and stockpot of novel, biologically-active
compounds, continuously expand [1]. The characteristic color of spines and armors of sea urchins
are attributed to calcium salts of polyhydroxynaphthoquinone pigments derivatives—spinochromes
and echinochromes—exhibiting a vast range of pharmacological activities. One of the most popular
pigments is the echinochrome A (6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone), which is known
to be a biologically-active compound with antimicrobial, antialgal, and antioxidant activities [2].
Most of all, it has been ascertained that a treatment with echinochrome protected the mitochondrial
functions in cardiomyocytes, against the acardiotoxic drugs (tert-Butyl hydroperoxide, sodium
nitroprusside) [3]. There are controversial data in the literature, in terms of Ech’s capacity to activate
an immune response, some data suggest that Ech has an ability to activate inflammation, whereas
others suggest that it can suppress inflammation [4,5]. Pharmacological studies in vitro and in vivo
demonstrated that naphthoquinone pigments have a wide therapeutic latitude and are nontoxic, at
therapeutic doses [6].
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In Russia, echinochrome is produced from the sand dollar Scaphechinus mirabilis. It is the active
substance in the cardioprotective and antioxidant drug Histochrome® (C (Ech) = 0.2 mg mL−1) and is
available in ampoules, permitted for subconjunctival, parabulbar, or intravenous administration [7,8].
One of the main setbacks to the wide use of Ech, is its insolubility in aqueous solutions and high
susceptibility to oxidative destruction. Improvement of therapeutic efficacy of drugs can be achieved by
modifying the formulation technique, for instance, by means of polymeric systems. Marine natural edible
polymers have been widely used in hydrogels, drug encapsulation, and drug delivery because of their
benefits, comprising such advantages as biocompatibility, biodegradability, and adhesiveness [9,10].
In order to provide a stable and biocompatible environment to the Ech, polymeric matrix systems,
based on polysaccharides from red algae, have been proposed to be suitable candidates for oral
delivery [11]. Polysaccharides of red algae, carrageenans (CRGs) are a class of linear galactans
with alternating 1,3- and 1,4-linked galactose residues (D- and G-units). Several types of these
polysaccharides were identified, based on the structure of their disaccharide repeating units, the
pattern of sulfation, and the presence of 3,6-anhydrogalactose (DA-unit), as a 4-linked residue [12].
The three most industrially-exploited types, in the order of increasing sulfation degrees and decreasing
gelation capabilities, respectively, are the κ-, ι- and λ- CRGs. Natural CRGs are often hybrids of
more than one of these units and are composed of several carrabiose moieties, the proportions and
structures of which vary with species, the life stages of seaweeds, and the ecophysiological and
developmental conditions [13–15]. CRGs are widely utilized due to their excellent physical properties,
such as thickening, gelling, and stabilizing effects in the food industry [16,17]. CRGs have successfully
become appealing tools in immunotherapy and drug delivery, due to their immuno-active features
and valuable physical properties as gelling [18,19].
Recently we have established that Ech is incorporated into the CRG supramolecular structure,
which results in formation of complexes with altered Ech properties, such as decreased oxidative
degradation and improved solubility. Along with the suitable physico-chemical properties, an Ech
complex with CRG, in mice, revealed a high gastroprotective activity, surpassing the effect of either of
the components used alone [11].
Unravelling the influence of CRGs–Ech complexes on some immunological parameters
(ROS formation in phagocytic cells, the cytokine production in human whole blood model) and
on human epithelial cell monolayers, will provide essential information for the rational design of
CRG-based matrices for Ech delivery, for oral administration. It would also inspire the design of new
approaches in assessing the modification of biological properties of biomaterials, used in delivery
systems. The aim of this work was to investigate the biological properties of Ech that was included in
a CRG matrix.
2. Results
CRGs were isolated by aqueous extraction from the non-fruited form of red algae Chondrus armatus
(Gigartinaceae), Tichocarpus crinitus (Tichocarpaceae), and Ahnfeltiopsis flabelliformis (Phyllophoraceae),
harvested along the Russian coast of the Japanese Sea and separated using 4% KCl into the
KCl-insoluble and KCl-soluble fractions. The structures of polysaccharides were studied by 13C-NMR
and FT-IR-spectroscopy. The obtained spectra have been compared with the spectra of polysaccharides,
which we had isolated earlier, from the above-mentioned species of algae [20–22]. The identity of the
spectra indicates that the KCl-insoluble fraction form of C. armatus, T. crinitus, A. flabelliformis, were κ-,
κ/β-, and ι/κ-types, respectively, and a KCl-soluble fraction from was C. armatus–λ-CRG.
The structures of disaccharide repeating units of the carrageenans and the sulfate content, as well
as the average molecular weights of all the samples investigated, are summarized in Table 1. CRGs
differ from each other in number and position of sulfated groups, and in the presence (κ, κ/β and ι/κ)
or absence (λ) of 3,6-anhydrogalactose units (DA). The degree of sulfation decreased in the following
row: λ > ι/κ > κ > κ/β.
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Table 1. The structures of disaccharides repeating units of carrageenans from algae of Gigartinaceae
and Phyllophoraceae families.
Reference Algal Species CRG Sample




[20] C. armatus λ G2S D2S, 6S 26
[20] C. armatus κ G4S DA 22
[21] T. crinitus κ/β G4S/G DA/DA 19
[22] A. flabelliformis ι/κ G4S/G4S DA2S/DA 20
2.1. Toxicity
As a cellular model to study spermotoxic and embryotoxic properties, we used the spermatozoa
and developing embryos of the sea urchin S. intermedius.
The spermotoxicities of Ech, CRGs, and the complexes Ech/CRGs were investigated by the Sea
Urchins Sperm Cell Toxicity Test (SUSCT)-test [23,24]. These activities were determined by the degree
of inhibition of the spermatozoa’s ability to fertilize the sea urchin eggs. Previously, all types of CRGs
(κ, λ, ι/κ) were investigated for spermotoxicity in seawater, at a concentration 50 to 200 μg mL−1.
The results showed that all of the studied CRGs had no toxic effect on the spermatozoa fertilization
ability, at these concentrations. The current study with Ech in the concentration range from 1 to
10 μg mL−1 revealed that this substance exhibited spermotoxicity. The spermotoxicity of Ech was
expressed in the 50% inhibition of the spermatozoa’s ability to fertilize the egg-cells (IC50 values were
of 3 μg mL−1), at a sperm:egg ratio of 300:1. When the Ech was added to a solution of CRGs, with a
concentration of the 100 μg mL−1, the spermotoxicity of the Ech decreased significantly. The higher the
concentration of the Ech, the greater was the protective effect of the CRG (Figure 1a). The protection
of various CRGs types, against the spermotoxicity of the Ech (C = 3 μg mL−1) was studied by the
SUSCT-test, at the spermatozoa to eggs ratios of 300:1 and 150:1 (Figure 1b). From the data presented
in Figure 1b, it can be seen that λ-CRG, with a higher degree of sulfation, showed a greater protective
activity. This dependence of the protective effects of the CRGs on their structures, was particularly
noticeable at the spermatozoa to eggs ratio of 150:1, when the sensitivity of the method was the highest.
To determine the embryotoxic effects of the Ech and its complex, with the CRG (100 μg mL−1),
fertilized eggs from the sea urchins were used. In a concentration range from 2–36 μg mL−1, the Ech
did not affect the division and development of early embryos of the sea urchin Strongylocentrotus
intermedius, as well as its complex with the CRGs.
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Figure 1. (a) The influence of Echinochrome (Ech) and its complex with the κ-carrageenans (CRGs)
(100 μg mL−1), on the sea urchin spermatozoa fertilizing ability (spermatozoa to eggs ratio 300:1).
(b) The spermatozoa fertilizing ability of various types of CRGs (100 μg mL−1), in the presence of Ech
(3 mg mL−1). * p < 0.05.
2.2. Reactive Oxygen Species (ROS)-Inducing Activity of the CRG and the Ech on the Human Blood Cells
The ROS induction in human neutrophils, in the presence of the Ech and its complexes with CRGs,
was determined with the Ech concentration varying from 1 to 10 μg mL−1. To assess the effect of the
content of the polysaccharide in the complex with the Ech, on the formation of ROS, we used CRG
concentrations in the range of 5 to 200 μg mL−1. Thus, complexes with different CRGs/Ech ratios
(5:1, 10:1, and 20:1) were prepared.
The corresponding effects were detected using a fluorescent probe and measured by means of flow
cytometry (Figure 2). Lipopolysaccharide (LPS) from E. coli was used as a reference immunomodulator,
in the current test, and the ROS production induced by the LPS, as a positive control, was approximately
twice as much as the negative control (the vehicle). At low concentrations, the activity of Ech towards
the ROS formation was comparable to the negative control, whereas at high concentrations its
effect was lower than that of the control by 20%. The influence of the CRGs on the activation of
ROS, at lower concentrations, was not significant except for the λ-CRG. In contrast, the CRGs at a
concentration of 100 μg mL−1 intensified the induction of the ROS by up to 25–55%, relative to the
negative control. The addition of the Ech to the CRGs, especially at high concentrations, resulted
in significant diminishment of the ROS formation induced by the CRGs alone. The action of the
complexes was compared to the negative control, where at higher concentrations, the effect of the
samples was more noticeable.
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Figure 2. Neutrophils reactive oxygen species (ROS) formation in the presence of the Ech, CRGs, and
their complexes. The concentration of the lipopolysaccharide (LPS) was 10 μg mL−1 and of the Ech
was 1.0, 5.0, or 10.0 μg mL−1, final value. The concentrations of the CRGs alone and in complexes with
the Ech changed in the following ratios row: = 5:1; = 10:1;  = 20:1. The results are expressed as
% change in ROS, relative to the control (100%), * p < 0.05.
2.3. IL-10-Inducing Action of the CRGs and the Ech on the Human Blood Cells
The action of the carragenans, Ech, and their complexes on the pro-inflammatory (IL-6 and TNFα)
and anti-inflammatory (IL-10) cytokines induction was conducted. In this experiment, Ech was used at
one concentration, 1 μg mL−1 whereas, CRG concentrations individually and in complexes, varied in
the following row 5.0, 10.0, and 20 μg mL−1. As seen in Figure 3, κ- and λ-types (10 and 20 μg mL−1)
induced the expression of IL-10 in cells, by approximately 120 and 100 pg mL−1, in comparison to the
negative control, respectively. Ech significantly inhibited the synthesis of IL-10, reducing the induction
of this anti-inflammatory cytokine by 50%, compared to the control. At the same time, the inclusion of
Ech into the CRG complex increased the induction of IL-10 synthesis, compared to Ech. The greatest
effect was shown by the complex of Ech with ι/κ-CRG (Figure 3). Regarding the pro-inflammatory
cytokines, Ech (1 μg mL−1) was a strong inductor, in comparison to the highest concentrations of
the CRGs, but its action was decreased, especially in the complexes with the κ- or λ-types, by about
300 pg mL−1 for IL-6 and 350 pg mL−1 for TNFα. However, the combined action of the CRNs and the
Ech complexes on the IL-6 still remained high, compared to the control. The ι/κ-CRG influenced the
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effect of Ech with less degree than the others, as complexes had formed. Thus, the CRGs modified the
activity of Ech by decreasing its pro-inflammatory effect.
Figure 3. The induction of the necrosis factor-α, IL-6, and IL-10, in the presence of λ-, κ-, ι/κ-CRGs, Ech,
and their complexes. The concentration of the LPS was 0.01 μg mL−1 and that of Ech was 1 μg mL−1,
which were the final value. The concentrations of the CRGs, alone and in complexes with the Ech
(1 μg mL−1), changed in the following rows:  = control (saline/1 μg mL−1 of Ech); = 5 μg mL−1,
final value; = 10 μg mL−1, final value;  = 20 μg mL−1, final value. * p < 0.05.
2.4. Influence of the CRGs, the Ech and Their Complex, on the HT-29 Tumor Cells
The effect of the Ech, alone and in carrageenans complexes, on the HT-29 cells treated with ethanol
was investigated. The exposure of cells to EtOH permits an assessment of the samples’ ability to affect
cell viability and, as a result, the permeability of the epithelial monolayer. All of the investigated
samples were inert, in response to the intestinal epithelial HT-29 cells, under normal conditions.
Under stress conditions, only the κ/β-CRG and the Ech, as well their complex, restored the cell
viability after exposure to the EtOH. As to the CRG, the most prominent action was detected for the
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lowest concentrations, where protective effect preserved. The complex of κ/β-CRG with the Ech, also
possessed an ability to restore the HT-29 cells after an exposure to ethanol (Figure 4).
Figure 4. Time and dose-dependent cellular response profiling of HT-29 intestinal epithelial cells, in
the presence of the κ/β-carrageenan, Ech, and their complex. Representative data are averaged from
five wells. All experiments were repeated at least two times. Four stages of the experimental design are
indicated with dashed lines: 1—Growth of HT-29 cells to confluence; 2—the stage of samples addition;
3—incubation with ethanol; 4—after the ethanol exposure. Concentration of the Ech (1 μg mL−1, final
value) was fixed. After each stage, the culture medium (McCoy’s 5A Modified) was refreshed.
3. Discussion
Ech, a water-insoluble compound, is the active substance (P N002362/01) of the drug
Histochrome®, registered in the Russian Federation. Earlier we have shown that Ech is soluble in
aqueous solutions of CRGs, up to the concentration of 0.1 mg mL−1. Moreover, the CRG environment
protects the Ech from autooxidation [11]. In this work, we showed that carrageenans modified the
biological activity of the Ech.
One of the manifestations of the biological effect of the drug is its ability to cause some disorders
in the development and death of embryos (spermotoxic, embryotoxic, and cytostatic activities).
The widespread use of the sea urchin embryos to test the toxicological and pharmacological effects
of various drugs is due to the simplicity of the incubation of the synchronously developing embryos,
under controlled conditions, and the ease of the intravital observation. The influence of the Ech and
its complex with CRG, on sperm, was determined by the degree to which it inhibited the ability of
spermatozoa to fertilize the sea urchin eggs and the further development of the early embryos of
sea urchins, in comparison to the control. As the results showed, the CRGs significantly decreased
the spermotoxicity of the Ech, towards the sea urchin S. intermedius sperm. Furthermore, neither the
Ech, nor its complex with CRG, affected the division and development of the early embryos of the
sea urchin.
Oxidative processes occurring during the neutrophils activation could be traced by the
change in the ROS production [25]. In the case of the phagocytosis of the pathogens, the
ROS were produced by the nicotinamide adenine dinucleotide phosphate oxidase (NOX) in a
small volume of the phagosome [26]. During our study, we used an APF fluorescent probe
(2-[6-(4-amino)phenoxy-3H-xanthen-3-on-9]benzoic acid), with a strong specificity towards the species
of the reactive oxygen, localized predominantly in the phagosomes [27]. It should be noted that, in
general, the activating effect of the CRGs was dependent on the polysaccharide concentration and the
sulfation degree. In this study, a positive correlation between the impact on the ROS formation and
the sulfation degree of the CRG (except for its highest concentration) was observed. Generally, the
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complex of the λ-CRG, with the Ech, was the most active out of all three types, their effect (complexes
of the CRGs and the Ech with concentrations of 200:5 and 100:5 μg mL−1) was about 15%, compared to
control (Figure 2). The importance of the CRG sulfation degree, with regards to monocyte behaviour,
have also been observed, previously [28].
In the complexes of the Ech with polysaccharides, containing 3,6-anhydrogalactose and the lower
sulfate group contents (κ, ι/κ), the resultant action was closer to the level of the Ech alone. This was
supported by results from the literature, which reported that the Ech significantly prevented an increase
in the ROS levels in rat cardiac myoblast H9c2 cells and cardiomyocytes induced by some cardiotoxic
agents [3], as well as in intraocular inflammation caused by endotoxin-induced uveitis [29]. Overall,
this experiment indicated the modulation of the inductions of the ROS, in complexes with substances
containing pro- (CRGs) and anti- (Ech) activating properties.
Depending on the ROS location in cells, the function of these molecules changes enormously.
For example, mitochondrial ROS have a particularly interesting role in the immune response,
since these ROS are currently considered essential for pathways initiating the production of
pro-inflammatory cytokines [30]. The influence of the investigated samples on the synthesis of
the immune mediators enabled the study of another facet of their immune activity, both separately
and as complexes. Pro-inflammatory cytokines were exemplified by the IL-6, the most important
inducer of the acute-phase proteins, and the TNFα, another pro-inflammatory molecule with cytotoxic
effects in antitumor immunity, whereas the IL-10 is an important immunoregulatory cytokine with
multiple biologic effects and strong tendencies of anti-inflammatory action [31]. The CRGs stimulated
the induction of anti-inflammatory IL-10, whereas, the Ech inhibited the synthesis of this cytokine, and
the addition of the CRGs to the Ech increased the induction of the expression of the anti-inflammatory
IL-10 (Figure 3). Ech, at a concentration 1 μg mL−1, increased the IL-6 and TNFα synthesis; however,
the complexes with CRGs exhibited much less activity in the case of synthesizing the pro-inflammatory
cytokine TNFα. The effect of the Ech on the cytokine balance towards the pro-inflammatory
response corresponded to the literature data, which reported that spinochromes act as inductors
of TNF-α production in LPS-stimulated macrophage cell cultures [5]. Another study underlined a
pro-inflammatory action of the naphthoquinones, in mice [32].
Literature data suggest that the CRGs do not affect the epithelial cells of human gastrointestinal
tract [33], but the influence of the Ech towards these cells, which is of special interest when one
considers an oral administration of a drug, has not been investigated, to our knowledge.
HT-29 is a colorectal cancer cell line used as an in vitro model, for the intestinal epithelium,
because it is a mucin secreting cell line which retains many features attributed to the lower small
intestine [34]. Previously we have studied the influence of CRGs on these cells, under stress conditions
and have found out that only the low-sulfated CRG had a protective action towards the HT-29 intestinal
epithelial cells [35]. Our purpose in the study described in this report, was to determine the protective
action of the Ech alone and in combination with the low-sulfated CRG on the survival of monolayers
of these cells, treated with EtOH (Figure 4). The stress effect of ethanol on the state of the HT-29 cells
provided an opportunity to assay the protective properties of polysaccharides from the red algae and
the Ech. The Ech (1 μg mL−1) also preserved the HT-29 cells, under stress conditions, to an extent
similar to the κ/β-CRG (25 μg mL−1). These results provide an opportunity to propose the CRGs as
a possible matrix system, for oral delivery of Ech, which preserves the Ech-favorable qualities and
mitigates its negative biological properties.
In general, the CRGs modified the Ech toxicity and the immunological properties. Our results
showed that the CRGs significantly decreased the spermotoxicity of the Ech, against the sea urchin
S. intermedius sperm. The Ech, as well as its complex with CRG, did not affect the division and
development of the early embryos of the sea urchin. The influence of the investigated substances on
the induction of the ROS, in the neutrophils, confirmed that Ech in a complex with a polysaccharide
inhibited the induction of ROS induced by CRG.
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The complexes obtained by us illustrated the modulation of the ROS induction, by these
substances, with pro- (CRGs) and anti- (Ech) activating properties of the initial components. The CRG
decreased the Ech’s ability to induce the expression of pro-inflammatory cytokines and increased the
expression of anti-inflammatory cytokines. Whereas, the Ech’s protective action towards the intestinal
cells exposed to EtOH, remained invariable in the complex with the κ/β-CRG.
4. Materials and Methods
The standardized echinochrome (pentahydroxyethylnaphthoquinone, Ech), registration number
in the Russian Federation was P N002362/01 [Russian State Register of Drugs (as of 5 December
2016) Part 2]. It was obtained in powder form, from the G.B. Elyakov Pacific Institute of Bioorganic
Chemistry, Vladivostok. The purity of the Ech (99.0%) was confirmed by liquid chromatography,
coupled with mass spectrometry (LC-MS) data (Shimadzu LCMS-2020, Kyoto, Japan). The purified
Ech that looked like red-brown needles, was soluble in ethanol, had a melting point of 219–221.5 ◦C,
and a similar nuclear magnetic resonance (NMR) spectra to that reported previously in Reference [36].
We used an ethanolic solution of the Ech, at a concentration 10 mg mL−1, as a stock solution.
The CRGs were isolated by aqueous extraction from the Chondrus armatus (Gigartinaceae),
Tichocarpus crinitus (Tichocarpaceae), and Anfeltiopsis flabelliformis (Phyllophoraceae) red algae,
harvested along the Russian coast of the Japanese Sea. The polysaccharides were separated into gelling
KCl-insoluble and non-gelling KC1-soluble fractions and their structures were established according
to the published protocols [20–22]. Viscosimetric molecular weights of the CRGs were calculated using
the Mark-Houwink equation: [η] = KMα, where [η] is the intrinsic viscosity and K and α are empirical
constants constituting 3 × 10−3 and 0.95 at 25 ◦C in 0.1 M NaCl, for the CRGs. The commercial LPS was
from the bacterium Escherichia coli 055:B5 (Catalog No. L2880, Lot No. 102M4017V, Sigma, St. Louis,
MO, USA). An APF probe (2-[6-(4-amino)phenoxy-3H-xanthen-3-on-9]benzoic acid) was purchased
from Assay Designs (cat No 906-043).
4.1. Sea Urchin Models
The test samples in these experiments were polysaccharides of three CRG types. They were
dissolved in sea water at 50 ◦C, to the level of the initial concentrations, from 0.5 to 1.0 mg mL−1.
Ech dissolved in 50% EtOH was used at the initial concentrations of 0.5 and 1 mg mL−1. Adult sea
urchins Strongylocentrotus intermedius (collected in the Troitsa Bay (Peter the Great Bay, the Sea of Japan)
during August–September 2017, at a depth of 5–10 m) were stored in an aquarium with a closed-filter
system, at a seawater temperature of 20 ◦C and salinity of 32 ± 0.5‰. Pooling male and female
gametes and eggs, fertilizations were performed according to the standard procedures described in
References [37,38]. The quality of the isolated sperms and eggs was checked with fertilization, prior to
experiment. The fertilization membrane was formed within 1–2 min, after insemination, in at least
95–99% of the eggs, under normal conditions.
4.2. Sea Urchins Sperm Cell Toxicity Test (SUSCT Test)
We used the standard bioassay record of the SUSCT test for the analysis of the obtained
preparations [23,24]. Sperm from sea urchins (15 × 106 cell mL−1), prior to the experiment, were
sustained in seawater for 30 min, with various concentrations of the substances. Next, the spermatozoa
were added to the suspension of eggs (2.5 × 103 cell mL−1). The final sperm:egg ratios were about
300 and 150:1. After 15 min, the percentage of fertilized eggs were counted on a Motic AE 21 inverted
microscope (Xiamen, China). The experiments were carried out in triplicate using a 12-well plate.
The effect of substance toxicity was assessed, visually, according to the number of unfertilized eggs
in the four fields of view, in each experiment. The number of eggs fertilized by the sperms, after
incubation in the seawater, without substances (control), was assumed to be 95–100%.
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4.3. Sea Urchin Embryos Development Test
The preliminary fertilized eggs (2.5 × 103 cell mL−1) were stored in seawater, with different
concentrations of the tested Ech (10 to 40 μg mL−1) and its complexes with CRGs, for 30 min, after
which a suspension of native sperm was added. The number of embryos developed up to the stage
of 2–4 blastomeres and of early blastula, in the presence of the test compounds, was evaluated using
a microscope.
4.4. Ethical Approval for Human Blood Samples
The medical ethical committee of the local hospital (Vladivostok, Russian Federation) approved
the study protocol. All subjects who participated in the experiments wrote an informed consent.
4.5. Leukocytes
Leukocytes were rapidly isolated from venous citrated blood by lyzing erythrocytes in a solution
containing 0.15 M NH4Cl, 10 mM NaHCO3, and 0.1 mM EDTA [39].
4.6. Detection of Reactive Oxygen Production
Reactive oxygen production was detected by flow cytometry, with APF, as described
elsewhere [40]. Cells (200,000 cells/well) were incubated for 1 hour, with the samples (12.5, 25,
50, and 100 μg mL−1; final value). Free cells with (phosphate buffer saline) PBS, instead of the samples,
were used as the negative control and were considered to be 100%. After 10 min on ice, the cells were
analyzed, immediately, by a four color FACSCalibur (Becton Dickinson, San Jose, CA, USA) flow
cytometer. Forward and side scatter light was used to identify the neutrophils cell populations.
4.7. IL-6-, IL-10- and TNFα-Inducing Activity of CRGs and Ech on Human Blood Cells
Blood processing was performed using the procedure described by De Groote et al. [41].
Heparinated peripheral blood was diluted 1:5 in sterile Medium 199 (Sigma, St. Louis, MO, USA) with
glutamine (300 mg L−1) (Gibco, Darmstadt, Germany) and gentamicin (50 μg ml−1). Diluted blood
(0.1 mL) was incubated with the investigated samples, in saline (37 ◦C, 5% CO2). The CRGs were
added to obtain the final concentrations of 5, 10, and 20 μg mL−1 Ech (to 1 μg mL−1) and their
complexes, to obtain final concentration values corresponding to the substances, separately. After 24 h,
the supernatants were collected and frozen, followed by determining the cytokine content, using
specific ELISA kits, according to the manufacture's protocol (“Cytokine”, Saint-Petersburg, Russia).
4.8. Cell culture
The human cancer cell line HT-29 was obtained from the American Type Culture Collection
(https://www.lgcstandards-atcc.org/). HT-29 cells were incubated at 37 ◦C in a 5% CO2 humidified
atmosphere, in McCoy’s 5a Medium Modified, containing 10% v/v FBS (Lot RWH35894, HyClone,
Logan, UT, USA), 2 mM L-glutamine, and 1% penicillin/streptomycin (Invitrogen, Paisley, UK).
4.9. xCELLigence System
Experiments on the xCELLigence system were conducted by means of the Real-Time Cell Analyzer
Dual Plate (RTCA-DP) instrument (ACEA Bioscience, San Diego, CA, USA). The recommendations
proposed by Ke et al. [42] and Sokolova et al. [35] were applied to study the effect of the samples on
human intestinal epithelial cell monolayers.
Samples were added as follows:
Single samples. Carrageenans (20 μL, C = 250, 500, and 1000 μg mL−1); Ech (20 μL, C = 10 μg mL−1).
Complex samples. Carrageenan (10 μL, C = 500, 1000, and 2000 μg mL−1) + Ech (10 μL,
C = 20 μg mL−1). (Concentrations are expressed as initial values.)
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4.10. Statistical Analysis
All data are presented as means ± standard deviations. Statistical calculation was conducted
by ANOVA one-way analysis of variance. Differences were suggested when statistically probable at
p < 0.01.
5. Conclusions
The inclusion of Ech into the carrageenan matrix enables a decrease the spermotoxicity of the Ech
(besides protection of the substance from oxidation and improvement its solubility [11]), preserving its
protective properties against the ROS synthesis by neutrophils, and the protective action towards the
HT-29 intestinal epithelial cells.
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Abstract: The GalNAc/Gal-specific lectin from the sea mussel Crenomytilus grayanus (CGL) with
anticancer activity represents a novel lectin family with β-trefoil fold. Earlier, the crystal structures
of CGL complexes with globotriose, galactose and galactosamine, and mutagenesis studies have
revealed that the lectin contained three carbohydrate-binding sites. The ability of CGL to recognize
globotriose (Gb3) on the surface of breast cancer cells and bind mucin-type glycoproteins, which are
often associated with oncogenic transformation, makes this compound to be perspective as a biosensor
for cancer diagnostics. In this study, we describe results on in silico analysis of binding mechanisms
of CGL to ligands (galactose, globotriose and mucin) and evaluate the individual contribution of the
amino acid residues from carbohydrate-binding sites to CGL activity by site-directed mutagenesis.
The alanine substitutions of His37, His129, Glu75, Asp127, His85, Asn27 and Asn119 affect the CGL
mucin-binding activity, indicating their importance in the manifestation of lectin activity. It has
been found that CGL affinity to ligands depends on their structure, which is determined by the
number of hydrogen bonds in the CGL-ligand complexes. The obtained results should be helpful for
understanding molecular machinery of CGL functioning and designing a synthetic analog of CGL
with enhanced carbohydrate-binding properties.
Keywords: galactose-specific lectin; Crenomytilus grayanus; carbohydrate-binding site; molecular
docking; site-specific mutagenesis; carbohydrate-binding activity
1. Introduction
Lectins are specific carbohydrate-binding proteins, found in animals, plants and microorganisms,
and involved in various biological processes including cell adhesion, innate immunity, fertilization,
differentiation et al. [1–4]. First, classifications of lectins were based on the glycan structures, to which
they exhibited high affinity [5]. Later, lectins were classified into families on the basis of similarity of
amino acid sequences of their carbohydrate recognition domains (C-type lectins, L-, M-, P-, R-, F-type
lectins, galectins et al.) [1,2,6]. To date, the amino acid sequences of several hundreds of lectins have
been determined, and a number of their three-dimensional structures have been elucidated. Recently,
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a new lectin classification based on their three-dimensional structures was proposed and 48 lectin
families were characterized [7].
In the last two decades, many lectins from marine invertebrates were identified, and their functions
in various immune events were demonstrated [3]. Earlier, we reported on a novel GalNAc/Gal-specific
lectin from the mussel Crenomytilus grayanus (CGL), which did not share sequence homology with
known lectins and consisted of three tandem-repeat subdomains with high (up to 73%) sequence
identity to each other [8,9]. Three-dimensional structure prediction revealed that CGL adopted a
ß-trefoil fold and contained three binding sites including conserved HPY(K)G motifs [9,10], which was
later confirmed by X-ray analysis [11,12].
CGL was shown to possess anti-cancer activity through binding globotriose Gb3 [12]. The ability of
CGL to recognize Gb3 on the surface of breast cancer cells [12] and bind mucin-type glycoproteins [8,9],
which are often associated with oncogenic transformation, makes structural studies highly valuable to
discern mechanistic details of its function. In our previous study the role of three conserved HPK(Y)G
motifs in hemagglutinating and carbohydrate binding activities of CGL was experimentally shown by
site-specific mutagenesis studies [10]. To investigate CGL functions and peculiarities of its molecular
organization in more detail, in this study we evaluated the contribution of individual amino acid
residues from CGL binding sites into the lectin activity using analysis of recombinant CGL mutants
and in silico evaluation of mono- and oligosaccharide structures impacts on CGL binding properties.
2. Results
2.1. Analysis of CGL Contacts with Galactose/Galactosamine for Mutagenesis
The theoretical model of the spatial structure of lectin CGL was previously constructed by us [10]
based on the crystal structure of the lectin MytiLec determined at 1.05 Å resolution (Protein Data
Bank accession: PDB 3WMV) [13]. Superimposition of all Cα atoms of obtained CGL model and CGL
crystal structure (PDB 5F8S) [12] showed that they were almost completely superimposable (values of
the root-mean-square deviation (RMSD) were 0.4 Å). Thus, the predicted structure of the lectin CGL
was in good agreement with the experimentally established CGL structure and suitable for in silico
mutagenesis and molecular docking studies.
The analysis of CGL contacts with α-galactose (Protein Data Bank accession: PDB 5F8W) and
galactosamine (PDB 5F8Y) showed that CGL amino acid residues His37 and Asn119 from Site 1;
His85 and Asn27 from Site 2; Asp127, His129, and Glu75 from Site 3 formed hydrogen bonds with
these monosaccharides (Figure 1). These residues were selected for mutagenesis experiments.
2.2. Mutagenesis Studies
To obtain the recombinant CGL of the wild type and Asn27Ala, His37Ala, Glu75Ala, His85Ala,
Asn119Ala, Asp127Ala and His129Ala mutants, expression plasmids were constructed on the basis
of pET40/CmAP plasmid described earlier [10,14]. The alkaline phosphatase CmAP in the hybrid
CGL-CmAP protein allowed for monitoring recombinant lectins during expression and purification
steps [10,14].
CGL was shown to exhibit high affinity to porcine stomach mucin [15]. The mucin-binding
activity of the recombinant CGL of the wild and mutant types was evaluated by measuring the alkaline
phosphatase activity provided by CmAP domain [10] (Figure 2).
The mucin-binding activity of the obtained mutants varied in a wide range and was from 9% to
73% of the wild lectin (Figure 2). CGL mutants with the alanine substitutions of His37, His129, Glu75,
Asp127 and His85, Asn27, Asn119 showed decreased mucin-binding activities in 1.4, 2.3, 3.2, 4.5, 5.0,
5.9 and 11.1 times, respectively.
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Figure 1. 2D-diagrams of the galactose-binding sites (Site 1, 2, 3) in the wild type CGL. Hydrogen
bonds lost in the corresponding mutant are indicated with a cross (x).
 
Figure 2. Mucin-binding activity of the wild and mutant types of CGL. The lectin-mucin complexes
(axis X—mucin concentration) were monitored by measuring the phosphatase activity of CGL/CmAP
hybrid (axis Y).
2.3. Analysis of Contacts in Complexes of CGL and Its Mutants with Oligosaccharides
It was found that the mucin-binding activities of the obtained mutants did not correlate with
changes in the calculated binding energy of galactose with CGL mutants that can be explained by the
fact that CGL affinity to different ligands depends on their structure (Table 1). To clarify the impact of
the ligand structure on CGL binding activity and binding mechanisms of the attachment of CGL to
ligands, in silico analysis of contacts of CGL mutants in complexes with globotriose Gb3 was carried
out with MOE 2018.01 program. The obtained results showed that the alanine substitution of His37,
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His129, Glu75, Asp127, His85, Asn27 and Asn119 residues changed CGL contacts with Gb3 (Figure 3)
and the total binding energy of CGL with ligands (Table 1).
Table 1. The mucin-binding activity of the recombinant CGL of wild and mutant types and the change
in the binding energy (ΔE = Emut-Ewt) of the CGL mutants with galactose and globotriose.
Lectin
Gal Binding ΔE a,
kcal/mol
Globotriose Binding ΔE b,
kcal/mol
Mucin-Binding Activity c, %
Asn119Ala * 1.9 4.9 9
Asn27Ala ** 2.0 5.2 17
Asp127Ala *** 4.0 4.3 22
His85Ala ** 3.6 3.4 20
Glu75Ala *** 3.4 4.7 31
His129Ala *** 3.5 3.6 43
His37Ala * 3.5 3.1 73
a/b—change in the binding energy of the CGL mutants with galactose (ΔE a) or globotriose (ΔE b); c—mucin-binding
activity of the wild type CGL was 100%; *—amino acid residues (aa) from Site 1, **—aa from Site 2, ***—aa from Site 3.
Figure 3. 2D-diagram of Gb3-binding sites (Site 1, 2, 3) and mucin binding in Site 3 of the wild type
CGL. Hydrogen bonds lost in the corresponding mutant are indicated with a cross (x).
The analysis of contacts between CGL and Gb3 has shown that Asn27 and Asn119 residues
formed the hydrogen bond not only with C6-OH group of Gb3 terminal galactose residue, but also
with the neighboring galactose residue (Figure 3).
It was found that Asn27Ala and Asn119Ala mutants lost three hydrogen bonds with Gb3 in Sites
1 and 2 in comparison with the wild type CGL (Figure 3), what correlates with a drastic decrease in
their affinity towards mucin that has two terminal galactose as Gb3 (Table 1, Figure 2).
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The residue Glu75 in CGL Site 3 is located in the same position as Asn27 and Asn119 from Sites 1
and 2 and forms the hydrogen bond with C6-OH group of terminal monosaccharide residue similarly
to Asn27 and Asn119. According to the modeling results, the mutant Glu75Ala lost only one hydrogen
bond (Figure 3) and therefore retained a higher percentage (31%) of the lectin activity than Asn27Ala
and Asn119Ala mutants (Table 1).
The His37, His85 and His129 residues form two hydrogen bonds only with the terminal Gb3
monosaccharide residue and the binding energy of His37Ala, His85Ala and His129Ala mutants
with both galactose and globotriose are similar (Table 1, Figure 3). However, the lectin activities
of the mutants His37Ala, His85Ala and His129Ala were different (Table 1, Figure 2). Apparently,
the activities of these CGL mutants depend also on the structural rearrangement of the sites after
alanine substitutions of His37, His85 and His129. Distinctive affinities of Sites 1–3 of CGL toward
galactose were also shown by NMR titrations [12].
According to the modeling data, Asp127 forms only one hydrogen bond with the terminal
monosaccharide of Gb3 (Figure 3). These results fully coincided with crystallographic data from
Protein Data Bank (PDB accession numbers: 5F8W, 5F8Y and 5F90). However, the mutant Asp127Ala
activity with the use of porcine stomach mucin (PSM) as ligand was only 22% compared to the wild
lectin although only one hydrogen bond disappeared in the complexes with galactose and globotriose
(Table 1, Figure 3).
To explain the drastic change in the activity of this mutant, a model of the mutant Asp127Ala
complex with the PSM oligosaccharide was constructed using molecular docking of CGL with the
PSM-like trisaccharide of the blood group A epitope GalNAcα1-3Gal [Fucα1-2] since data concerning
crystal structure of PSM itself were not available in literature (Figures 3 and 4).
Figure 4. 3D-superimposition of globotriose (Gb3) and porcine stomach mucine (PSM) trisaccharides
in the binding Site 3 of the wild-type CGL. The structures of the ligands are shown as stick in blue
(Gb3) and in pink (PSM).
The analysis of contacts between Site 3 of CGL and the PSM-trisaccharide GalNAcα1-3Gal
[Fucα1-2] has shown that Asp127 forms a hydrogen bond with C3-OH group of the terminal
monosaccharide galactose and two additional hydrogen bonds with OH groups at C2 and C3 of
the third residue fucose (Figures 3 and 4). Asp127Ala mutant lost all three hydrogen bonds with the
PSM trisaccharide, which can explain a sharp decrease (down to 22% of the wild type CGL) in the
mucin-binding activity of Asp127Ala mutant (Table 1, Figure 2).
Asp35 and Asp83 residues in the binding Sites 1 and 2 are located in the same positions as Asp127
in Site 3 and can form three hydrogen bonds with the PSM trisaccharide. The activities of Asp35Ala
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and Asp83Ala mutants have not been yet studied experimentally, but it may be assumed those will
decreased like the case of Asp127Ala mutant.
3. Discussion
CGL is the GalNAc/Gal- and mucin-specific lectin with an amino acid sequence that distinguishes
it from lectins of known families [9]. To date, this new lectin family which was proposed to name
mytilectin [13] includes, besides CGL, five lectins from the sea mussels Mytilus trossulus (MTL),
Mytilus galloprovincialis (MytiLecs 1–3) and Mytilus californianus (MCL) [15–19]. These lectins share
common ß-trefoil fold and contain three carbohydrate-binding sites [9–13,19]. A β-trefoil fold was
proposed for the first time for the crystal structure of Kunitz soybean tripsin inhibitor [20]. Now,
it is known that β-trefoil fold is shared by proteins from several subfamilies, including cytokines,
ricin B-like lectins, agglutinins, actin-cross-linking proteins etc. [21], which have no sequence similarity
and have distinctive ligands, modes of ligand binding and functions.
According to the crystal data, CGL exhibits a characteristic pseudo three-fold symmetry and
contains three structurally conserved subdomains [11,12]. Each of these subdomains is composed of
four β-strands. Two strands from each subdomain collectively form a six-stranded β-barrel and the
remaining two β-strands from each subdomain together form a β-hairpin triplet that caps one end
of the barrel [11]. The putative glycan-binding pocket in the first CGL subdomain is formed by the
side chains of His16, Tyr18, Val31, His33, Asp35, His37 and Arg39, and the backbone of Gly19 and
Gly20 (HYGGVHDHR). The second binding pocket of CGL is formed by the same amino acid residues
(HYGGVHDHR). Whereas in the third pocket of CGL, tyrosine is substituted by lysine, and arginine is
replaced by alanine (HKGGVHDHA) [11]. The structure of the CGL-galactosamine complex obtained
by Liao et al. [12] also revealed in CGL three carbohydrate-binding sites: Site 1 consisted of His16,
Gly19, Asp35, His37 and Asn119; Site 2 included His64, Gly67, Asp83, His85, and Asn27; Site 3
comprised His108, Gly111, Asp127, His129, and Glu75. Superimposition of the three carbohydrate
binding sites indicates that all three sites contain the same amino acid compositions except for the
replacement of Asn for Glu in Site 3. These data confirmed our predications based on homology
modeling [10].
In our previous study, we evaluated the contribution of three conserved HPK(Y)G motifs in
hemagglutinating and carbohydrate binding activities of CGL by site-specific mutagenesis [10].
According to the obtained data, alanine substitutions of His16, Pro17, Gly19 of Site 1 and His64,
Pro65 and Gly67 in Site 2 resulted in complete loss of the CGL hemagglutinating and mucin-binding
activities, whereas the mutant CGL with His108Ala, Pro109Ala and Gly111Ala mutations in the Site 3
kept the binding activity against mucin [10].
In this study, we applied the same approach to elucidate the individual contribution of the amino
acid residues from CGL binding Sites 1–3 to the carbohydrate binding activity. It was found that
the alanine substitution of none of the studied amino acid residues (His37 and Asn119 from Site 1;
His85 and Asn27 from Site 2; Asp127, His129, and Glu75 from Site 3) did not lead to the complete
loss of the mucin-binding activity of CGL due to the presence of two other normal Sites. But the
contribution of these amino acid residues to the mucin-binding activity of CGL was not the same.
The replacements of Asn119Ala in Site 1 and Asn27Ala in Site 2 were found to lead to the greater
decreasing of the mucin-binding activity of CGL (up to 9% and 17%, respectively) in comparison
with the alanine substitution of Glu75 located in Site 3 in the same position as Asn119 and Asn27
from Sites 1 and 2, respectively (Table 1). This confirmed the suggestion of Jakób with co-authors [11]
about differences in the affinity (or specificity) for glycan moieties between binding sites and with our
previous experimental data [10].
Moreover, in silico analysis of the CGL binding to galactose, globotriose and mucin have shown
that the affinity of CGL to these ligands depends on their structures, which determine the number of
hydrogen bonds in the CGL-ligand complex and, consequently, its binding energy in total. The maximal
decrease in the mucin-binding activity observed for the mutants Asn119Ala in Site 1 and Asn27Ala in
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Site 2 could be explained by the loss of all three hydrogen bonds with two terminal galactose residues
of oligosaccharides in comparison with the wild-type CGL (Table 1, Figure 3). The amino acid residue
Asp127 in Site 3 (and similar residues Asp35 and Asp83 in Sites 1 and 2) was found to play a decisive
role in the higher lectin specificity to mucin than globotriose (Figure 4). Thus, the efficiency of CGL
binding depends on the composition of terminal monosaccharide units in oligosaccharides due to the
different capability of CGL amino acid residues from Site 1–3 to bond with OH-groups of the second
galactose and third fucose in the addition to the binding with the terminal galactose.
4. Materials and Methods
4.1. In Silico Analysis of Contacts between CGL and Ligands and Mutagenesis
The model of CGL spatial structure was constructed as described previously [10] on the basis of
the crystal structure of the lectin MytiLec established with a resolution of 1.05 Å (PDB code 3WMV) [13].
The analysis of contacts between CGL and ligands, in silico mutagenesis, molecular docking and
visualization of the results were carried out with the Ligand interaction and Dock modules of
MOE 2018.01 program [22]. The crystal structure of CGL complexes with galactose (PDB 5F8W),
galactosamine (PDB 5F8Y), globotriose Gb3 (PDB 5F90) and trisaccharide motif GalNAcα1-3Gal
[Fucα1-2] from porcine stomach mucin (PSM-trisaccharide), which is identical with terminal
trisaccharide of the blood group A human histo-blood group antigen (HBGA A-trisaccharide) (PDB
2WMI) [23], were used in docking analysis. Molecular docking of PSM-trisaccharide GalNAcα1-3Gal
[Fucα1-2] with CGL was carried out using complex with galactosamine (PDB 5F8Y) as a template.
The ligand binding energy (the molecular mechanics generalized Born interaction energy) was the
non-bonded interaction energy between the receptor and the ligand and comprised van der Waals,
Coulomb and generalized Born implicit solvent interaction energies [24]. The change in the binding
energy of the CGL mutants with galactose or globotriose was calculated as ΔE = Emut-Ewt. The results
were obtained with the use of IACP FEB RAS Shared Resource Center “Far Eastern Computing
Resource” equipment (https://cc.dvo.ru).
4.2. Construction of Recombinant Plasmids, Protein Expression and Purification
Expression plasmid encoding CGL mutants was constructed as described earlier [10] on the
basis of pET40/CmAP plasmid which carried the gene of alkaline phosphatase CmAP as a reporter
gene. CGL mutants were genetically engineered by oligonucleotide-specific mutagenesis approach.
The amino acid substitutions were introduced into the forward and reverse gene-specific primers
(Table 2).
Table 2. Primers for construction of the recombinant plasmids.
Mutation Sense Primer Antisense Primer
Asn27Ala 5′–AGTAGCAACCCTGCTAACGCCACTAAGTTG−3′ 5′–GCAGGACCAACTTAGTGGCGTTAGCAGGGT−3′
His37Ala 5′–GTCCTGCATAGCGATATCGCTGAAAGAATG−3′ 5′–GGAAGTACATTCTTTCAGCGATATCGCTAT−3′





The resultant mutant genes were amplified with the primers CGL-dir: 5′-AGCTGAGCTCGATG
ACGATGACAAGATGACAACGTTTCTTATCAAACACAAGGCCAGTG-3′ and CGL-rev: 5′-AGC
TGTCGACTTAGGCATAAACTAAAACGCGCTTGTCTTT-3′, and ligated with the vector of pET-
40b(+)/CmAP linearized by endonucleases SacI and SalI. The correct CGL cDNA sequence was
verified by sequencing with ABI Prism Big Dye Terminator 3.1 Cycle Sequencing Kit and ABIPrism
310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
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Recombinant lectins were expressed in E. coli Rosetta (DE3) and purified as described
previously [10].
4.3. Lectin Activity Assay
The lectin activity assay was performed as described earlier (10). Briefly, 150 of porcine stomach
mucin (PSM) with concentration of 0.1 mg/mL (0.1 M carbonate buffer, pH 9.5, containing 0.15 M
NaCl) was added to each well of a polystyrene 96-well ELISA microtiter plate Maxisorp (Thermo
Fisher Scientific, Waltham, MA, USA), incubated at 4 ◦C overnight, washed three times with the buffer
containing 0.01 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.05% Triton X-100 (TBS-T) and three times with
water. Bovine serum albumin (1 mg/mL) in TBS-T was added as described above. Samples containing
recombinant CGL (0.2 mg/mL) were two-fold serially diluted in TBS-T and added in 150 mL aliquots
to each well. The plate was incubated at room temperature for 1 h and then washed three times as
described above. TBS-T was used as a negative control. Standard assay for alkaline phosphatase
activity was carried out as described earlier [10]. One unit of AP activity was defined as the quantity of
the enzyme required to release 1.0 μmol of p-nitrophenol from pNPP in 1 min. The specific activity was
calculated as units per 1 mg of protein. All lectin activity assays were performed in three independent
parallels for three to five times. Data were analyzed using the Student’s t-test of the SigmaPlot 2000
version 6.0 program (SPSS Inc.). Differences from controls were considered significant at p ≤ 0.05.
5. Conclusions
In this report we presented new details of structure-function relationships for a novel lectin
from the mussel C. grayanus. In silico analysis of CGL complexes with galactose, globotriose and
PSM-trisaccharide helped us to suggest the binding mechanisms of CGL. For the first time, it was
shown that point mutation of residues that form hydrogen bonds with a terminal monosaccharide
and not included in the conservative motif HPY(K)G, led to a change in the mucin-binding activity of
mutants. The maximal decrease in the mucin-binding activity of the mutants Asn119Ala in Site 1 and
Asn27Ala in Site 2 was due to the loss of all three hydrogen bonds with two terminal galactose residues
of oligosaccharides in comparison with the wild type CGL. However, the efficiency of CGL binding
depends on the composition of at least three terminal monosaccharide units in oligosaccharides.
The amino acid residue Asp127 in Site 3 (and similar residues Asp35 and Asp83 in Sites 1 and 2) was
found to play a decisive role in the higher lectin affinity to mucin due to forming an additional bond
with the third fucose.
The ability of CGL to recognize Gb3 on the surface of breast cancer cells and bind mucin-type
glycoproteins, which are often associated with oncogenic transformation, make it prospect in
construction of a biosensor for cancer diagnostics. In this regard, the results elicited the individual
contribution of His37, His129, Glu75, Asp127, His85, Asn27 and Asn119 amino acid residues from
carbohydrate-binding sites to CGL activity could be helpful for designing an artificial analog of
CGL with enhanced Gb3- and mucin-binding properties for applying in cancer diagnostics or
anticancer therapy.
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Abstract: Context: Seaweed metabolites (fucoidans, carrageenans, ulvans, lectins, and polyphenols)
are biologically active compounds that target proteins or genes of the influenza virus and host
components that are necessary for replication and reproduction of the virus. Objective: This review
gathers the information available in the literature regarding to the useful properties of seaweeds
metabolites as potential agents for the prevention and therapy of influenza infection. Materials and
methods: The sources of scientific literature were found in various electronic databases (i.e., PubMed,
Web of Science, and ScienceDirect) and library search. The retrospective search depth is 25 years.
Results: Influenza is a serious medical and social problem for humanity. Recently developed drugs
are quite effective against currently circulating influenza virus strains, but their use can lead to the
selection of resistant viral strains. In this regard, new therapeutic approaches and drugs with a broad
spectrum of activity are needed. Metabolites of seaweeds fulfill these requirements. This review
presents the results of in vitro and in vivo experimental and clinical studies about the effectiveness
of these compounds in combating influenza infection and explains the necessity of their use as a
potential basis for the creation of new drugs with a broad spectrum of activity.
Keywords: Flu; alga; sulphated polysaccharides; alginates; lectins; polyphenols; anti-viral activity
1. Introduction
The socioeconomic losses associated with viral infections of the respiratory tract are enormous at
present. In Russia, acute respiratory infections (ARIs), including influenza, occupy a leading position
for infectious diseases [1]. According to the Russian Federal Service for Surveillance on Consumer
Rights Protection and Human Wellbeing (Rospotrebnadzor), 27.3–41.2 million cases of these diseases
are registered in Russia each year. The total economic damage from ARIs in Russia ranges from 40 to
100 billion rubles annually [2]. In the United States, more than 400,000 people per year are hospitalized
with respiratory viral infections [3].
Influenza is a serious medical and social problem for humanity. This acute infectious disease
is caused by an enveloped ribonucleic acid (RNA) containing virus belonging to the family
Orthomyxoviridae. Every year, more than 500 million people in the world get the flu; about 2 million
of them die [4]. In Russia, every seventh person is involved in the influenza virus’ annual epidemic [5].
When a new antigenic variant of the virus appears, a new pandemic covers all regions of the Earth. It is
characterized by high morbidity with a large number of patients requiring hospitalization and mortality
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among all age groups of the population [6]. The 2009 pandemic of influenza A (H1N1)pdm09 was
accompanied by wide coverage of the population of many countries of the world, including the Russian
Federation, with serious clinical complications and high mortality [7,8]. Adverse outcomes were
observed not only among immunocompromised individuals in high risk groups but also in healthy
young people with no significant previous pathology, including pregnant women. The influenza virus
can cause disease not only in humans but also in various animals (e.g., birds, pigs, horses) [9]. In recent
years, cases of human infection with avian influenza viruses of the H5N1, H7N7, and H7N9 subtypes
have been reported [10].
Despite the presence of a significant number of anti-influenza drugs, this infection is still dangerous,
as annual flu epidemics remain insufficiently controlled. Recently developed drugs are quite effective
against currently circulating influenza virus strains, but their use can lead to the selection of resistant
viral strains [11]. In this regard, there is a need for new therapeutic approaches and drugs with a
broad spectrum of activity. Sulphated polysaccharides of algae (red and brown), such as carrageenans
and fucoidans fulfill these requirements. This review presents the in vitro and in vivo results of
experimental and clinical studies demonstrating the excellent effectiveness of these compounds in
combating influenza infection and explain the need to use them as a potential basis for the creation
of new drugs with a broad spectrum of activity. Despite their pronounced antiviral properties, they
have not been entered the category of drugs yet, because of the difficulties of these compounds’
standardization [12].
The purpose of this review is to draw the attention of researchers working on the problem of
prevention and therapy of influenza to coordinate their efforts for the creation of standard samples of
these highly active biopolymers.
2. Influenza Virion
Influenza virions are particles with a diameter of 80–100 nm, coated with a lipid membrane with
an integrated surface of three types of glycoproteins: hemagglutinin (HA), neuraminidase (NA), and
the viral ion channel (M2) [13]. On one side, this membrane is in contact with the cytoplasmic domains
of HA and NA, and on another, with the core of the virion. The ribonucleoprotein (RNP) is represented
by eight segments of the genome: single-stranded negative-polarity RNA in a complex with the
nucleoprotein protein and three subunits of the polymerase complex [14,15]. After the virus enters
the cell, the ribonucleoprotein gets to the nucleus, where transcription, translation, and replication of
segments of the viral genome occur (Figure 1).
 
Figure 1. The life cycle of influenza virus.
192
Mar. Drugs 2019, 17, 373
The binding of the influenza virus with cell sial-containing receptors creates surface glycoproteins,
i.e., hemagglutinin (HA), neuraminidase (NA), and viral ion channel (M2). Influenza virus penetration
into the cell and fusion with endosome: HA contributes to the release of free nucleocapsid in the
cytoplasm (the so-called fusion sites). M2 is involved process of "disassembly" of the virus in endosomes
and the Golgi apparatus. Transcription and replication of the viral genome creates transcription and
replication of virus-specific RNAs carried out by a viral polymerase complex. Ribonucleoprotein
(RNP) enters the cytoplasm and then into the nucleus. The release of the RNA virus in the cytoplasm
allows for NA to end the replication and helps to separate matured virion from epithelial cells. Further,
the matrix protein (M1) comes into contact with the cytoplasmic domains of HA, NA, and the core of
virion. M1 plays an important role in the assembly and disassembly processes of new virus particle.
Transcription and replication of virus-specific RNAs are carried out by a viral polymerase complex.
Unlike the polymerases of eukaryotic cells, viral polymerase has no error correction mechanism.
Therefore, the frequency of mutations of the viral genome is, according to various estimates, from
10−4 to 10−6 nucleotides per replication cycle [16,17]. This is several orders of magnitude higher than
the rate of mutation in bacteria and eukaryotes [18]. Due to a short life cycle, the evolution of the
influenza virus is fast. As a result, the rapid appearance of mutations allows the virus to escape the
host’s immune response [19,20]. Thus, it can cause annual epidemics, despite the formation of an
immune layer in the population due to vaccination and natural incidence. In addition, as result of the
use of antiviral drugs, drug-resistant strains of the virus have developed, leading in a decrease in the
effectiveness of antiviral chemotherapy [21].
Influenza virus, like all complex viruses, has a supercapsid, i.e., an additional envelope or peplos,
the structural elements of which are peplomer, including HA and NA [22]. The capsid encloses the
genome of the virus. Three types of influenza virus (genera) have been described: A, B, and C [23].
Type B and C viruses cause disease only in humans. Hemagglutinin and neuraminidase carry antigenic
determinants of the influenza virus and determine its subtype (H5N1, H3N2, H1N1, etc.). Influenza
hemagglutinin is a highly variable surface glycoprotein, with 17 known antigenic subtypes [24].
The main function of hemagglutinin is receptory, i.e., it mediates the attachment of virions to target
cells by binding to sial-containing receptors [25]. Hemagglutinin is the main specific antigen of the
virus, causing the formation of antibodies that neutralize the infectivity of the virus. The presence
of antibodies against HA is the main criterion for assessing the post-infectious or post-vaccination
humoral immune response to the influenza virus [21].
However, the value of HA is not limited to physical contacts between the virus and the cell.
It continues to act in the subsequent stages of infection, contributing to the release of free nucleocapsid
into the cytoplasm. This occurs in the acidic environment of endosomes (phagolysosomes), due
to the special structures of HA (its so-called fusion sites) that promote the unification of viral and
cellular membranes.
The NA of influenza destroys sialic acid-based cell receptors on infected cell surfaces and on
virions after generation, and thereby prevents virion self-aggregation, facilitating the passage of the
virus through mucin during a natural infection. In influenza A viruses, there are nine subtypes of NA,
but there is only one NA in B and C viruses. The NA separates the virions from sialylated mucins
that cover the mucosa, promoting virus attachment to the surface of epithelial cells. At the end of the
replication cycle, it helps to separate mature virions from epithelial cells. In both cases, NA acts as a
spreading factor, expanding the area of infection. That is why antibodies to NA show a protective
effect, but weaker than antibodies against HA [26].
The nucleoprotein of influenza virus (NP) is the main antigen recognized by cytotoxic T
lymphocytes. Amino acid sequences 260–283 of the nucleoprotein of influenza A virus induce
the T cell response. The NP of influenza virus is a major factor in the cycle of viral infection when
switching the synthesis of influenza virus RNA from transcription mode to replication mode [25].
Protein M1 is the matrix protein of the influenza virus; it covers the lipid membrane. It is in
contact with the cytoplasmic tails of HA and NA, and it is bound to the ribonucleoprotein complex of
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the virus [27]. This protein plays an important role in the assembly and disassembly processes of new
virus particles [28]. Membrane protein M2 is an influenza virus surface protein that participates in
the creation of an ion channel that regulates pH while disassembling the virus in endosomes and the
Golgi apparatus. An acidic pH is a prerequisite for disassembly the virus and stabilizing it during
intracellular transport. Viruses with a defect in the activity of this ion channel have poor reproduction
efficiency [29].
3. Pathogenic Targets of Influenza Viruses in Humans
Cells of the single-layer multi-row cylindrical ciliated epithelium of the respiratory tract are
main targets of the influenza virus. For infection, the virus must overcome the factors of non-specific
resistance of the organism such as the viscous properties of mucus, the movement of the cilia of the
cylindrical epithelium, action of non-specific inhibitors of viral replication in mucus, the macrophagal
barrier and IgA [30]. With the help of HA, the virus attaches to the receptors of target cells and
penetrates them, where the replication cycle takes place [5]. After 4–6 h, a batch of new viruses
appears in the cell and then they are pushed out through the cell membrane to the outside. After 24 h,
the number of viruses whose “parent” entered the cell can reach several hundred million. The released
virions infect neighboring cells and some of them enter in the blood. The subsequent death of epithelial
cells is caused not only by the cytopathogenic effect of the virus but also by the inability of the cell to fully
recover after the replication of the pathogen. In the early stages of infection, Toll-like receptors (TLR)
are involved in the recognition of conservative molecules characteristic of pathogenic microorganisms.
The influenza virus stimulates the TLR responses of innate and adaptive immunity [31]. On the cell
membrane, TLR4 and C-type lectin receptors (MMR-mannose and MGL-galactose) interact with the
glycoproteins of the viral membrane, HA, and NA [32]. Inside cells, the endosomal receptors TLR3,
TLR7, TLR10, and cytoplasmic RIG1 respond to viral RNA and RNP [33,34].
Since this article summarizes obtaining experimental data on potential next generation of
anti-viral agents: biopolymers from brown, red, and green algae, the above-discussed information
concerning virus action is important for understanding of mechanisms of the action of marine sulphated
polysaccharides on the influenza virus and its targets in the body.
4. Recent Anti-Influenza Drugs
Despite the use of a significant number of anti-influenza drugs in medicine of different countries,
the search for and development of new, effective and whenever possible harmless drugs continue [35,36].
Currently, for the prevention and treatment of influenza infection, a number of drugs are available with
different mechanisms of action, such as limiting the infection at the early stages, stimulating innate
immunity, and manipulating the effect of interferons (Table 1).
For a long time, rimantadine and amantadine were very actively used to treat the flu.
Leibbrand et al. [37] reported that these anti-influenza drugs act on two stages of the life cycle
of the influenza virus: stripping the virus and releasing virus particles from the cell after replication.
Rimantadine is able to increase the acidity inside vacuoles surrounding viral particles after they
penetrate into the cell. As a result, the fusion of the influenza virus with the vacuole membrane is
prevented, which makes it impossible to transfer viral genetic material from the virus particle to the
cytoplasm of the cell. Thus, rimantadine becomes an obstacle between the influenza virus and the
genome of the host. Along with clinical efficacy, these drugs caused side effects in the gastrointestinal
tract and the nervous system [38]. In addition, many influenza A viruses (for example, H3N2, H1N1)
quickly became resistant to these agents [39].
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Mechanism of Action of Antiviral Drugs Side Effects
Oseltamivir
(Tamiflu)
Competitive and selective inhibitor of
neuraminidase of influenza viruses A and B
The gastrointestinal tract can be involved
(nausea and vomiting; diarrhea, abdominal
bloating, and fecal incontinence); central
nervous system (dizziness, migraine, sleep
disturbance, weakness); respiratory tract
system (bronchitis, cough, infections of the
upper respiratory tract); generalized pain
Zanamivir
(Relenza)
Selective inhibitor of neuraminidase of
influenza viruses A, inhibitor of replication





A specific inhibitor of the fusion of a viral
lipid membrane with cell membranes.
Interacts with NA, prevents its
conformation, which is necessary for the
fusion of NA with endosome membranes.
Interferon inductor. Stimulator of humoral
and cellular immunity




Inhibitor of viral RNA synthesis and
replication of genomic fragments
Allergies; the gastrointestinal tract can be
involved (nausea and vomiting; diarrhea,
abdominal bloating, and fecal incontinence)
Rimantadine,
amantadine
M2 channel blockers. An inhibitor of the
early stage of virus reproduction from the
moment it enters the cell until the beginning
of the transcription process. RNA inhibitor
The gastrointestinal tract can be involved
(diarrhea); central nervous system
(dizziness, migraine, sleep disturbance,
weakness); respiratory tract system (cough);
generalized pain; allergies
At present, adamantane group of drugs are recommended in case all other measures fail. In the
last decade, a number of drugs with direct action on the influenza virus (direct-acting antivirals, DAA)
have appeared [39]. These include NA inhibitors (oseltamivir/TamifluTM and undecivir/RelenzaTM),
M2 channel blockers, and fusion inhibitors (umifenovir/ArbidolTM). Zanamivir and oseltamivir have
shown lower than expected efficacy in clinical trials. At the same time, these drugs are more effective
in children, in whom the drugs reduce the duration of the disease if they are applied within 48 h after
the onset of the first symptoms; they also reduce the number of serious complications. Moreover,
these drugs are successfully used to prevent and reduce the intensity of symptoms of seasonal flu.
The disadvantages of these chemotherapy drugs are a decrease in their effectiveness during the later
stages of infection [40]. In cases of prolonged, complicated flu, pathogenic therapy preparations are
used to eliminate the effects of the cytokine storm, reducing the severity of reactive processes [15].
Such processes are induced by the virus, but are carried out by the host mechanisms. These include
toxic shock syndrome, hyperproduction of proinflammatory cytokines, cellular tissue infiltration,
haemorrhagic syndrome, etc. Although modern drugs are quite effective against currently circulating
influenza virus strains, their use often leads to the selection of resistant viruses and resistant strains [11].
In this regard, we need new therapeutic approaches and broad-spectrum drugs. Drugs aimed
at various viruses or impairing different stages of influenza virus replication will represent a serious
means of fighting infections and minimizing the development of resistant viruses. The sulphated
polysaccharides of algae (red, brown and green), such as carrageenans, fucoidans, and ulvans, have
been studied as anti-influenza drugs and met these requirements. At the same time, there are other
compounds from algae that also have antiviral effects, including anti-influenza action, which should
be subjected to further experimental and clinical study.
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5. Polysaccharides
These compounds represent a class of biopolymers, the content and structure of which vary
depending on the type of algae, its place of growth, climatic conditions, harvest season, method
of extraction and many other factors [41]. According to the literature, sulphated polysaccharides
(fucoidans, galactofucans, dextran sulphates, carrageenans, sulphated chitosans, synthetic polyvinyl,
and polyethylene sulphates) have antiviral activity not only against the influenza virus but also against
many other viruses, such as those that cause hepatitis C, tick-borne encephalitis, haemorrhagic fever
with renal syndrome, dengue fever, and AIDS. It is known that, in the human body, the most
prevalent heteropolysaccharides are glycosaminoglycans, negatively charged long unbranched
polysaccharides consisting of disaccharides repeating units [42]. The binding of glycosamines with
different ligands leads to post-translational modifications that facilitate cell migration, proliferation,
and differentiation. The glycosaminoglycans, a class of heparan/heparan sulphates present in the
basement membrane, in the extracellular matrix, and on the cell surface that are able to specifically
interact with macromolecules of the extracellular matrix (fibronectin and laminin), enzymes, and
an extensive class of heparan-binding molecules (growth factors and chemokines) [42]. Mimetics of
glycosaminoglycan, including heparan/heparan sulphates provide a wide range of biological effects
and modulate the effect of many signaling molecules in cells [43]. Sulphated polysaccharides of
algae are natural mimics of heparan sulphates. Fucoidans and carrageenans can mimic the action of
endogenous factors and regulate the functions of microorganism systems through key cell and enzyme
receptors. Due to this, sulphated polysaccharides have the ability to bind to various receptors on the
surface of the host cell and compete with viruses for glycoprotein receptors [44].
One of the characteristic features of algal polysaccharides is the presence of sulphate groups
and uronic acid residues in their structures, which distinguishes them from the polysaccharides of
land plants [45]. In the last decade, quite a lot of scientific articles have appeared that presents the
effectiveness of fucoidans and carrageenans in influenza infection, as well as acute viral “colds”.
5.1. Carrageenans
Carrageenans are sulphated polysaccharides of red algae whose chemical structure is based on a
disaccharide repeating unit consisting of two D-galactose residues joined with each other by β-1,4
glycosidic bonds. These units are bound in polysaccharides by α-1,3 bonds [46]. The structural diversity
of carrageenans is due to the presence of β-(l,4)-linked residues in the form of 3,6-anhydrogalactose,
as well as the number and position of sulphate groups in monosaccharide residues [47]. Regular
polysaccharides, the polymer chain of which is built from repeating disaccharide units of the same type,
represent a different class of carrageenans. Natural carrageenans are rarely regular, as more often they
contain repeating units of several types and have an irregular or hybrid structure (Figure 1), structures
of which are explained by the multi-stage biosynthesis of polysaccharides in the algal cell wall.
The variability of the primary structure of carrageenans determines the diversity of their
macromolecular organisation and defines a wide range of their biological activity [46]. The uniqueness
of these hydrocolloids is in the alternating galactose and 3,6-anhydrogalactose residues, which are
linked by α-1,3 and β-1,4 glycosidic bonds. A characteristic feature of carrageenan molecules is the
large number of sulphate groups [48].
The quantity and location of sulphuric acid residues determine the type, form, and functions
of carrageenans, which are actively used in food industry for the production of meat, dairy, and
confectionery to improve the microtexture of nutritive products, i.e., as gelling agents, emulsifiers,
and thickeners. Among the polysaccharides of algae, carrageenans are the most studied regarding
their toxicity, pyrogenicity, and allergenicity [49]. The safety of their use in food and medical purposes
has been confirmed by numerous studies [50]. Among the diverse biological properties of these
sulphated polysaccharides, their antiviral, anticoagulant, immunomodulatory, antitumor, and anti-ulcer
activity are currently attracting the greatest interest [46,51,52]. Sulphated polysaccharides interact
with a variety of eukaryotic cell proteins and have a multidirectional effect on the body’s immune
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response, both inhibitory and stimulatory, which makes it possible to consider carrageenans as possible
immunomodulators. It is assumed that the immunomodulatory effect of carrageenans is initiated by
α-Gal-(1,3)-Gal epitopes [53]. Recently, new data have appeared on the antioxidant activity of algae
polysaccharides [46,54].
Carrageenans have attracted the attention of researchers investigating the problem of influenza
and other acute respiratory viral infections, particularly in terms of the possibility of creating a
physical barrier in the nasal cavity against respiratory viruses, including the flu virus [55]. For this
purpose, kappa (k), iota (ι), and lambda (λ) carrageenans were used. It is known that carrageenans
block the interaction of viruses with cells and also inhibit the formation of a syncytium, induced by
influenza A viruses. A. Leibbrand et al. [37] carried out an investigation showing the effectiveness
of carrageenan against human influenza A viruses. The authors determined the sensitivity of the
H1N1 influenza virus strains, as well as the pandemic H3N2 strain, to carrageenan subtypes ι and k
using the plaque formation method in canine kidney epithelial cells (MDCK). The most active in this
test was ι-carrageenan (IC50 or 50% inhibitory concentration = 0.04 μg/mL); k-carrageenan was less
active (IC50 = 0.3 μg/mL). The purity of the ι- and k-carrageenans used in these studies was above
95%, and the molecular weight of both polymers was more than 100,000 Da. At the concentrations of
40 and 4 μg/mL, ι-carrageenan effectively reduced viral replication by 2–4 log units within 96 h after
infection. Thus, it was found that ι-carrageenan contributes to the survival of cells infected with the
virus by direct exposure to the virus. In another series of experiments, the same authors investigated
the effect of carrageenans on an influenza virus-infected primary cell culture of the human epithelium
from the nasal cavity. Under these conditions, ι-carrageenan inhibited the formation of plaques by
the pandemic strain H1N1/2009 (IC50 about 0.04 μg/mL). At the same time, an interesting fact was
established: to obtain an effect when cells were infected with another virus (A/PR8/34 H1N1), a higher
concentration of polysaccharide was required, i.e., the sensitivity of different strains to carrageenan
was different.
Carrageenans are high molecular weight compounds and therefore it is unlikely that they can pass
through the barriers of the body. However, local administration has a pronounced effect, for example,
with influenza infection and other viral diseases of the respiratory system. In this case, carrageenans
reduce the spread of the virus in the surface epithelium of the respiratory organs of infected animals
and contribute to survival.
Unfortunately, the solubility of carrageenans is limited, especially in aqueous solutions containing
potassium and calcium ions [52], since in their presence carrageenans form viscous gels. Another
disadvantage of carrageenans is their anticoagulant properties. Despite this, ι-carrageenan has passed
clinical trials and a nasal spray based on it has already been successfully sold in Europe for use in viral
infections of the respiratory tract in humans. The effectiveness of the spray for ARIs was also reported
by Eccles et al. [56]. The authors showed that, compared with persons receiving placebo, patients in
the experimental group noted such significantly reduced symptoms of the disease as nasal congestion,
runny nose, cough, and sneezing. Moreover, nasal congestion at the end of the observation period was
noted by 63.6% of persons in the placebo group and 28.6% of the group receiving carrageenan. Viral
capacity in the nasal mucosa in patients treated with the spray was significantly decreased (92%), while
placebo treatment did not affect viral replication. The nasal spray was effective when used during the
first 48 h after the onset of symptoms. Similar results were obtained by Ludvig et al. [57].
Spray application reduced the expression of pro-inflammatory cytokines and increased the level
of IL-1 and IL-12p40 receptor antagonists, which are known to have anti-inflammatory action in the
nasal lavage of patients with respiratory viral infections [56]. It is known that IL-12p40 is necessary for
inhibiting the hyperactivity of airway and peribronchial fibrosis [58]. The expression of inflammatory
mediators during viral infection may complicate underlying diseases in the form of asthma [59,60].
In this regard, a decrease in the intensity of the immune response due to a lower viral load seems to be an
attractive property of treatment of ι-carrageenan. To increase their efficiency, oligosaccharides and their
sulphated derivatives having a lower molecular weight were obtained from the high molecular weight
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ATP carrageenan [61]. So, the oligosaccharide CO-1 with a molecular weight of 1–3 kDa effectively
dose-dependently inhibited the replication of influenza A (H1N1) virus in MDCK cells (selectivity index
>25.0). CO-1 did not bind to the cell surface, but it was bound to viral particles during the pre-treatment
process. Unlike high molecular weight native carrageenan, this oligosaccharide can penetrate into
MDCK cells and inhibit the expression of viral proteins and mRNA after its internalization into the
cell, but before it leaves the cell, i.e. in one replication cycle. The main factors affecting the antiviral
activity of oligosaccharides are the degree of sulphation and Mw. The most active oligosaccharide
CO-1 contained 0.8–1.0 mol/mol sulphate, and its molecular weight was 1–3 kDa. The preparation
CO-1 and its full sulphated derivative (COS) significantly increased the survival rate of mice infected
with a lethal dose of influenza virus and reduced the viral load in the lungs of these animals [62].
Taking into account these findings, the authors proposed using low molecular weight oligosaccharides
of carrageenan in the treatment of influenza as an alternative strategy to combat this infection.
Shao et al. [63] investigated the molecular mechanisms of cell protection using k-carrageenan
against SW731 influenza virus penetration. The authors showed that the polysaccharide specifically
and effectively inhibited the reproduction of the influenza virus. The MDCK cells were infected with
various strains of the influenza virus, after which they were treated with carrageenan at different
doses. After 24 h, a dose-dependent decrease in the titer of SW731 and CA04 viruses (homologous
MDCK) was recorded. The remaining experimental strains of influenza virus (PR8, WSN, ZB07, and
H1N1) were insensitive to carrageenan. Thus, k-carrageenan prevented the development of the extra-
and intracellular stages of influenza virus replication. To determine the stage of reproduction of the
virus affected by carrageenan, the authors added polysaccharide to infected cells during the period of
adsorption (0 h), internalization (1 h), early replication (2–6 h), and release (8 h). Then, after 24 h, the
inhibitory effect was evaluated, in response to treatment at the time points of 0, 1, 2, 4, and 6 h. After
8 h, there was no inhibition. Thus, it was shown that not only extracellular, but also some intracellular
stages of influenza virus replication were affected by k-carrageenan. The titer of influenza virus SW731
was decreased in cases where the virus was treated with the polysaccharide before or during infection
of the cells. When treating cells with carrageenan, there was no such effect, i.e. the best results were
obtained by the action of the polysaccharide at the adsorption stage. The same authors showed that
carrageenan does not inactivate the influenza virus, since no differences were found between the
pre-treatment group and the adsorption group. Carrageenan specifically inhibited the binding of
the HA virus to its receptor, sialic acid. The effect of polysaccharides on the exit stage was insignificant.
The authors have proposed the use of carrageenan against the H1N1/2009 influenza virus and other
viruses containing HA/H1N1/2009. The carrageenan used in these experiments contained both high-
and low-molecular components, and therefore it acted on the extracellular and intracellular stages
of reproduction.
Other authors [64], investigating the polysaccharides of the red alga Gyrodinium impudicum,
obtained sulphated galactan conjugated with uronic acid and studied its activity as an anti-influenza
agent. As in the studies by Wang W. [61,62] it was shown that the antiviral activity (IC50 against the
influenza virus at doses 0.19–0.48 μg/mL) of the galactan is related to its ability to interact with viral
particles, which preventing virus adsorption and internalization.
Yu et al. [65] suggested using hybrid carrageenan (ı/κ/ν-carrageenan) as a potential inhibitor of
influenza A virus. In this study, the authors obtained three polysaccharides from the red alga Eucheuma
denticulatum by successive extraction with cold and hot water and an aqueous solution of NaOH:
hybrid polysaccharide (EW), preparation EH, containing only ι-carrageenan, and α-1,4α-d-glucan
(EA), which consisted of 88% of glucan and 12% carrageenan as an impurity. The molecular weights
of the compounds were 480, 580, and 510 kDa, respectively. Antiviral activity against the H1N1
influenza virus was highest when used the hybrid polysaccharide (276.5 μg/mL), and the H1N1 virus
suppression index was 52% using a polysaccharide dose of 250 μg/mL. The IC50 for ι-carrageenan EH
was 366.4 μg/mL. The polysaccharide EA showed the lowest antiviral activity (IC50 > 430 μg/mL).
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The study of Fazekas T. et al. [66] was very important, because it was conducted in a clinical
setting with the participation of patients (children and adults aged from 1 to 18 years) with respiratory
viral infections, including influenza B. Intranasal spray was used three times a day in for seven days.
Symptom dynamics was monitored and viral load was determined. In this study iota-carrageenan did
not alleviate symptoms in children with acute symptoms of common cold, but significantly reduced
viral load in nasal secretions that may have important implications for future studies. In this study,
v-carrageenan as part of the spray did not reduce the severity of symptoms in children with acute cold
symptoms, but significantly reduced the viral load in the nasal lavage of patients who received the
spray compared with the control group (27% versus 13%, respectively).
A positive evaluation of the effectiveness of nasal sprays in patients with acute respiratory
viral infections was provided in two randomized double-blind, placebo-controlled trials by
Koenighofer et al. [67]. In patients treated with carrageenan, the duration of the disease decreased by
two days, there were fewer relapses, and the body was cleared of viruses more rapidly. The spray was
effective in both children and adults. The treatment of patients with influenza by carrageenan gel was
shown to significantly facilitate respiratory tract, reduces the duration of illness, and the severity of
symptoms of intoxication. Carrageenans were found to provide a more pronounced synergistic effect
with anti-influenza drugs with a different mechanism of action.
A number of authors have proposed increasing the effectiveness of the treatment by combining
carrageenan with other drugs. Thus, a combined intranasal spray, including carrageenan and zanamivir
(an NA inhibitor) was proposed by Morokutti-Kurz et al. [68]. Previously, the authors investigated
the efficacy of in vivo and in vitro intranasal administration of zanamivir in different doses for the
prevention and treatment of influenza. Their study showed that treatment of animals before infection
and 36 h after infection with a virus was not accompanied by adverse events.
Zanamivir and carrageenan separately exhibited different antiviral activity against different strains
of the influenza virus. Since the mechanism of action of these agents is quite different, one could
expect protection against a wider spectrum of viruses than with their individual use. Both compounds
and the complex preparation were non-toxic at the highest concentration (400 μg/mL zanamivir and
533 μg/mL carrageenan). The effectiveness of the suppression of the replication by both substances
depended on the virus strain. The IC50 value for zanamivir ranged from 0.18 μg/mL for H5N1 and
22.97 μg/mL for H7N7. The IC50 values for carrageenan ranged from 0.39 μg/mL to 118.40 μg/mL for
H1N1 and H7N7, respectively. Thus, zanamivir and carrageenan target different strains of influenza
virus to varying degrees and, therefore, they can provide broader anti-influenza activity by acting
synergistically. At the same time, the physical interaction of carrageenan with the virus did not violate
the inhibition of NA by zanamivir. The effectiveness of the spray increased when ı-and k-carrageenans
were used simultaneously. Mice infected with a lethal dose of the influenza virus that received the
placebo dies, as did the animals in all groups receiving monotherapy; however, the combined spray
statistically significantly increased the survival of animals. The authors believed that if a vaccine does
not keep up with a virus that has changed its composition, such a spray will to some extent protect the
population from the impending epidemic.
In addition, an interesting combination of two drugs was suggested [69]. For more than 50 years,
xylometazoline has been used to relieve vasoconstriction and oedema of the nasal mucosa in acute
respiratory viral infections caused by a wide variety of respiratory viruses, including the influenza
virus. The authors combined this vasoconstrictor and ı-carrageenan in one preparation, which had
an antiviral effect. It was found that the polysaccharide did not reduce the efficacy and safety of
xylometazoline, and the antiviral efficacy of ı-carrageenan remained unchanged.
Thus, carrageenan is currently widely used as a therapeutic and prophylactic agent and was also
proposed as an integral part of various antiviral drugs. On the other hand, there is evidence in the
literature that oral administration of carrageenan by laboratory animals can lead to the development of
inflammation of the gastrointestinal tract [52,70]. However, carrageenan compounds are considered
safe and approved for use [48,71]. The Joint Expert Committee on Food Additives (JECFA) concluded
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that the use of carrageenan is acceptable, even in childhood: “The use of carrageenan in a formula
for children or for special medical purposes at concentrations up to 1000 mg/mL does not cause
concern” [72]. This confusion, it seems, may be due to imperfect terminology. Some authors combine
low molecular weight products of carrageenan hydrolysis, such as polyginan and degraded carrageenan,
which are clearly toxic, and native non-degraded food carrageenan, which is considered safe, under
the general term “carrageenan” [71]. However there have already been reports of the ability of dietary
λ-carrageenan to cause enteritis in rats with prolonged oral ingestion [70].
Among the many study associated with influenza infection, we did not find reports of adverse
side effects of carrageenans at intranasal use. Moreover, in Europe, as already mentioned above, the
use of the spray for intranasal administration as a preventive and therapeutic agent for influenza and
ARIs is permitted. Apparently, attention should be paid to reports of negative phenomena associated
with the use of carrageenans and to study this issue separately with respect to these infections.
Thus, it was reported that carrageenans created a physical barrier in the nasal cavity against
respiratory viruses, including various strains of influenza virus. At an early stage of viral infection
carrageenans are directly associated with the influenza virus, preventing its adsorption, penetration,
and replication. At the same time, the antiviral effect of carrageenans is specific and is due to the
screening of the cellular structures involved in the binding of the virus to its receptors.
5.2. Fucoidans
Fucoidans are highly sulphated, usually branched polysaccharides, often containing, in addition
to fucose residues, glucose, galactose, xylose, mannose, and uronic acids, as well as acetyl groups [45].
The structures of polysaccharides from brown algae are very diverse and depends on the type of alga,
its reproductive status, and other abiotic factors. In fact, each new polysaccharide isolated from algae
is a new substance, and its molecule contain unique structural elements. This is why the determination
of the structure of fucoidans, as well as the clarification of the structure/function relationship of these
polysaccharides, is extremely difficult.
It should be noted that the effectiveness of fucoidans of brown algae as potential anti-influenza
agents has been studied quite actively in recent years due to the polyvalence of their effects (antiviral,
antibacterial, anti-inflammatory, immunomodulatory effects, etc.), as well as the fact that fucoidans
penetrate biological membranes. Efficiency of oral administration of fucoidan is confirmed by data of
its transformation in macroorganism, which are presented in articles [73,74]. The possibility of the
appearance of fucoidan derivatives in the peripheral blood was confirmed by Irhimeh M.R. et al. [73].
Authors using monoclonal antibodies to highly sulfated fucoidan found its derivatives in plasma
of healthy participants who took orally for 12 days at 3 g/d Undaria algae powder, containing 10%
of fucoidan derivatives and purified galactofucane sulfate. The average concentration of fucoidan
detected in plasma was 4.002 mg/L and 12.989 mg/L, respectively. Tokita Y. et al. [74] also found
fucoidan from Cladosiphon okamuranus in the serum and urine of healthy participants 6 and 9 h after
ingestion of the polysaccharide orally. These facts indicate the possibility of degradation of fucoidan
molecules in the human body and the participation of its derived structures in the implementation of
antiviral properties.
After administration, these polysaccharides can be detected in the urine and serum [74,75].
Histological studies using monoclonal antibodies against fucoidan made it possible to detect it
in the small intestine, the epithelial cells of the jejunum, in mononuclear cells, and in sinusoidal
non-parenchymal cells of the liver [76]. The same authors established the active transport of fucoidan
through a monolayer of Caco2 cells in vitro and the excretion of fucoidan in the urine of a patient after
oral administration. The level of fucoidan increased from 3 to 9 h after administration [77]. To prevent
the destruction of fucoidan in the stomach, it is suggested to enclose it in chitosan nanocapsules.
A study on the anti-influenza activity of polysaccharides from the sporophylls of the brown
alga Undaria pinnatifida allowed Synytsya et al. [78] to establish that in mice, infected in vivo with
avian influenza A viruses (subtypes H5N3 and H7N2), the level of virus replication decreased and the
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production of specific antibodies increased. Oral administration of the polysaccharide blocked the
release of the virus from cells and significantly increased the titer of virus-neutralizing antibodies and
IgA. This polysaccharide presents as a low molecular weight (Mw 9 kDa) fucogalactan, consisting
of partially sulphated and acetylated fucose and galactose residues in approximately equal amounts
and having a complex structure. Previously, Hayashi et al. [79] investigated the effectiveness of this
O-acetylated sulphated fucogalactan in immunocompetent and immunocompromised mice infected
with a lethal dose of influenza virus. The use of this polysaccharides reduced virus replication, weight
loss, and mortality in animals of both groups and increased their lifespan. Oral administration of
fucoidan caused an increase in the titre of neutralizing antibodies in the blood and mucous membranes.
In immunocompromised mice, drug-resistant viruses often multiply after treatment with oseltamivir.
No resistant viruses were isolated from mice treated with fucoidan. The authors proposed the combined
treatment with oseltamivir and fucoidan, because in this case there was no recurrence of influenza
virus reproduction, as is sometimes the case when treating only with oseltamivir. Combined treatment
with fucoidan and oseltamivir was thus recommended by the authors as a new treatment strategy for
influenza infection.
The fucoidan from the brown alga Kjelmaniella crassifolia (Mw about 536 kDa, sulphate content
30.1%, purity more than 98%) is a glucuronomanan with branches in the form of oligosaccharides at
position 3 of the fucose residues. Oligosaccharides (degree of polymerisation from 0 to 6) consist of
3-linked glucose residues, sulphated at positions 2 and 4 [62]. Intranasal (for four days) application of
fucoidan increased the survival of mice (80% versus 30%) and their lifespan and reduced the viral load
of the lungs in influenza-infected animals compared to the control group (p < 0.05). When treated with
oseltamivir alone, 90% of the mice survived. All influenza viruses used in the experiment were sensitive
to treatment with fucoidan, but the most susceptible virus was H1N1 (Ca109) (IC50 < 6.5 μg/mL).
Treatment with fucoidan reduced the severity of flu symptoms and pathological changes in the lungs.
One valuable quality of fucoidan was the lack of formation of resistant strains of the virus under
the action of this polysaccharide. In the supernatants of spleen cells, the levels of interferon-gamma
(IFN-γ) and interleukin-2 (IL-2) increased following treatment with fucoidan compared with the
control animals. In addition, a direct effect of fucoidan on viral particles was found. It was shown that
pre-incubation of the virus with fucoidan at concentrations of 31.25–250 μg/mL significantly reduced
the number of plaques in MCDK cell culture, i.e. this polysaccharide can inactivate viral particles by
direct contact. This polysaccharide inhibited the activation of the epidermal growth factor receptor
(EGFR-epidermal growth factor receptor) and was able to bind to viral NA and inhibit its activity.
In this regard, the authors believed that such inhibitors of the EGFR pathway and NA can be used
alone or with other drugs to block the processes of penetration and the release of influenza A virus
from cells. The investigated fucoidan is a potential candidate for creating a medicine in the form of a
spray or drops.
Using SPEV cell culture sensitive to the reproduction of influenza A (H5N1), Makarenkova et al. [80]
investigated the in vitro antiviral effect of a fucoidan from the brown seaweed Laminaria japonica against
the H5N1 influenza virus. The results showed that the fucoidan did not possess cytotoxic properties in
concentrations from 500 μg/50 μL to 125 μg/50 μL and did not change the morphological properties of the
SPEV cell culture. Fucoidan had a virucidal effect and suppressed the infectious properties of the H5N1 flu
virus (a decrease in virus titer of 3.0–3.3 log units relative to the control), but did not protect the cell culture
against cytopathogenic effects of the influenza A virus at 48 and 72 h after infection. At the same time, the
fucoidan showed antiviral activity at an early stage of infection, i.e. during the first 24 h. The application of
fucoidan to the cell culture in various concentrations an hour before the virus was introduced resulted in a
decrease in the titer of the influenza virus by 2.3–3.3 log units. With simultaneous introduction of influenza
A virus and fucoidan into the cell culture, the virus titer was decreased by 2.3–2.8 log units relative to the
control. These results open up prospects in terms of developing new approaches to interrupting virus
adsorption by sensitive cells.
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A number of reports have been devoted to comparative studies of the anti-influenza effectiveness
of polysaccharides from several families of algae [81]. Song et al. [82] assessed Grateloupia filicina
(family Rhodophita), Ulva pertusa (family Chlorophyta), and Sargassum qingdaoense (Ochrophyta) in
their studies. The yield of polysaccharide was 19.7% (G. filicina, GFP), 12.1% (U. pertusa, UPP), and 7.2%
(S. qingdaoense, SQP). The content of sulphate groups in the polysaccharide was also different: 13.54%
in UPP, 19.89% in GFP, and 5.64% in SQP. The structure of all three polysaccharides was established,
and their biological activities were investigated in vivo and in vitro. The safe concentration for SQP
and UPP was 5 mg/mL, and for GFP this was 2.5 μg/mL. The in vitro antiviral effects were evaluated
against the H9N2 influenza virus. In the hemagglutination test, the most active were UPP and SQP.
Under the action of these polysaccharides, the titer of influenza B virus decreased significantly. GFP
was the most active in reducing virus replication and SQP was the least active. The most effective
dose of the polysaccharide was 20 μg/mL. Using real-time polymerase chain reaction (PCR), it was
shown that the expression of the H9N2 gene was significantly reduced under the influence of the
studied polysaccharides. The best inhibitory effect was observed with a GFP dose of 20 μg/mL. In the
same study, the authors showed that all three polysaccharides had immunomodulatory potential as
the studied polysaccharides were active in the spleen lymphocyte proliferation test. The greatest
activity in this test was shown by SQP, the effect of which was dose-dependent. Maximum values
were obtained when using the sulphated polysacchrides at a dose of 500 μg/mL. In the experimental
group of mice treated with the polysaccharide, the levels of IFN-γ and IL-4 were significantly increased
(p < 0.05). All polysaccharides increased numbers of CD3+ and CD4+ lymphocytes in the blood
compared to controls, but only SQP increased the level of CD8+ cells. Thus, the best effect was
obtained with the polysaccharide of the brown alga S. quingdaoense, especially at a dose of 50 mg/kg.
The authors attributed this phenomenon to the presence of fucose residues in its structure, which play
a significant role in immunomodulation [83]. The content of fucose in the PCA was 0.02, 0.05, and 1%
for UPP, GFP, and SQP, respectively. The authors also observed immunological phenomena as such the
proliferation of spleen cells and the humoral immune response, connected with the presence of fucose
in these preparations. The more pronounced suppression of the replication of the influenza virus by
the GFP polysaccharide was explained by the higher content of sulphate groups in the structure of
this polysaccharide [84,85]. The authors suggest the use of all three polysaccharides as a potential
alternative to vaccination, as well as to suppress the replication of the influenza virus.
In another study [81], as a result of a comparative study of sulphated polysaccharides activity
from algae of different families (red algae: Polysiphonia lanosa, Furcellaria lumbricalis, and Palmaria
palmate; brown algae: Ascophyllum nodosum and Fucus vesiculosis; green alga: Ulva latuca), it was found
that fucoidans from brown algae, i.e., F. vesiculosis and A. nodosum, had the highest anti-influenza
activity. The total sugar content in the polysaccharides studied varied from 15.4% (U. latuca) to 91.4%
(F. lumbricalis). Galactans (agars or carrageenans) were mainly isolated from P. lanosa, xylans from
P. palmate, and fucoidans from brown algae. Heteropolysaccharides were isolated from green algae.
The interaction between the H5N1 influenza virus and fucoidan were investigated by
Bobrovnitsky [86]. For the first time, the authors visualized this process by scanning probe microscopy,
which provides information about the surface microrelief and measures the length and height of
observed objects. In this case, measurements were made of the height of viral particles before and
after treatment with fucoidans from two types of algae. The concentration of fucoidans was 1 and
100 ng/mL. It was found that the average size of the virus particles after treatment with fucoidans
changed significantly. In the case of a lower concentration, the average height of the particles increased
from 40 to 45 nm. With increasing concentrations, the height of the virus particles reached 50 nm.
These results indicate an interaction between the positively charged groups of lipoproteins of the viral
envelope and the negatively charged sulphate groups of fucoidans; this interaction may be the cause
of the antiviral effect of polysaccharides. The antiviral effect of these compounds is probably due to the
encapsulation of viral particles and their deactivation as a result of this. Adhesion of fucoidan on the
surface of viral particles is an irreversible process.
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Based on this evidence, fucoidans have not only a direct effect on influenza viruses but also affect
the processes of viral attachment and replication, interact with neuraminidase, and inhibit the release of
viruses from cells [62,80]. In addition, they promote antiviral immunity, enhance antioxidant protection,
and reduce the appearance of inflammation. Numerous studies [75,85,87,88] have demonstrated
the influence of these compounds on factors important in innate and adaptive immunity, such as
the antioxidant system. Another positive quality of fucoidans is their antibacterial action, which in
some cases will allow them to be used to prevent bacterial complications, which often aggravates the
course of influenza infection.
6. Lectins
Lectins are widespread carbohydrate-binding proteins and glycoproteins that can specifically
and reversibly non-covalently bind mono- and oligosaccharides, both in solution and localized on the
cell surface [89,90]. In this way, lectins contribute the so-called first line of defence against bacteria
and viruses. These compounds exhibit high specificity in relation of glycoconjugates of bacteria and
viruses. Most studied and characterized lectins have been isolated from higher plants; lectins from
algae have been studied less thoroughly. However, the observed antiviral and antitumor effects
of these compounds have led scientists to look at them from a new perspective. It was previously
known that lectins have two or more carbohydrate-binding sites [91]. Connecting to the surface of
microorganisms, the lectin can agglutinate and prevent the spread of pathogens throughout the body.
In recent years, new families of lectins have been found in the cyanobacterium Oscillatoria agardhii
(OAA) [92–95], as well as in the red algae Eucheuma serra and Kappaphycus alvaresii (KAA-2) [96]. They
usually have two or four tandem repeats consisting of highly conserved sequences, but do not have
homology with other protein families. The uniqueness of these lectins is that they bind carbohydrates
with exceptionally high specificity for high-mannose (HM) glucans in the trisaccharide core, including
Manα(1-3) Manα(1-6)Man. At low nanomolar levels, these lectins have potential antiviral activity
against the influenza virus due to the recognition of HM-glucans in the composition of the glycoproteins
of the spikes of the influenza virus.
Mu et al. [97] isolated lectin HRL40 from the green alga Halimeda renschii, which was highly
specific to HM-N-glycans with (1,3)-bound monosaccharide residues. Lectin HRL40, by binding to
the hemagglutinin of the virus, effectively inhibited (with an ED50 2.45 nM) the infectious process
in NCI-H292 cells caused by the influenza A/H3N2/Udom/72 virus. Additionally, a lectin with
anti-influenza activity was obtained by Sato et al. [98] from the red alga Eucheuma serra. This compound,
called by the authors a “high mannose-specific lectin” and designated as KAA-2, effectively inhibited
the entry of the influenza virus into cells. The carbohydrate-binding profile of this lectin was determined
by centrifugation and ultrafiltration. KAA-2 was associated exclusively with high mannose N-glycans,
but not with other glycans. The authors tested this lectin against various strains of influenza virus,
including the pandemic variant H1N1-2009. With the immunofluorescent method, it was shown that
lectin prevented the virus from entering the host cells. Using ELISA, it was found that the lectin KAA-2
was directly associated with the HA of the influenza virus. It was proposed the use of this lectin as a
future means of preventing influenza infection.
In the study by Sato et al. [99], the anti-influenza activity of lectins with various carbohydrate
specificities was investigated on MDCK cells using different strains (clinical isolates) of the influenza
virus (H1N1-2009, A/Oita/ou1P3-3/09). The best results in terms of inhibiting influenza infection were
obtained with the HM-binding lectin ESA-2. The EC50 in this case was 12.4 nM. This lectin recognized
the branched structure of HM-glycans, including the trisaccharide containing Manα(1-3)Manα(1-6)Man
in the D2 branch as a primary target. The direct interaction between the lectin ESA-2 with the viral
envelope glycoprotein HA was demonstrated by ELISA. This interaction was effectively suppressed
by glycoproteins carrying HM-glycans, suggesting that ESA-2 binds to the HA of the influenza virus
through HM-glycans. The lectin inhibited the penetration of the virus into cells most effectively when
simultaneously introducing the virus and the lectin into the cell culture. When processing ESA-2 cells,
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viral antigens were not detected in the cells, which indicated that this lectin inhibited the initial stages
of virus penetration into the cells. At the same time, no cytopathic effect was observed in infected
cells. The antiviral profile of ESA-2 was similar to the lectin KAA-2 from Kappaphycus alvarezii, which
belongs to the same anti-HIV lectin family [98]. The lectin was non-toxic up to 1000 nM (the highest
dose used in this experiment). Sensitivity to lectin depended on the strain of influenza virus. The most
susceptible were strains A/Philippines/2/82 (EC50 17.2 ± 3.9) and WSN/33 (EC50 34.6 ± 2.7 nM). In this
case it was also proposed to use the lectin ESA-2 in the future as a disinfectant or prophylactic agent.
7. Polyphenols of Algae
The composition of the polyphenol fraction of brown algae is characterized by the predominant
content of phorotannins, which are unique complex biopolymers of marine origin and the main
cytoplasmic components of these hydrobionts. These compounds are contained inside the cell in
both the free and bound state [100]. Phlorotannins have antioxidant, hepatoprotective, anti-allergic,
anti-tumour, anti-inflammatory, anti-bacterial, and anti-diabetic properties [101]. Ryu et al. [102]
purified from the brown alga Ecklonia cava phlorotannin, which proved to be an effective selective
inhibitor of the NA of influenza virus (72% at a dose of 30μg/mL). By fractionating the ethyl acetate layer,
five phlorotannins were obtained, identified as phloroglucinol, ecol, 7-phloracol, fluorofucofuroecol,
and diecol. The inhibitory activities of these components were assessed against influenza viruses from
NA group 1 (A/Bervig_Mission/1/18[H1N1]), A/PR/8/34[H1N1]) and group 2 (A/Hong Kong/8/68[H3N2),
A/Chicken/Korea/MS96[H9N2]). All five phlorotannin derivatives were found to be selective inhibitors
of NA. Fluorofucofuroecol showed the strongest inhibitory activity against NA viruses of group 1
(IC50 of 4.5 and 14.7 mmol, respectively); diecol inhibited the NA of influenza virus strains of group 2
more effectively. All derivatives of phlorotannin enhanced the NA-inhibitory effect of ozaltamivir.
8. Biopolymers of Algae Are Adjuvants for the Influenza Vaccines
Biopolymers of algae are currently being also investigated as candidate adjuvants for the next
generation of influenza vaccines. The main direction of improvement for anti-influenza vaccines is to
increase their safety. That is why, from whole virion vaccines, the transition was made to split vaccines,
and from there to subunit vaccines. However, immunogenicity is often reduced with highly purified
antigens [103]. In this regard, scientists study the polysaccharides of algae, whose influence on the
formation of innate and adaptive immunity has been described in numerous papers in Russia and
in other countries [75,87,88,104]. In the analysis of adjuvant technologies for the creation of vaccines,
preference is given to modifiers of functions of the receptors of innate immunity and their signaling
pathways [105]. The sulphate polysaccharides of brown algae have some excellent properties as
adjuvants: almost complete absence of toxicity, safety, and excellent biocompatibility [106].
In the mechanisms of action of polysaccharides, which are important for the manifestation of the
adjuvant effect, one should highlight the ability to exhibit the properties of TLR agonists of innate
immunity cells, designed to recognize microbial pathogen-associated molecules. TLRs are major
targets for the development of new adjuvants, and TLR agonists are the most preferred adjuvants
for vaccines. In the investigation of the specific interaction of polysaccharides with human TLRs,
it was found that fucoidans from algae Saccharina japonica, Saccharina cichorioides, and Fucus evanescens
specifically bind TLR2 and TLR4, causing activation of the nuclear factor NF-κB. Subsequent expression
of genes of proinflammatory cytokines and interferon-inducible genes promote the activation of
immunocompetent cells, and the development of an adaptive immune response to unrelated antigens
of the Th1 type [107]. Experimental data demonstrate the adjuvant properties of polysaccharides in
relation to various antigens and vaccine strains of infectious agents, including influenza virus [104,108].
The results of our experimental studies also indicate the adjuvant activity of fucoidan from the brown
alga F. evanescens, manifested as an increase in the immunogenicity of the inactivated influenza
virus A/California/7/09 H1N1pdm09. At the same time, the effect of fucoidan was more pronounced
compared with the traditional licensed adjuvant aluminum hydroxide. In addition, with repeated
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immunization of animals, fucoidan provided a reduction in antigenic load. The results indicate
the promising application of fucoidan as an adjuvant in vaccines of influenza [109]. Of significant
interest are the results of a randomized, double-blind, placebo-controlled study with elderly volunteers,
focusing on the ability of fucoidan to have an adjuvant effect when administered orally. The volunteers
took the fucoidan from U. pinnatifida at a dose of 300 mg/day orally for 4 weeks. Subsequent
immunization with the trivalent influenza vaccine led to the identification of higher antibody titers
against all strains of the virus contained in the vaccine, compared with antibody titers in individuals
who received placebo. In the group of volunteers who received fucoidan, after nine weeks, there was
a clear tendency to increase the activity of natural killer cells, and the absence of allergic and other
undesirable immune reactions [110]. Despite the positive results of testing of sulphated polysaccharides
as adjuvants, it should be taken into account that the use of fucoidans as drugs is currently limited,
due to difficulties with obtaining structurally characterized and homogeneous samples or oligomeric
fractions of fucoidans. In this regard, active work is underway to obtain low molecular weight
polysaccharides or fucooligosaccharides (homo- or hetero-oligosaccharides containing from 2 to
10 monosaccharide residues) related to natural fucoidans. A number of studies have indicated the high
immunomodulatory activity of low molecular weight, structurally characterized fractions of fucoidan
or its oligosaccharides, but studies on their adjuvant properties are rare [109]. Thus, the adjuvant
activity of low molecular weight polysaccharides obtained from the brown alga F. evanescens was
investigated; this was done using enzymes that provided a stable, reproducible structure. The authors
considered that this substance can be used as a pharmaceutical substance or adjuvant as a part of
vaccine preparations [109]. Therefore, polysaccharides from brown algae can apparently be used as
safe and effective adjuvants in the composition of next generation influenza vaccines. Fucoidans may
form a new molecular basis for the creation of immune adjuvants, including for influenza vaccines,
due to their high biocompatibility, lack of toxicity, and good tolerance by the human body.
9. Conclusions
Last decade, there have been many works devoted to the antiviral potencies of sulphated
polysaccharides. The formation of pathogen resistance to drugs on the pharmaceutical market requires
new approaches to the treatment of viral diseases, including influenza. To do this, it is necessary
to have drugs with different mechanisms of action, which in addition to antiviral effects, have
anti-inflammatory, antioxidant, and immunomodulatory activity and to which viruses form resistance
only on rare occasions. As presented in this review, the sulphated polysaccharides of brown, red, and
green algae have such properties in relation to influenza infection (Figure 2).
 
Figure 2. Antiviral activity of algae metabolites.
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The pharmaceutical market currently offers a carrageenan-based spray for local (intranasal)
application. There are no other drugs based on polysaccharides, which is associated with difficulties
in standardization. To standardize these compounds, the physicochemical parameters such as
molecular weight, monosaccharide composition, degree of sulphation and other structural features of
polysaccharides should be determined. One approach to solving this problem is to obtain structurally
characterized and homogeneous samples of native polysaccharides with a low molecular weight or
oligomeric fractions. At the same time, due to the wide spectrum of biological activity of polysaccharides
and, most importantly, their ability to exert a virucidal effect, that prevent the penetration of influenza
viruses into cells and suppress the replication of viral particles, these unique compounds can be
used as the basis for the creation of a new generation of medicines. In addition, the almost complete
absence of toxicity and pathogen resistance, relatively low cost, a significant yield of the final product,
good solubility, significant reserves of natural sources, and the possibility of cultivation algae make
polysaccharides promising candidates for the development of drugs with antiviral activity, in particular
anti-influenza activity.
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Abstract: A novel extracellular alkaline phosphatase/phosphodiesterase from the structural protein
family PhoD that encoded by the genome sequence of the marine bacterium Cobetia amphilecti
KMM 296 (CamPhoD) has been expressed in Escherichia coli cells. The calculated molecular weight,
the number of amino acids, and the isoelectric point (pI) of the mature protein’s subunit are equal
to 54832.98 Da, 492, and 5.08, respectively. The salt-tolerant, bimetal-dependent enzyme CamPhoD
has a molecular weight of approximately 110 kDa in its native state. CamPhoD is activated by Co2+,
Mg2+, Ca2+, or Fe3+ at a concentration of 2 mM and exhibits maximum activity in the presence
of both Co2+ and Fe3+ ions in the incubation medium at pH 9.2. The exogenous ions, such as
Zn2+, Cu2+, and Mn2+, as well as chelating agents EDTA and EGTA, do not have an appreciable
effect on the CamPhoD activity. The temperature optimum for the CamPhoD activity is 45 ◦C.
The enzyme catalyzes the cleavage of phosphate mono- and diester bonds in nucleotides, releasing
inorganic phosphorus from p-nitrophenyl phosphate (pNPP) and guanosine 5′-triphosphate (GTP),
as determined by the Chen method, with rate approximately 150- and 250-fold higher than those of
bis-pNPP and 5′-pNP-TMP, respectively. The Michaelis–Menten constant (Km), Vmax, and efficiency
(kcat/Km) of CamPhoD were 4.2 mM, 0.203 mM/min, and 7988.6 S−1/mM; and 6.71 mM, 0.023 mM/min,
and 1133.0 S−1/mM for pNPP and bis-pNPP as the chromogenic substrates, respectively. Among the
3D structures currently available, in this study we found only the low identical structure of the
Bacillus subtilis enzyme as a homologous template for modeling CamPhoD, with a new architecture of
the phosphatase active site containing Fe3+ and two Ca2+ ions. It is evident that the marine bacterial
phosphatase/phosphidiesterase CamPhoD is a new structural member of the PhoD family.
Keywords: recombinant alkaline phosphatase; bimetal-dependent phosphodiesterase; marine
bacterium; Cobetia amphilecti; PhoD
1. Introduction
Alkaline phosphatases are widely distributed in marine bacteria, which release inorganic phosphate
(Pi) from phosphorus-containing compounds dissolved in the ocean and utilize them for their own
growth and reproduction [1–3]. Globally, marine bacteria and diatoms have been shown to store
and concentrate Pi and then release it into the local marine environment using phosphatase (Pho)
activity, thus biologically inducing and controlling phosphorite and apatite nucleation [4,5]. Moreover,
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the enzymes from marine sources have flexible molecular structures, and therefore work better at
ambient or lower temperatures, which opens the possibility to decrease temperatures of production
processes for their application in biotechnology [6–9].
Currently, three large families of prokaryotic alkaline phosphatases are known, namely PhoA,
PhoD, and PhoX. They differ from each other in structure, substrate specificity, and the dependence on
different metal ions for the manifestation of their activities [10]. It has been shown that the PhoD-like
phosphatases belonging to the phosphatase/phosphodiesterase family more commonly occur in marine
and soil bacteria than PhoA and PhoX [11]. This is due to the presence in the environment of available
sources of phosphorus and cofactors in their habitat. It has been proven that the PhoD family is
common in the bacteria living in phosphorus- and metal-depleted conditions [3,5,11]. Previously,
natural and recombinant alkaline phosphatases isolated from marine bacteria have been described, but
information about their alkaline phosphodiesterases is still lacking [6,12–15].
There are many families of phosphodiesterases, which include phospholipases C and D, autotaxin,
sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases. However,
phosphodiesterases usually refer to the cyclic nucleotide phosphodiesterases degrading cyclic adenosine
and guanosine monophosphates (cAMP and cGMP). According to the primary structure and differences
in the catalytic domains, they are divided into three known classes: (1) the eukaryotic enzymes;
(2) enzymes such as phosphodiesterases from the yeast Dictyostelium and the bacteria Vibrio; and (3) the
bacterial enzymes homologous to purple acid phosphatases and dimetallophosphoesterases, including
the three subclasses A, B, and C [16]. The bacterial phosphodiesterases were isolated and characterized
from Aphanothece halophytica [9], Delftia acidovorans [17], Sphingobium sp. TCM1 [18], E. coli [19],
B. subtilis [20], as well as a novel unclassified enzyme from the metagenome of an Indian coalbed [16].
All these metal-dependent phosphodiesterases showed maximal activities in the alkaline pH range, and
needed different metal ions, such as Ca2+, Zn2+, Mg2+, or Mn2+, for their catalytic activity. The isolated
phosphodiesterases were capable of cleaving phosphoric acid residues from specific substrates, such
as Bis-p-nitrophenyl phosphate (Bis-pNPP) and thymidine-5′-monophosphate-p-nitrophenylester
(5′-pNP-TMP), which are mostly used as DNA models for studies of phosphodiester hydrolysis [16,21].
It has been previously assumed that the role of PhoD-like enzymes is to participate in the nucleic
acid exchange in cells during the main metabolism, taking into account their ability to hydrolyze the
phosphodiester bonds [22].
Among three types of phosphoester bonds existing in nature (mono-, di-, and triester),
the phosphodiester bond is exceptionally stable, with a half-life of approximately 3 × 107 years
at a moderate temperature and a neutral pH, while an acceleration of its cleavage up to 1016-fold
in biological processes can be achieved through enzymatic hydrolysis of this bond by the highly
specialized metalloenzymes, such as nucleases and phosphoesterases [23,24]. However, finding and
exploring novel enzymes with phosphoesterase activity is still a challenge in biotechnology because of
some their inherent limitations, such as undesirable selectivity, difficulties in extraction or synthesis,
high cost, narrow functional temperature, and pH range [25]. The phosphoesterase function in nature
may be related to hydrolyzing a wide range of biomolecules (proteins, nucleic acids, and lipids)
implicated in DNA repair, post-translational modification, biomineralization, and energy metabolism,
as well as in signal transduction through regulation of the circulation of secondary metabolites,
particularly free nucleotides and their analogues [26,27]. The phosphodiesterase families are mostly
considered to have a common catalytic domain pocket, with the universal mechanism of nucleophilic
attack to control the intracellular levels of cyclic nucleotides, and to be regulators of many physiological
and pathophysiological processes [28]. Due to their important role in intracellular signal transduction
and the possibility of finding their exact subcellular localization, phosphodiesterases are considered
very attractive pharmacological targets [29,30]. Therefore, there is a growing interest in finding ways
to disrupt, block, or manipulate quorum sensing (QS) signaling in bacteria [29]. The producers of
QS signals have been found among both the free-living and associated marine bacteria inhabiting
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invertebrates and algae [31]. Consequently, they are promising sources for new bioactive compounds,
such as the QS modulators or inhibitors [29].
The QS-related phosphodiesterases of marine origin have yet to be investigated. However, two
alkaline phosphatases of the juvenile Euprymna scolopes light organ were found to play an active role
in dephosphorylating lipid A of the luminous marine bacterium Vibrio fischeri, which changes its
signaling properties in relation to the host tissues during their symbiotic colonization [32]. The PhoA
alkaline phosphatase (CmAP) of the marine bacterium C. amphilecti KMM 296 (Collection of Marine
Microorganisms, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, the
Russian Academy of Sciences (PIBOC FEB RAS)) isolated from the coelomic fluid of the mussel,
Crenomytilus grayanus, was suggested to promote the host mollusk shell’s mineralization and biofilm
regulation of many species of food-derived pathogens [6,7,12]. The mechanism of the CmAP biological
action is still unclear and remains under investigation.
Thus, it has been recently shown that the biological role of alkaline phosphatases is more
complex and broader than previously assumed. Alkaline phosphatases appear to be involved in major
cellular events, such as the regulation of protein phosphorylation, cell growth, apoptosis, and cellular
migration [32–34]. Therefore, most human conditions or diseases are accompanied by a change in
the level of alkaline phosphatase expression, which is the basis of diagnostics. A newly discovered
function of alkaline phosphatases is in maintaining tissue and organ homeostasis by inactivation
of bacterial lipopolysaccharides (LPS), and by regulation of cell secretion, microbiome and tumor
behavior, and possibly detoxication of hyperphosphorylated extracellular tau proteins, which play
a key role in progression of Alzheimer’s disease [32–34]. Recently, bovine and human intestinal
recombinant alkaline phosphatases underwent clinical trials related to inactivating LPS and preventing
inflammation for the treatment of surgical diseases and metabolic disorders [33–35]. It is possible that
the search for marine enzymes with dephosphorylating activity and the study of their mechanism of
action will also present an application for the new treatment.
The genome sequence analysis of C. amphilecti KMM 296 has shown that the bacterium produces
not only the highly active alkaline phosphatase CmAP, belonging to the PhoA family (GenBank ID:
WP_084589490.1), but also the functionally active PhoD-like phosphatase/phosphodiesterase (GenBank
ID: WP_043333989.1), with a novel structure and properties [6,12,36]. This article presents the results of
isolation of the gene encoding for the PhoD-like protein from C. amphilecti KMM 296, and in producing
the recombinant enzyme CamPhoD with the alkaline phosphatase and phosphodiesterase activities
and properties.
2. Results and Discussion
2.1. CamPhoD Isolation and Characterization by Enzymatic Activity and Primary Structure
The heterologous expression of the C. amphilecti KMM 296 gene (GenBank ID: WP_043333989)
corresponding to the open reading frame (ORF) of the PhoD-like phosphatase (CamPhoD) resulted
in obtaining an enzymatically active recombinant protein with a specific phosphatase activity of
18.2 U/mg (with p-NPP as a substrate) after purification using the modified scheme described earlier [6].
The CamPhoD phosphodiesterase activity at the cleavage of bis-pNPP was 0.3 U/mg. The isolation of
this enzyme confirmed the ability of C. amphilecti to produce the functionally active alkaline bifunctional
phosphatase/phosphodiesterase CamPhoD with a calculated molecular weight of 54839.8 kDa for the
mature protein, without the 33-letter leader peptide, according to the Simple Modular Architecture
Research Tool (SMART) database [37]. The obtained data were in agreement with the polyacrylamide
gel electrophoresis (PAGE) estimation of its molecular weight (Figure 1).
Apart from the leader peptide indicating an extracellular intent of the enzyme, the CamPhoD
492 amino acid (aa) sequence includes the region of the fibronectin type III repeat (FN3) from 43
to 118 aa residues, containing a cell recognition region of Arg-Gly-Asp (RGD) in a flexible loop
between 2 strands, according to the new functional classification of proteins via subfamily domain
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architectures [38]. RGD is the cell attachment site of a large number of adhesive extracellular matrix and
cell surface proteins, which are recognized by transmembrane receptors activating signal transduction.
FN3-like domains were also found in bacterial glycosyl hydrolases [38]. It has been shown that the
bacterial extracellular proteins with the RGD motif may be located on the surface of the bacterial type
IV secretion pili. They mimic fibronectin in triggering cell spreading, focal adhesion formation, and
activation of several tyrosine kinases during interaction with various mammalian cell lines [39,40].
Thus, the RGD motif of CamPhoD may be a player in pathogenesis or the symbiotic relationships
between the bacterium and host mollusk during its shell mineralization [12,36]. The part of the
CamPhoD molecule from 149 to 505 aa residues is the PhoD-like phosphatase (pfam09423), with
characteristic active and ion-binding sites [38].
 
Figure 1. SDS-PAGE image of CamPhoD. Line 1-the crude extract from the recombinant E. coli cells;
line 2-the purified CamPhoD before the enterokinase treatment; line 3-the purified CamPhoD after
the treatment with enterokinase to remove the 34.2 kDa His-tagged N-end of the plasmid pET 40b(+)
sequence (shaperon DsbC); line 4-the marker of the protein molecular weights (BioRad).
The values of CamPhoD-specific activities corresponded to the activities of the PhoD
phosphatase/phosphodiesterase from Aphanothece halophytica and alkaline phosphatase from Vibrio sp.,
whose molecular weights were also similar to CamPhoD and other alkaline phosphatases [10,41–45].
Thus, the molecular weights of the alkaline phosphatases’ monomers from Streptomyces griseus IMRU
3570, Pyrococcus abyssi, and Thermotoga maritima were 62 kDa, 54 kDa, and 45 kDa, respectively [42–44].
The enzymes with exclusively phosphodiesterase-related activity possess subunits with lower molecular
weight, such as in the enzyme ZiPD from E. coli (36 kDa) [45]. Alkaline phosphatases generally
have a dimeric structure, but the literature also describes a trimer for the phosphodiesterase from
Delftia acidovorans with a molecular weight of 85 kDa [17]. According to the gel chromatography
data, the native CamPhoD tended to form an active dimer with a molecular weight of approximately
100–120 kDa in the conditions used (see Experimental Procedure section).
2.2. Expression Conditions for CamPhoD Production
The study of optimal expression conditions for the recombinant CamPhoD showed that its highest
yield was achieved when cultivating the recombinant E. coli strain over 6 h at 37 ◦C, with an addition
of 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) in the Luria–Bertani (LB) medium (Figure 2).
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It was also found that the alkaline phosphatase activity of the recombinant CamPhoD increased when
the cells were cultured in a medium depleted by phosphorus. The growth of the recombinant E. coli
cells in a MX medium containing 80 mM KH2PO4 described earlier [46] significantly reduced the
alkaline phosphatase activity of CamPhoD down to 0.035 U/mg compared with the activity of the
enzyme, which was produced in the standard phosphate-free LB medium, similarly to the phoD
phosphatase isolated from Streptomyces coelicolor [47].
 
Figure 2. Determination of the expression conditions for the recombinant CamPhoD production:
(A) the dependence of the CamPhoD concentration (mg/mL) on the cultivation time at 37 ◦C in the
presence of (1) 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), (2) 0.2 mM IPTG, (3) 0.3 mM
IPTG, and (4) 0.5 mM IPTG; (B) the dependence of the CamPhoD phosphatase activity (U/mg) on the
cultivation time at 37 ◦C in the presence of (1) 0.1 mM IPTG, (2) 0.2 mM IPTG, (3) 0.3 mM IPTG, and (4)
0.5 mM IPTG.
2.3. Physicochemical and Enzymatic Properties of CamPhoD
The optimum pH for the CamPhoD maximum activity was determined to be 9.2, which lies in
the range of pH 8.0–11.0 inherent for most alkaline phosphatases and phosphodiesterases (Figure 3).
For comparison, the phosphodiesterases from Sphingobium sp. TCM1 and E. coli exhibited the maximal
activity at pH 9.5 and 8.5–9.8, respectively [18,19].
 
Figure 3. Effect of the pH value on the CamPhoD phosphatase activity for conducting the enzymatic
reaction in various buffer solutions: (1) glycine buffer, (2) acetate buffer, (3) Tris-HCl buffer, and (4)
bicarbonate buffer.
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The significant effect of KCl on the activity and the absence of activity without any salt
in the incubation medium indicated that CamPhoD was a highly salt-tolerant enzyme, which
is a common trait of many enzymes of marine origin [6,9,48,49]. Moreover, the PhoD alkaline
phosphatase/phosphodiesterase from a halotolerant cyanobacterium, Aphanothece halophytica, has been
shown to be induced and secreted out of cells by salt stress [9]. In the presence of KCl in a concentration
up to 1 M, CamPhoD was 2–3 times more active than in the presence of NaCl at the same concentration
(Figure 4).
 
Figure 4. Effect of NaCl and KCl on the CamPhoD alkaline phosphatase activity.
Concentration of both KCl and NaCl of more than 1 M decreased the CamPhoD activity.
A similar effect was noted for the salt-tolerant alkaline phosphatase from eggs of the sea urchin
Strongylocentrotus intermedius [48,50] and the enzyme from the halophilic bacterium Halomonas sp.
593 [49].
It was found that the addition of Co2+ and Mg2+ to the incubation mixture containing the lysate
with the recombinant CamPhoD after ultrasonic homogenization of the E. coli cells increased its activity
by 100% compared to the control. The addition of CaCl2 and FeCl3 activated CamPhoD from the cell
lysate by 70% and 60%, respectively. For the CamPhoD purified up to level of homogenous protein,
the salts of divalent metals Zn 2+, Mn 2+, and Cu 2+ at a concentration of 2 mM had almost no effect on
its ability to cleave pNPP, while the salts of Co 2+, Mg 2+, Ca 2+, Fe 3+, and Ni 2+ drastically activated
the enzyme, indicating its metal dependence (Table 1).
Table 1. Effect of metal cations on the alkaline phosphatase CamPhoD from Cobetia amphilecti KMM 296.










Co 2+ + Fe 3+ 100
Ca 2+ + Fe 3+ 66
* The various metal ions were added to the reaction mixture at the 2 mM salt concentration. The phosphatase
activity was measured using the standard method described in Experimental Procedures. The retained activity is
expressed as the specific phosphatase activity of CamPhoD relative to the activity of the enzyme incubated in the
control reaction mixture in the absence of any metal ion.
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However, the maximal CamPhoD activity was achieved by the simultaneous addition of Co2+
and Fe3+ to the incubation mixture, whereas only an 80% or 50% increase of the activity was observed
after the addition of Co2+ and Fe3+ separately. It is evident that CamPhoD is the first bimetal
Co2+–Fe3+-dependent phosphatase/phosphodiesterase characterized to date. Previously, the PhoD-like
phosphatase from B. subtilis was described as being closely related to purple acid phosphatases (PAPs)
with tyrosinate-ligated Fe3+ ions, but differed from them by having two Ca2+ ions instead of a single
extra Fe2+, Mn2+, or Zn2+ ion [15]. The Ca2+ dependence of the phosphatase/phosphodiesterase from
Aphanothece halophytica [9] as well as the activation of the alkaline phosphatase from Pyrococcus abyssi
in the presence of Mg2+, Zn2+, and Co2+ ions have already been shown [43]. In addition, the alkaline
phosphatase of the hyperthermophilic bacterium Termatoga maritima was shown to contain Co2+ and
Mg2+ in the active center [44], while the active center of an E. coli alkaline phosphatase possessing
the phosphodiesterase activity contained two Zn2+ and one Mg2+ [51], similar to most of the PhoA
alkaline phosphatases, for example CmAP from C. amphilecti KMM 296 [6,24,52].
In spite of the obvious CamPhoD metal-dependence, the addition of EDTA and EGTA to the
incubation medium at a concentration of 2 mM led to almost no effect on its activity, probably due
to the deeply hidden metal-binding site in the core domain, a common trait of extracellular marine
enzymes [6]. The narrow enzymatic cavity directed towards the catalytic aa residues, which is packed
with metal ions, protects the extracellular C. amphilecti KMM 296 alkaline phosphatase CmAP from the
damaging effects of chelating agents [6].
The treatment of CamPhoD with dithiothreitol (DTT) at a concentration of 10 mM completely
inhibited enzyme activity (Figure 5). The sensitivity to sulfhydryl reagent has been shown previously
for the highly active alkaline phosphatase CmAP, which was previously isolated from the same
bacterium C. amphilecti KMM 296 [6]. This indicates that the presence of SH groups in the protein
structure is necessary for enzyme activity, although CmAP does not have any intermolecular disulfide
bond [6,12].
 
Figure 5. Effect of dithiothreitol (DTT) on the CamPhoD phosphatase activity.
Adding the non-ionic detergent Triton X-100 to the CamPhoD incubation mixture at concentrations
of 1%, 0.1%, and 0.01% also reduced its activity by 80%, 70%, and 46%, respectively. This could
influence the hydrophobic interactions in the protein, the importance of which were shown for the
overall thermal stability of psychrophilic and mesophilic enzymes [53].
The alkaline phosphatase CamPhoD retained its activity during incubation for 60 min at
temperatures ranging from 15 to 45 ◦C, while incubation at 65 ◦C completely inhibited its activity after
20 min (Figure 6). The CamPhoD thermostability and the optimal temperature of 45 ◦C (Figure 7) are
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similar to the CmAP properties [6]. As for phosphatases and phosphodiesterases, their temperature
optimums cover a wide range, allowing them to belong to both thermolabile and thermostable enzymes.
Alkaline phosphodiesterases from Sphingobium sp. and Delftia acidovorans exhibit maximum activity at
55 ◦C and 65 ◦C, respectively [17,18].
 
Figure 6. Effect of temperature on the CamPhoD stability.
  
Figure 7. Effect of temperature on the CamPhoD phosphatase activity.
2.4. Substrate Specificity of CamPhoD
The study on substrate specificity of CamPhoD has shown that the enzyme catalyzes the cleavage
of the phosphate group from deoxy- and ribonucleoside mono-, -di-, and-triphosphates in the following
order according to catalytic rate: pNPP ≥ CMP ≥ GTP ≥ UMP ≥ dCMP ≥ AMP ≥ TMP ≥ CTP ≥ GDP
≥ GMP ≥ UDP = CDP ≥ bis-pNPP ≥ 5′-pNP-TMP (Table 2). According to the Chen method [54] of
free phosphorus determination, Pi was released from pNPP and GTP under the CamPhoD catalysis
approximately 150 and 250 times faster than from bis-pNPP and 5′-pNP-TMP, respectively (Table 2).
The CamPhoD activities toward the chromogenic substrates pNPP, bis-pNPP, and 5′-pNP-TMP
obtained by the spectrophotometric determination of the p-nitrophenyl concentration were similar.
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The ability of CamPhoD to cleave the phosphate group of the diesters bis-pNPP and 5′-pNP-TMP,
as well as different phosphate monoesters, allowed us to assign this enzyme to the bifunctional
phosphatase/phosphodiesterase [9,10,16–20,55]. For comparison, the binuclear zinc phosphodiesterase
ZiPD from E. coli possessed activity towards phosphodiester bonds of bis-pNPP and 5′-pNP-TMP only,
and did not catalyze the cleavage of other phosphates, such as AMP, ADP, ATP, cyclic phosphates,
or nucleic acids [45]. Despite a wide variety of nucleoside mono-, di-, and triphosphates used as
substrates, CamPhoD did not catalyze the cleavage of the λ DNA, plasmid pUC19 DNA (Thermo
Scientific, Vilnus, Lithuania), oligonucleotides (Evrogen, Moscow), or c-di-GMP (Sigma) up to inorganic
phosphorus Pi (Table 2), similar to the phosphodiesterase PhoD from B. subtilis [15].
Table 2. Substrate specificity of the alkaline phosphatase/phosphodiesterase CamPhoD from
Cobetia amphilecti KMM 296 *.

























* These results were obtained using a molybdate reagent with ascorbic acid [54]. Various substrates were added to
the reaction mixture at 2–15 mM concentrations. For each substrate, a control consisting of a specific substrate and a
buffer containing 25 mM Tris-HCl (pH 9.0), 2 mM CoCl2, and 2 mM FeCl3 was used.
2.5. Catalytic Properties of CamPhoD
The Michaelis constant (Km) of the alkaline phosphatase/phosphodiesterase CamPhoD at pH
9.0 in the presence of Co2+ and Fe3 + with the use of chromogenic pNPP as a substrate was 4.2 mM,
the maximum velocity (Vmax) was 0.203 mM/min, and the efficiency (kcat/Km) was 7988.6 S−1/mM.
Using the chromogenic phosphate bis-pNPP, Km was determined to have values of 6.71 mM,
Vmax = 0.046 mM/min, and efficiency (kcat/Km) = 1133.0 S−1/mM. The kinetic parameters obtained for
CamPhoD are similar to those previously obtained for other phosphatases and phosphodiesterases
(Table 3). For example, Km of the alkaline phosphatase from Termatoga maritima had a value of
175 mM [44], while Km of the alkaline phosphodiesterases from Sphingobium sp. TCM1 and A. halophytica
for pNPP were 1.5 mM and 3.38 mM, respectively [10,18].
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45 9.2 6.7 7603.2 1133.0 4.2 33552 7988.6
C. amphilecti KMM 296
(CmAP)
40–50 10.3 - - - 13.2 28300 2144 [6]
Aphanothece halophytica - 10 3.13 - - 3.38 - - [10]
Bacillus subtilis 25 8.0 - - - 0.05 1.2 24 [15]
Metagenome 25 8.5 10.21 615 × 104 602 × 103 - - - [16]
Delftia acidovorans 65 10 2.9 52740 18186.2 5.0 10260 2052 [17]
Sphingobium sp. TCM1 55 9.5 6.1 325 53.3 1.5 37.9 25.3 [18]
Escherichia coli (YfcE) - 9.8 9.74 19.8 2.03 - - - [19]
Termatoga maritima 75 8.0 175 16 0.091 [44]
E. coli (ElaC, ZiPD) - - 4 59 14.75 - - - [45]
The CamPhoD catalytic efficiency (kcat/Km) in relation to pNPP was seven-fold higher than that with
the use of bis-pNPP as the substrate, indicating that the enzyme mainly has a phosphomonoesterase
structure with phosphodiesterase capability, similar to other PhoD-like enzymes [15]. However,
the value of its catalytic efficiency for diester bonds is much higher when compared with many
monospecific phosphodiesterases, excluding the enzyme from an unknown protein family with
recently established structure and properties, which was isolated from the metagenome [18,19,45].
2.6. 3D Modeling of CamPhoD
A theoretical model for the PhoD-like phosphodiesterase/phosphatase from the marine bacterium
C. amphilecti KMM 296 (GenBank ID: WP_043333989) was generated using structural bioinformatics
methods (Figure 8A–C). Among the 3D structures currently available in the protein database (PDB),
the low identical alkaline phosphatase D from B. subtilis (PDB ID: 2YEQ), which has a new architecture
of the phosphatase active site based on Fe3+ and two Ca2+ ions, is apparently a single homologous
template for modeling CamPhoD, which is a new member of the PhoD family inherent in the marine
bacteria (data not shown). The amino acid sequences of CamPhoD and the template possess 20.5%
identity and 38% similarity. (Figure 8A). The aa residues of the CamPhoD binding Ca2+/Co2+ atoms in
the active center are highly conserved. However, the bonds of the iron atom in the CamPhoD active
center differ from the template bonds in replacing Cys 124 with Gly 117 (Figure 8A). In comparison
with the template, the phosphate molecule in the modeled CamPhoD active site interacts with Tyr 158,
Asp 221, and with one Fe3+ atom, two Ca2+ atoms, and three water molecules (Figure 8C).
A similar interaction with phosphate is observed when two Ca2+ atoms are replaced with Co2+
(Figure 9). The superimposition of the CamPhoD model and template showed that the root mean
square deviation (RMSD) for 473 Cα atoms is 1 Å. The structural differences are in the structure of
some of the loops on the outer surface of the protein (Figure 8C). In the CamPhoD structure, there is no
α-helix at the C-terminus of the molecule, which is presented in the template, which possibly regulates
the availability of the active center to accept the substrate (Figure 8A,C).
The analysis of contacts in the CamPhoD complexes with the reaction product PO43− showed that
the enzyme forms fewer contacts with the product than the template due to the shortened C-terminal
region (Figure 9). The model of the CamPhoD complex with the substrate molecule has made it
possible to determine the amino acid residues of the enzyme associated with the substrate binding
(Figure 10).
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Figure 8. (A) Modeling of the CamPhoD 3D structure. An alignment of the amino acid sequences of
the alkaline phosphatase/phosphodiesterase CamPhoD from the marine bacterium C. amphilecti KMM
296 (GenBank ID: WP_043333989) and alkaline phosphatase (phosphodiesterase) D from B. subtilis
(PDB ID: 2YEQ). The amino acid sequences identity and similarity (color boxed) and the secondary
structure of the template are highlighted. Note: α-helixes = red sticks; β-structure = blue arrows; the
binding of amino acid (aa) residues (Ca2+/Co2+) = *; the binding of conserved aa residues (Fe3+) = o;
and the residue Cys 124 of the template = •. (B) The 3D structure model of CamPhoD with the reaction
product Pi and metal ions in the active center (the protein structure is a ribbon diagram, Pi is in stick
form, and Ca2+ is shown as spheres). (C) The 3D superimposition of the CamPhoD model (orange)
and the template (PDB ID: 2YEQ) (shown in pink, with the blue C-terminal part).
2.7. Effect of CamPhoD on Bacterial Biofilms
In order to study the effect of alkaline phosphatase/phosphodiesterase CamPhoD on the inhibition
of biofilm formation or on their destruction, bacterial biofilms of both individual and mixed species
were grown. The study found that CamPhoD (0.1 U/mg) had a slight inhibitory effect on the biofilm
formation of three species of Bacillus, namely B. licheniformis, B. aegricola, and B. berkelogi (18–32%),
and dispersed the already formed biofilms of these species by 8–15% (Table 4). At the same time,
CamPhoD did not inhibit the formation of biofilms in B. subtilis and Pseudomonas aeruginosa and did
not degrade them.
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Figure 9. A 2D diagram of the contacts of the CamPhoD active center (A) and the template (PDB ID:
2YEQ) (B).
 
Figure 10. A model of the CamPhoD complex with the substrate 5′-pNP-TMP (A), and a 2D diagram
of the contacts of 5′-pNP-TMP in the CamPhoD active center (B).
Table 4. Effect of the alkaline phosphatase/phosphodiesterase CamPhoD from Cobetia amphilecti KMM
296 on the bacterial biofilms.
Strain
Biofilm Formation %
(3 Days, 22–24 ◦C)
Biofilm Destruction %
(30 min, 37 ◦C)
K * 100 0
B. subtilis 100 0
B. licheniformis 74 15
B. aegricola 68 14
B. berkelogi 82 8
P. aeruginosa 100 0
Y. pseudotuberculosis 85 23
S. enteritidis 93 11
Y. pseudotuberculosis + S. enteritidis 87 24
* K-control strains grown without treatment with the enzyme.
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Under natural conditions, biofilms are most often formed by not just one but by several types
of bacteria [56]. In view of this, the study of such mixed biofilms is of great fundamental and
practical importance. We investigated the formation of biofilms by mono and mixed cultures of
Yersinia pseudotuberculosis and Salmonella enteritidis, as well as the effect of CamPhoD during the 3 day
incubation with the enzyme (Table 4). The destruction of mature biofilms by the studied enzyme
ranged from 11% to 24% depending on the strain. For comparison, DNase I degraded about 30% of the
biofilm formed by Y. pseudotuberculosis and more than half of the B. subtilis biofilm [57].
The alkaline phosphatase CmAP from C. amphilecti KMM 296 was also shown to effectively inhibit
the growth of the new biofilms and degradation of the mature biofilms of S. enteritidis, as well as
P. aeruginosa and B. subtilis [7], in contrast to CamPhoD. The antibacterial activity of the alkaline
phosphatase against P. aeruginosa has been found in E. coli, which is known as a causative agent of
diarrhea [58]. The effect of alkaline phosphatases on pathogens has been studied by exploring the gut
microbiota modulation ability in the alkaline phosphatase of the intestinal PhoA enzymes, in which
the level of decrease or dysfunction is associated with intestinal inflammation, dysbiosis, bacterial
translocation, and subsequently systemic inflammation [33–35].
The presence of extracellular alkaline phosphatases of the structural families PhoA (GenBank ID:
WP_084589490.1) and PhoD (GenBank ID: WP_043333989.1) in the marine gamma-proteobacterium
C. amphilecti KMM 296 may indicate either their distinct or cooperative functions for the hydrolysis
of various phosphorus-containing organic molecules, depending on the environmental conditions
and cell lifestyle [7,36]. The analogous PhoD enzyme from B. subtilis is thought to target specific
phosphate-containing molecules, such as teichoic acids linked to the wall peptidoglycan via
phosphodiester bonds. It is possible that other PhoD family members also have specific biological roles
rather than operating as general phosphatases, such as members of the PhoA and PhoX families [15].
In spite of the absence of both CamPhoD and CmAP ability to cleave an important signaling molecule
c-di-GMP, they may provide a level of Pi, acting on other extracellular phosphate-containing substrates
and playing a crucial role in the bacterial behavior. For example, the phosphorylated lipid A or the
linear intermediate product of the c-di-GMP hydrolysis, pGpG, have also been recently found as
substrates for alkaline phosphatases and phosphodiesterases and as participants in cell signaling [32,59].
The mechanism of the putative participation of any alkaline phosphatase from C. amphilecti KMM 296
in the bacterial cell signaling has yet to be clarified, including regulation of biofilms or the species
content in the bacterial consortium, with which the marine bacterium has to coexist in the mollusk
digestive system.
3. Materials and Methods
3.1. Reagents and Materials
The reagents of chemical grade qualifications were obtained from Merck (Munchen, Germany),
Sigma (Sigma-Aldrich Rus LLC, Moscow, Russia), and Helicon (Moscow, Russia). The molecular
biology kits for restriction, ligation, Taq polymerase, and oligonucleotides were from Evrogen (Moscow,
Russia) and Thermo Fisher Scientific RU (Moscow, Khimki, Russia); kanamycin was from Sintez
(Moscow, Russia). Yeast extract, bactoagar, tripton, and pepton were from Helicon and Dia-M (Moscow,
Russia). DNA and protein molecular weight markers were from BioRad (California, USA).
3.2. Construction of Plasmid pET40CamPhoD
The recombinant plasmid pET40CamPhoD was constructed by insertion into the NcoI/SacI
fragment of plasmid pET-40b (+) (Thermo Fisher Scientific-RU, Moscow, Khimki, Russia), the gene
encoding for the PhoD-like full-length phosphatase/phosphodiesterase, which was synthesized
by polymerase chain reaction (PCR) using the genomic DNA of Cobetia amphilecti KMM 296
(Collection of Marine Microorganisms PIBOC FEB RAS) as a template and the gene-specific
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primers CamPhoD-NcoI-dir: 5′ -TATACCATGGAAGGACGGCGCCCGCGCATGCCCTC-3′ and
CamPhoD-SacI-rev: 5′ -TATAGAGCTCTTAGACACTGGCGGCGGCGGGGGTC-3′.
The reaction conditions were: 1 μL 10 × Encyclo buffer, 0.2 μl 50 × Encyclo polymerase mixture
(Encyclo PCR kit; Evrogen, Moscow, Russia), 0.2 μl 50 × dNTP mixture (10 mM of each), a mixture
of primers (1 μl 5 μM of each), and 1 μl 20 ng DNA. The volume of the reaction mixture was 10 μL.
The amplification process consisted of 40 cycles of PCR (15 s, 95 ◦C, 1 min 40 s, 72 ◦C). After amplification,
the PCR product was purified by electrophoresis in 1% agarose gel. The PCR fragment (1 μg) was
treated with the restriction enzymes NcoI and SacI in an optimal buffer (Thermo Fisher Scientific RU)
for 3 h at 37 ◦C, and then the enzymes were removed from the reaction mixture using phenol (1: 1).
Here, 1/10 volume of 0.3 M sodium acetate, pH 5.2, and 1/2 volume of isopropyl alcohol were added to
the aqueous fraction containing the PCR fragment, then incubated at −20 ◦C for 30 min. Then, this was
centrifuged at 14,000 rpm for 20 min, the precipitate was washed with 75% ethanol, then dried at room
temperature. The precipitate was dissolved in 20 μl of deionized water.
In total, 2 μg of the pET-40b (+) plasmid DNA (Thermo Fisher Scientific-RU) was treated with the
NcoI and SacI restriction endonucleases in accordance with the procedure described above.
The obtained fragment of the CamPhoD gene and the NcoI /SacI part of the plasmid pET-40b (+)
were ligated using a ligase reaction in 50 μl of ligation buffer, according to the instructions (Thermo
Fisher Scientific RU). Then, 10 μL of the reaction mixture was used to transform the competent E. coli
Rosetta cells (DE3). Transformants were grown on the Luria–Bertani (LB) agar containing 25 μg/mL
kanamycin. After incubation for 16 h at 37 ◦C, the clones were screened, and then the targeted plasmid
DNA was isolated and screened for mutations.
3.3. Optimization of Conditions for CamPhoD Expression
To determine the optimal IPTG concentration, the E. coli Rosetta (DE3) cells transformed with the
pET40 plasmid carrying the CamPhoD gene were grown on LB agar containing 25 mg/mL kanamycin
overnight at 37 ◦C. Single colonies were selected and grown in 5 mL of the liquid LB medium containing
25 mg/mL kanamycin at 200 rpm for 16 h at 37 ◦C. Then, the inoculum was placed into the flasks
with 20 mL of fresh LB medium containing kanamycin at a concentration of 25 mg/mL and incubated
at 37 ◦C in a shaker at 200 rpm, up to an optical density 0.6–0.8 (λ 600 nm). Next, 0.1 mM, 0.2 mM,
0.3 mM, and 0.5 mM IPTG were added to induce the expression of CamPhoD, then incubation was
continued at 37 ◦C. To determine the phosphatase activity, 5 mL of each sample was taken at 0, 3, 6,
and 24 h after the start of expression and ultra-sonication for the bacterial cells and determination of
the CamPhoD alkaline phosphatase activity.
To determine the dependence of CamPhoD activity on the presence of phosphate in the growth
medium, the E. coli Rosetta (DE3) cells transformed with the pET40CamPhoD plasmid were grown in
25 mL of the liquid medium containing: bacto-trypton 10 g/L, yeast extract 7.5 g/L, sorbitol 70 g/L,
MgCl2 5 mM, KH2PO4 80 mM, and 25 mg/mL kanamycin at 200 rpm for 16 h at 37 ◦C [46]. Then,
the cells were placed in 1 L of the fresh medium of the abovementioned composition and incubated at
37 ◦C on a rocking chair at 200 rpm, up to an optical density 0.6–0.8 (λ 600 nm). Next, 0.1 mM IPTG was
added to induce the expression of CamPhoD and incubation was continued at 37 ◦C for 6 h at 200 rpm.
After this, CamPhoD was isolated, purified, and its activity was determined as described below.
3.4. The Recombinant CamPhoD Production
The recombinant E. coli Rosetta (DE3) strain was grown in 25 mL of the LB liquid medium
containing 25 mg/mL kanamycin at 200 rpm for 16 h at 37 ◦C. Then, the cells were placed in the fresh
LB medium (1 L) containing kanamycin at a concentration of 25 mg/mL and incubated at 37 ◦C in a
shaker at 200 rpm, up to an optical density at 600 nm of 0.6–0.8. After that, 0.1 mM IPTG was added to
induce expression of the enzyme and incubation was continued at 37 ◦C for 6 h at 200 rpm.
The cells were precipitated by centrifugation at 4000 rpm for 15 min at 8 ◦C, suspended in
35 mL of 25 mM Tris-HCl buffer (pH 9.0) with phenylmethylsulfonyl fluoride (PMSF) added to a final
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concentration of 0.15 mM, and subjected to ultrasonication at 22 kHz and 0–4 ◦C with intervals of 30 s,
up to clarification of the suspension. The suspension was centrifuged at 11,000 rpm for 30 min at 8 ◦C,
the precipitate was discarded, and the activity and properties of CamPhoD were determined in the
resulting extract.
3.5. The Recombinant CamPhoD Isolation and Purification
For isolation of CamPhoD, CaCl2 and MgCl2 were added to the recombinant cell extract to a final
concentration of 10 mM, DNase was (SkyGen, Moscow, Russia) to a final concentration of 5 μg/mL,
these were incubated at 37 ◦C for 1 h, and then centrifuged at 11000 rpm for 20 min. The resulting
supernatant was introduced into a 25 × 3.2 cm Ni-IMAC-Sepharose column (GE Healthcare Life
Sciences, Buckinghamshire, UK) equilibrated with 25 mM Tris-HCl, pH 9.0 (buffer A), and washed with
five volumes of the same buffer. The recombinant protein was eluted with a linear gradient of 0–0.5 M
imidazole in 25 mM Tris-HCl buffer, pH 9.0, and 0.5 M NaCl (6 column volume), at a rate of 1.3 mL/min.
The CamPhoD-containing fraction was purified on a 10 × 1.4 cm Source 15 Q column (GE Healthcare
Life Sciences) equilibrated with buffer A, then the protein was eluted with a linear gradient of 0–0.5 M
NaCl in the 25 mM Tris-HCl buffer at pH 9.0. Ion exchange chromatography was performed at a rate
of 1 mL min; the volume of the fractions was 1 mL. The CamPhoD-containing fractions were collected
and treated with enterokinase at a final concentration of 1 U per 1 mg of protein for 22 h at 25 ◦C.
Then, the protein solution was applied to a Superdex 200 PG column (105 × 2 cm) (GE Healthcare Life
Sciences), previously equilibrated with buffer A with 0.15 M NaCl at a rate of 0.5 mL/min, with 1 mL
fractions. The CamPhoD-containing fractions were collected and subjected to chromatography using a
mono-Q HR column (4 × 0,8 cm) (GE Healthcare Life Sciences, Buckinghamshire, UK) equilibrated
with buffer A, washed with 10 volumes of buffer A, and then the target protein was eluted with a linear
gradient of 0–0.5 M NaCl in buffer A at a rate of 0.5 mL/min and with fractions of 1 mL. The purified
preparation of CamPhoD was used to study the physicochemical properties and substrate specificity.
3.6. Enzyme Activity Assay
The enzyme activity of CamPhoD was determined at 37 ◦C for 30 min with the use of 2 mM
p-nitrophenyl phosphate (p-NPP), thymidine-5′-monophosphate-p-nitrophenylester (5′-pNP-TMP)
or bis-p-nitrophenyl phosphate (Bis-p-NPP) as chromogenic substrates in 25 mM Tris-HCl buffer, pH
9.0, 2 mM CoCl2, 2 mM FeCl3. The volume of the reaction mixture was 0.5 mL. The reaction was
stopped by adding 1 mL of cooled 0.5 M NaOH to the reaction mixture. The absorption of the formed
p-nitrophenol was measured at an optical density of 400 nm. The amount of enzyme required for
the conversion of 1 μM p-nitrophenyl from a substrate over 1 min was taken as a unit of activity.
The specific activity is given in units calculated per 1 mg of protein. The protein concentration was
determined using Bradford’s method [60].
3.7. Substrate Specificity
The substrate specificity of CamPhoD was determined by adding 2 mM CMP, CDP, CTP, dCMP,
dCTP, UMP, UDP, UTP, TMP, TTP, GMP, GDP, GTP, dGMP, dGTP, AMP, ATP, dAMP, bis-pNPP,
5′-pNP-TMP, c-di-GMP, and pNPP to a standard incubation mixture, containing 25 mM Tris-HCl buffer,
pH 9.0, 2 mM CoCl2, 2 mM FeCl3. The mixture was incubated at 37 ◦C for 60 min. The volume of
the reaction mixture was 1 mL. Then, a molybdate reagent with ascorbic acid (4 mL) was added to
the incubation mixture and again incubated at 37 ◦C for 60 min. The mixture was cooled to room
temperature, and absorbance of the formed product of dephosphorylation by CamPhoD was measured
at an optical density of 820 nm. The amount of inorganic phosphate Pi (mkM) released during
dephosphorylation of the studied substrates with the enzyme was determined using a calibration
curve with KH2PO4, according to Chen’s method [54].
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3.8. Determination of Thermostability and Temperature Optimum
The effect of temperature on CamPhoD and the optimum temperature were determined by
incubating the standard incubation mixture at temperatures ranging from 15 to 65 ◦C, at 10 ◦C
intervals. Alkaline phosphatase activity was determined using the standard method for determining
for CamPhoD, as described above.
3.9. Effect of Metal Ions and Chelating Agents
The influence of divalent metal ions on CamPhoD was determined using the standard method for
determining the alkaline phosphatase activity, with the addition of Mg2+, Ca2+, Mn2+, Zn2+, Co2+,
Ni2+, Cu2+, Cs2+, Fe3+ ions, EDTA, and EGTA at a concentration of 2 mM to the incubation mixture.
The incubation mixture without cations and chelating agents was used as a control.
3.10. Effect of NaCl and KCl
The effects of Na+ and K+ were investigated by adding NaCl and KCl to a standard incubation
mixture at a concentration of 0–1.5 M. The alkaline phosphatase activity was determined as
described above.
3.11. Determination of Molecular Weight
The molecular weight of CamPhoD was determined using gel filtration on a calibrated Superdex
G200 PG (GE Healthcare Life Sciences, Amersham Place, Little Chalfont, Buckinghamshire, HP7, 9NA,
UK) column (105 × 2 cm) and polyacrylamide gel electrophoresis under denaturing conditions (sodium
dodecyl sulfate polyacrylamide gel electrophoresis) using the Lammley method [61].
3.12. Determination of Catalytic Parameters
Kinetic parameters were calculated by plotting the rate of p-NPP and bis-p-NPP splitting at
concentrations from 5 to 15 mM in a buffer containing 25 mM Tris-HCl, pH 9.0, 2 mM CoCl2, 2 mM
FeCl3. The reaction was carried out at 25 ◦C. The Michaelis constant Km, the maximum reaction rate
Vmax, and the turnover number kcat were determined by plotting the Layuver–Burk graph using the
OriginPro 8.5 program.
3.13. Molecular Modeling
The target template alignment customization of the modeling process and 3D model building for
CamPhoD (GenBank: WP_043333989) were carried out using the Molecular Operating Environment
(MOE) version 2018.01 package, using the Amber12: EHT forcefield (EHT-Extended Hueckel
Theory) [62]. The alkaline phosphatase D from B. subtilis (PDB code: 2YEQ) was used as a template,
which had a high-resolution crystal structure. The evaluation of structural parameters, contact structure
analysis, physicochemical properties, and visualization of the results were carried out with the ligand
interaction and dock modules in the MOE 2018.01 program [62].
3.14. Biofilms Growth and Enzymatic Treatment
The strains of Bacillus subtilis, Bacillus licheniformis, Bacillus aegricola, Bacillus berkelogi,
Pseudomonas aeruginosa, Yersinia pseudotuberculosis, and Salmonella enteritidis were used. An
overnight bacterial culture was diluted with the appropriate nutrient medium and incubated in a
96-well plate at 200 μl per well for 24 h at 37 ◦C, or for 3 days at 22–24 ◦C. After incubation, loose cells
were removed from the wells, and wells were washed three times with 0.85% NaCl. The biofilm was
stained with 0.5% crystal violet (CV) for 20 min at room temperature. The dye was removed from the
wells, and unbound CV was washed with tap water. The plates were air dried, 2% acetic acid in 95%
ethanol was added to each well, and the absorbance was determined at 600 nm.
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Inhibition of biofilm formation was tested using the method in [63]. Test substances at various
concentrations were added to the wells. All experiments were repeated four times. The destruction of
biofilms by the investigated substances was carried out as follows. After the formation of biofilms for a
certain time, unattached cells were removed and the wells were washed with 0.85% NaCl. The enzyme
was added to each well in the appropriate buffer and incubated under the conditions for determination
of the activity of the studied enzyme. Then, the plate was processed as described above.
4. Conclusions
The PhoD-like enzyme gene was firstly isolated from the marine bacterium Cobetia amphilecti
KMM 296 and cloned into E.coli. The effects of chemicals, metal ions, kinetic parameters, and substrate
specificity on the enzymatically active recombinant product, CamPhoD, expressed from this gene
confirmed that the enzyme carries a metabolic function of phosphatase/phosphodiesterase of the PhoD
family in the marine environment. The enzyme bimetal dependence coincides with the modeling
results for the enzymatic complex, with phosphate in the active center surrounded by two Co2+
ions and one Fe3+ ion. This enzyme of marine origin has been concluded to be a new member of
the bifunctional PhoD-like phosphatase/phosphodiesterase class, with a characteristic structure and
important biological functions.
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Abstract: We obtained two novel draft genomes of type Zobellia strains with estimated genome
sizes of 5.14 Mb for Z. amurskyensis KMM 3526Т and 5.16 Mb for Z. laminariae KMM 3676Т.
Comparative genomic analysis has been carried out between obtained and known genomes of Zobellia
representatives. The pan-genome of Zobellia genus is composed of 4853 orthologous clusters and
the core genome was estimated at 2963 clusters. The genus CAZome was represented by 775 GHs
classified into 62 families, 297 GTs of 16 families, 100 PLs of 13 families, 112 CEs of 13 families,
186 CBMs of 18 families and 42 AAs of six families. A closer inspection of the carbohydrate-active
enzyme (CAZyme) genomic repertoires revealed members of new putative subfamilies of GH16
and GH117, which can be biotechnologically promising for production of oligosaccharides and rare
monomers with different bioactivities. We analyzed AA3s, among them putative FAD-dependent
glycoside oxidoreductases (FAD-GOs) being of particular interest as promising biocatalysts for
glycoside deglycosylation in food and pharmaceutical industries.
Keywords: marine flavobacteria; Zobellia; comparative genomics; carbohydrate-active enzymes
1. Introduction
Seaweeds are a rich source of bioactive compounds particularly with regard to polysaccharides.
Red seaweeds (Rhodophyceae) produce sulfated galactans, such as agar and carrageenan. Other sulfated
polysaccharides, such as ulvans or fucans, are found in green (Chlorophyceae) or brown (Phaeophyceae)
seaweeds, respectively. Non-sulfated polysaccharides, mainly laminarans and alginates, are isolated
from brown seaweeds. These polysaccharides are being actively studied due to their pharmacological
anti-inflammatory, antioxidant, antiviral, antitumor, immunomodulatory, anticoagulant, hypolipidemic,
and prebiotic activities [1,2]. Physical-chemical properties and biological activities of their derivatives
are of great interest for study. Previous works showed they have the potential to be used as
bioactive molecules and functional materials in food, pharmaceutical, and cosmetic industries [3–5].
Among seaweed polysaccharides, agar and carrageenan are valuable sources of various oligosaccharides
with beneficial effects for human health, and these effects depend on the degree of depolymerization [6].
The oligosaccharides, in turn, are a source of rare sugars, such as 3,6-anhydro-l-galactose (L-AHG),
which has been recently suggested to be a new anticariogenic sugar [7]. Importantly, AHG-containing
oligosaccharides have been reported to demonstrate anti-inflammatory, antitumor, and anticariogenic
activities [8–10]. They can be also used in cosmetic dermatology for skin moisturizing and
whitening [11,12].
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The most eco-friendly methods for improving the yield and quality of algal polysaccharides
and their derivatives are enzyme-based techniques [1,4]. Therefore, there is a demand for highly
specific hydrolytic enzymes, which in turn stimulates the search for marine bacteria specialized
in the degradation of various polysaccharides. Bacterial carbohydrate-active enzymes (CAZymes)
are responsible for synthesis and degradation of polysaccharides as well as their derivatives [13].
They include glycoside hydrolases (GHs), glycosyltransferases (GTs), polysaccharide lyases (PLs),
and carbohydrate esterases (CEs). Now, they also include auxiliary activity (AAs) enzymes and
carbohydrate-binding modules (CBMs). CAZymes have been successfully used in biotechnological,
medical, and industrial applications [14]. It is necessary to take into account that the CAZyme repertoire
of microorganisms might be determined by both the taxonomic level and ecological niche they
occupy [15]. Therefore, a comparative genomics approach provides insights into a “core” CAZome that
is conserved among organisms and an organism-specific “accessory” CAZome that encodes uniquely
for each particular organism enzyme.
The phylum Bacteroidetes accommodates bacteria distributed across diverse habitats, including
terrestrial, aquatic, and gut ecosystems [16–20]. Marine representatives of the Bacteroidetes are involved
in many biogeochemical processes and specialize in the degradation of various biopolymers [20] due
to their metabolic flexibility and special enzymatic repertoires [21]. It is known that Flavobacteriia, the
most numerous class of the phylum, are specialized in the degradation of algal polysaccharides [22–25].
To date, genome investigations of marine Flavobacteriia, such as Gramella forsetii KT0803T [26],
Cellulophaga algicola IC166T [27], Polaribacter sp. Hel1_85 [28], Formosa agariphila M-2Alg 35-1T [29], and
Zobellia galactanivorans DsijT [30], have revealed an abundance of CAZyme genes, confirming their
specialization in the utilization of polysaccharides in marine environments.
Recently, Z. galactanivorans DsijT has been comprehensively studied and has become a model
organism for polysaccharide degradation investigation among marine flavobacteria [30]. The genus
Zobellia was created by Barbeyron et al. [31], and to date it contains five validly described representatives:
Z. galactanivorans DsijT, Z. uliginosa DSM 2061T, Z. amurskyensis KMM 3526T, Z. laminariae KMM 3676T,
and Z. russellii KMM 3677T, which were isolated from diverse ecological niches. Although many
isolates have also demonstrated an ability to degrade different polysaccharides [32], little is known
about the genomic organization of hydrolytic systems within the Zobellia genus.
In this study, we performed de novo genome sequencing of two type Zobellia strains to produce
the first genomics analysis of the genus and provide insights into the role of the CAZyme genomic
repertoire in the degradation potential of marine bacteria. Some polysaccharide degradation systems
received particular attention due to their biotechnological and medical applications.
2. Results and Discussion
2.1. Genome Sequencing and Assembly
Among five currently described Zobellia species, there are four genomes available to the public
on the NCBI database as of October 2019: Z. galactanivorans DsijT (PRJEB8976), Z. galactanivorans
OII3 1c (PRJNA377409), Z. uliginosa DSM 2061T (PRJNA329763), and Z. amurskyensis MAR 2009 138
(PRJNA248513, revised from “Z. uliginosa MAR 2009 138”). However, only two genomes were obtained
from type strains. We obtained two novel draft genomes of the other Zobellia species, deposited in the
collection of marine microorganisms (KMM WDCM644) of PIBOC FEB RAS.
Type strains Z. amurskyensis KMM 3526Т and Z. laminariae KMM 3676Т were isolated from
seawater (Amur Bay, Vladivostok, Russia) and brown alga Laminaria japonica (Troitsa Bay, Zarubino,
Russia), respectively, and validly described by Nedashkovskaya et al. [33]. Draft genomes of both
flavobacteria were obtained using Roche-454 technology; additionally, the genome of Z. laminariae was
produced using Ion Torrent technology. De novo genome assembly was performed using trimmed
high-quality sequencing reads (>Q20). Assembly statistics are presented in Table 1. The total amount
of genomic data on average provided more than 15-fold coverage per genome.
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Table 1. Genome assembly statistics of two Zobellia strains.
Criteria Z. amurskyensis KMM 3526Т Z. laminariae KMM 3676Т
Total number of aligned bases 79,609,284 386,897,826
Total number of contigs 157 35
Number of contigs > 1 kb 100 17
Number of contigs > 0.5 kb 110 24
Lengths of the longest contig, bp 221,511 1,629,023
N50, bp 94,524 1,429,896




Genome assemblies were validated by remapping sequencing reads back to contigs using the
Bowtie2 program (Table 2). The number of reads aligned exactly one time exceeded 95%, and more
than once did not exceed 1%, which reflected the high accuracy of assemblies. It is shown that the
combination of the two sequencing technologies enables a higher-quality version of the genome
assembly to be obtained. Therefore, the draft genomes of Z. amurskyensis and Z. laminariae were
obtained in sufficient quality for the subsequent bioinformatics analysis.
Table 2. Assembly validation metrics.
Criteria Z. amurskyensis KMM 3526Т Z. laminariae KMM 3676Т
Filtered reads 251,270 2,482,522
Aligned 0 times (%) 10,951 (4.36) 44,386 (1.79)
Aligned exactly 1 time (%) 239,721 (95.40) 2,417,097 (97.36)
Aligned >1 times (%) 598 (0.24) 21,039 (0.85)
Overall alignment rate (%) 95.64 98.21
2.2. Phylogenetic Analysis
A phylogenetic tree of the Zobellia genus including all type strains and representatives of related
genera was inferred based on 16S rRNA partial sequences, which were retrieved from genomic
sequences and a nucleotide sequence for Z. russellii KMM 3677T. According to the neighbor-joining
(NJ) tree (Figure 1), all Zobellia clustered together and three subclades could be distinguished.
One subclade included Z. uliginosa and strains of Z. galactanivorans, while the other subclade included
Z. laminariae and strains of Z. amurskyensis. This clustering indicates a closer sequence similarity of
the strains within subclades. Interestingly, Z. russellii branched deeply within the Zobellia clade and
demonstrated significant evolutionary divergence from all other strains in the genus, supported by
high bootstrap values.
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Figure 1. Phylogenetic relationships of Zobellia species and representatives of the related genera of the
family Flavobacteriaceae, based on 16S rRNA gene sequence comparisons. The phylogenetic tree was
constructed using the neighbor-joining (NJ) approach [34] with bootstrap support of 1000 replications.
The scale bars represent 0.01 substitutions per site.
In order to clarify in detail the phylogenetic relationships of Zobellia species based on obtained
and known draft genomes, further phylogenomic measures were performed using the JSpecies Web
Server (JSpeciesWS; http://jspecies.ribohost.com/jspeciesws/). JSpeciesWS is a web service for in silico
calculation of the extent of identity between genomes. The service measures the average nucleotide
identity (ANI) based on BLASTþ (ANIb) and MUMmer (ANIm), as well as correlation indexes of
tetranucleotide (Tetra) signatures [35].
The ANI and Tetra values were calculated and are summarized in Table 3. Consistent with the NJ
tree, the genomes of Z. galactanivorans OII3 1c and Z. amurskyensis MAR 2009 138 strains showed ANI
values above 97% with their corresponding type strains, which clearly matched the recommended
cut-off point for species delineation of ∼96% ANI [36]. Some discrepancies between ANI and Tetra
values were observed for Z. uliginosa. Although Tetra signatures were in range >0.989, implying that
Z. uliginosa is closely related to strains of Z. galactanivorans, the estimated ANI values of 92%–94% were
slightly lower than the species delineating threshold. Therefore, these strains could either belong to
the same species from which Z. uliginosa recently diverged, or they are two discrete, albeit closely
related, species.
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Table 3. Results of average nucleotide identity (ANI; %) and tetranucleotide (Tetra) calculations using
JSpecies Web Server (JSpecies WS).
Tetra
ANIb/ANIm, %
1 2 3 4 5 6



























4. Z. amurskyensis MAR 2009 138 0.99923 0.7949 0.98223 77.60/83.21
77.45/
83.10
5. Z. galactanivorans OII3 1c 0.792 0.99968 0.72942 0.799 92.94/94.06
6. Z. uliginosa 0.78333 0.99905 0.71978 0.7902 0.99887
2.3. Comparative Genomics
Since Z. galactanivorans DsiJT and Z. galactanivorans OII3 1c represent the same species, the genome
of strain OII3 1c was excluded from the analysis. However, despite the ANI values, the genome of
Z. amurskyensis MAR 2009 138 was taken into comparative analysis along with a novel draft genome of
the type strain KMM 3526Т.
Gene prediction and preliminary annotation of Z. amurskyensis and Z. laminariae genomes
were performed with the Rapid Annotation using Subsystems Technology (RAST) server (http:
//rast.theseed.org/FIG/rast.cgi). In addition to the identification of genes, RAST groups annotated genes
into functional subsystems represented by 27 categories of well-characterized metabolic processes
and structural complexes [37–39]. Based on such data, we could estimate the contribution of diverse
metabolic processes to bacterial life strategies. The total number of protein-coding sequences of
4248 and 4334 accounted for KMM 3526Т and KMM 3676Т genomes, among which only 2683 and
2699 genes were functionally annotated, respectively. According to the server, about 1500 genes for
both flavobacteria are in subsystems, among which “Carbohydrates” was ranked first in gene content.
Genome characteristics of Z. amurskyensis and Z. laminariae in comparison to publicly available
Zobellia genomes are shown in Table 4. Genome sizes ranged slightly within 5.14 Mb to 5.52 Mb.
Estimated GC content ranged from 36.77% in Z. laminariae to 42.8% in Z. galactanivorans. It is worth
noting that the comparison was made between draft genomes, for which reason overall metrics strongly
depend on genome assembly completeness and annotation methods. Since the obtained genomes
were annotated using RAST, other genomes from NCBI were also passed through the RAST server for
further comparative analysis.












Genome size, Mb 5.142451 5.159845 5.52171 5.358000 5.303163
GC Contents, % 38.02 36.77 42.80 38.10 42.60
CDS (by RAST) 4248 4334 4676 4501 4712
CDS (by NCBI) - - 4515 4339 4356
Genome-wide exploration of orthologous genes/clusters across different species is important
in comparative genomics to understand molecular evolution, structure of genes and genomes, as
well as adaptive capabilities [40]. Orthologs or orthologous genes originate by vertical descent
from a single gene in the last common ancestor [41]. Comparison and annotation of orthologous
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clusters between five Zobellia genomes were performed using the web server OrthoVenn2 (https:
//orthovenn2.bioinfotoolkits.net/home) [42]. Inferred proteins for each genome by RAST annotation
were used as input. Consistent with phylogenomic analysis, the pairwise heatmap (Figure 2)
demonstrates the phylogenetic proximity of Z. galactanivorans to Z. uliginosa at the ortholog level.
Figure 2. The pairwise heatmap of overlapping cluster numbers across the genomes.
The Venn diagram is widely used to visualize similarities and differences between genomes.
The distribution of shared orthologous clusters and singletons for each strain is depicted in Figure 3.
Singletons are genes for which no orthologs could be found in other species; single-copy gene clusters are
clusters that contain single-copy genes in each species [42]. According to cluster analysis, the genomes
shared 4853 clusters constituting a supposed pan-genome of the Zobellia genus. The core-genome
represented in all strains was estimated in 2963 clusters whose functions were mostly assigned to the
cellular metabolic process.
Figure 3. The Venn diagram plotted by OrthoVenn2 shows shared orthologous protein clusters among
the genomes of five Zobellia strains. The numbers of shared and unique genes, singletons are shown.
From Figure 3, it is apparent that 516 orthologous clusters composed of 1044 genes were represented
only in Z. galactanivorans and Z. uliginosa genomes, while the genomes of Z. amurskyensis KMM 3526Т
and Z. amurskyensis MAR 2009 138 shared 324 clusters of 658 genes. Such clusters are presumably
species-specific. Gene ontology (GO) analysis revealed an enrichment of GO:0005983 “starch catabolic
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process” in both groups. The group of 516 clusters had additionally GO:0016139 “glycoside catabolic
process” and the second group had GO:0008484 “sulfuric ester hydrolase activity”.
The dispensable genome of the Zobellia genus is composed of singletons or inparalogs, which were
unique to each strain. The Z. laminariae genome contained the highest number of unique genes, including
633 singletons and 11 clusters of 26 inparalogs. For Z. uliginosa, Z. galactanivorans, and Z. amurskyensis
MAR 2009 138 617/562/454 singletons and 48/23/58 inparalogs, respectively, were identified. In the
genome of Z. amurskyensis KMM 3526Т, there were only 304 singletons. These accessory genes possibly
affect metabolic differences within Zobellia representatives and determine peculiarities of lifestyle in
certain ecological niches, such as sediment, seaweeds, or seawater. However, it should be noted that
these differences also could be explained by different completeness of the genomes.
2.4. Repertoire of CAZymes
We focused on investigation and comparison of the CAZymes genes in the Zobellia genomes in
order to speculate about their bacterial lifestyles, as well as to identify relevant CAZymes for potential
application in medicine and biotechnology.
CAZymes are a class of enzymes that synthesize, modify, or break down saccharides, and their
classification comprises the following modules: Glycoside hydrolase families (GHs), polysaccharide
lyase families (PLs), carbohydrate esterase families (CEs), glycosyltransferase families (GTs), auxiliary
activity families (AAs), and carbohydrate-binding module (CBM) families [13].
A genomic approach was used to explore all CAZymes of a genome (CAZome) more profoundly.
Identification of CAZymes across Zobellia genomes was carried out using the dbCAN2 meta server
(http://cys.bios.niu.edu/dbCAN2). The server allows us to make a more accurate prediction of
the CAZome because it integrates three annotation tools: HMMER, DIAMOND, and Hotpep
searches [43]. The proportions of CAZymes predicted in the genomes of Zobellia are shown in
Table 5. Calculations were based on the data obtained by RAST gene prediction and dbCAN2
CAZyme annotation.
Table 5. Proportions of predicted carbohydrate-active enzymes (CAZymes) in the genomes of
Zobellia strains.
Strain No. of genes No. of CAZymes % CAZymes
Z. amurskyensis KMM 3526Т 4248 276 6.49
Z. laminariae KMM 3676Т 4334 257 5.93
Z. galactanivorans DsiJT 4676 315 6.74
Z. amurskyensis MAR 2009
138 4501 299 6.64
Z. uliginosa DSM 2061 4712 296 6.28
As discussed by Barbeyron et al. [30] and Boncan et al. [14], a CAZome is characteristic of species,
which gives insights into bacterial behavior, lifestyle, and ecological niche. Therefore, for free-living
species the proportion of CAZymes in their genomes typically corresponds to 1%–5% of all predicted
coding sequences. In the five Zobellia strains studied, the proportion of CAZymes in the genomes
ranged from 5.93% in Z. laminariae KMM 3676Т to 6.74% in Z. galactanivorans DsiJT, indicating the ability
to consume various polysaccharides. Other Zobellia had slightly lower proportion of CAZymes than
Z. galactanivorans DsiJT, these values being sufficient to argue that a broad biodegradation potential is
conserved at the genus level. Total statistics of CAZymes’ classes predicted across the genomes are in
Figure 4.
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Figure 4. Carbohydrate-active enzymes in Zobellia species. GH, glycoside hydrolase; GT,
glycosyltransferase; PL, polysaccharide lyase; CE, carbohydrate esterases; AA, auxiliary activities;
CBM, carbohydrate-binding module.
The determination of core and pan CAZomes for the Zobellia genus is of particular interest and
importance. Obviously, the core CAZomes are composed of genus-specific enzymes, while the enzymes
identified in singletons and inparalogs are species-specific. In terms of lifestyle peculiarities, the
most interesting are the core multigenic CAZyme families. According to this idea, the core and pan
CAZomes of the Zobellia genus were determined, and the repertoire of CAZymes is summarized in
Figure 5 and Table S1.
GHs are enzymes that catalyze the hydrolytic cleavage of the glycosidic bond between two or
more carbohydrates or between a carbohydrate and a non-carbohydrate moiety. These enzymes
are involved in the degradation of the majority of biomass, including seaweeds [44]. In the present
study, a total of 775 GHs were classified into 62 families in five Zobellia genomes. Among the
identified core glycoside hydrolases, the most dominant were the GH29, GH109, GH2, GH13,
and GH117 families in order of abundance. It is worth noting that seven particular GH13
subfamilies—GH13_11, GH13_19, GH13_3, GH13_31, GH13_38, GH13_7, and GH13_9—were predicted.
Based on the CAZy database (http://www.cazy.org/) definitions, enzymes of predicted families might
act as broad spectrum α-fucosidases, α-N-acetylgalactosaminidase, β-glycosidases with Koshland
double-displacement mechanism, as well as glycosidases acting on substrates withα-glucoside linkages,
and α-1,3-L-(3,6-anhydro)-galactosidases.
GTs are principal enzymes that catalyze oligosaccharide, polysaccharide, and glycoconjugate
synthesis. They also assist in glycosyl group transfer to specific acceptor molecules and utilize various
sugar-1-phosphate derivatives [45]. A total of 16 GT families including 297 GTs were identified for the
strains. The GT2 and GT4 families were ranked as key glycosyltransferases for the genus, which are
polyspecific enzymes.
PLs are a group of enzymes that cleave uronic acid-containing polysaccharides via a β-elimination
mechanism [46]. In the Zobellia genomes, a total of 100 PLs were classified in 13 families, among which
PL14 lyases, possessing alginate, exo-oligoalginate, and β-1,4-glucuronan lytic activities, were the
most abundant.
CEs are a class of esterases that catalyze the de-O or de-N-acylation of substituted saccharides [47].
There are two core multigenic families, namely CE1 and CE10, with wide substrate specificities, which
generally help to degrade substrates leading to saccharification [48].
CBMs are non-catalytic proteins with carbohydrate-binding activity, capable of binding
carbohydrate ligands and enhancing the catalytic efficiency of other CAZymes [49]. In the present
study, a total of 186 CBMs were classified into 18 families, among which three multigenic families
(CBM6, CBM47, CBM50) were identified in Zobellia genus.
AAs are the last class created in the CAZy classification, comprising enzymes that break glycosidic
bonds via an oxidation mechanism [50]. Today, CAZy lists 16 AA families of enzymes playing a
significant role in the degradation of biopolymers (CAZy database; http://www.cazy.org/). CAZyme
annotation revealed that there are six different AA families in Zobellia strains: AA1, AA2, AA3, AA5,
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AA7, and AA12. The majority of AAs are AA3 with up to five AA3 family members in individual
genomes. Moreover, this enzyme group was observed in all studied Zobellia strains, while other
families were less populated (from zero to two AAs per genome).
Figure 5. Number of CAZymes in the Zobellia species. Number of (A) GH families; (B) PL
families; (C) CE families; (D) AA families; (E) CBM families; (F) GT families; GHs, glycoside
hydrolases; PLs, polysaccharide lyases; AAs, Auxiliary Activities; CBMs, carbohydrate-binding
modules; GTs, glycosyltransferases.
2.5. Phylogenetic Analysis of Biotechnologically Relevant Cazymes
2.5.1. Polysaccharide-Degrading GH Systems
A closer inspection of the CAZyme genomic repertoires for four Zobellia species (Figure 5
and Table S1) revealed representatives of some GH families targeting red and brown algal
polysaccharides, namely four (Z. amurskyensis and Z. laminariae) to 14 (Z. galactanivorans and Z.
uliginosa) GH16 enzymes, including β-agarases, β-porphyranases, laminarinases and κ-carrageenases;
one (Z. uliginosa) to two (Z. galactanivorans) GH64 laminarinases; one (Z. laminariae) to three
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(Z. galactanivorans and Z. uliginosa) GH82 ι-carrageenases; six to seven (Z. galactanivorans, Z. laminariae,
and Z. uliginosa) to eight to nine (strains of Z. amurskyensis) GH117 α-1,3-(3,6-anhydro)-L-galactosidases;
two to three (Z. amurskyensis and Z. laminariae) to four (Z. galactanivorans and Z. uliginosa)
GH127 α-1,3-(3,6-anhydro)-D-galactosidases. All five Zobellia genomes encode for one GH129
α-1,3-(3,6-anhydro)-D-galactosidase, and only Z. laminariae has one enzyme assigned to GH50β-agarase.
No representatives from the other agarolytic enzymes GH86, GH96, GH118, or GH150 were identified.
Previously, Z. galactanivorans has been extensively investigated in degradation of various algal
polysaccharides through genomic and transcriptomic analysis combined with computer modeling
and experimental validation [30,51–54]. Therefore, the majority of key genes of agar, laminarin,
and carrageenan utilization systems of Z. galactanivorans can serve as reference sequences for the
annotation of hydrolytic enzymes from other Zobellia genomes. Our analysis showed that the genomes of
Z. galactanivorans and Z. uliginosa shared the largest reservoir of agarolytic genes among Zobellia genomes.
Their polysaccharide-degrading systems were represented by GH16 enzymes, including four to five
β-porphyranases PorA-E, four to fiveβ-agarases AgaA-D, three to four laminarinases LamA-D, and one
κ-carrageenases CgkA. Based on the phylogenetic analysis (Figure S1) of the GH16 catalytic module, the
enzymatic systems of other Zobellia species were represented by only PorD (Zam_1698, Zmar_1649, and
Zlam_2939), PorB (Zam_2877, Zmar_2570, and absent in Z. laminariae), AgaC (Zam_3480, Zmar_956,
and absent in Z. laminariae), AgaB (Zam_3011, Zmar_1702, and Zlam_2991), and LamB (Zlam_4246,
absent in Z. amurskyensis). The genome of Z. laminariae also codes Zlam_2677 as a new putative GH16
subfamily, which occupies an intermediate position on the tree, between the branches CgkA and LamA.
The orthologues genes for AgaA and AgaD, as well as for PorA and PorC, which encode secreted
enzymes responsible for the initial attack on agars and porphyrans [51,55], were absent in both Z.
amurskiensis and Z. laminariae genomes. Therefore, PorD, PorB, AgaC, and AgaB, as well as LamB are
the genus-specific GH16 enzymes, potentially possessing broader substrate specificities. It has been
recently shown that Z. galactanivorans AgaC, defined as a new GH16 subfamily, can hydrolyze not
only agarose, but also complex agars [56]. Interestingly, the Z. uliginosa genome encodes two strongly
different AgaC sequences, classical AgaC Zuli_2505 and AgaC-like Zuli_8, which can be of a great
biotechnological interest because it is a new β-agarase. Therefore, the Zobellia β-agarases, which play a
key role in agar depolymerization with the release of a range of neoagarooligosaccharides, are likely to
be considered for use in industrial and biotechnological applications.
The Zobellia genomes contained the multigenic GH117 family coding exolytic 3,6
anhydro-α-L-galactosidases, which cleave neoagarooligosaccharides and produce L-AHG, and
therefore perform a key role in terminal steps of polysaccharide saccharification. Previously, the
products of some GH117 genes of Z. galactanivorans (Zga_4663 (ZgAhgA), Zga_3615, and Zga_3597)
were biochemically and structurally characterized [57]. The multigenic GH117 families consisted
of six (Z. galactanivorans), seven (Z. uliginosa and Z. laminariae) or eight (Z. amurskiensis) genes. Our
phylogenetic analysis (Figure S2) is in agreement with the previously obtained GH117 tree [58], with
the exception of the additional clades formed by GH117 of Z. amurskiensis strains: Clade 8 (ZamT_1387
and ZamMar_2539) and Clade 9 (ZamT_1385 and ZamMar_2537). We consider these additional clades
of GH117 enzymes to reflect new enzymatic specificities.
Analysis of the genomic regions around GH16 and GH117 genes revealed a number of potential
GH2 β-galactosidase genes. Recently, a novel agarolytic GH2 β-galactosidase has been found
in the marine bacterium Vibrio sp. EJY3 [59]. Therefore, we suggested that these GH2s might
be exo-β-1,4-galactosidases, removing galactose at the non-reducing end of agarooligosaccharides.
Previously, a similar genomic sequence containing several GH2s, GH16s, and GH117s was identified
as a putative agarolytic cluster in the human intestinal bacterium Bacteroides uniformis Bu NP1 [60].
It was suggested that the products of GH16s were cyclically degraded into monosaccharides by the
coordinated work of GH117B and GH2C, respectively.
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Since there is a demand for highly specific agarolytic enzymes, the investigation of multigenic
families encoding enzymes with slightly different activities and specificities may be the best solution for
production of valuable oligosaccharides and rare monomers with different bioactivities or applications.
2.5.2. Auxiliary Activity Family 3 Enzymes
According to the CAZyme annotation (Figure 5 and Table S1), AA3 is characterized by a
multiplicity of members (up to five candidate proteins) for the Zobellia genus. AA3 belongs to the
glucose-methanol-choline (GMC) oxidoreductase family first outlined by Cavener [61]. It was reported
that GMC oxidoreductases were flavoproteins containing FAD-binding domain with the strictly
conserved Rossmann fold or β-α-β dinucleotide-binding motif GXGXXG [62]. Our results demonstrate
that proteins in the studied Zobellia strains predicted as AA3 enzymes also have such motif, suggesting
that they may act as GMC oxidoreductases (Figure S3).
The GMC oxidoreductases are a very large and functionally diverse enzyme superfamily divided
into four subfamilies, which include cellobiose dehydrogenases, glucose oxidoreductases, aryl-alcohol
oxidases, alcohol oxidases, and pyranose oxidoreductases [63]. In 2012, Kim et al. [64] identified
GMC oxidoreductase from a Rhizobium sp. strain GIN611 with glycoside deglycosylation activity
different from that of common glycosidases (GHs). Later [65] they characterized its homologs
in Stenotrophomonas maltophilia, Sphingobacterium multivorum, and Agrobacterium tumefaciens strains,
catalyzed the deglycosylation via the same mechanism, and suggested these enzymes as a new GMC
oxidoreductase subfamily—FAD-dependent glycoside oxidoreductase (FAD-GO). Interestingly, the
authors showed broad glycone and aglycon specificities for these enzymes that makes them very
attractive in their industrial applications.
We performed a phylogenetic analysis by comparing the amino acid sequences of Zobellia AA3
members with characterized FAD-GOs. According to the phylogenetic tree (Figure S4), the Zobellia
enzymes formed two clades, one of which (Clade A) was orthologous to the FAD-GO proteins.
Sequence comparison of Zobellia Clade A enzymes and glycoside oxidoreductases revealed relatively
high identity between them (53%–58%) (Table S2). Moreover, His493 residue considered as a catalytic
FAD-GO amino acid for an initial oxidation step was observed within protein sequences for all studied
Zobellia (Figure S3). This gives us the opportunity to suggest that Zobellia AA3 enzymes could have
the same glycoside oxidase activity, identification of which may be the subject for further research.
Due to the broad substrate specificity, putative Zobellia FAD-GOs are of particular interest and can
be considered as promising biocatalysts for glycoside deglycosylation in food and pharmaceutical
industries [65].
3. Materials and Methods
3.1. Genome Sequencing and Assembly
Genomic DNA was isolated from stationary phase cultures of Z. amurskyensis KMM 3526Т
and Z. laminariae KMM 3676Т using a NucleoSpin kit (Macherey-Nagel, Düren, Germany)
following manufacturer’s instructions. The quantity and quality of isolated DNA were analyzed
using NanoPhotometer Pearl (IMPLEN, Munich, Germany). The shotgun DNA libraries were
constructed according to the methodological recommendations described in the GS Junior Titanium
Rapid Library Preparation Method Manual, GS Junior Titanium emPCR Amplification Method
Manual—Lib-L, GS Junior Titanium Sequencing Method Manual, NEBNextR dsDNA FragmentaseR,
NEXTflex™ DNA-Sequencing Kit for Ion Platforms, KAPA Library Quantification Kit Ion Torrent™
Platforms, Ion 520™ & Ion 530™ Kit-Chef. Libraries of both flavobacteria were sequenced on
the 454 GS Junior (454 Life Sciences, Branford, CT, USA); additional library of the KMM 3676Т
was sequenced at Far Eastern Federal University, School of Biomedicine, on the Ion Torrent
IonS5 XL platform (Thermo Fisher Scientific, Waltham, MA, USA). All sequencing reads were
preprocessed with FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and Prinseq
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(http://edwards.sdsu.edu/cgi-bin/prinseq/prinseq.cgi) to remove the adaptor sequences and low-quality
data. A de novo assembly of filtered reads was performed using Newbler version 3.0 (454 Life Sciences,
Branford, CT, USA and SPAdes version 3.11.1 [66]; validation of an assembly was done by remapping
filtered reads to the contigs by using Bowtie2 (Galaxy version 2.3.4.3+galaxy0) [67]; metrics were
calculated with the help of QUAST (Galaxy version 5.0.2+galaxy0) [68].
3.2. Genome Annotation
Gene prediction and automated genome annotation were carried out using Rapid Annotation
using Subsystem Technology (RAST) v. 2.0 with default parameters [37–39] followed by manual
curation of the some annotations by comparing translated sequences with the NCBI non-redundant
database, InterPro (https://www.ebi.ac.uk/interpro/), and Pfam (https://pfam.xfam.org/) databases.
For more accurate annotation of carbohydrate-active enzymes, their classification into existing CAZy
families and identification of a CAZome repertoire of Zobellia genus were performed using the dbCAN2
meta server (http://cys.bios.niu.edu/dbCAN2) [43].
3.3. Phylogenetic, PhylogenomicAnalyses, and Comparative Genomics
Phylogenetic analysis of 16S rRNA gene sequences, also members of GHs and AAs from Zobellia
species, was performed using the NJ [34] method with bootstrap supporting of 1000 replicates in
MEGA v.6.06 [69]. Phylogenomic measures were calculated with the JSpecies Web Server [35] to
determine ANI values and Tetra signatures. Genome-wide analysis of orthologous clusters and
gene ontology analysis among all predicted protein-coding genes was performed using OrthoVenn2
(https://orthovenn2.bioinfotoolkits.net/home) [42].
3.4. Deposition of the Nucleotide Sequence Accession Number
The whole-gGenome shotgun sequences of Z. amurskyensis KMM 3526Т and Z. laminariae
KMM 3676Т have been deposited at DDBJ/ENA/GenBank under the accessions RCNR00000000
and RCNS00000000, respectively. The versions described in this paper are RCNR01000000
and RCNS01000000.
4. Conclusions
Today, some of the most eco-friendly methods for obtaining algal polysaccharides and their
derivatives are enzyme-based techniques. Therefore, the search for marine bacteria specialized in
the degradation of various polysaccharides is of particular interest. The marine flavobacterium
Z. galactanivorans DsijT is a model organism for polysaccharide degradation investigation among marine
flavobacteria. However, little has been known about the genomic basics of hydrolytic potential of the
Zobellia genus. To determine the CAZyme content at the species and genus taxonomic levels, we performed
genome sequencing of two type Zobellia strains and comparative genomic analysis. We identified a
relatively high proportion of CAZymes in the genomes of five Zobellia strains. Our comparative
study strongly suggests a specialization of the Zobellia genus in the algal polysaccharide degradation.
These microorganisms can be used as both strain-degraders and valuable sources of novel enzymes for
potential application in biotechnology, food, and medical industries.
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